{"id":15873,"date":"2021-12-14T12:47:06","date_gmt":"2021-12-14T12:47:06","guid":{"rendered":"https:\/\/incilab.az\/biokimya-testl%c9%99r-qrupu\/"},"modified":"2023-09-14T09:01:07","modified_gmt":"2023-09-14T09:01:07","slug":"group-of-biochemistry-tests","status":"publish","type":"page","link":"https:\/\/incilab.az\/en\/group-of-biochemistry-tests\/","title":{"rendered":"Group of biochemistry tests"},"content":{"rendered":"

[vc_row][vc_column]

\r\n \r\n <\/div>\r\n
<\/div>
\r\n

5-NUKLEOT\u0130DAZA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a05-NT<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong>\u00a02-10 U\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Hepatobiliar x\u0259st\u0259likl\u0259rin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olunur. \u0130ntra v\u0259 ya ekstrahepatik biliar obstruksiyalar, qaraciy\u0259rin b\u0259d xass\u0259li t\u00f6r\u0259m\u0259l\u0259ri, biliar sirroz v\u0259 hamil\u0259liyin son trimesterind\u0259 5-NT s\u0259viyy\u0259si y\u00fcks\u0259lir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

C4 (KOMPLEMENT C4)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0C4<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (mayi)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Nefelometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
Serum<\/td>\nG\u00f6b\u0259k ciy\u0259si qan\u0131<\/td>\n7-23 mg\/dL<\/td>\n<\/tr>\n
Yenido\u011fulmu\u015f<\/td>\n7-23 mg\/dL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n7-25 mg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-3 ay<\/td>\n7-30 mg\/dL<\/td>\n<\/tr>\n
4 ay-1 ya\u015f<\/td>\n8-42 mg\/dL<\/td>\n<\/tr>\n
2-12 ya\u015f<\/td>\n15-42 mg\/dL<\/td>\n<\/tr>\n
> 12 ya\u015f<\/td>\n15-50 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0K\u0259skin faza reaktant\u00adlar\u0131ndan biridir. Komplement siste\u00admind\u0259ki klassik yolda yer al\u0131r. K\u0259s\u00adkin iltihabi x\u0259st\u0259likl\u0259r v\u0259 b\u0259dxass\u0259li \u015fi\u015fl\u0259rd\u0259 C4 s\u0259viyy\u0259si art\u0131r; SLE, k\u0259s\u00adkin qlomerulomefrit, xroniki hepatit, autoimmun x\u0259st\u0259likl\u0259r, irsi angio-\u00f6dem, z\u00fclal itkisi il\u0259 ged\u0259n x\u0259st\u0259\u00adlik\u00adl\u0259r v\u0259 kongenital \u00e7at\u0131\u015fmazl\u0131q zaman\u0131 is\u0259 serumda C4 s\u0259viyy\u0259si azala bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

C3 (KOMPLEMENT C3)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0C3<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum, maye<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum), d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (maye)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Nefelometrik<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
Serum<\/td>\nG\u00f6b\u0259k ciy\u0259si qan\u0131<\/td>\n57-116 mg\/dL<\/td>\n<\/tr>\n
Yar\u0131m\u00e7\u0131q do\u011fulan<\/td>\n57-116 mg\/dL<\/td>\n<\/tr>\n
<1 ay<\/td>\n50-120 mg\/dL<\/td>\n<\/tr>\n
2-3 ay<\/td>\n60-150 mg\/dL<\/td>\n<\/tr>\n
4-6 ay<\/td>\n60-175 mg\/dL<\/td>\n<\/tr>\n
7-12 ay<\/td>\n70-180 mg\/dL<\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n75-180 mg\/dL<\/td>\n<\/tr>\n
>3 ya\u015f<\/td>\n85-200 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0K\u0259skin faza reaktant\u00adlar\u0131ndan biridir. Komplement siste\u00admin\u00add\u0259ki klassik v\u0259 alternativ yollar C3 pill\u0259sind\u0259 birl\u0259\u015fir. C3 s\u0259viy\u00ady\u0259sind\u0259 artma iltihabi x\u0259st\u0259lil\u0259r, ato\u00adpik dermatit, biliar obstruksiya v\u0259 amiloidozla \u0259laq\u0259li ola bil\u0259r. Autoimmun x\u0259st\u0259likl\u0259r, bakteremiya, toxuma z\u0259d\u0259l\u0259nm\u0259si, xroniki hepatit, nefrit, malnutrisiya, DIC v\u0259 kon\u00adge\u00adnital \u00e7at\u0131\u015fmazl\u0131qlar is\u0259 C3 s\u0259viy\u00ady\u0259sind\u0259 azalmaya s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BETTA-2 TRANSFERR\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Burun ifrazat\u0131, qulaq ifrazat\u0131<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u00ad\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL Burun v\u0259 ya qulaq ifrazat\u0131 v\u0259 1 mL serum<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0\u0130mmunfiksasiya elektro\u00adforezi<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>BOM-da transferrinin 2 izoformas\u0131 tap\u0131l\u0131r. Bunlarda biri\u00a0 nor\u00admada serumda da olur v\u0259 beta-1 frak\u00adsiyas\u0131 adland\u0131r\u0131l\u0131r. Dig\u0259ri is\u0259 yaln\u0131z BOM-da olur v\u0259 beta-2 ad\u00adland\u0131r\u0131l\u0131r. Beta-2 transferrin se\u00adrum, qulaq mayel\u0259ri, burun sekresiyalar\u0131, a\u011f\u0131z suyu, g\u00f6zya\u015f\u0131, b\u0259l\u011f\u0259m, v\u0259 limfa v\u0259zil\u0259rind\u0259 olmur. Bu mayel\u0259rd\u0259 betta-2 transferrinin olmas\u0131 BOM-dan ke\u00e7diyi bar\u0259d\u0259 d\u00fc\u015f\u00fcnd\u00fcr\u00fcr. X\u00fc\u00adsusil\u0259 otoreya (qulaqdan ifrazat\u0131n axmas\u0131) v\u0259 rinoreyan\u0131n (burundan ifr\u00adazat\u0131n axmas\u0131) diaqnozunda testin h\u0259s\u00ad\u00adsasl\u0131\u011f\u0131 \u00e7ox y\u00fcks\u0259kdir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BETA-HCG (S\u0130D\u0130K)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim: \u03b2<\/strong>-hCG; Human chorionic gonadotropin; Hamil\u0259lik testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik (s\u0259\u00adh\u0259r ilk sidik m\u0259sl\u0259h\u0259t g\u00f6r\u00fcl\u00fcr)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259ril\u00adm\u0259\u00adlidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Strip<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hamil\u0259liyin t\u0259yinind\u0259 is\u00adti\u00adfad\u0259 edilir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BETA-2 M\u0130KROGLOBUL\u0130N (S\u0130D\u0130K)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik, Bir\u00add\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Si\u00addiyin pH-\u0131 <6.0 olarsa \u00fcz\u0259rin\u0259 1M NaOH \u0259lav\u0259 edil\u0259r\u0259k\u00a0\u03b2<\/strong>2<\/sub>M-nin sta\u00adbilliyi qorunmal\u0131d\u0131r. Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131d\u0131r. 24 saatl\u0131q sidik n\u00fc\u00admu\u00adn\u0259l\u0259rinin g\u00f6t\u00fcr\u00fclm\u0259si daha \u0259lve\u00adri\u015f\u00adlidir. Sidik n\u00fcmun\u0259l\u0259ri menstu\u00adra\u00adsiya d\u00f6vr\u00fcnd\u0259 g\u00f6t\u00fcr\u00fclm\u0259m\u0259lidir, 24 saatl\u0131q sidiyin h\u0259cmi bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0pH-\u0131 <6.0 olan sidik n\u00fcmun\u0259l\u0259ri<\/p>\n

Referens:<\/strong>\u00a00.02-0.25 mg\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Normal insanlarda\u00a0\u03b2<\/strong>2<\/sub>M sabit s\u00fcr\u0259tl\u0259 sintez olunur. Sonra b\u00f6y\u00adr\u0259kl\u0259rd\u0259 \u00f6nc\u0259 filtirasiya olunur v\u0259 ard\u0131nca reabsorbsiya edilir. Son olaraq\u00a0\u03b2<\/strong>2<\/sub>M proksimal tubulyar h\u00fc\u00adceyr\u0259l\u0259rd\u0259 katabolizm\u0259 u\u011fray\u0131r. Nor\u00admal halda sidikd\u0259\u00a0\u03b2<\/strong>2<\/sub>M-in miqdar\u0131 \u00e7ox az olur, lakin d\u0259rman, m\u00fcxt\u0259lif x\u0259st\u0259likl\u0259r, a\u011f\u0131r metallar v\u0259 s. s\u0259b\u0259b\u00adl\u0259rd\u0259n proksimal tubulyar h\u00fcceyr\u0259 z\u0259d\u0259l\u0259nm\u0259si ba\u015f verdikd\u0259 sidikl\u0259\u00a0\u03b2<\/strong>2<\/sub>M-in ifraz\u0131 art\u0131r. Bu bax\u0131mdan b\u00f6y\u00adr\u0259kl\u0259rin tubulyar funksiyalar\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BETA-2 M\u0130KROGLOBUL\u0130N (BOM)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

Referens:<\/strong>\u00a0<2.4 mg\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>M\u0259rk\u0259zi sinir sistemini \u0259hat\u0259 ed\u0259n k\u0259skin leykoz v\u0259 limfo\u00admalarda BOM-da\u00a0\u03b2<\/strong>2<\/sub>M arta bil\u0259r. Eyni zamanda serumdak\u0131 s\u0259viyy\u0259\u00adsi\u00adnin d\u0259 t\u0259yin olunmas\u0131 daha m\u0259qs\u0259\u00add\u0259uy\u011fundur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

5-NT (5-NUKLEOT\u0130DAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a05-NT<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong>\u00a02-10 U\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Hepatobiliar x\u0259st\u0259likl\u0259rin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olunur. \u0130ntra v\u0259 ya ekstrahepatik biliar obstruksiyalar, qaraciy\u0259rin b\u0259d xass\u0259li t\u00f6r\u0259m\u0259l\u0259ri, biliar sirroz v\u0259 hamil\u0259liyin son trimesterind\u0259 5-NT s\u0259viyy\u0259si y\u00fcks\u0259lir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

5-H\u0130DROKS\u0130\u0130NDOLASETAT TUR\u015eUSU<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>\u00a05-HIAA; 5-OH-indolase\u00adtat tur\u015fusu<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Asetat tur\u015fusu \u00fcz\u0259rin\u0259 toplan\u0131lmal\u0131d\u0131r. 6N HCl v\u0259 Bor tur\u015fusu \u00fcz\u0259rin\u0259 y\u0131\u011f\u0131lan sidikl\u0259r d\u0259 q\u0259bul edil\u0259 bil\u0259r<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0T\u0259rkibind\u0259 serotonin olan bad\u0131mcan, pomidor, qoz, banan, f\u0131nd\u0131q, f\u0131sd\u0131q, avakado v\u0259 s. kimi b\u0259zi qidalar son 72 saat m\u00fcd\u00add\u0259tind\u0259 q\u0259bul edilm\u0259m\u0259lidir. H\u0259m\u00ad\u00e7inin son 72 saat \u0259rzind\u0259 isti\u00adfa\u00add\u0259 olunan d\u0259rmanlar haqq\u0131nda m\u0259lu\u00admat verilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>HPLC<\/p>\n

Referens:\u00a0<\/strong>10.4-31.2 \u03bcmol\/g\u00fcn<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Karsinoid \u015fi\u015fl\u0259rin diaq\u00adnozunda istifad\u0259 olunur. H\u0259m\u00e7inin celiac sprue, whipple x\u0259st\u0259liyi v\u0259 bronx karsinomalar\u0131nda 5-HIAA s\u0259\u00adviyy\u0259si art\u0131r, depressiya, nazik ba\u011f\u0131r\u00adsa\u011f\u0131n rezeksiyas\u0131, fenilke\u00adtonuriya v\u0259 Hartnup x\u0259st\u0259liyind\u0259 is\u0259 bu g\u00f6st\u0259rici azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

5-HIAA (5-H\u0130DROKS\u0130\u0130NDOLASETAT TUR\u015eUSU)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>\u00a05-HIAA; 5-OH-indolase\u00adtat tur\u015fusu<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Asetat tur\u015fusu \u00fcz\u0259rin\u0259 toplan\u0131lmal\u0131d\u0131r. 6N HCl v\u0259 Bor tur\u015fusu \u00fcz\u0259rin\u0259 y\u0131\u011f\u0131lan sidikl\u0259r d\u0259 q\u0259bul edil\u0259 bil\u0259r<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0T\u0259rkibind\u0259 serotonin olan bad\u0131mcan, pomidor, qoz, banan, f\u0131nd\u0131q, f\u0131sd\u0131q, avakado v\u0259 s. kimi b\u0259zi qidalar son 72 saat m\u00fcd\u00add\u0259tind\u0259 q\u0259bul edilm\u0259m\u0259lidir. H\u0259m\u00ad\u00e7inin son 72 saat \u0259rzind\u0259 isti\u00adfa\u00add\u0259 olunan d\u0259rmanlar haqq\u0131nda m\u0259lu\u00admat verilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>HPLC<\/p>\n

Referens:\u00a0<\/strong>10.4-31.2 \u03bcmol\/g\u00fcn<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Karsinoid \u015fi\u015fl\u0259rin diaq\u00adnozunda istifad\u0259 olunur. H\u0259m\u00e7inin celiac sprue, whipple x\u0259st\u0259liyi v\u0259 bronx karsinomalar\u0131nda 5-HIAA s\u0259\u00adviyy\u0259si art\u0131r, depressiya, nazik ba\u011f\u0131r\u00adsa\u011f\u0131n rezeksiyas\u0131, fenilke\u00adtonuriya v\u0259 Hartnup x\u0259st\u0259liyind\u0259 is\u0259 bu g\u00f6st\u0259rici azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

2.5-HEGZAND\u0130ON<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>5 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259\u00adril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Qaz xromatoqrafiya (GC)<\/p>\n

Referens: <<\/strong>0.5 mg\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0n-hegzan il\u0259 i\u015fl\u0259y\u0259n \u015f\u0259xs\u00adl\u0259r\u0259 bu madd\u0259nin n\u0259 q\u0259d\u0259r t\u0259sir et\u00addiyini t\u0259yin etm\u0259k \u00fc\u00e7\u00fcn istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

A1AT (ALFA-1 ANT\u0130TR\u0130PS\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>A1<\/sub>AT; AAT; \u221e1-<\/sub>Anti\u00adtrip\u00adsin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Nefelometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
< 7 g\u00fcn<\/td>\n100-270 mg\/dL<\/td>\n<\/tr>\n
7g\u00fcn-5ya\u015f<\/td>\n80-20 mg\/dL<\/td>\n<\/tr>\n
> 5 ya\u015f<\/td>\n80-200 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Pozitiv k\u0259skin faza rea\u00adgentl\u0259rind\u0259ndir. Protein elektro\u00adfo\u00adrezind\u0259 \u221e1<\/sub>\u00a0lentinin b\u00f6y\u00fck hiss\u0259sini t\u0259\u015fkil edir. H\u0259m\u00e7inin serumda \u0259n y\u00fck\u00ads\u0259k konsentrasiyada olan proteza inhibitorudur. H\u0259r c\u00fcr infeksiya, to\u00adxuma nekrozu, travmalar, oral kon\u00adtra\u00adseptivl\u0259rin istifad\u0259si v\u0259 hamil\u0259lik zaman\u0131 AAT s\u0259viyy\u0259si y\u00fcks\u0259lir. AAT-nin\u00a0 s\u0259viyy\u0259sinin h\u0259dd\u0259n art\u0131q d\u00fc\u015f\u00adm\u0259si zaman\u0131 xroniki a\u011fciy\u0259r v\u0259 qaraciy\u0259r x\u0259st\u0259likl\u0259ri inki\u015faf ed\u0259 bil\u0259r. A\u011f\u0131r d\u0259r\u0259c\u0259li irsi AAT \u00e7at\u0131\u015f\u00admazl\u0131qlar\u0131 zaman\u0131 x\u00fcsusil\u0259 u\u015faqlarda neonatal hepatit sindromu v\u0259 infantil sirroz kimi a\u011f\u0131r klinik m\u0259nz\u0259r\u0259l\u0259r inki\u015faf ed\u0259 bil\u0259r. B\u00f6y\u00fckl\u0259rd\u0259 is\u0259 em\u00adfizema v\u0259 xroniki bronxit kimi\u00a0 xro\u00adniki a\u011fciy\u0259r x\u0259st\u0259likl\u0259rinin inki\u015faf\u0131na \u015f\u0259rait yarada bil\u0259r.<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AAT (ALFA-1 ANT\u0130TR\u0130PS\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>A1<\/sub>AT; AAT; \u221e1-<\/sub>Anti\u00adtrip\u00adsin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Nefelometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
< 7 g\u00fcn<\/td>\n100-270 mg\/dL<\/td>\n<\/tr>\n
7g\u00fcn-5ya\u015f<\/td>\n80-20 mg\/dL<\/td>\n<\/tr>\n
> 5 ya\u015f<\/td>\n80-200 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Pozitiv k\u0259skin faza rea\u00adgentl\u0259rind\u0259ndir. Protein elektro\u00adfo\u00adrezind\u0259 \u221e1<\/sub>\u00a0lentinin b\u00f6y\u00fck hiss\u0259sini t\u0259\u015fkil edir. H\u0259m\u00e7inin serumda \u0259n y\u00fck\u00ads\u0259k konsentrasiyada olan proteza inhibitorudur. H\u0259r c\u00fcr infeksiya, to\u00adxuma nekrozu, travmalar, oral kon\u00adtra\u00adseptivl\u0259rin istifad\u0259si v\u0259 hamil\u0259lik zaman\u0131 AAT s\u0259viyy\u0259si y\u00fcks\u0259lir. AAT-nin\u00a0 s\u0259viyy\u0259sinin h\u0259dd\u0259n art\u0131q d\u00fc\u015f\u00adm\u0259si zaman\u0131 xroniki a\u011fciy\u0259r v\u0259 qaraciy\u0259r x\u0259st\u0259likl\u0259ri inki\u015faf ed\u0259 bil\u0259r. A\u011f\u0131r d\u0259r\u0259c\u0259li irsi AAT \u00e7at\u0131\u015f\u00admazl\u0131qlar\u0131 zaman\u0131 x\u00fcsusil\u0259 u\u015faqlarda neonatal hepatit sindromu v\u0259 infantil sirroz kimi a\u011f\u0131r klinik m\u0259nz\u0259r\u0259l\u0259r inki\u015faf ed\u0259 bil\u0259r. B\u00f6y\u00fckl\u0259rd\u0259 is\u0259 em\u00adfizema v\u0259 xroniki bronxit kimi\u00a0 xro\u00adniki a\u011fciy\u0259r x\u0259st\u0259likl\u0259rinin inki\u015faf\u0131na \u015f\u0259rait yarada bil\u0259r.<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ACE (ANG\u0130OTENZ\u0130N \u00c7EV\u0130R\u0130C\u0130 FERMENT)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ACE (Angiotensin Con\u00adverting Enzyme)<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Heparinli plazma, BOM, bronxoalveolyar lavaj mayesi<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Ya\u015f\u0131l qapaql\u0131 s\u0131naq \u015f\u00fc\u00ad\u015f\u0259si (plazma), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u00ad\u015f\u0259si (maye)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>Qan al\u0131n\u00admaz\u00addan 12 saat \u0259vv\u0259l ACE inhibi\u00adtorlar\u0131n\u0131n istifad\u0259si k\u0259silm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>T\u00fcrbidimetrik, kinetik<\/p>\n

Referens:\u00a0<\/strong>8-52 U\/L (plazma)<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Sarkoidozun diaqnos\u00adtika\u00ads\u0131nda istifad\u0259 olunur. Aktiv sar\u00adkoidoz zaman\u0131 ACE s\u0259viyy\u0259si >35 U\/L olur. H\u0259m\u00e7inin k\u0259skin v\u0259 xro\u00adni\u00adki bronxit, a\u011fciy\u0259r fibrozu, revmo\u00adtoid artrit, servikal adenit, birl\u0259\u015fdirici toxuma x\u0259st\u0259likl\u0259ri, Gaucher x\u0259st\u0259\u00adliyi, hipertiroidizim, histoplazmoz v\u0259 dig\u0259r g\u00f6b\u0259l\u0259k x\u0259st\u0259likl\u0259ri zaman\u0131 ACE miqdar\u0131 arta bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ACLIQ QAN \u015e\u018fK\u018fR\u0130 (QL\u00dcKOZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Acl\u0131q qan \u015f\u0259k\u0259ri; AQ\u015e<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, florid\/ok\u00adsa\u00adlatl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Boz qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (florid\/oksalatl\u0131 plazma), Q\u0131r\u00adm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200\u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0Q\u0131r\u00adm\u0131\u00adz\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259sin\u0259 qan al\u0131\u00adn\u0131bsa gecikm\u0259d\u0259n sentrifuqadan ke\u00ad\u00e7i\u00adril\u0259r\u0259k serumu tez ayr\u0131lmal\u0131d\u0131r<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 8 saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 laz\u0131md\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, fer\u00admen\u00adtativ, kinetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Se\u00adrum ayr\u0131lmadan q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259sind\u0259 saxlan\u0131lm\u0131\u015f qan<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si qan\u0131<\/td>\n45-96 mg\/dL<\/td>\n<\/tr>\n
Yar\u0131m\u00e7\u0131q do\u011fulan<\/td>\n20-60 mg\/dL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n40-60 mg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-1 ay<\/td>\n50-80 mg\/dL<\/td>\n<\/tr>\n
2 ay-15 ya\u015f<\/td>\n60-100 mg\/dL<\/td>\n<\/tr>\n
16-60 ya\u015f<\/td>\n70-100 mg\/dL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n80-115 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Karbohidrat metobo\u00adliz\u00admi\u00adnin qiym\u0259tl\u0259ndirilm\u0259siond\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ADA (ADENOZ\u0130N DEAM\u0130NAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ADA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:\u00a0<\/strong>Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>1 ml<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik<\/p>\n

Referens:\u00a0<\/strong>5-20 U\/L<\/p>\n

Istifad\u0259si:<\/strong>\u00a0Hepatit, sirroz, hemaxro\u00admatoz, prostat v\u0259 sidik kis\u0259si kar\u00adsinomalar\u0131, hemolitik anemiya, tala\u00adsemiya major, v\u0259r\u0259m, autoimmun x\u0259st\u0259likl\u0259r, infeksion mononukleoz v\u0259 \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131nda serumda ADA miqdar\u0131 art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ADENOZ\u0130N DEAM\u0130NAZA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ADA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:\u00a0<\/strong>Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>1 ml<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik<\/p>\n

Referens:\u00a0<\/strong>5-20 U\/L<\/p>\n

Istifad\u0259si:<\/strong>\u00a0Hepatit, sirroz, hemaxro\u00admatoz, prostat v\u0259 sidik kis\u0259si kar\u00adsinomalar\u0131, hemolitik anemiya, tala\u00adsemiya major, v\u0259r\u0259m, autoimmun x\u0259st\u0259likl\u0259r, infeksion mononukleoz v\u0259 \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131nda serumda ADA miqdar\u0131 art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ADENOZ\u0130N DEAM\u0130NAZA (Maye)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Beyin-onur\u011fa beyni mayesi, maye<\/p>\n

N\u00fcmun\u0259 qab\u0131:\u00a0<\/strong>\u00a0Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>1 ml<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Beyin onur\u011fa beyni mayesind\u0259<\/td>\n<6 U\/L<\/td>\n<\/tr>\n
Maye<\/td>\n>40 U\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si: \u018fsas\u0259n v\u0259r\u0259m\u00a0 eksudat\u00adla\u00adr\u0131\u00adn\u0131n v\u0259 v\u0259r\u0259m meningitinin t\u0259yi\u00adnin\u00add\u0259 istifad\u0259 olunur. Limfoma, siste\u00admik q\u0131rm\u0131z\u0131 qurde\u015f\u0259n\u0259yi (SLE) v\u0259 ade\u00adno\u00adkarsinomalar zaman\u0131 da ma\u00adyed\u0259ki ADA s\u0259viyy\u0259si y\u00fcks\u0259l\u0259 bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AL (AL\u00dcM\u0130N\u0130UM)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Al<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum, 24 saatl\u0131q sidik, bird\u0259f\u0259lik sidik, BOM, dializ mayesi<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum) (\u018fvv\u0259lc\u0259d\u0259n is\u00adtifad\u0259 edilm\u0259mi\u015f v\u0259 ya nitrat tur\u015fusu il\u0259 yuyulmu\u015f, distill\u0259 olunmu\u015f v\u0259 ya ionsuzla\u015fd\u0131r\u0131lm\u0131\u015f su il\u0259 yaxalanm\u0131\u015f s\u0131naq \u015f\u00fc\u015f\u0259sind\u0259 g\u00f6nd\u0259rilm\u0259lidir),\u00a0 24 saatl\u0131q sidik (Soyuq \u015f\u0259raitd\u0259 saxla\u00adn\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir. Bor tur\u015f\u00adusu v\u0259 ya asetat tur\u015fusu \u00fcz\u0259rin\u0259 y\u0131\u011f\u0131\u00adlan sidikl\u0259r d\u0259 q\u0259bul edilir. Bax \u018fla\u00adv\u0259 P), gelsiz steril s\u0131naq \u015f\u00fc\u015f\u0259si (BOM, maye)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Al\u00fc\u00admi\u00adniumun xarici m\u00fchitd\u0259n konta\u00adminasiya riski \u00e7ox y\u00fcks\u0259k oldu\u00ad\u011fun\u00addan n\u00fcmun\u0259 al\u0131nark\u0259n kontami\u00adna\u00adsiyaya x\u00fcsusil\u0259 diqq\u0259t yetirilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>analiz \u00fc\u00e7\u00fcn qan n\u00fcmun\u0259si verm\u0259zd\u0259n \u0259vv\u0259lki son 24 saat \u0259rzind\u0259 t\u0259rkibind\u0259 al\u00fc\u00admi\u00adnium olan antiasit preparatlar v\u0259 di\u00adg\u0259r d\u0259rmanlar istifad\u0259 olunma\u00admal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>AAS-Zeeman<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
Serum<\/td>\n1-14 \u03bcg\/L<\/td>\n<\/tr>\n
Sidik<\/td>\n7-40 \u03bcg\/L<\/td>\n<\/tr>\n
Dializ mayesi<\/td>\n<10 \u03bcg\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hemodializ x\u0259st\u0259l\u0259rinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur. B\u00f6y\u00adr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, dializl\u0259 \u0259laq\u0259li de\u00admen\u00adsiya, Hodgkin x\u0259st\u0259liyi v\u0259 mu\u00adkovissidozlar (kistik fibrozis) zaman\u0131 al\u00fcminyum s\u0259viyy\u0259si art\u0131r. 100\u03bcg\/L\u2013d\u0259n y\u00fcks\u0259k n\u0259tic\u0259l\u0259r tok\u00adsi\u00adki t\u0259sir g\u00f6st\u0259rir. Al(OH)3<\/sub>, m\u0259d\u0259 an\u00adtia\u00adsitl\u0259ri v\u0259 ya dializ x\u0259st\u0259l\u0259rind\u0259 fos\u00adfat birl\u0259\u015fdirici vasit\u0259 kimi istifad\u0259 olundu\u011fundan bu x\u0259st\u0259l\u0259rd\u0259 al\u00fcmi\u00adnium toksikozuna diqq\u0259t edilm\u0259lidir. H\u0259m\u00e7inin serumda Al s\u0259viyy\u0259si 100 \u03bcg\/L \u2013d\u0259n y\u00fcks\u0259k olan x\u0259st\u0259l\u0259rd\u0259 Al m\u0259n\u015f\u0259li osteomaliyasiyaya diqq\u0259t edilm\u0259lidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ALA (AM\u0130NOLEVUL\u0130N TUR\u015eUSU)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Delta-ALA; DALA; ALA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a024 saatl\u0131q sidik, bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Asetat tur\u015fusu \u00fcz\u0259\u00adrin\u0259 y\u0131\u011f\u0131laraq g\u00f6nd\u0259rilm\u0259lidir. 6N HCl \u00fcz\u0259rin\u0259 y\u0131\u011f\u0131lan sidikl\u0259r d\u0259 q\u0259bul edilir. Qaranl\u0131q yerd\u0259 y\u0131\u011f\u0131lmal\u0131 v\u0259 i\u015f\u0131qdan qorunaraq g\u00f6nd\u0259rilm\u0259lidir (Bax \u018flav\u0259 P)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a010 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 sa\u00adatl\u0131q sidiyin miqdar\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Xromatoqrafik, spektro\u00adfotometrik<\/p>\n

Referens:\u00a0<\/strong><<\/strong>7 mg\/g\u00fcn<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>K\u0259skin porfiriyan\u0131n diaq\u00adnozu v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahid\u0259si \u00fc\u00e7\u00fcn istifad\u0259 olunur. X\u00fcsusil\u0259 k\u0259s\u00adkinl\u0259\u015fm\u0259 zaman\u0131 g\u00f6t\u00fcr\u00fcl\u0259n n\u00fcmu\u00adn\u0259d\u0259 (bird\u0259f\u0259lik v\u0259 ya 24 saatl\u0131q sidik) ALA, porfobilinogen v\u0259 sidik porfirinl\u0259rinin t\u0259yini\u00a0 porfiriya diaq\u00adnozunu t\u0259sdiq v\u0259 ya inkar etm\u0259y\u0259 imkan verir. Qur\u011fu\u015fun z\u0259h\u0259rl\u0259nm\u0259si, herediter tirozinemiya, diabetik keto\u00adasidoz, hamil\u0259lik v\u0259 b\u0259zi q\u0131colma \u0259lehin\u0259 d\u0259rmanlar ALA s\u0259viy\u0259sind\u0259 y\u00fcks\u0259lm\u0259y\u0259 s\u0259b\u0259b oldu\u011fu halda, alkaqolla \u0259laq\u0259li qaraciy\u0259r x\u0259st\u0259lik\u00adl\u0259ri zaman\u0131 sidikd\u0259 ALA s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ALAN\u0130N (AM\u0130NTUR\u015eULAR, K\u018fM\u0130YY\u018fTC\u018f (Plazma, Sidik v\u0259 BOM))<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Heparinli plazma, bird\u0259f\u0259lik sidik, BOM. X\u0259st\u0259nin h\u0259kimi t\u0259r\u0259find\u0259n doldurulmu\u015f anket formas\u0131 v\u0259 ya x\u0259st\u0259nin anamnezi n\u00fcmun\u0259 il\u0259 b\u0259rab\u0259r g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Ya\u015f\u0131l qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (plazma), gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0Plazma 1 mL, Sidik 5 mL, BOM 1mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Plaz\u00adma n\u00fcmun\u0259si b\u00f6y\u00fckl\u0259r v\u0259 u\u015faqlarda 12 saatl\u0131q, k\u00f6rp\u0259l\u0259rd\u0259 is\u0259 \u0259n az 4 saatl\u0131q acl\u0131qdan sonra al\u0131nmal\u0131d\u0131r. N\u00fc\u00admun\u0259d\u0259 hemoliz v\u0259 fibrin olma\u00admal\u0131d\u0131r. N\u00fcmun\u0259l\u0259r dondurularaq sax\u00adlan\u0131lmal\u0131 v\u0259 m\u00fctl\u0259q soyuq \u015f\u0259\u00adraitd\u0259 g\u00f6nd\u0259rilm\u0259lidir. Bird\u0259f\u0259lik sidik dondurularaq saxlan\u0131lmal\u0131 v\u0259 soyuq m\u00fchitd\u0259 g\u00f6nd\u0259rilm\u0259lidir. 6N HCl v\u0259 ya bor tur\u015fusu \u00fcz\u0259rin\u0259 y\u0131\u011f\u0131lan sidikl\u0259r d\u0259 q\u0259bul edilir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>HPLC<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>N\u00fc\u00admu\u00adn\u0259nin hemoliz\u0259 u\u011framas\u0131, fibrinli olmas\u0131 v\u0259 laboratoriyaya soyuq \u015f\u0259\u00adraitd\u0259 g\u00f6nd\u0259rilm\u0259m\u0259si<\/p>\n

Referens<\/strong>: N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Amintur\u015fu patolo\u00adgiya\u00adla\u00adr\u0131n\u0131n t\u0259yini v\u0259 m\u00fc\u015fahid\u0259sind\u0259 isti\u00adfad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ALAN\u0130N AM\u0130NOTRANSFERAZA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ALT, Serum glutamik piruvat transaminaza, SGPT<\/p>\n

N\u00fcmun\u0259 qab\u0131:\u00a0<\/strong>\u00a0q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250 \u03bcl<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0spektrofotometrik, kinetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0he\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
g\u00f6b\u0259k ciy\u0259sind\u0259n al\u0131nm\u0131\u015f qanda<\/td>\n10-90 u\/l<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n10-90 u\/l<\/td>\n<\/tr>\n
7 g\u00fcn-1 ya\u015f<\/td>\n10-80 u\/l<\/td>\n<\/tr>\n
1-60 ya\u015f<\/td>\n10-60 u\/l<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n10-70 u\/l<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qaraciy\u0259rin funksional test\u00adl\u0259rind\u0259n biridir. Qaraciy\u0259r x\u0259s\u00adt\u0259\u00adlikl\u0259ri, \u00f6d yollar\u0131 obstruksiyas\u0131, \u0259z\u0259l\u0259 z\u0259d\u0259l\u0259nm\u0259l\u0259ri, \u0259z\u0259l\u0259 distrofiyalar\u0131, k\u0259skin pankreatit, k\u0259skin \u00fcr\u0259k \u00e7a\u00adt\u0131\u015fmazl\u0131\u011f\u0131, b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 hepatatoksik preparatlar\u00a0 ALT-nin miq\u00ad\u00addar\u0131nda artmaya s\u0259b\u0259b olur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ALBUM\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 qab\u0131:\u00a0<\/strong>\u00a0q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>200 \u03bcl<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0spektrofotometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259sind\u0259n al\u0131nm\u0131\u015f qanda<\/td>\n3.6-4.4 g\/dL<\/td>\n<\/tr>\n
Erk\u0259n do\u011fulmu\u015f u\u015faqlarda<\/td>\n3.3-4.0 g\/dL<\/td>\n<\/tr>\n
<7g\u00fcn<\/td>\n2.8-4.4 g\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-15 ya\u015f<\/td>\n3.8-5.4 g\/dL<\/td>\n<\/tr>\n
16-60 ya\u015f<\/td>\n3.5-5.0 g\/dL<\/td>\n<\/tr>\n
>60ya\u015f<\/td>\n3.4-5.0 g\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qidalanma v\u0259ziyy\u0259ti v\u0259 qa\u00adn\u0131n onkotik t\u0259zyiqi haqq\u0131nda m\u0259\u00adlu\u00admat verir. Dehidratasiya v\u0259 ampi\u00adsillin istifad\u0259si albumin miqdar\u0131n\u0131n y\u00fcks\u0259klm\u0259sin\u0259 s\u0259b\u0259b oldu\u011fu halda, venadaxili qidaland\u0131rma, s\u00fcr\u0259tli hid\u00adratasiya, sirroz v\u0259 dig\u0259r qaraciy\u0259r x\u0259s\u00adt\u0259likl\u0259ri, alkoqolizm, hamil\u0259lik, nefrotik sindrom, malabsorbsiya, malnutriasiya, neoplaziyalar, z\u00fclal itkisi il\u0259 m\u00fc\u015faiy\u0259t olunan ba\u011f\u0131rsaq x\u0259st\u0259likl\u0259ri (Crohn x\u0259st\u0259liyi, xoral\u0131 kolit), hipertiroidizm, yan\u0131qlar, uzun\u00adm\u00fcd\u0259tli immobilizasiya, \u00fcr\u0259k \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131 v\u0259 dig\u0259r xronik x\u0259st\u0259likl\u0259rd\u0259 albumin miqdar\u0131 azal\u0131r. X\u0259st\u0259y\u0259 ve\u00adna\u00addaxili m\u00fcalic\u0259 verilmirs\u0259 v\u0259 ya qa\u00adraciy\u0259r v\u0259 b\u00f6yr\u0259k x\u0259st\u0259liyi yoxsa, serumda albumin s\u0259viyy\u0259sinin\u00a0 a\u015fa\u011f\u0131 olmas\u0131 orqanizmdak\u0131 protein rezerv\u00adl\u0259rinin azald\u0131\u011f\u0131n\u0131 g\u00f6st\u0259rir. Albumin, prealbumin v\u0259 transferrin il\u0259 birlikt\u0259 neqativ k\u0259skin faza reagenti\u00a0 olaraq q\u0259bul edilir. K\u0259skin iltihabi prosesl\u0259r zaman\u0131 da serumda albuminin miq\u00addar\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ALBUM\u0130N (BOM)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>BOM (numun\u0259d\u0259 qan olmamal\u0131d\u0131r)<\/p>\n

N\u00fcmun\u0259 qab\u0131:\u00a0<\/strong>Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Nefelometrik<\/p>\n

Referens:\u00a0<\/strong>15-40 mg\/dL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Bakterial meningit, Guil\u00adlain-Barre sindromu v\u0259 travmalardan sonra BOM albumin s\u0259viyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ALBUM\u0130N (Maye)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Orqanizm mayel\u0259ri (plevral maye v\u0259 b.)<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Nefelometrik<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Orqanizm mayel\u0259rind\u0259ki albumin onkotik t\u0259zyiqin \u0259sas ele\u00admentidir. Portal hipertenziyaya s\u0259b\u0259b olan hallarda (sirroz, sa\u011f m\u0259d\u0259cik \u00e7a\u00adt\u0131\u015fmazl\u0131\u011f\u0131, konjestiv perikardit v\u0259 b.) serum\u00a0 il\u0259 orqanizm\u00a0 mayel\u0259ri ara\u00ads\u0131ndak\u0131\u00a0 albumin f\u0259rqi <1.1 g\/dL olur. Portal hipertenziyan\u0131n olma\u00add\u0131\u00ad\u011f\u0131, v\u0259r\u0259m, malignizasiyalar, SLE, mik\u00ads\u00f6dema, b\u0259zi yumurtal\u0131q x\u0259st\u0259\u00adlikl\u0259ri v\u0259 ciddi hipoalbuminemiyada bu f\u0259rq < 1.1 g\/dL-dir. Qaraciy\u0259r x\u0259st\u0259l\u0259rinin 15-20%-d\u0259 is\u0259 bu f\u0259rq >2.5 g\/dL olur v\u0259 bunlara y\u00fcks\u0259k proteinli assit adlan\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ALDOLAZA<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, fer\u00admentativ<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
< 5ya\u015f<\/td>\n1.5-18.8 U\/L<\/td>\n<\/tr>\n
6-15 ya\u015f<\/td>\n2.3-13.5 U\/L<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n3.1-7.6\u00a0 U\/L (Ki\u015fi), 2.7-5. 3\u00a0 U\/L (Qad\u0131n)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>K\u0259skin hepatitl\u0259r v\u0259 dig\u0259r qaraciy\u0259r x\u0259st\u0259likl\u0259ri, Duchenne \u0259z\u0259\u00adl\u0259 distrofiyas\u0131, \u0259z\u0259l\u0259 travmas\u0131, der\u00adma\u00adtomiozit, polimiozit, miotonik dis\u00adtro\u00adfi\u00adya, rabdomioliz, AMI, hemorragik pan\u00ad\u00adkreatit, trixinelloz, qanqrenalar, pros\u00ad\u00adtat \u015fi\u015fl\u0259ri, qranulositoz v\u0259 me\u00adqa\u00adloblastik anemiyalar, delirium tremens (alkoqol say\u0131qlamas\u0131), k\u0259skin psixoz v\u0259 \u015fizofreniyalar (60-80 %-ind\u0259), teta\u00adnus, infeksion mononukleoz\u00a0 v\u0259 m\u00fcx\u00adt\u0259lif malignizasiyalarda aldolaza s\u0259\u00adviy\u00ady\u0259si y\u00fcks\u0259lir. X\u00fcsusil\u0259 \u0259z\u0259l\u0259 disro\u00adfiyalar\u0131n\u0131n diaqnozu v\u0259 m\u00fc\u015fahid\u0259sind\u0259 yerini CK il\u0259 m\u00fcqayis\u0259d\u0259 daha infor\u00admativdir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AL\u00dcM\u0130N\u0130UM<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Al<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum, 24 saatl\u0131q sidik, bird\u0259f\u0259lik sidik, BOM, dializ mayesi<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum) (\u018fvv\u0259lc\u0259d\u0259n is\u00adtifad\u0259 edilm\u0259mi\u015f v\u0259 ya nitrat tur\u015fusu il\u0259 yuyulmu\u015f, distill\u0259 olunmu\u015f v\u0259 ya ionsuzla\u015fd\u0131r\u0131lm\u0131\u015f su il\u0259 yaxalanm\u0131\u015f s\u0131naq \u015f\u00fc\u015f\u0259sind\u0259 g\u00f6nd\u0259rilm\u0259lidir),\u00a0 24 saatl\u0131q sidik (Soyuq \u015f\u0259raitd\u0259 saxla\u00adn\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir. Bor tur\u015f\u00adusu v\u0259 ya asetat tur\u015fusu \u00fcz\u0259rin\u0259 y\u0131\u011f\u0131\u00adlan sidikl\u0259r d\u0259 q\u0259bul edilir. Bax \u018fla\u00adv\u0259 P), gelsiz steril s\u0131naq \u015f\u00fc\u015f\u0259si (BOM, maye)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Al\u00fc\u00admi\u00adniumun xarici m\u00fchitd\u0259n konta\u00adminasiya riski \u00e7ox y\u00fcks\u0259k oldu\u00ad\u011fun\u00addan n\u00fcmun\u0259 al\u0131nark\u0259n kontami\u00adna\u00adsiyaya x\u00fcsusil\u0259 diqq\u0259t yetirilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>analiz \u00fc\u00e7\u00fcn qan n\u00fcmun\u0259si verm\u0259zd\u0259n \u0259vv\u0259lki son 24 saat \u0259rzind\u0259 t\u0259rkibind\u0259 al\u00fc\u00admi\u00adnium olan antiasit preparatlar v\u0259 di\u00adg\u0259r d\u0259rmanlar istifad\u0259 olunma\u00admal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>AAS-Zeeman<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
Serum<\/td>\n1-14 \u03bcg\/L<\/td>\n<\/tr>\n
Sidik<\/td>\n7-40 \u03bcg\/L<\/td>\n<\/tr>\n
Dializ mayesi<\/td>\n<10 \u03bcg\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hemodializ x\u0259st\u0259l\u0259rinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur. B\u00f6y\u00adr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, dializl\u0259 \u0259laq\u0259li de\u00admen\u00adsiya, Hodgkin x\u0259st\u0259liyi v\u0259 mu\u00adkovissidozlar (kistik fibrozis) zaman\u0131 al\u00fcminyum s\u0259viyy\u0259si art\u0131r. 100\u03bcg\/L\u2013d\u0259n y\u00fcks\u0259k n\u0259tic\u0259l\u0259r tok\u00adsi\u00adki t\u0259sir g\u00f6st\u0259rir. Al(OH)3<\/sub>, m\u0259d\u0259 an\u00adtia\u00adsitl\u0259ri v\u0259 ya dializ x\u0259st\u0259l\u0259rind\u0259 fos\u00adfat birl\u0259\u015fdirici vasit\u0259 kimi istifad\u0259 olundu\u011fundan bu x\u0259st\u0259l\u0259rd\u0259 al\u00fcmi\u00adnium toksikozuna diqq\u0259t edilm\u0259lidir. H\u0259m\u00e7inin serumda Al s\u0259viyy\u0259si 100 \u03bcg\/L \u2013d\u0259n y\u00fcks\u0259k olan x\u0259st\u0259l\u0259rd\u0259 Al m\u0259n\u015f\u0259li osteomaliyasiyaya diqq\u0259t edilm\u0259lidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ALT (ALAN\u0130N AM\u0130NOTRANSFERAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ALT, Serum glutamik piruvat transaminaza, SGPT<\/p>\n

N\u00fcmun\u0259 qab\u0131:\u00a0<\/strong>\u00a0q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250 \u03bcl<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0spektrofotometrik, kinetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0he\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
g\u00f6b\u0259k ciy\u0259sind\u0259n al\u0131nm\u0131\u015f qanda<\/td>\n10-90 u\/l<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n10-90 u\/l<\/td>\n<\/tr>\n
7 g\u00fcn-1 ya\u015f<\/td>\n10-80 u\/l<\/td>\n<\/tr>\n
1-60 ya\u015f<\/td>\n10-60 u\/l<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n10-70 u\/l<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qaraciy\u0259rin funksional test\u00adl\u0259rind\u0259n biridir. Qaraciy\u0259r x\u0259s\u00adt\u0259\u00adlikl\u0259ri, \u00f6d yollar\u0131 obstruksiyas\u0131, \u0259z\u0259l\u0259 z\u0259d\u0259l\u0259nm\u0259l\u0259ri, \u0259z\u0259l\u0259 distrofiyalar\u0131, k\u0259skin pankreatit, k\u0259skin \u00fcr\u0259k \u00e7a\u00adt\u0131\u015fmazl\u0131\u011f\u0131, b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 hepatatoksik preparatlar\u00a0 ALT-nin miq\u00ad\u00addar\u0131nda artmaya s\u0259b\u0259b olur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ALP \u0130ZOENZ\u0130ML\u018fR\u0130 (ALKALEN FOSFATAZA \u0130ZOENZ\u0130M ELEKTROFOREZ\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ALP izoenziml\u0259ri<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Agaroza gel elektro\u00adforezi<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Q\u0259l\u0259vi fosfataza y\u00fcks\u0259k\u00adliyinin m\u0259nb\u0259yinin m\u00fc\u0259yy\u0259n edil\u00adm\u0259\u00adsi m\u0259qs\u0259dil\u0259 istifad\u0259 olunur. ALP qa\u00adra\u00adciy\u0259r, s\u00fcm\u00fck v\u0259 \u0259g\u0259r vard\u0131rsa, in\u00adtes\u00adtinal v\u0259 plasental fraksiyalara ayr\u0131\u00adl\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ALP (ALKALEN FOSFATAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ALP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik, fer\u00admen\u00adtativ, kinetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Hemoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
<7 gun<\/td>\n95-600 U\/L<\/td>\n<\/tr>\n
7 g\u00fcn-1ay<\/td>\n100-1076 U\/L<\/td>\n<\/tr>\n
2-3 ay<\/td>\n115-1076 U\/L<\/td>\n<\/tr>\n
4-6 ay<\/td>\n110-1076 U\/L<\/td>\n<\/tr>\n
7 ay-1 ya\u015f<\/td>\n95-1107 U\/L<\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n90-673 U\/L<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n80-644 U\/L<\/td>\n<\/tr>\n
6 -11 ya\u015f<\/td>\n80-720 U\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
12-15 ya\u015f<\/td>\n75-936 U\/L<\/td>\n75-448 U\/L<\/td>\n<\/tr>\n
16-20 ya\u015f<\/td>\n25-360 U\/L<\/td>\n25-320 U\/L<\/td>\n<\/tr>\n
>20 ya\u015f<\/td>\n25-270 U\/L<\/td>\n25-240 U\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qraciy\u0259r, \u00f6d kis\u0259si v\u0259 s\u00fc\u00adm\u00fck toxumas\u0131na aid x\u0259st\u0259likl\u0259rin qiy\u00adm\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Biliar obstruksiya, biliar atre\u00adziya, sirroz, s\u00fcm\u00fck deformasiyalar\u0131, hiperparatiroidizm, Paget x\u0259st\u0259liyi, in\u00adfiltirativ qaraciy\u0259r x\u0259st\u0259likl\u0259ri, in\u00adfek\u00adsion mononukleoz, metastatik s\u00fc\u00adm\u00fck \u015fi\u015fl\u0259ri, metabolik s\u00fcm\u00fck x\u0259s\u00adt\u0259lil\u0259ri, virus hepatitl\u0259ri, hamil\u0259lik, konjestiv \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 u\u015faq\u00adlar\u0131n b\u00f6y\u00fcm\u0259 d\u00f6vr\u00fcnd\u0259 ALP s\u0259\u00adviy\u00ady\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ALKALEN FOSFATAZA (Q\u0259l\u0259vi fosfataza) \u0130ZOENZ\u0130M ELEKTROFOREZ\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ALP izoenziml\u0259ri<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Agaroza gel elektro\u00adforezi<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Q\u0259l\u0259vi fosfataza y\u00fcks\u0259k\u00adliyinin m\u0259nb\u0259yinin m\u00fc\u0259yy\u0259n edil\u00adm\u0259\u00adsi m\u0259qs\u0259dil\u0259 istifad\u0259 olunur. ALP qa\u00adra\u00adciy\u0259r, s\u00fcm\u00fck v\u0259 \u0259g\u0259r vard\u0131rsa, in\u00adtes\u00adtinal v\u0259 plasental fraksiyalara ayr\u0131\u00adl\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ALKALEN FOSFATAZA (Q\u0259l\u0259vi fosfataza)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ALP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik, fer\u00admen\u00adtativ, kinetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Hemoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
<7 gun<\/td>\n95-600 U\/L<\/td>\n<\/tr>\n
7 g\u00fcn-1ay<\/td>\n100-1076 U\/L<\/td>\n<\/tr>\n
2-3 ay<\/td>\n115-1076 U\/L<\/td>\n<\/tr>\n
4-6 ay<\/td>\n110-1076 U\/L<\/td>\n<\/tr>\n
7 ay-1 ya\u015f<\/td>\n95-1107 U\/L<\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n90-673 U\/L<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n80-644 U\/L<\/td>\n<\/tr>\n
6 -11 ya\u015f<\/td>\n80-720 U\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
12-15 ya\u015f<\/td>\n75-936 U\/L<\/td>\n75-448 U\/L<\/td>\n<\/tr>\n
16-20 ya\u015f<\/td>\n25-360 U\/L<\/td>\n25-320 U\/L<\/td>\n<\/tr>\n
>20 ya\u015f<\/td>\n25-270 U\/L<\/td>\n25-240 U\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qraciy\u0259r, \u00f6d kis\u0259si v\u0259 s\u00fc\u00adm\u00fck toxumas\u0131na aid x\u0259st\u0259likl\u0259rin qiy\u00adm\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Biliar obstruksiya, biliar atre\u00adziya, sirroz, s\u00fcm\u00fck deformasiyalar\u0131, hiperparatiroidizm, Paget x\u0259st\u0259liyi, in\u00adfiltirativ qaraciy\u0259r x\u0259st\u0259likl\u0259ri, in\u00adfek\u00adsion mononukleoz, metastatik s\u00fc\u00adm\u00fck \u015fi\u015fl\u0259ri, metabolik s\u00fcm\u00fck x\u0259s\u00adt\u0259lil\u0259ri, virus hepatitl\u0259ri, hamil\u0259lik, konjestiv \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 u\u015faq\u00adlar\u0131n b\u00f6y\u00fcm\u0259 d\u00f6vr\u00fcnd\u0259 ALP s\u0259\u00adviy\u00ady\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ALFA-1 ANT\u0130TR\u0130PS\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>A1<\/sub>AT; AAT; \u221e1-<\/sub>Anti\u00adtrip\u00adsin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Nefelometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
< 7 g\u00fcn<\/td>\n100-270 mg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-5 ya\u015f<\/td>\n80-20 mg\/dL<\/td>\n<\/tr>\n
> 5 ya\u015f<\/td>\n80-200 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Pozitiv k\u0259skin faza rea\u00adgentl\u0259rind\u0259ndir. Protein elektro\u00adfo\u00adrezind\u0259 \u221e1<\/sub>\u00a0lentinin b\u00f6y\u00fck hiss\u0259sini t\u0259\u015fkil edir. H\u0259m\u00e7inin serumda \u0259n y\u00fck\u00ads\u0259k konsentrasiyada olan proteza inhibitorudur. H\u0259r c\u00fcr infeksiya, to\u00adxuma nekrozu, travmalar, oral kon\u00adtra\u00adseptivl\u0259rin istifad\u0259si v\u0259 hamil\u0259lik zaman\u0131 AAT s\u0259viyy\u0259si y\u00fcks\u0259lir. AAT-nin\u00a0 s\u0259viyy\u0259sinin h\u0259dd\u0259n art\u0131q d\u00fc\u015f\u00adm\u0259si zaman\u0131 xroniki a\u011fciy\u0259r v\u0259 qaraciy\u0259r x\u0259st\u0259likl\u0259ri inki\u015faf ed\u0259 bil\u0259r. A\u011f\u0131r d\u0259r\u0259c\u0259li irsi AAT \u00e7at\u0131\u015f\u00admazl\u0131qlar\u0131 zaman\u0131 x\u00fcsusil\u0259 u\u015faqlarda neonatal hepatit sindromu v\u0259 infantil sirroz kimi a\u011f\u0131r klinik m\u0259nz\u0259r\u0259l\u0259r inki\u015faf ed\u0259 bil\u0259r. B\u00f6y\u00fckl\u0259rd\u0259 is\u0259 em\u00adfizema v\u0259 xroniki bronxit kimi\u00a0 xro\u00adniki a\u011fciy\u0259r x\u0259st\u0259likl\u0259rinin inki\u015faf\u0131na \u015f\u0259rait yarada bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ALFA-1 ANT\u0130TR\u0130PS\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>A1<\/sub>AT; AAT; \u221e1-<\/sub>Anti\u00adtrip\u00adsin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Nefelometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
< 7 g\u00fcn<\/td>\n100-270 mg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-5 ya\u015f<\/td>\n80-20 mg\/dL<\/td>\n<\/tr>\n
> 5 ya\u015f<\/td>\n80-200 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Pozitiv k\u0259skin faza rea\u00adgentl\u0259rind\u0259ndir. Protein elektro\u00adfo\u00adrezind\u0259 \u221e1<\/sub>\u00a0lentinin b\u00f6y\u00fck hiss\u0259sini t\u0259\u015fkil edir. H\u0259m\u00e7inin serumda \u0259n y\u00fck\u00ads\u0259k konsentrasiyada olan proteza inhibitorudur. H\u0259r c\u00fcr infeksiya, to\u00adxuma nekrozu, travmalar, oral kon\u00adtra\u00adseptivl\u0259rin istifad\u0259si v\u0259 hamil\u0259lik zaman\u0131 AAT s\u0259viyy\u0259si y\u00fcks\u0259lir. AAT-nin\u00a0 s\u0259viyy\u0259sinin h\u0259dd\u0259n art\u0131q d\u00fc\u015f\u00adm\u0259si zaman\u0131 xroniki a\u011fciy\u0259r v\u0259 qaraciy\u0259r x\u0259st\u0259likl\u0259ri inki\u015faf ed\u0259 bil\u0259r. A\u011f\u0131r d\u0259r\u0259c\u0259li irsi AAT \u00e7at\u0131\u015f\u00admazl\u0131qlar\u0131 zaman\u0131 x\u00fcsusil\u0259 u\u015faqlarda neonatal hepatit sindromu v\u0259 infantil sirroz kimi a\u011f\u0131r klinik m\u0259nz\u0259r\u0259l\u0259r inki\u015faf ed\u0259 bil\u0259r. B\u00f6y\u00fckl\u0259rd\u0259 is\u0259 em\u00adfizema v\u0259 xroniki bronxit kimi\u00a0 xro\u00adniki a\u011fciy\u0259r x\u0259st\u0259likl\u0259rinin inki\u015faf\u0131na \u015f\u0259rait yarada bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AM\u0130LAZA<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik, fer\u00admen\u00adtativ, kinetik<\/p>\n

Referens<\/strong>:\u00a0 10-100 IU\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>M\u0259d\u0259alt\u0131 v\u0259zin funksional testl\u0259rind\u0259n biridir. Pankreatit, pan\u00adkreatik kista v\u0259 psevdokistalar, qu\u00adlaq\u00adalt\u0131 v\u0259zin infeksiyalar\u0131, intestinal obstruksiya v\u0259 infaktlar, ektopik ha\u00admil\u0259lik, \u00f6d yollar\u0131 x\u0259st\u0259likl\u0259ri, dia\u00adbe\u00adtik ketoasidoz, peritonit, makroami\u00adlazemiya, b\u0259zi a\u011fciy\u0259r v\u0259 yumurtal\u0131q \u015fi\u015fl\u0259rind\u0259, b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, ERCP, abdominal travmalar, ba\u015f-beyin travmalar\u0131, virus infeksiyalar\u0131 v\u0259 alkaqol istifad\u0259si serumda ami\u00adlazan\u0131n s\u0259viyy\u0259sini art\u0131rd\u0131\u011f\u0131 halda, pankreas \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, mukovissidoz (kistik fibrozis), a\u011f\u0131r qaraciy\u0259r x\u0259s\u00adt\u0259likl\u0259ri v\u0259 pankreatektomiyadan son\u00adra amilaza s\u0259viyy\u0259si azal\u0131r. H\u0259m\u00ad\u00e7inin Oddi sfinktorunda spazm t\u00f6\u00adr\u0259d\u0259n narkotik analgetikl\u0259r v\u0259 dig\u0259r b\u0259zi d\u0259rmanlar da serumda amila\u00adzan\u0131n s\u0259viyy\u0259sinin artmas\u0131na s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AM\u0130LAZA (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Bird\u0259f\u0259lik sidik, m\u00fc\u00ad\u00ad\u0259y\u00ad\u00ady\u0259n zaman m\u00fcdd\u0259tind\u0259 topla\u00adnan sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxla\u00adn\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131: S<\/strong>idik toplanm\u0131\u015fd\u0131rsa, toplanma m\u00fcdd\u0259ti (m\u0259s. 24 saat) v\u0259 h\u0259cmi qeyd olun\u00admal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik, fer\u00admentativ, kinetik<\/p>\n

Referens<\/strong>:<\/p>\n\n\n\n\n\n
<6 ay<\/td>\n25-400 IU\/L<\/td>\n<\/tr>\n
7 ay-15 ya\u015f<\/td>\n25-500 IU\/L<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n75-750 IU\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>K\u0259skin v\u0259 ya xroniki pankreatitli x\u0259st\u0259l\u0259rin m\u00fc\u015fahid\u0259sind\u0259 v\u0259 pankreatitin diferensial diaqnos\u00adtikas\u0131nda istifad\u0259 olunur. Serum amilazas\u0131nda artmaya s\u0259b\u0259b olan x\u0259st\u0259likl\u0259rd\u0259n f\u0259rqli olaraq b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 makroamilazemiyada sidikd\u0259 amilaza s\u0259viyy\u0259si normal v\u0259 ya a\u015fa\u011f\u0131d\u0131r. H\u0259m\u00e7inin k\u0259skin pan\u00adkreatit tutmas\u0131ndan sonra sidikd\u0259 ami\u00adlaza s\u0259viyy\u0259sinin iki h\u0259ft\u0259d\u0259n \u00e7ox yks\u0259k qalmas\u0131 psevdokistan\u0131n varl\u0131\u011f\u0131na \u0259sas verir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

APO A (APOL\u0130POPROTE\u0130N A)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Apo A; Apo A-1<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0T\u00fcrbidimetrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n40-105 mg\/dL<\/td>\n40-105 mg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-3 ya\u015f<\/td>\n60-150 mg\/dL<\/td>\n60-150 mg\/dL<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n65-150 mg\/dL<\/td>\n60-150 mg\/dL<\/td>\n<\/tr>\n
6-15 ya\u015f<\/td>\n80-150 mg\/dL<\/td>\n80-150 mg\/dL<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n80-160 mg\/dL<\/td>\n80-200 mg\/dL<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n80-170 mg\/dL<\/td>\n80-205 mg\/dL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n80-170 mg\/dL<\/td>\n120-220 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>HDL, xilomikronlar v\u0259 VLDL-nin ba\u015fl\u0131ca z\u00fclal kompo\u00adnen\u00adtidir. Koronar \u00fcr\u0259k x\u0259st\u0259liyi riskinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Abetalipoproteinemiya, irsi hi\u00adpo\u00adalfalipopro\u00adteinemiyalar, lipo\u00adpro\u00adtein lipaza kofaktor (Apo C-II) \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131, fish-eye disease, hiper\u00adtriq\u00adli\u00adseridemiya, kontrolsuz diabet, hepa\u00adto\u00adsellular x\u0259st\u0259likl\u0259r, xolestaz, nef\u00adro\u00adtik sindrom, xro\u00adniki b\u00f6yr\u0259k \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131 v\u0259 siqaret \u00e7\u0259km\u0259k serumda Apo A-1 s\u0259viyy\u0259sind\u0259 azalmaya s\u0259\u00adb\u0259b olur. Apo A-1-in azl\u0131\u011f\u0131 erk\u0259n ko\u00adronar \u00fcr\u0259k x\u0259st\u0259liyi ba\u00adx\u0131m\u0131ndan risklidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130TR\u0130PS\u0130N (ALFA-1 ANT\u0130TR\u0130PS\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>A1<\/sub>AT; AAT; \u221e1-<\/sub>Anti\u00adtrip\u00adsin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Nefelometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
< 7 g\u00fcn<\/td>\n100-270 mg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-5 ya\u015f<\/td>\n80-20 mg\/dL<\/td>\n<\/tr>\n
> 5 ya\u015f<\/td>\n80-200 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Pozitiv k\u0259skin faza rea\u00adgentl\u0259rind\u0259ndir. Protein elektro\u00adfo\u00adrezind\u0259 \u221e1<\/sub>\u00a0lentinin b\u00f6y\u00fck hiss\u0259sini t\u0259\u015fkil edir. H\u0259m\u00e7inin serumda \u0259n y\u00fck\u00ads\u0259k konsentrasiyada olan proteza inhibitorudur. H\u0259r c\u00fcr infeksiya, to\u00adxuma nekrozu, travmalar, oral kon\u00adtra\u00adseptivl\u0259rin istifad\u0259si v\u0259 hamil\u0259lik zaman\u0131 AAT s\u0259viyy\u0259si y\u00fcks\u0259lir. AAT-nin\u00a0 s\u0259viyy\u0259sinin h\u0259dd\u0259n art\u0131q d\u00fc\u015f\u00adm\u0259si zaman\u0131 xroniki a\u011fciy\u0259r v\u0259 qaraciy\u0259r x\u0259st\u0259likl\u0259ri inki\u015faf ed\u0259 bil\u0259r. A\u011f\u0131r d\u0259r\u0259c\u0259li irsi AAT \u00e7at\u0131\u015f\u00admazl\u0131qlar\u0131 zaman\u0131 x\u00fcsusil\u0259 u\u015faqlarda neonatal hepatit sindromu v\u0259 infantil sirroz kimi a\u011f\u0131r klinik m\u0259nz\u0259r\u0259l\u0259r inki\u015faf ed\u0259 bil\u0259r. B\u00f6y\u00fckl\u0259rd\u0259 is\u0259 em\u00adfizema v\u0259 xroniki bronxit kimi\u00a0 xro\u00adniki a\u011fciy\u0259r x\u0259st\u0259likl\u0259rinin inki\u015faf\u0131na \u015f\u0259rait yarada bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AN\u0130ON GAP<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ISE + Autoanalizator<\/p>\n

Referens:\u00a0<\/strong>\u00a07-16 mol\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Serumdak\u0131 kationlar v\u0259 anionlar aras\u0131ndak\u0131 f\u0259rqi g\u00f6st\u0259rir. Metabolik asidozda anion GAP art\u0131r, hipokalemiya, hipokalsemiya, hipo\u00admaqnezemiya, rabdomioliz, hiper\u00adqammaqlobulinemiya, hipoalbuminemiya v\u0259 mielomada is\u0259 bu g\u00f6st\u0259rici azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AMN\u0130ON MAYES\u0130 FOSFOL\u0130P\u0130DL\u018fR\u0130 (LESITIN \/ SPINGOMYELIN N\u0130SB\u018fT\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0L\/S nisb\u0259ti; Amnion mayesi fosfolipidl\u0259ri<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Amnion mayesi<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Nazik t\u0259b\u0259q\u0259li xroma\u00adtoqrafiya<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Sar\u0131l\u0131ql\u0131 (ikterik) v\u0259 ya hemorragik n\u00fcmun\u0259l\u0259r, n\u00fcmun\u0259nin anan\u0131n sidiyi v\u0259 ya mekonium il\u0259 kontamin\u0259 olmas\u0131<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n
<1.5<\/td>\nYeti\u015fm\u0259mi\u015f (immature)<\/td>\n<\/tr>\n
1.5-1.9<\/td>\nKe\u00e7id (transizyonal<\/td>\n<\/tr>\n
>2.0<\/td>\nYeti\u015fmi\u015f (mature)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u00f6l\u00fcn a\u011fciy\u0259rinin inki\u015fa\u00adf\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 isti\u00adfad\u0259 olunur. L\/S nisb\u0259ti hamil\u0259liyin 34-c\u00fc h\u0259ft\u0259sind\u0259n sonra artma\u011fa ba\u015flad\u0131\u00ad\u011f\u0131ndan, x\u0259st\u0259nin hamil\u0259lik ya\u015f\u0131 n\u0259z\u0259r\u0259 al\u0131naraq n\u0259tic\u0259 qiy\u00adm\u0259tl\u0259n\u00addirilm\u0259lidir. L\/S m\u00fcayin\u0259sind\u0259ki ye\u00adti\u015f\u00admi\u015f (mature) n\u0259tic\u0259l\u0259rin prediktiv d\u0259y\u0259ri 95-100 %, yeti\u015fm\u0259mi\u015f (immature) n\u0259tic\u0259l\u0259rin d\u0259y\u0259ri is\u0259 33-50 % aras\u0131nda olur. Kontrol edilm\u0259\u00ady\u0259n diabetli hamil\u0259likl\u0259d\u0259 L\/S nisb\u0259\u00adtinin d\u0259yi\u015f\u0259 bilm\u0259 ehtimal\u0131 n\u0259z\u0259r\u0259 al\u0131nmal\u0131d\u0131r. Plazmada lesitin v\u0259 spin\u00adqomielin oldu\u011fundan, aminion ma\u00adyesin\u0259 qan qar\u0131\u015fmas\u0131 L\/S m\u00fcayi\u00adn\u0259sinin n\u0259tic\u0259sin\u0259 t\u0259sir ed\u0259 bil\u0259r. H\u0259m\u00e7inin\u00a0 mekoniumda lesitin v\u0259 spinqomiyelin olmasa da, amniyon mayesind\u0259 mekoniumun olmas\u0131 n\u0259tic\u0259nin h\u0259ssasl\u0131\u011f\u0131n\u0131 azalda bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AMMONYAK<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>NH3<\/sub>; NH4<\/sub>; Ammonium<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0EDTA-l\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>S\u0131naq \u015f\u00fc\u015f\u0259sinin \u00fcz\u0259rind\u0259ki x\u0259tt\u0259 q\u0259d\u0259r qan al\u0131nmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259, gecik\u00adm\u0259\u00add\u0259n laboratoriyaya \u00e7atd\u0131r\u0131l\u00admal\u0131d\u0131r. Gecikdirilmi\u015f n\u00fcmun\u0259l\u0259rd\u0259 ammon\u00adyak s\u0259viyy\u0259sinin arta bilm\u0259 ehtimal\u0131 n\u0259z\u0259r\u0259 al\u0131nmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik, fer\u00admentativ<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>S\u0131\u00adnaq \u015f\u00fc\u015f\u0259sind\u0259ki i\u015far\u0259li yer\u0259 q\u0259d\u0259r qan al\u0131nmamas\u0131, n\u00fcmun\u0259nin soyuq \u015f\u0259raitd\u0259 laboratoriyaya \u00e7atd\u0131r\u0131l\u00adma\u00admas\u0131, hemolizli v\u0259 ya uzun m\u00fcdd\u0259t g\u00f6zl\u0259mi\u015f olmas\u0131, lipemiya<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259sind\u0259n al\u0131nm\u0131\u015f qanda<\/td>\n0.90-1.50<\/td>\n<\/tr>\n
Erk\u0259n do\u011fulmu\u015f u\u015faqlarda<\/td>\n0.90-3.00<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n0.90-3.00<\/td>\n<\/tr>\n
7 g\u00fcn-1 ay<\/td>\n0.30-2.00<\/td>\n<\/tr>\n
2-3 ay<\/td>\n0.30-1.50<\/td>\n<\/tr>\n
4-12ay<\/td>\n0.30-1.40<\/td>\n<\/tr>\n
>1 ya\u015f<\/td>\n0.24-1.02\u00a0(Ki\u015fi)<\/td>\n<\/tr>\n
>1 ya\u015f<\/td>\n0.19-0.87 (Qad\u0131n)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qaraciy\u0259r ensefalopa\u00adti\u00adya\u00ads\u0131n\u0131n diaqnozu v\u0259 hiperalimen\u00adtasiya m\u00fcalic\u0259si alan x\u0259st\u0259l\u0259rin m\u00fc\u015fa\u00adhi\u00add\u0259\u00adsind\u0259 istifad\u0259 olunur. Qaraciy\u0259r \u00e7a\u00adt\u0131\u015f\u00ad\u00admazl\u0131\u011f\u0131, Reye sindromu, sirroz, m\u0259d\u0259-ba\u011f\u0131rsaq qanaxmalar\u0131, portal-sistemik \u015funtlar v\u0259 b\u0259zi b\u00f6yr\u0259k x\u0259s\u00adt\u0259likl\u0259rind\u0259 d\u0259 ammonyak s\u0259viyy\u0259si arta bil\u0259r. Sidik c\u00f6vh\u0259ri m\u00fcbadi\u00adl\u0259\u00adsi\u00adnin pozulmas\u0131 il\u0259 m\u00fc\u015faiy\u0259t olunan x\u0259st\u0259likl\u0259rd\u0259n I tip hiperammo\u00adniemi\u00adya, argininemiya v\u0259 ornitinemiyada acl\u0131q amonyak s\u0259viyy\u0259si artd\u0131\u011f\u0131 hal\u00adda, II tip hiperammoniemiya, sitruli\u00adnuriya, argininosuksinl-asiduriya v\u0259 lizin intolerans\u0131 zaman\u0131 is\u0259 p\u0259hrizl\u0259 z\u00fclal q\u0259bulunun ard\u0131ndan ammonyak s\u0259viyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AMMON\u0130UM (AMMONYAK)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>NH3<\/sub>; NH4<\/sub>; Ammonium<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0EDTA-l\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>S\u0131naq \u015f\u00fc\u015f\u0259sinin \u00fcz\u0259rind\u0259ki x\u0259tt\u0259 q\u0259d\u0259r qan al\u0131nmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259, gecik\u00adm\u0259\u00add\u0259n laboratoriyaya \u00e7atd\u0131r\u0131l\u00admal\u0131d\u0131r. Gecikdirilmi\u015f n\u00fcmun\u0259l\u0259rd\u0259 ammon\u00adyak s\u0259viyy\u0259sinin arta bilm\u0259 ehtimal\u0131 n\u0259z\u0259r\u0259 al\u0131nmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik, fer\u00admentativ<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>S\u0131\u00adnaq \u015f\u00fc\u015f\u0259sind\u0259ki i\u015far\u0259li yer\u0259 q\u0259d\u0259r qan al\u0131nmamas\u0131, n\u00fcmun\u0259nin soyuq \u015f\u0259raitd\u0259 laboratoriyaya \u00e7atd\u0131r\u0131l\u00adma\u00admas\u0131, hemolizli v\u0259 ya uzun m\u00fcdd\u0259t g\u00f6zl\u0259mi\u015f olmas\u0131, lipemiya<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259sind\u0259n al\u0131nm\u0131\u015f qanda<\/td>\n0.90-1.50<\/td>\n<\/tr>\n
Erk\u0259n do\u011fulmu\u015f u\u015faqlarda<\/td>\n0.90-3.00<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n0.90-3.00<\/td>\n<\/tr>\n
7 g\u00fcn-1 ay<\/td>\n0.30-2.00<\/td>\n<\/tr>\n
2-3 ay<\/td>\n0.30-1.50<\/td>\n<\/tr>\n
4-12ay<\/td>\n0.30-1.40<\/td>\n<\/tr>\n
>1 ya\u015f<\/td>\n0.24-1.02\u00a0(Ki\u015fi)<\/td>\n<\/tr>\n
>1 ya\u015f<\/td>\n0.19-0.87 (Qad\u0131n)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qaraciy\u0259r ensefalopa\u00adti\u00adya\u00ads\u0131n\u0131n diaqnozu v\u0259 hiperalimen\u00adtasiya m\u00fcalic\u0259si alan x\u0259st\u0259l\u0259rin m\u00fc\u015fa\u00adhi\u00add\u0259\u00adsind\u0259 istifad\u0259 olunur. Qaraciy\u0259r \u00e7a\u00adt\u0131\u015f\u00ad\u00admazl\u0131\u011f\u0131, Reye sindromu, sirroz, m\u0259d\u0259-ba\u011f\u0131rsaq qanaxmalar\u0131, portal-sistemik \u015funtlar v\u0259 b\u0259zi b\u00f6yr\u0259k x\u0259s\u00adt\u0259likl\u0259rind\u0259 d\u0259 ammonyak s\u0259viyy\u0259si arta bil\u0259r. Sidik c\u00f6vh\u0259ri m\u00fcbadi\u00adl\u0259\u00adsi\u00adnin pozulmas\u0131 il\u0259 m\u00fc\u015faiy\u0259t olunan x\u0259st\u0259likl\u0259rd\u0259n I tip hiperammo\u00adniemi\u00adya, argininemiya v\u0259 ornitinemiyada acl\u0131q amonyak s\u0259viyy\u0259si artd\u0131\u011f\u0131 hal\u00adda, II tip hiperammoniemiya, sitruli\u00adnuriya, argininosuksinl-asiduriya v\u0259 lizin intolerans\u0131 zaman\u0131 is\u0259 p\u0259hrizl\u0259 z\u00fclal q\u0259bulunun ard\u0131ndan ammonyak s\u0259viyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AM\u0130NOLEVUL\u0130N TUR\u015eUSU<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Delta-ALA; DALA; ALA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a024 saatl\u0131q sidik, bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Asetat tur\u015fusu \u00fcz\u0259\u00adrin\u0259 y\u0131\u011f\u0131laraq g\u00f6nd\u0259rilm\u0259lidir. 6N HCl \u00fcz\u0259rin\u0259 y\u0131\u011f\u0131lan sidikl\u0259r d\u0259 q\u0259bul edilir. Qaranl\u0131q yerd\u0259 y\u0131\u011f\u0131lmal\u0131 v\u0259 i\u015f\u0131qdan qorunaraq g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a010 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 sa\u00adatl\u0131q sidiyin miqdar\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Xromatoqrafik, spektro\u00adfotometrik<\/p>\n

Referens:\u00a0<\/strong><<\/strong>7 mg\/g\u00fcn<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>K\u0259skin porfiriyan\u0131n diaq\u00adnozu v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahid\u0259si \u00fc\u00e7\u00fcn istifad\u0259 olunur. X\u00fcsusil\u0259 k\u0259s\u00adkinl\u0259\u015fm\u0259 zaman\u0131 g\u00f6t\u00fcr\u00fcl\u0259n n\u00fcmu\u00adn\u0259d\u0259 (bird\u0259f\u0259lik v\u0259 ya 24 saatl\u0131q sidik) ALA, porfobilinogen v\u0259 sidik porfirinl\u0259rinin t\u0259yini\u00a0 porfiriya diaq\u00adnozunu t\u0259sdiq v\u0259 ya inkar etm\u0259y\u0259 imkan verir. Qur\u011fu\u015fun z\u0259h\u0259rl\u0259nm\u0259si, herediter tirozinemiya, diabetik keto\u00adasidoz, hamil\u0259lik v\u0259 b\u0259zi q\u0131colma \u0259lehin\u0259 d\u0259rmanlar ALA s\u0259viy\u0259sind\u0259 y\u00fcks\u0259lm\u0259y\u0259 s\u0259b\u0259b oldu\u011fu halda, alkaqolla \u0259laq\u0259li qaraciy\u0259r x\u0259st\u0259lik\u00adl\u0259ri zaman\u0131 sidikd\u0259 ALA s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

APO A-1 (APOL\u0130POPROTE\u0130N A)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Apo A; Apo A-1<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0T\u00fcrbidimetrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n40-105 mg\/dL<\/td>\n40-105 mg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-3 ya\u015f<\/td>\n60-150 mg\/dL<\/td>\n60-150 mg\/dL<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n65-150 mg\/dL<\/td>\n60-150 mg\/dL<\/td>\n<\/tr>\n
6-15 ya\u015f<\/td>\n80-150 mg\/dL<\/td>\n80-150 mg\/dL<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n80-160 mg\/dL<\/td>\n80-200 mg\/dL<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n80-170 mg\/dL<\/td>\n80-205 mg\/dL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n80-170 mg\/dL<\/td>\n120-220 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>HDL, xilomikronlar v\u0259 VLDL-nin ba\u015fl\u0131ca z\u00fclal kompo\u00adnen\u00adtidir. Koronar \u00fcr\u0259k x\u0259st\u0259liyi riskinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Abetalipoproteinemiya, irsi hi\u00adpo\u00adalfalipopro\u00adteinemiyalar, lipo\u00adpro\u00adtein lipaza kofaktor (Apo C-II) \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131, fish-eye disease, hiper\u00adtriq\u00adli\u00adseridemiya, kontrolsuz diabet, hepa\u00adto\u00adsellular x\u0259st\u0259likl\u0259r, xolestaz, nef\u00adro\u00adtik sindrom, xro\u00adniki b\u00f6yr\u0259k \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131 v\u0259 siqaret \u00e7\u0259km\u0259k serumda Apo A-1 s\u0259viyy\u0259sind\u0259 azalmaya s\u0259\u00adb\u0259b olur. Apo A-1-in azl\u0131\u011f\u0131 erk\u0259n ko\u00adronar \u00fcr\u0259k x\u0259st\u0259liyi ba\u00adx\u0131m\u0131ndan risklidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

APO B (APOL\u0130POPROTE\u0130N B)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Apo B; Apoprotein B<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>N\u00fcmun\u0259 al\u0131n\u00admas\u0131 \u00fc\u00e7\u00fcn 10 saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 laz\u0131md\u0131r. Pasiyent n\u00fcmun\u0259 ver\u00adm\u0259z\u00add\u0259n 12-16 saat \u0259vv\u0259l gimnastika il\u0259 m\u0259\u015f\u011ful olmamal\u0131d\u0131r; 5 d\u0259qiq\u0259 isti\u00adrah\u0259t etdik\u00add\u0259n sonra n\u00fcmun\u0259nin al\u0131n\u00admas\u0131 daha m\u0259q\u00ads\u0259d\u0259uy\u011fundur. N\u00fcmu\u00adn\u0259 x\u0259st\u0259nin uzanm\u0131\u015f v\u0259ziyy\u0259tind\u0259 al\u0131narsa yalan\u00e7\u0131 a\u015fa\u011f\u0131 n\u0259tic\u0259l\u0259r \u0259ld\u0259 oluna bil\u0259r. H\u0259m\u00ad\u00e7inin n\u00fcmun\u0259 al\u0131nark\u0259n turna m\u00fcmk\u00fcn q\u0259d\u0259r az saxlan\u0131lmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0T\u00fcrbidimetrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
<5 ya\u015f<\/td>\n25-75 mg\/dL<\/td>\n25-75 mg\/dL<\/td>\n<\/tr>\n
>5 ya\u015f<\/td>\n40-120 mg\/dL<\/td>\n40-115 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>LDL-in ba\u015fl\u0131ca z\u00fclal kom\u00adponentidir. Koronar \u00fcr\u0259k x\u0259s\u00adt\u0259\u00adliyi v\u0259 enm\u0259 riskinin qiym\u0259tl\u0259ndi\u00adril\u00adm\u0259siond\u0259 istifad\u0259 olunur. Apo A-1\/Apo B nis\u00adb\u0259ti hiperbetalipoproteinemiyan\u0131n t\u0259\u00adyi\u00adnind\u0259 istifad\u0259 olunur. Hiper\u00adlipo\u00adpro\u00adteinemiya IIa, IIb, IV v\u0259 V tipl\u0259r, erk\u0259n koronar \u00fcr\u0259k x\u0259st\u0259liyi, diabet, hipertiroidizim, nefrotik sinrom, b\u00f6y\u00adr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, qaraciy\u0259r x\u0259st\u0259likl\u0259ri, Cushing sindromu, porfiriya, hami\u00adl\u0259lik, v\u0259 anoreksiya nervosa zaman\u0131 serumda Apo B s\u0259viyy\u0259si art\u0131r, I tip hiperlipoproteinemiya, hipertiroidizm, malnutrisiya, malabsorbsiya, xroniki anemiyalar, Reye sindromu, k\u0259skin stres, xroniki a\u011fciy\u0259r x\u0259st\u0259likl\u0259ri, mieloma v\u0259 ar\u0131qlama zaman\u0131 Apo B s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

APOL\u0130POPROTE\u0130N A<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Apo A; Apo A-1<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0T\u00fcrbidimetrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n40-105 mg\/dL<\/td>\n40-105 mg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-3 ya\u015f<\/td>\n60-150 mg\/dL<\/td>\n60-150 mg\/dL<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n65-150 mg\/dL<\/td>\n60-150 mg\/dL<\/td>\n<\/tr>\n
6-15 ya\u015f<\/td>\n80-150 mg\/dL<\/td>\n80-150 mg\/dL<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n80-160 mg\/dL<\/td>\n80-200 mg\/dL<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n80-170 mg\/dL<\/td>\n80-205 mg\/dL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n80-170 mg\/dL<\/td>\n120-220 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>HDL, xilomikronlar v\u0259 VLDL-nin ba\u015fl\u0131ca z\u00fclal kompo\u00adnen\u00adtidir. Koronar \u00fcr\u0259k x\u0259st\u0259liyi riskinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Abetalipoproteinemiya, irsi hi\u00adpo\u00adalfalipopro\u00adteinemiyalar, lipo\u00adpro\u00adtein lipaza kofaktor (Apo C-II) \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131, fish-eye disease, hiper\u00adtriq\u00adli\u00adseridemiya, kontrolsuz diabet, hepa\u00adto\u00adsellular x\u0259st\u0259likl\u0259r, xolestaz, nef\u00adro\u00adtik sindrom, xro\u00adniki b\u00f6yr\u0259k \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131 v\u0259 siqaret \u00e7\u0259km\u0259k serumda Apo A-1 s\u0259viyy\u0259sind\u0259 azalmaya s\u0259\u00adb\u0259b olur. Apo A-1-in azl\u0131\u011f\u0131 erk\u0259n ko\u00adronar \u00fcr\u0259k x\u0259st\u0259liyi ba\u00adx\u0131m\u0131ndan risklidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

APOL\u0130POPROTE\u0130N B<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Apo B; Apoprotein B<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>N\u00fcmun\u0259 al\u0131n\u00admas\u0131 \u00fc\u00e7\u00fcn 10 saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 laz\u0131md\u0131r. Pasiyent n\u00fcmun\u0259 ver\u00adm\u0259z\u00add\u0259n 12-16 saat \u0259vv\u0259l gimnastika il\u0259 m\u0259\u015f\u011ful olmamal\u0131d\u0131r; 5 d\u0259qiq\u0259 isti\u00adrah\u0259t etdik\u00add\u0259n sonra n\u00fcmun\u0259nin al\u0131n\u00admas\u0131 daha m\u0259q\u00ads\u0259d\u0259uy\u011fundur. N\u00fcmu\u00adn\u0259 x\u0259st\u0259nin uzanm\u0131\u015f v\u0259ziyy\u0259tind\u0259 al\u0131narsa yalan\u00e7\u0131 a\u015fa\u011f\u0131 n\u0259tic\u0259l\u0259r \u0259ld\u0259 oluna bil\u0259r. H\u0259m\u00ad\u00e7inin n\u00fcmun\u0259 al\u0131nark\u0259n turna m\u00fcmk\u00fcn q\u0259d\u0259r az saxlan\u0131lmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0T\u00fcrbidimetrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
<5 ya\u015f<\/td>\n25-75 mg\/dL<\/td>\n25-75 mg\/dL<\/td>\n<\/tr>\n
>5 ya\u015f<\/td>\n40-120 mg\/dL<\/td>\n40-115 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>LDL-in ba\u015fl\u0131ca z\u00fclal kom\u00adponentidir. Koronar \u00fcr\u0259k x\u0259s\u00adt\u0259\u00adliyi v\u0259 enm\u0259 riskinin qiym\u0259tl\u0259ndi\u00adril\u00adm\u0259siond\u0259 istifad\u0259 olunur. Apo A-1\/Apo B nis\u00adb\u0259ti hiperbetalipoproteinemiyan\u0131n t\u0259\u00adyi\u00adnind\u0259 istifad\u0259 olunur. Hiper\u00adlipo\u00adpro\u00adteinemiya IIa, IIb, IV v\u0259 V tipl\u0259r, erk\u0259n koronar \u00fcr\u0259k x\u0259st\u0259liyi, diabet, hipertiroidizim, nefrotik sinrom, b\u00f6y\u00adr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, qaraciy\u0259r x\u0259st\u0259likl\u0259ri, Cushing sindromu, porfiriya, hami\u00adl\u0259lik, v\u0259 anoreksiya nervosa zaman\u0131 serumda Apo B s\u0259viyy\u0259si art\u0131r, I tip hiperlipoproteinemiya, hipertiroidizm, malnutrisiya, malabsorbsiya, xroniki anemiyalar, Reye sindromu, k\u0259skin stres, xroniki a\u011fciy\u0259r x\u0259st\u0259likl\u0259ri, mieloma v\u0259 ar\u0131qlama zaman\u0131 Apo B s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

APOPROTE\u0130N B (APOL\u0130POPROTE\u0130N B)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Apo B; Apoprotein B<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>N\u00fcmun\u0259 al\u0131n\u00admas\u0131 \u00fc\u00e7\u00fcn 10 saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 laz\u0131md\u0131r. Pasiyent n\u00fcmun\u0259 ver\u00adm\u0259z\u00add\u0259n 12-16 saat \u0259vv\u0259l gimnastika il\u0259 m\u0259\u015f\u011ful olmamal\u0131d\u0131r; 5 d\u0259qiq\u0259 isti\u00adrah\u0259t etdik\u00add\u0259n sonra n\u00fcmun\u0259nin al\u0131n\u00admas\u0131 daha m\u0259q\u00ads\u0259d\u0259uy\u011fundur. N\u00fcmu\u00adn\u0259 x\u0259st\u0259nin uzanm\u0131\u015f v\u0259ziyy\u0259tind\u0259 al\u0131narsa yalan\u00e7\u0131 a\u015fa\u011f\u0131 n\u0259tic\u0259l\u0259r \u0259ld\u0259 oluna bil\u0259r. H\u0259m\u00ad\u00e7inin n\u00fcmun\u0259 al\u0131nark\u0259n turna m\u00fcmk\u00fcn q\u0259d\u0259r az saxlan\u0131lmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0T\u00fcrbidimetrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
<5 ya\u015f<\/td>\n25-75 mg\/dL<\/td>\n25-75 mg\/dL<\/td>\n<\/tr>\n
>5 ya\u015f<\/td>\n40-120 mg\/dL<\/td>\n40-115 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>LDL-in ba\u015fl\u0131ca z\u00fclal kom\u00adponentidir. Koronar \u00fcr\u0259k x\u0259s\u00adt\u0259\u00adliyi v\u0259 enm\u0259 riskinin qiym\u0259tl\u0259ndi\u00adril\u00adm\u0259siond\u0259 istifad\u0259 olunur. Apo A-1\/Apo B nis\u00adb\u0259ti hiperbetalipoproteinemiyan\u0131n t\u0259\u00adyi\u00adnind\u0259 istifad\u0259 olunur. Hiper\u00adlipo\u00adpro\u00adteinemiya IIa, IIb, IV v\u0259 V tipl\u0259r, erk\u0259n koronar \u00fcr\u0259k x\u0259st\u0259liyi, diabet, hipertiroidizim, nefrotik sinrom, b\u00f6y\u00adr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, qaraciy\u0259r x\u0259st\u0259likl\u0259ri, Cushing sindromu, porfiriya, hami\u00adl\u0259lik, v\u0259 anoreksiya nervosa zaman\u0131 serumda Apo B s\u0259viyy\u0259si art\u0131r, I tip hiperlipoproteinemiya, hipertiroidizm, malnutrisiya, malabsorbsiya, xroniki anemiyalar, Reye sindromu, k\u0259skin stres, xroniki a\u011fciy\u0259r x\u0259st\u0259likl\u0259ri, mieloma v\u0259 ar\u0131qlama zaman\u0131 Apo B s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ARSEN<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>As<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a024 saatl\u0131q sidik, sa\u00e7<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 sax\u00adlanmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir. 6N HCl, asetat tur\u015fusu v\u0259 ya bor tur\u015fusu \u00fcz\u0259\u00adrin\u0259 y\u0131\u011f\u0131lan sidik n\u00fcmun\u0259l\u0259ri d\u0259 q\u0259\u00adbul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL (sidik), 10 q sa\u00e7<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 saatl\u0131q sidiyin h\u0259cmi bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Sidik<\/td>\n5-50 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
Sa\u00e7<\/td>\n<1 \u03bcg\/sa\u00e7<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

As (ARSEN)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>As<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a024 saatl\u0131q sidik, sa\u00e7<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 sax\u00adlanmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir. 6N HCl, asetat tur\u015fusu v\u0259 ya bor tur\u015fusu \u00fcz\u0259\u00adrin\u0259 y\u0131\u011f\u0131lan sidik n\u00fcmun\u0259l\u0259ri d\u0259 q\u0259\u00adbul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL (sidik), 10 q sa\u00e7<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 saatl\u0131q sidiyin h\u0259cmi bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Sidik<\/td>\n5-50 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
Sa\u00e7<\/td>\n<1 \u03bcg\/sa\u00e7<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>K\u0259skin v\u0259 ya xroniki ar\u00adsen z\u0259h\u0259rl\u0259nm\u0259l\u0259rinin diaqnozunda istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ASA (SAL\u0130S\u0130LAT)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Asetilsalisil tur\u015fusu; ASA; Salisil tur\u015fusu<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Fermentativ<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n
Analgetik konsentrasiya<\/td>\n30-100 \u03bcg\/mL<\/td>\n<\/tr>\n
\u0130ltihab \u0259leyhin\u0259 konsentrasiya<\/td>\n\u00a0150-300 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksik konsentrasiya<\/td>\n>300 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u00ad\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ASET\u0130LSAL\u0130S\u0130L TUR\u015eUSU (SAL\u0130S\u0130LAT)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Asetilsalisil tur\u015fusu; ASA; Salisil tur\u015fusu<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Fermentativ<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n
Analgetik konsentrasiya<\/td>\n30-100 \u03bcg\/mL<\/td>\n<\/tr>\n
\u0130ltihab \u0259leyhin\u0259 konsentrasiya<\/td>\n\u00a0150-300 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksik konsentrasiya<\/td>\n>300 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u00ad\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ASO (ANT\u0130STREPTOL\u0130Z\u0130N O (K\u0259miy\u00ady\u0259tc\u0259))<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ASO; Streptolizin O an\u00adticisimi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0T\u00fcrbidimetrik<\/p>\n

Referens:\u00a0<\/strong><200 IU\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Streptococcus pyogenes<\/em>-\u0259 m\u0259xsus streptolizin O-ya qar\u015f\u0131 \u0259m\u0259l\u0259 g\u0259l\u0259n anticisiml\u0259rdir. A qrup beta-hemolitik streptokok infeksiyalar\u0131n\u0131n diaqnostika v\u0259 m\u00fc\u015fahid\u0259sind\u0259 istifa\u00add\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ASPARTAT AM\u0130NOTRANSFERAZA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>AST; SGOT; Serum glu\u00adtamik oksaloasetik transminaz<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Sperktrofotometrik, ki\u00adnetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
<7 g\u00fcn<\/td>\n25-75 IU\/L<\/td>\n<\/tr>\n
7 ya\u015f-1ya\u015f<\/td>\n15-60 IU\/L<\/td>\n<\/tr>\n
2-12 ya\u015f<\/td>\n15-50 IU\/L<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n10-45 IU\/L<\/td>\n<\/tr>\n
16-60 ya\u015f<\/td>\n10-42 IU\/L<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n12-50 IU\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Orqanizmin b\u00fct\u00fcn toxu\u00adma\u00adlar\u0131nda olsa da, qaraciy\u0259r, \u00fcr\u0259k v\u0259 sklet \u0259z\u0259l\u0259sind\u0259 daha \u00e7ox toplan\u0131r. H\u0259r hans\u0131 bir s\u0259b\u0259bd\u0259n qaraciy\u0259r h\u00fc\u00adcey\u00adr\u0259sinin z\u0259d\u0259l\u0259nm\u0259si v\u0259 ya da\u011f\u0131l\u00admas\u0131, xolestatik v\u0259 obstruktiv sar\u0131l\u0131q, xroniki hepatil\u0259r, infeksion monu\u00adnukleoz, \u00fcr\u0259k v\u0259 ya sklet \u0259z\u0259l\u0259sinin nek\u00adroz v\u0259 ya travmas\u0131,\u00a0 h\u0259m\u00e7inin iltihabi x\u0259st\u0259likl\u0259ri, k\u0259skin miokard infakt\u0131, a\u011f\u0131r idman, \u00fcr\u0259k \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u00ad\u011f\u0131, a\u011f\u0131r d\u0259r\u0259c\u0259li yan\u0131qlar, hipoti\u00adro\u00adidizm, ba\u011f\u0131rsaq obstruksiyalar\u0131, b\u0259d\u00adxass\u0259li hipertermiya v\u0259 talasemiya ma\u00adjor zaman\u0131 serumda\u00a0 AST s\u0259viy\u00ady\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AST (ASPARTAT AM\u0130NOTRANSFERAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>AST; SGOT; Serum glu\u00adtamik oksaloasetik transminaz<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Sperktrofotometrik, ki\u00adnetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
<7 g\u00fcn<\/td>\n25-75 IU\/L<\/td>\n<\/tr>\n
7 ya\u015f-1ya\u015f<\/td>\n15-60 IU\/L<\/td>\n<\/tr>\n
2-12 ya\u015f<\/td>\n15-50 IU\/L<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n10-45 IU\/L<\/td>\n<\/tr>\n
16-60 ya\u015f<\/td>\n10-42 IU\/L<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n12-50 IU\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Orqanizmin b\u00fct\u00fcn toxu\u00adma\u00adlar\u0131nda olsa da, qaraciy\u0259r, \u00fcr\u0259k v\u0259 sklet \u0259z\u0259l\u0259sind\u0259 daha \u00e7ox toplan\u0131r. H\u0259r hans\u0131 bir s\u0259b\u0259bd\u0259n qaraciy\u0259r h\u00fc\u00adcey\u00adr\u0259sinin z\u0259d\u0259l\u0259nm\u0259si v\u0259 ya da\u011f\u0131l\u00admas\u0131, xolestatik v\u0259 obstruktiv sar\u0131l\u0131q, xroniki hepatil\u0259r, infeksion monu\u00adnukleoz, \u00fcr\u0259k v\u0259 ya sklet \u0259z\u0259l\u0259sinin nek\u00adroz v\u0259 ya travmas\u0131,\u00a0 h\u0259m\u00e7inin iltihabi x\u0259st\u0259likl\u0259ri, k\u0259skin miokard infakt\u0131, a\u011f\u0131r idman, \u00fcr\u0259k \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u00ad\u011f\u0131, a\u011f\u0131r d\u0259r\u0259c\u0259li yan\u0131qlar, hipoti\u00adro\u00adidizm, ba\u011f\u0131rsaq obstruksiyalar\u0131, b\u0259d\u00adxass\u0259li hipertermiya v\u0259 talasemiya ma\u00adjor zaman\u0131 serumda\u00a0 AST s\u0259viy\u00ady\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BENCE-JONES PROTE\u0130N\u0130 (\u0130MMUNF\u0130KSAS\u0130YA ELEKTROFOREZ\u0130- Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Bence-Jones proteini<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Elektroforez<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Analizl\u0259 sidikl\u0259 ifraz olu\u00adnan Lambda v\u0259 Kappa y\u00fcng\u00fcl z\u0259n\u00adci\u00adrinin varl\u0131\u011f\u0131 qiym\u0259tl\u0259ndirilir. X\u00fc\u00adsu\u00adsil\u0259 multiple myeloman\u0131n qiym\u0259tl\u0259n\u00addirilm\u0259sind\u0259 istigad\u0259 olunur. Ami\u00adloidoz, Fanconi sindromu v\u0259 Wal\u00addenstr\u00f6m makroqlobulinemiyas\u0131 za\u00adman\u0131 da sidikl\u0259 ifraz olunan y\u00fcn\u00fcl z\u0259ncirin miqdar\u0131 art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

B\u0130KARBONAT<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>HCO3<\/sub><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Heparinli plazma, serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), Ya\u015f\u0131l qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (heparinli plazma)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nark\u0259n v\u0259 labaratoriya g\u00f6n\u00add\u0259\u00adril\u0259rk\u0259n anaerob \u015f\u0259rtl\u0259r\u0259 riay\u0259t olun\u00admal\u0131d\u0131r. G\u00f6zl\u0259y\u0259n n\u00fcmun\u0259l\u0259rd\u0259 bikarbonat s\u0259viyy\u0259si azal\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong>\u00a023-29 mEq\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Q\u0259l\u0259vi-tur\u015fu balans\u0131n\u0131n qiy\u00adm\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Kompensasiya olunmu\u015f respi\u00adrator asidoz, metabolik alkaloz, mor\u00adfin, barbituratlar, kortikosteroidl\u0259r v\u0259 b\u0259zi diuretik v\u0259 i\u015fl\u0259dicil\u0259rin istifa\u00add\u0259si zaman\u0131 plazmada HCO3<\/sub>\u00a0s\u0259viy\u00ady\u0259\u00adsi art\u0131r. Metabolik asidoz, kom\u00adpen\u00ad\u00ad\u00adsasiya olunmu\u015f respirator alka\u00adloz, etilenqlikol z\u0259h\u0259rl\u0259nm\u0259si, me\u00adtanol v\u0259 salisilat toksikozlar\u0131n\u0131n gec d\u00f6vrl\u0259rind\u0259, asetozolamid v\u0259 siklo\u00adsporin istifad\u0259si is\u0259 HCO3<\/sub>-\u00fcn s\u0259\u00adviyy\u0259sini azald\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

B\u0130L\u0130RUB\u0130N (D\u00fcz)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Birl\u0259\u015fmi\u015f bilirubin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fcmun\u0259 al\u0131nd\u0131qdan sonra d\u00fcz i\u015f\u0131q \u015f\u00fcalar\u0131ndan qorunmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, kinetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259sind\u0259n al\u0131nm\u0131\u015f qanda<\/td>\n<0.2 mg\/dL<\/td>\n<\/tr>\n
Erk\u0259n do\u011fulmu\u015f u\u015faqlarda<\/td>\n<1.0 mg\/dL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n<1.0 mg\/dL<\/td>\n<\/tr>\n
>7 g\u00fcn<\/td>\n<0.54 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qaraciy\u0259r v\u0259 \u00f6d kis\u0259si funksiyalar\u0131n\u0131n qiym\u0259tl\u0259ndiril\u00adm\u0259\u00adsin\u00add\u0259 istifad\u0259 olunur. \u0130ntrahepatik (qa\u00adra\u00adciy\u0259r daxili) v\u0259 ekstra\u00adhepatik (qa\u00adra\u00adciy\u0259r xarici) \u00f6d yollar\u0131 dur\u011fun\u00adluqlar\u0131, qaraciy\u0259r h\u00fcceyr\u0259l\u0259rinin z\u0259\u00add\u0259\u00adl\u0259nm\u0259si, xolestaz, Dubin-Johnson sindromu v\u0259 Rotor sindromunda se\u00adrumda d\u00fcz bilirubinin s\u0259viyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

B\u0130L\u0130RUB\u0130N (Total)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131 :\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra d\u00fcz i\u015f\u0131q \u015f\u00fca\u00adlar\u0131ndan qorunmal\u0131d\u0131r.<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, ki\u00adnetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259sind\u0259n al\u0131nm\u0131\u015f qanda<\/td>\n0.30-2.00 mg\/dL<\/td>\n<\/tr>\n
Erk\u0259n do\u011fulmu\u015f u\u015faqlarda<\/td>\n0.30-12.00 mg\/dL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n0.30-16.00 mg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-1 ay<\/td>\n0.30-10.00 mg\/dL<\/td>\n<\/tr>\n
2-3 ay<\/td>\n0.30-2.00 mg\/dL<\/td>\n<\/tr>\n
>3 ay<\/td>\n0.30-1.35 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qaraciy\u0259r v\u0259 \u00f6d kis\u0259si funksiyalar\u0131n\u0131n qiym\u0259tl\u0259ndiril\u00adm\u0259\u00adsin\u00add\u0259 istifad\u0259 olunur. Qaraciy\u0259r h\u00fc\u00adcey\u00adr\u0259l\u0259rinin z\u0259d\u0259l\u0259nm\u0259si (iltihab, toksik, neoplastik), \u0130ntrahepatik (qaraciy\u0259r daxili) v\u0259 ekstrahepatik (qa\u00adra\u00adciy\u0259r xarici) \u00f6d yollar\u0131 dur\u011funluqlar\u0131, he\u00admo\u00adlitik x\u0259st\u0259likl\u0259r, neonatal fizioloji sar\u0131l\u0131q, Crigler-Najar sindromu, Gilbert x\u0259st\u0259liyi, Dubin-Johnson sindromu, fruktoza intolerans\u0131 v\u0259 hipotiroidizim zaman\u0131 serumda \u00fcm\u00fcmi bilirubinin s\u0259viyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

B\u0130RL\u018f\u015eM\u0130\u015e B\u0130L\u0130RUB\u0130N (B\u0130L\u0130RUB\u0130N \u2013 D\u00fcz)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Birl\u0259\u015fmi\u015f bilirubin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fcmun\u0259 al\u0131nd\u0131qdan sonra d\u00fcz i\u015f\u0131q \u015f\u00fcalar\u0131ndan qorunmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, kinetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qaraciy\u0259r v\u0259 \u00f6d kis\u0259si funksiyalar\u0131n\u0131n qiym\u0259tl\u0259ndiril\u00adm\u0259\u00adsin\u00add\u0259 istifad\u0259 olunur. \u0130ntrahepatik (qa\u00adra\u00adciy\u0259r daxili) v\u0259 ekstra\u00adhepatik (qa\u00adra\u00adciy\u0259r xarici) \u00f6d yollar\u0131 dur\u011fun\u00adluqlar\u0131, qaraciy\u0259r h\u00fcceyr\u0259l\u0259rinin z\u0259\u00add\u0259\u00adl\u0259nm\u0259si, xolestaz, Dubin-Johnson sindromu v\u0259 Rotor sindromunda se\u00adrumda d\u00fcz bilirubinin s\u0259viyy\u0259si art\u0131r<\/p>\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259sind\u0259n al\u0131nm\u0131\u015f qanda<\/td>\n<0.2 mg\/dL<\/td>\n<\/tr>\n
Erk\u0259n do\u011fulmu\u015f u\u015faqlarda<\/td>\n<1.0 mg\/dL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n<1.0 mg\/dL<\/td>\n<\/tr>\n
>7 g\u00fcn<\/td>\n<0.54 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BMI (XOLESTEROL-TOTAL)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Total xolesterol<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250\u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Pay\u0131z v\u0259 q\u0131\u015f aylar\u0131nda serumda \u00fcmumi xolesto\u00adrolun s\u0259viyy\u0259si daha y\u00fcks\u0259k olur. H\u0259m\u00e7inin qan alma v\u0259ziyy\u0259ti, \u0259n son q\u0259bul edil\u0259n qida, emosioanal stress v\u0259 menstural sikl d\u0259 \u00fcmumi xoles\u00adterol miqdar\u0131na t\u0259sir edir.<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik, fer\u00admen\u00adtativ.<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si qan\u0131 kan\u0131<\/td>\n45-100 mg\/dL<\/td>\n<\/tr>\n
<3 ay<\/td>\n50-135 mg\/dL<\/td>\n<\/tr>\n
4-6 ay<\/td>\n60-145 mg\/dL<\/td>\n<\/tr>\n
7-12 ay<\/td>\n60-160 mg\/dL<\/td>\n<\/tr>\n
1-5 ya\u015f<\/td>\n70-175 mg\/dL<\/td>\n<\/tr>\n
6-15 ya\u015f<\/td>\n110-200 mg\/dL<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n125-200 mg\/dL<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n135-200 mg\/dL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n140-200 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hipolipidemiya v\u0259 hiper\u00adlipidemiyan\u0131n diaqnozunda isti\u00adfad\u0259 olu\u00adnur. Xolesterol s\u0259viyy\u0259sinin b\u00f6\u00ady\u00fck\u00adl\u0259rd\u0259 200 mg\/dL, u\u015faqlarda is\u0259 170 mg\/dL-d\u0259n az olmal\u0131d\u0131r. B\u00f6\u00ady\u00fck\u00adl\u0259rd\u0259 200-239 mg\/dL \u201cs\u0259rh\u0259d\u0259 yax\u0131n y\u00fcks\u0259k\u201d, >239 mg\/dL is\u0259 \u201cy\u00fcks\u0259k\u201d kimi qiym\u0259tl\u0259ndirilm\u0259lidir. Boy v\u0259 \u00e7\u0259ki \u00f6l\u00e7\u00fcl\u0259rinin d\u0259 verilm\u0259si laz\u0131m g\u0259ldikd\u0259, b\u0259d\u0259n k\u00fctl\u0259 indeksi (body mass index) hesablan\u0131laraq verilir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BNP<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>B-tipli natriuretik peptid<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan (4 saat \u0259rzind\u0259 laboratoriyaya \u00e7atd\u0131r\u0131lmal\u0131d\u0131r) v\u0259 ya EDTA-l\u0131 plazma (dondurularaq saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir)<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a03 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0FPIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admun\u0259nin plazmas\u0131 ayr\u0131lmadan sax\u00adlan\u0131lmas\u0131<\/p>\n

Referens:<\/strong>\u00a0<100 pg\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Asimptomatik x\u0259st\u0259l\u0259r d\u0259 daxil olmaqla b\u00fct\u00fcn k\u0259skin \u00fcr\u0259k \u00e7a\u00adt\u0131\u015fmazl\u0131qlar\u0131n\u0131n diaqnozunda, m\u0259r\u00adh\u0259\u00ad\u00adl\u0259sinin m\u00fc\u0259yy\u0259n edilm\u0259sind\u0259, proq\u00adnozu v\u0259 m\u00fc\u015fayi\u0259tind\u0259 istifad\u0259 olunur.<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

BUN (UREA N\u0130TROGEN\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0BUN<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, fer\u00admentativ, kinetik<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si<\/td>\n21-40 mg\/dL<\/td>\n<\/tr>\n
Premat\u00fcre<\/td>\n3-25 mg\/dL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n4-12 mg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-6 ay<\/td>\n5-15 mg\/dL<\/td>\n<\/tr>\n
7 ay-3 ya\u015f<\/td>\n5-18 mg\/dL<\/td>\n<\/tr>\n
4-15 ya\u015f<\/td>\n5-25 mg\/dL<\/td>\n<\/tr>\n
16-60 ya\u015f<\/td>\n7-25 mg\/dL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n7-28 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>B\u00f6yr\u0259yin funksional test\u00adl\u0259rind\u0259n biridir. Z\u00fclal m\u00fcbadil\u0259sinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Ya\u015f v\u0259 qida il\u0259 q\u0259bul olunan z\u00fclal miqda\u0131 art\u0131qca BUN s\u0259viyy\u0259si d\u0259 art\u0131r. B\u00f6yr\u0259k perfuziyas\u0131n\u0131n azal\u00add\u0131\u011f\u0131 hallar, k\u0259skin v\u0259 xroniki b\u00f6yr\u0259k x\u0259st\u0259likl\u0259ri, postrenal obstruksiya v\u0259 y\u00fcks\u0259k z\u00fclall\u0131 qidalanma serumda BUN s\u0259viyy\u0259sini art\u0131r\u0131r. Az z\u00fclall\u0131 qidalanma, hamil\u0259liyin son m\u0259r\u00adh\u0259l\u0259si, infantilizm, akromeqaliya, a\u011f\u0131r qaraciy\u0259r x\u0259st\u0259likl\u0259ri v\u0259 celiac sprue zaman\u0131 is\u0259 serumda BUN s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

B\u018fD\u018fN K\u00dcTL\u018f \u0130NDEKS\u0130 (XOLESTEROL-TOTAL)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Total xolesterol<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250\u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Pay\u0131z v\u0259 q\u0131\u015f aylar\u0131nda serumda \u00fcmumi xolesto\u00adrolun s\u0259viyy\u0259si daha y\u00fcks\u0259k olur. H\u0259m\u00e7inin qan alma v\u0259ziyy\u0259ti, \u0259n son q\u0259bul edil\u0259n qida, emosioanal stress v\u0259 menstural sikl d\u0259 \u00fcmumi xoles\u00adterol miqdar\u0131na t\u0259sir edir.<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik, fer\u00admen\u00adtativ.<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si qan\u0131 kan\u0131<\/td>\n45-100 mg\/dL<\/td>\n<\/tr>\n
<3 ay<\/td>\n50-135 mg\/dL<\/td>\n<\/tr>\n
4-6 ay<\/td>\n60-145 mg\/dL<\/td>\n<\/tr>\n
7-12 ay<\/td>\n60-160 mg\/dL<\/td>\n<\/tr>\n
1-5 ya\u015f<\/td>\n70-175 mg\/dL<\/td>\n<\/tr>\n
6-15 ya\u015f<\/td>\n110-200 mg\/dL<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n125-200 mg\/dL<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n135-200 mg\/dL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n140-200 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hipolipidemiya v\u0259 hiper\u00adlipidemiyan\u0131n diaqnozunda isti\u00adfad\u0259 olu\u00adnur. Xolesterol s\u0259viyy\u0259sinin b\u00f6\u00ady\u00fck\u00adl\u0259rd\u0259 200 mg\/dL, u\u015faqlarda is\u0259 170 mg\/dL-d\u0259n az olmal\u0131d\u0131r. B\u00f6\u00ady\u00fck\u00adl\u0259rd\u0259 200-239 mg\/dL \u201cs\u0259rh\u0259d\u0259 yax\u0131n y\u00fcks\u0259k\u201d, >239 mg\/dL is\u0259 \u201cy\u00fcks\u0259k\u201d kimi qiym\u0259tl\u0259ndirilm\u0259lidir. Boy v\u0259 \u00e7\u0259ki \u00f6l\u00e7\u00fcl\u0259rinin d\u0259 verilm\u0259si laz\u0131m g\u0259ldikd\u0259, b\u0259d\u0259n k\u00fctl\u0259 indeksi (body mass index) hesablan\u0131laraq verilir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

C-REAKT\u0130V PROTE\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>CRP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0T\u00fcrbidimetrik<\/p>\n

Referens:\u00a0<\/strong><3 mg\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qeyri spesifik k\u0259skin faza reaktant\u0131d\u0131r. \u0130nfeksiya v\u0259 iltihabi prosesl\u0259rin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 is\u00adti\u00adfad\u0259 olunur. CRP virus v\u0259 spiroxet m\u0259n\u015f\u0259li infeksiyalar zaman\u0131 artma\u00add\u0131\u00ad\u011f\u0131ndan, x\u00fcsusil\u0259 bakterial infek\u00adsi\u00adyalar\u0131n t\u0259yinind\u0259 \u00e7ox \u0259h\u0259miyy\u0259tlidir. CRP-nin y\u00fcks\u0259lm\u0259si koronar \u00fcr\u0259k x\u0259st\u0259liyi riskinin erk\u0259n g\u00f6st\u0259ricisi oldu\u011fundan, bu riskin skrininqi m\u0259qs\u0259dil\u0259 d\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Ca (KALS\u0130UM)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Ca<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 10 saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 laz\u0131md\u0131r. N\u00fcmun\u0259 al\u0131nark\u0259n turna 10 d\u0259qiq\u0259d\u0259n \u00e7ox saxlan\u0131l\u00admamal\u0131d\u0131r. Qanda Ca s\u0259viyy\u0259si saat 02.00-04.00 aras\u0131nda minimal, 20.00 da is\u0259 maksimal s\u0259viyy\u0259d\u0259 olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, n\u00fcmun\u0259nin uy\u011fun olmayan s\u0131naq \u015f\u00fc\u015f\u0259sin\u0259 al\u0131nmas\u0131<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259sind\u0259n al\u0131nm\u0131\u015f qanda<\/td>\n8.2-11.5 mg\/dL<\/td>\n<\/tr>\n
Yenido\u011fulanlar<\/td>\n6.2-11.0 mg\/dL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n8.0-10.6 mg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-12 ya\u015f<\/td>\n8.8-10.8 mg\/dL<\/td>\n<\/tr>\n
13-60 ya\u015f<\/td>\n8.4-10.2 mg\/dL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n8.4-10.0 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0M\u00fcxt\u0259lif endokrin v\u0259 me\u00adtabolik poz\u011funluqlar\u0131n qiym\u0259tl\u0259n\u00addi\u00adrilm\u0259sind\u0259 istifad\u0259 olunur. \u0130lkin v\u0259 geriy\u0259 d\u00f6n\u0259n hiperparatiroidizm, s\u00fc\u00adm\u00fck metastazlar\u0131, m\u00fcxt\u0259lif\u00a0 b\u0259dxas\u00ads\u0259\u00adli t\u00f6r\u0259m\u0259l\u0259r, polisitemiya vera, feo\u00adxro\u00admasitoma, sarkoidoz, D vita\u00admini intoksikasiyas\u0131, s\u00fcd q\u0259l\u0259vi sind\u00adromu, tirotoksikoz, akromeqaliya v\u0259 dehidratasiyaya s\u0259b\u0259b olan hallarda serumda kalsium s\u0259viyy\u0259si art\u0131r. Hi\u00adpoparatiroidizm, psevdohipo\u00adparati\u00adroidzm, D vitamini \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, xro\u00adniki b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, Mg \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131, k\u0259skin pankreatit, hiper\u00adfosfatemiya, sistinoz, osto\u00admali\u00adya\u00adsi\u00adya, alkoqolizm, qaraciy\u0259r sirrozu v\u0259 hipoalbuminemiya zaman\u0131 serumda Ca s\u0259viyy\u0259si azal\u0131r. H\u0259m\u00e7inin total Ca s\u0259viyy\u0259si qandak\u0131 z\u00fclal konsen\u00adtrasiyas\u0131ndan as\u0131l\u0131d\u0131r. Z\u00fclal\u0131n miq\u00addar\u0131 1 g\/dL artarsa, Ca miqdar\u0131 t\u0259x\u00admin\u0259n 0.8 mg\/dL azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Ca1 (\u0130ONLA\u015eMI\u015e KALS\u0130UM)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Ca\u00a01<\/sub>, Ca+2<\/sup><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Heparinli tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Ya\u015f\u0131l qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>1 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 anaerob m\u00fchitd\u0259 al\u0131nmal\u0131 v\u0259 q\u0131sa m\u00fcdd\u0259td\u0259, soyuq \u015f\u0259raitd\u0259 laboratoriyaya \u00e7atd\u0131r\u0131lmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>ISE<\/p>\n

Referens:<\/strong>\u00a01.12-1.32 mmol\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Kalsiumun fizioloji ba\u00adx\u0131m\u00addan aktiv olan formas\u0131d\u0131r. Total kal\u00adsiumun 50-55%-i bu formada olur. Anormal total kalsium n\u0259tic\u0259\u00adl\u0259rinin v\u0259 yenido\u011fulan\u0131n kalsium s\u0259\u00adviyy\u0259sinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 is\u00adti\u00adfad\u0259 olunur. Birincili hiperpa\u00adratiroidizm, D vita\u00admi\u00adninin h\u0259ddind\u0259n art\u0131q q\u0259bulu v\u0259 b\u0259zi malignizasiyalar zaman\u0131 ionla\u015fm\u0131\u015f kal\u00adsiumun miqdar\u0131 art\u0131r, birincili hipopa\u00adra\u00adtiroidizm, psevdohipoparatiroidizm, D vitamini \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, maqnezium \u00e7a\u00adt\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131, \u0259m\u0259liyyatdan sonrak\u0131 v\u0259\u00adziy\u00ady\u0259t\u00adl\u0259r, travma, sepsis, yan\u0131qlar, pank\u00adreatit v\u0259 \u00e7oxsayl\u0131 orqan \u00e7at\u0131\u015fmaz\u00adl\u0131\u011f\u0131nda is\u0259 bu g\u00f6st\u0259rici azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Cd (KADM\u0130UM)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Cd<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0\u00a0<\/strong>EDTA-l\u0131 tam qan, bird\u0259f\u0259lik sidik, 24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (EDTA-l\u0131 tam qan)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>1 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259ril\u00adm\u0259\u00adli\u00addir. 6N HCl, asetat tur\u015fusu v\u0259 ya bor tur\u015fusu \u00fcz\u0259rin\u0259 \u0259lav\u0259 edil\u0259n si\u00addikl\u0259r d\u0259 q\u0259bul edilir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Siqaret \u00e7\u0259\u00adk\u0259nl\u0259rd\u0259 qanda kadiyum s\u0259viyy\u0259si siqaret \u00e7\u0259km\u0259y\u0259nl\u0259r\u0259 nisb\u0259t\u0259n daha y\u00fcks\u0259kdir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>AAS-Zeeman<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n
Tam qan<\/td>\n0.3-1.2 \u03bcg\/L<\/td>\n<\/tr>\n
Bird\u0259f\u0259lik sidik<\/td>\n0.5-4.7 \u03bcg\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Kadmiuma m\u0259ruz qalan \u015f\u0259xsl\u0259r\u0259 bu madd\u0259nin n\u0259 d\u0259r\u0259c\u0259d\u0259 t\u0259sir etdiyini t\u0259yin etm\u0259k \u00fc\u00e7\u00fcn istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

C\u0130V\u018f<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hg<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan (\u0259vv\u0259ll\u0259r he\u00e7 istifad\u0259 olunmam\u0131\u015f v\u0259 ya nitrat tur\u015fusu il\u0259 yuyulmu\u015f v\u0259 distill\u0259, yaxud, ionsuzla\u015fd\u0131r\u0131lm\u0131\u015f su il\u0259 yaxalanm\u0131\u015f s\u0131naq \u015f\u00fc\u015f\u0259sind\u0259 g\u00f6n\u00add\u0259\u00adrilm\u0259lidir), sa\u00e7<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (EDTA-l\u0131 tam qan)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL EDTA-l\u0131 tam qan, 10 g sa\u00e7<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Tam qan<\/td>\n<10 \u03bcg\/L<\/td>\n<\/tr>\n
Sa\u00e7<\/td>\n<1\u03bcg\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0K\u0259skin v\u0259 ya xroniki civ\u0259 z\u0259h\u0259rl\u0259nm\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 isti\u00adfad\u0259 olunur. B\u0259zi d\u0259rmanlar, fun\u00adqu\u00adsidl\u0259r v\u0259 s\u0259naye madd\u0259l\u0259rind\u0259 civ\u0259y\u0259 rast g\u0259linir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

C\u0130V\u018f (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik, bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a024 saatl\u0131q sidik \u00fc\u00e7\u00fcn qoruyucu laz\u0131m deyil. Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir. 6N HCl, asetat tur\u015fusu v\u0259 ya bor tur\u015fusu \u00fcz\u0259rin\u0259 y\u0131\u011f\u0131lan sidik n\u00fcmun\u0259l\u0259ri d\u0259 q\u0259bul olunur<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a010 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a024 saatl\u0131q sidiyin h\u0259cmi bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
24 saatl\u0131q sidik<\/td>\n<15 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n
Bird\u0259f\u0259lik sidik<\/td>\n<10 \u03bcg\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0K\u0259skin v\u0259 ya xroniki civ\u0259 z\u0259h\u0259rl\u0259nm\u0259l\u0259rinin m\u00fc\u015fahid\u0259\u00adsind\u0259 is\u00adti\u00adfad\u0259 olunur. Qeyri-\u00fczvi civ\u0259 miq\u00adda\u00adr\u0131n\u0131n m\u00fc\u0259yy\u0259n olunmas\u0131 \u00fc\u00e7\u00fcn si\u00addik\u00add\u0259 civ\u0259nin t\u0259yini m\u0259sl\u0259h\u0259t g\u00f6r\u00fcl\u00fcr<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

CK (KREAT\u0130N K\u0130NAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0CK; Total kreatin kinaza; CPK; Kreatin fosfokinaza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, ki\u00adnetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admoliz<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n
<7 g\u00fcn<\/td>\n22-500 IU\/L<\/td>\n<\/tr>\n
7 g\u00fcn-1ay<\/td>\n22-240 IU\/L<\/td>\n<\/tr>\n
<1 ay<\/td>\n22-220 IU\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Skelet v\u0259 \u00fcr\u0259k \u0259z\u0259l\u0259sind\u0259 degenrasiyaya s\u0259b\u0259b olan hallar\u0131n qiym\u0259tl\u0259ndirilm\u0259sid\u0259 istifad\u0259 olunur. KM\u0130, proqressiv \u0259z\u0259l\u0259 distrofiyalar\u0131, polimiozit, yan\u0131qlar, travma, a\u011f\u0131r id\u00adman, status epileptikus, \u0259m\u0259liyyat\u00addan sonrak\u0131 d\u00f6vr, yay\u0131lm\u0131\u015f beyin infarkt\u0131, hamil\u0259liyin son d\u00f6vrl\u0259ri v\u0259 do\u011fu\u015f, b\u0259dxass\u0259li hipertermiya, \u0130M infeksiyalar, q\u0131colmalar v\u0259 \u00fcr\u0259yin de\u00adfibriliyasiyas\u0131ndan sonra CK s\u0259\u00adviyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

CK-MB (KREAT\u0130N K\u0130NAZA, MB)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0\u0130mmunoinhibasiya (spek\u00adtro\u00adfotometrik, kinetik) v\u0259 ya mass \u00f6l\u00e7m\u0259 (MEIA)<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n
\u0130mmunoinhibasiya<\/td>\n<25 U\/L<\/td>\n<\/tr>\n
MEIA<\/td>\n<5 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>KM\u0130-nin diaqnosti\u00adka\u00ads\u0131n\u00adda istifad\u0259 olunur. CK\/CK-MB nisb\u0259ti m\u0259sl\u0259h\u0259t g\u00f6r\u00fcl\u00fcr. KM\u0130-d\u0259n sonra 4-8 saat \u0259rzind\u0259 y\u00fcks\u0259lm\u0259y\u0259 ba\u015flay\u0131r v\u0259 24 saata pik s\u0259viyy\u0259y\u0259 \u00e7a\u00adt\u0131r. H\u0259m\u00ad\u00e7inin \u00fcr\u0259k travmalar\u0131, mio\u00adkardit, kongestiv \u00fcr\u0259k \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131, koronar angioqrafiya, \u00fcr\u0259k c\u0259r\u00adra\u00adhiy\u0259si, \u0259z\u0259l\u0259 distrofiyas\u0131, poli\u00admio\u00adzit, SLE, ya\u00adn\u0131qlar, Reye sindromu, hipotermiya v\u0259 hipertermiyada CK-MB s\u0259viyy\u0259si y\u00fcks\u0259lir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Cn (S\u0130AN\u0130D)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Cn<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong>\u00a0<0.2 mg\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Sianidin bu madd\u0259 il\u0259 i\u015fl\u0259y\u0259n \u015f\u0259xsl\u0259r\u0259 t\u0259sirinin t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Cp (SERULOPLAZM\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Mis oksidaza; Cp<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Nefolometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
<6 ay<\/td>\n\u00a05-18 mg\/dL<\/td>\n<\/tr>\n
7-12 ay<\/td>\n33-43 mg\/dL<\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n26-55 mg\/dL<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n27-56 mg\/dL<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n20-54 mg\/dL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n20-63 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Mis birl\u0259\u015fdirici z\u00fclald\u0131r. Wilson x\u0259st\u0259liyinin diaqnos\u00adtikas\u0131nda v\u0259 k\u0259skin faza reaktant\u0131 kimi istifad\u0259 olunur. Hamil\u0259lik, esterogen v\u0259 oral kontraseptiv istifad\u0259si, iltihab, toxu\u00adma nekrozu, osteosarkomalar, biliar sirroz v\u0259 travmalarda serumda seru\u00adloplazminin s\u0259viyy\u0259si art\u0131r, Wilson x\u0259s\u00adt\u0259liyi, Menkes kinky hair sind\u00adro\u00admu v\u0259 qastroenteropatiyalarda azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

CPK (KREAT\u0130N K\u0130NAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0CK; Total kreatin kinaza; CPK; Kreatin fosfokinaza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, ki\u00adnetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admoliz<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n
<7 g\u00fcn<\/td>\n22-500 IU\/L<\/td>\n<\/tr>\n
7 g\u00fcn-1ay<\/td>\n22-240 IU\/L<\/td>\n<\/tr>\n
<1 ay<\/td>\n22-220 IU\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Skelet v\u0259 \u00fcr\u0259k \u0259z\u0259l\u0259sind\u0259 degenrasiyaya s\u0259b\u0259b olan hallar\u0131n qiym\u0259tl\u0259ndirilm\u0259sid\u0259 istifad\u0259 olunur. KM\u0130, proqressiv \u0259z\u0259l\u0259 distrofiyalar\u0131, polimiozit, yan\u0131qlar, travma, a\u011f\u0131r id\u00adman, status epileptikus, \u0259m\u0259liyyat\u00addan sonrak\u0131 d\u00f6vr, yay\u0131lm\u0131\u015f beyin infarkt\u0131, hamil\u0259liyin son d\u00f6vrl\u0259ri v\u0259 do\u011fu\u015f, b\u0259dxass\u0259li hipertermiya, \u0130M infeksiyalar, q\u0131colmalar v\u0259 \u00fcr\u0259yin de\u00adfibriliyasiyas\u0131ndan sonra CK s\u0259\u00adviyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Cr (XROM)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Cr<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik, bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 sax\u00adlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir. Asetat tur\u015fusu v\u0259 ya bor tur\u015fusu \u00fcz\u0259rin\u0259 y\u0131\u011f\u0131lan sidikl\u0259r d\u0259 q\u0259bul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>AAS-Zeeman<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n
24 saatl\u0131q sidik<\/td>\n<0.52 \u03bcg\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Xroma m\u0259ruz qalan \u015f\u0259xs\u00adl\u0259r\u0259 bu madd\u0259nin t\u0259sir d\u0259r\u0259c\u0259sini g\u00f6st\u0259rir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

CRP (C-REAKT\u0130V PROTE\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>CRP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0T\u00fcrbidimetrik<\/p>\n

Referens:\u00a0<\/strong><3 mg\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qeyri spesifik k\u0259skin faza reaktant\u0131d\u0131r. \u0130nfeksiya v\u0259 iltihabi prosesl\u0259rin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 is\u00adti\u00adfad\u0259 olunur. CRP virus v\u0259 spiroxet m\u0259n\u015f\u0259li infeksiyalar zaman\u0131 artma\u00add\u0131\u00ad\u011f\u0131ndan, x\u00fcsusil\u0259 bakterial infek\u00adsi\u00adyalar\u0131n t\u0259yinind\u0259 \u00e7ox \u0259h\u0259miyy\u0259tlidir. CRP-nin y\u00fcks\u0259lm\u0259si koronar \u00fcr\u0259k x\u0259st\u0259liyi riskinin erk\u0259n g\u00f6st\u0259ricisi oldu\u011fundan, bu riskin skrininqi m\u0259qs\u0259dil\u0259 d\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Cu (M\u0130S)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Cu<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS-Zeeman<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
<3 ay<\/td>\n20-70 \u03bcg\/dL<\/td>\n<\/tr>\n
4 ay-5 ya\u015f<\/td>\n85-190 \u03bcg\/dL<\/td>\n<\/tr>\n
6-15 ya\u015f<\/td>\n80-160 \u03bcg\/dL<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n80-155 \u03bcg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Mis metabolizminin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. \u0130nfeksiya, iltihab, hamil\u0259lik, ley\u00adkoz, biliar sirroz, Hockin x\u0259st\u0259liyi, pelleqra, a\u011fciy\u0259r v\u0259r\u0259mi, anemiya, talasemiya minor v\u0259 major, k\u0259skin miokard infarkt\u0131, beyin infarkt\u0131, revmatoid artrid, hipotireoidizim, hipertireoidizim, birl\u0259\u015fdirici toxuma x\u0259st\u0259likl\u0259ri, SLE v\u0259 b\u0259zi b\u0259dxass\u0259li t\u00f6r\u0259m\u0259l\u0259rd\u0259 serumda Cu-un s\u0259viy\u00ady\u0259si art\u0131r, Wilson x\u0259st\u0259liyi, qastro\u00adintestinal\u00a0 sistem x\u0259st\u0259likl\u0259ri, muko\u00advissidoz, nefrotik sindrom, yan\u0131qlar, z\u00fclal malnutrisiyas\u0131 v\u0259 xronik i\u015femik \u00fcr\u0259k x\u0259st\u0259likl\u0259rind\u0259 is\u0259 Cu s\u0259viyy\u0259si azal\u0131r. H\u0259m\u00e7inin esterogen, oral kontraseptiv v\u0259 antiepileptikl\u0259rin isti\u00adfad\u0259si v\u0259 hamil\u0259lik zaman\u0131, qaraciy\u0259rd\u0259 seruloplazmin sintezinin artmas\u0131 il\u0259 \u0259laq\u0259dar olaraq serumda Cu s\u0259viyy\u0259si d\u0259 art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

D-KS\u0130LOZA ABSORBS\u0130YA TEST\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Ksiloza absorbsiya testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum v\u0259 sidik<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Sidik qaranl\u0131q yerd\u0259 toplanmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 saxlanmal\u0131d\u0131r<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>X\u0259st\u0259 10 saatl\u0131q s\u0259h\u0259r a\u015fl\u0131\u011f\u0131 il\u0259 labarotoriyaya g\u0259lm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:\u00a0<\/strong>N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Malabsorbsiyan\u0131n t\u0259yini v\u0259 nazik ba\u011f\u0131rsa\u011f\u0131n proksimal hiss\u0259\u00adsind\u0259ki karbohidrat absorbsiyas\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Ba\u011f\u0131rsaq malabsorbsiyas\u0131, nazik ba\u011f\u0131rsaqda bakterial \u00e7oxalma, qus\u00adma, assit, gecikmi\u015f m\u0259d\u0259 bo\u015falmas\u0131 v\u0259 Whipple x\u0259st\u0259liyind\u0259 qan v\u0259 sidikd\u0259 ksilozan\u0131n miqdar\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

DALA (AM\u0130NOLEVUL\u0130N TUR\u015eUSU)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Delta-ALA; DALA; ALA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a024 saatl\u0131q sidik, bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Asetat tur\u015fusu \u00fcz\u0259\u00adrin\u0259 y\u0131\u011f\u0131laraq g\u00f6nd\u0259rilm\u0259lidir. 6N HCl \u00fcz\u0259rin\u0259 y\u0131\u011f\u0131lan sidikl\u0259r d\u0259 q\u0259bul edilir. Qaranl\u0131q yerd\u0259 y\u0131\u011f\u0131lmal\u0131 v\u0259 i\u015f\u0131qdan qorunaraq g\u00f6nd\u0259rilm\u0259lidir (Bax \u018flav\u0259 P)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a010 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 sa\u00adatl\u0131q sidiyin miqdar\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Xromatoqrafik, spektro\u00adfotometrik<\/p>\n

Referens:\u00a0<\/strong><<\/strong>7 mg\/g\u00fcn<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>K\u0259skin porfiriyan\u0131n diaq\u00adnozu v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahid\u0259si \u00fc\u00e7\u00fcn istifad\u0259 olunur. X\u00fcsusil\u0259 k\u0259s\u00adkinl\u0259\u015fm\u0259 zaman\u0131 g\u00f6t\u00fcr\u00fcl\u0259n n\u00fcmu\u00adn\u0259d\u0259 (bird\u0259f\u0259lik v\u0259 ya 24 saatl\u0131q sidik) ALA, porfobilinogen v\u0259 sidik porfirinl\u0259rinin t\u0259yini\u00a0 porfiriya diaq\u00adnozunu t\u0259sdiq v\u0259 ya inkar etm\u0259y\u0259 imkan verir. Qur\u011fu\u015fun z\u0259h\u0259rl\u0259nm\u0259si, herediter tirozinemiya, diabetik keto\u00adasidoz, hamil\u0259lik v\u0259 b\u0259zi q\u0131colma \u0259lehin\u0259 d\u0259rmanlar ALA s\u0259viy\u0259sind\u0259 y\u00fcks\u0259lm\u0259y\u0259 s\u0259b\u0259b oldu\u011fu halda, alkaqolla \u0259laq\u0259li qaraciy\u0259r x\u0259st\u0259lik\u00adl\u0259ri zaman\u0131 sidikd\u0259 ALA s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

DA\u015e ANAL\u0130Z\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sidik\u00e7\u0131xar\u0131c\u0131 sis\u00adte\u00admin da\u015flar\u0131<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0K\u0259miyy\u0259t<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Sidik\u00e7\u0131xar\u0131c\u0131 sistem da\u015f\u00adlar\u0131n\u0131n kimy\u0259vi t\u0259rkibinin t\u0259yinind\u0259 istifad\u0259 olunur. Da\u015fda karbonat, sis\u00adtin, fosfat, maqnezium, kalsium, am\u00admonium, sidik tur\u015fusu v\u0259 oksalat\u0131n olmas\u0131 t\u0259yin olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

DELTA-ALA (AM\u0130NOLEVUL\u0130N TUR\u015eUSU)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Delta-ALA; DALA; ALA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a024 saatl\u0131q sidik, bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Asetat tur\u015fusu \u00fcz\u0259\u00adrin\u0259 y\u0131\u011f\u0131laraq g\u00f6nd\u0259rilm\u0259lidir. 6N HCl \u00fcz\u0259rin\u0259 y\u0131\u011f\u0131lan sidikl\u0259r d\u0259 q\u0259bul edilir. Qaranl\u0131q yerd\u0259 y\u0131\u011f\u0131lmal\u0131 v\u0259 i\u015f\u0131qdan qorunaraq g\u00f6nd\u0259rilm\u0259lidir (Bax \u018flav\u0259 P)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a010 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 sa\u00adatl\u0131q sidiyin miqdar\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Xromatoqrafik, spektro\u00adfotometrik<\/p>\n

Referens:\u00a0<\/strong><<\/strong>7 mg\/g\u00fcn<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>K\u0259skin porfiriyan\u0131n diaq\u00adnozu v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahid\u0259si \u00fc\u00e7\u00fcn istifad\u0259 olunur. X\u00fcsusil\u0259 k\u0259s\u00adkinl\u0259\u015fm\u0259 zaman\u0131 g\u00f6t\u00fcr\u00fcl\u0259n n\u00fcmu\u00adn\u0259d\u0259 (bird\u0259f\u0259lik v\u0259 ya 24 saatl\u0131q sidik) ALA, porfobilinogen v\u0259 sidik porfirinl\u0259rinin t\u0259yini\u00a0 porfiriya diaq\u00adnozunu t\u0259sdiq v\u0259 ya inkar etm\u0259y\u0259 imkan verir. Qur\u011fu\u015fun z\u0259h\u0259rl\u0259nm\u0259si, herediter tirozinemiya, diabetik keto\u00adasidoz, hamil\u0259lik v\u0259 b\u0259zi q\u0131colma \u0259lehin\u0259 d\u0259rmanlar ALA s\u0259viy\u0259sind\u0259 y\u00fcks\u0259lm\u0259y\u0259 s\u0259b\u0259b oldu\u011fu halda, alkaqolla \u0259laq\u0259li qaraciy\u0259r x\u0259st\u0259lik\u00adl\u0259ri zaman\u0131 sidikd\u0259 ALA s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

D\u0130N\u0130TROFEN\u0130LH\u0130DRAZ\u0130N TEST\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kolorimetrik<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Leysinoz (maple syrup urine disease, MSUD) x\u0259st\u0259liyinin (a\u011fcaqay\u0131n siropu sidik x\u0259st\u0259liyi) diaqnostikas\u0131nda istifad\u0259 olunur. Fe\u00adnilketonuriya, histidinemiya, meto\u00adnin malabsorbsiyas\u0131 v\u0259 m\u00fcxt\u0259lif s\u0259\u00adb\u0259bli\u00a0 ketonuriyalar da pozitiv n\u0259\u00adtic\u0259l\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r. Skrininq testi uldu\u011fu \u00fc\u00e7\u00fcn pozitiv n\u0259tic\u0259l\u0259r d\u0259qiql\u0259\u015fdirilm\u0259lidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

D\u018fM\u0130R<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Fe<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>G\u00fcn\u00adl\u00fck variasiyas\u0131 vard\u0131r. Bel\u0259 ki, se\u00adrum\u00adda d\u0259mirin miqdar\u0131 s\u0259h\u0259r saat\u00adlar\u0131nda \u0259n y\u00fcks\u0259k s\u0259viyy\u0259d\u0259 olur<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin 10 saatl\u0131q acl\u0131qdan sonra al\u0131nmas\u0131 m\u0259sl\u0259h\u0259t g\u00f6r\u00fcl\u00fcr. H\u0259m\u00e7inin s\u0259h\u0259r al\u0131nan n\u00fcmun\u0259l\u0259rd\u0259ki d\u0259mir kon\u00adsen\u00adtrasiyas\u0131 g\u00fcnortadan sonrak\u0131lara nis\u00adb\u0259t\u0259n daha y\u00fcks\u0259k oldu\u011fundan n\u00fc\u00admu\u00adn\u0259l\u0259rin s\u0259h\u0259r al\u0131nmas\u0131na \u00fcst\u00fcnl\u00fck verilm\u0259lidir.\u00a0 N\u0259z\u0259r\u0259 almaq laz\u0131md\u0131r ki, infeksiya zaman\u0131 m\u00fcv\u0259qq\u0259ti ola\u00adraq serumda d\u0259mirin s\u0259viyy\u0259si azala bil\u0259r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kolorimetrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
<7 g\u00fcn<\/td>\n100-250 \u03bcg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-1 ya\u015f<\/td>\n40-100 \u03bcg\/dL<\/td>\n<\/tr>\n
2-15 ya\u015f<\/td>\n50-120 \u03bcg\/dL<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n50-175 \u03bcg\/dL (Ki\u015fi)<\/td>\n<\/tr>\n
40-170 \u03bcg\/dL (Qad\u0131n)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0H\u0259r n\u00f6v anemiya, d\u0259mir azl\u0131\u011f\u0131, talasemiya, sideroblastik anemiya v\u0259 d\u0259mir z\u0259h\u0259rl\u0259nm\u0259sinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Pernisioz, aplastik v\u0259 hemolitik anemiytalar, hemaxromatoz, k\u0259skin leykoz, qur\u011fu\u015fun z\u0259h\u0259rl\u0259nm\u0259si, k\u0259s\u00adkin hepatitl\u0259r, vitamin B6\u00ad<\/sub>\u00a0\u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131, talasemiya, t\u0259krarlanan qank\u00f6\u00ad\u00e7\u00fcr\u00fclm\u0259l\u0259r v\u0259 k\u0259skin d\u0259mir z\u0259h\u0259r\u00adl\u0259nm\u0259si zaman\u0131 serumda d\u0259mi\u00adrin miqdar\u0131 art\u0131r,\u00a0 d\u0259mir \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 ane\u00admiyas\u0131 k\u0259skin v\u0259 xroniki infek\u00adsiyalar, hipotiroidizim v\u0259 postope\u00adrativ m\u00fcdd\u0259td\u0259 is\u0259 bu g\u00f6st\u0259rici azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

D\u018fM\u0130R B\u0130RL\u018f\u015eD\u0130RM\u018f QAB\u0130L\u0130YY\u018fT\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TIBC; Total iron binding capacity<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin\u00a0 10 saatl\u0131q acl\u0131qdan sonra al\u0131nmas\u0131 m\u0259sl\u0259h\u0259t g\u00f6r\u00fcl\u00fcr<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kolorimetrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
<1 ya\u015f<\/td>\n100-400 \u03bcg\/dL<\/td>\n<\/tr>\n
>1 ya\u015f<\/td>\n250-450 \u03bcg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Serumda d\u0259mir miqda\u00adr\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olunur. Hipoxrom anemiyalar, k\u0259s\u00adkin hepatitl\u0259r v\u0259 hamil\u0259liyin son h\u0259ft\u0259l\u0259rind\u0259 TIBC art\u0131r, d\u0259mir \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131 il\u0259 \u0259laq\u0259dar olmayan ane\u00admiyalar, xroniki infeksiyalar, b\u0259d\u00adxass\u0259li t\u00f6r\u0259m\u0259l\u0259r, sirroz, hemo\u00adxromatoz, b\u00f6yr\u0259k x\u0259st\u0259likl\u0259ri v\u0259 tala\u00adsemiyalarda is\u0259 bu g\u00f6st\u0259rici azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

EAKULYATDA FRUKTOZA T\u018fY\u0130N\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Eakulyat (dondu\u00adru\u00adlaraq g\u00f6nd\u0259rilm\u0259lidir)<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0T\u0259miz, a\u011fz\u0131 qapaql\u0131 qab<\/p>\n

\u0130\u015f prinsipi\u00a0<\/strong>Spektrofotometrik<\/p>\n

Referens:<\/strong>150-600 mg\/dl<\/p>\n

\u0130stifad\u0259si:<\/strong>Toxum v\u0259zil\u0259rinin funk\u00adsio\u00adnal v\u0259 toxum axacaqlar\u0131n\u0131n a\u00e7\u0131q olma\u00ads\u0131n\u0131n t\u0259yini m\u0259qs\u0259dil\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

EPO (ER\u0130TROPO\u0130ET\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>EPO; s-EPO<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>\u00a0Sut\u00adkal\u0131q ritmi vard\u0131r v\u0259 s\u0259h\u0259r \u0259n y\u00fcks\u0259k s\u0259viyy\u0259d\u0259 olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0EIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admoliz<\/p>\n

Referens:\u00a0<\/strong>4.5-33.0 mU\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130lkin (polistemia vera) v\u0259 ikincili polisitemiyan\u0131n differen\u00adsiasi\u00adyas\u0131nda istifad\u0259 olunur. Anemiyalar,\u00a0 ikincili polisitemiya, eritropoietin\u00a0 if\u00adraz ed\u0259n \u015fi\u015fl\u0259r v\u0259 hamil\u0259likd\u0259 eritro\u00adpoietinin s\u0259viyy\u0259si art\u0131r, b\u00f6yr\u0259k \u00e7a\u00adt\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 ilkin (birincili) polisi\u00adtemiyada is\u0259 azal\u0131r. H\u0259m\u00e7inin a\u011f\u00adci\u00ady\u0259r v\u0259 ya kardiovaskuliyar hipoksiya il\u0259 \u0259laq\u0259dar eritrositoz zaman\u0131, k\u0259s\u00adkin qan axmalar v\u0259 arterial O2<\/sub>-nin t\u0259zyiqinin k\u0259skin azalmalar\u0131nda da eritropoetinin s\u0259viyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ER\u0130TROPO\u0130ET\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>EPO; s-EPO<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>\u00a0Sut\u00adkal\u0131q ritmi vard\u0131r v\u0259 s\u0259h\u0259r \u0259n y\u00fcks\u0259k s\u0259viyy\u0259d\u0259 olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0EIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admoliz<\/p>\n

Referens:\u00a0<\/strong>4.5-33.0 mU\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130lkin (polistemia vera) v\u0259 ikincili polisitemiyan\u0131n differen\u00adsiasi\u00adyas\u0131nda istifad\u0259 olunur. Anemiyalar,\u00a0 ikincili polisitemiya, eritropoietin\u00a0 if\u00adraz ed\u0259n \u015fi\u015fl\u0259r v\u0259 hamil\u0259likd\u0259 eritro\u00adpoietinin s\u0259viyy\u0259si art\u0131r, b\u00f6yr\u0259k \u00e7a\u00adt\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 ilkin (birincili) polisi\u00adtemiyada is\u0259 azal\u0131r. H\u0259m\u00e7inin a\u011f\u00adci\u00ady\u0259r v\u0259 ya kardiovaskuliyar hipoksiya il\u0259 \u0259laq\u0259dar eritrositoz zaman\u0131, k\u0259s\u00adkin qan axmalar v\u0259 arterial O2<\/sub>-nin t\u0259zyiqinin k\u0259skin azalmalar\u0131nda da eritropoetinin s\u0259viyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Fe (D\u018fM\u0130R)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Fe<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>G\u00fcn\u00adl\u00fck variasiyas\u0131 vard\u0131r. Bel\u0259 ki, se\u00adrum\u00adda d\u0259mirin miqdar\u0131 s\u0259h\u0259r saat\u00adlar\u0131nda \u0259n y\u00fcks\u0259k s\u0259viyy\u0259d\u0259 olur<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin 10 saatl\u0131q acl\u0131qdan sonra al\u0131nmas\u0131 m\u0259sl\u0259h\u0259t g\u00f6r\u00fcl\u00fcr. H\u0259m\u00e7inin s\u0259h\u0259r al\u0131nan n\u00fcmun\u0259l\u0259rd\u0259ki d\u0259mir kon\u00adsen\u00adtrasiyas\u0131 g\u00fcnortadan sonrak\u0131lara nis\u00adb\u0259t\u0259n daha y\u00fcks\u0259k oldu\u011fundan n\u00fc\u00admu\u00adn\u0259l\u0259rin s\u0259h\u0259r al\u0131nmas\u0131na \u00fcst\u00fcnl\u00fck verilm\u0259lidir.\u00a0 N\u0259z\u0259r\u0259 almaq laz\u0131md\u0131r ki, infeksiya zaman\u0131 m\u00fcv\u0259qq\u0259ti ola\u00adraq serumda d\u0259mirin s\u0259viyy\u0259si azala bil\u0259r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kolorimetrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
<7 g\u00fcn<\/td>\n100-250 \u03bcg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-1 ya\u015f<\/td>\n40-100 \u03bcg\/dL<\/td>\n<\/tr>\n
2-15 ya\u015f<\/td>\n50-120 \u03bcg\/dL<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n50-175 \u03bcg\/dL (Ki\u015fi)<\/td>\n<\/tr>\n
40-170 \u03bcg\/dL (Qad\u0131n)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0H\u0259r n\u00f6v anemiya, d\u0259mir azl\u0131\u011f\u0131, talasemiya, sideroblastik anemiya v\u0259 d\u0259mir z\u0259h\u0259rl\u0259nm\u0259sinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Pernisioz, aplastik v\u0259 hemolitik anemiytalar, hemaxromatoz, k\u0259skin leykoz, qur\u011fu\u015fun z\u0259h\u0259rl\u0259nm\u0259si, k\u0259s\u00adkin hepatitl\u0259r, vitamin B6\u00ad<\/sub>\u00a0\u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131, talasemiya, t\u0259krarlanan qank\u00f6\u00ad\u00e7\u00fcr\u00fclm\u0259l\u0259r v\u0259 k\u0259skin d\u0259mir z\u0259h\u0259r\u00adl\u0259nm\u0259si zaman\u0131 serumda d\u0259mi\u00adrin miqdar\u0131 art\u0131r,\u00a0 d\u0259mir \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 ane\u00admiyas\u0131 k\u0259skin v\u0259 xroniki infek\u00adsiyalar, hipotiroidizim v\u0259 postope\u00adrativ m\u00fcdd\u0259td\u0259 is\u0259 bu g\u00f6st\u0259rici azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FeCl3 TEST\u0130 (FERRUM XLOR\u0130D)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>FeCl3<\/sub><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>S\u0259h\u0259r ilk sidik n\u00fcmun\u0259si al\u0131nmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Fenilalanin metabolit\u00adl\u0259\u00adrind\u0259n fenilpiruvat tur\u015fusu t\u0259yin olu\u00adnur. Fenilketonuriya v\u0259 dig\u0259r meta\u00adbolik x\u0259st\u0259likl\u0259rin diaqnozunda, d\u0259r\u00adman v\u0259 alkoqol istifad\u0259sinin qiym\u0259t\u00adl\u0259n\u00addi\u00adrilm\u0259sind\u0259 istifad\u0259 olunur. Bun\u00addan ba\u015fqa, p\u0259hriz m\u00fcalic\u0259sin\u0259 ca\u00adva\u00adb\u0131n m\u00fc\u015fahid\u0259si \u00fc\u00e7\u00fcn d\u0259 \u0259h\u0259miy\u00ady\u0259tlidir. Skri\u00adninq test kimi istifad\u0259 olunma\u00admal\u0131d\u0131r.\u00a0 Levadopa, salisi\u00adlatlar v\u0259 feni\u00adtiazidl\u0259r yalan\u00e7\u0131 pozitiv n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FENOL<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259\u00adril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Qaz xromatografiya (GC)<\/p>\n

Referens:\u00a0<\/strong>4.5-20.7 mg\/g kreatinin<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Fenol, fenol-krezol v\u0259 ben\u00adzen il\u0259 i\u015fl\u0259y\u0259n \u015f\u0259xsl\u0259rin bu mad\u00add\u0259l\u0259rin t\u0259sirin\u0259 n\u0259 d\u0259r\u0259c\u0259d\u0259 m\u0259ruz qald\u0131qlar\u0131n\u0131 t\u0259yin etm\u0259k \u00fc\u00e7\u00fcn istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FERR\u0130T\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sa\u00adr\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Yenido\u011fulmu\u015f<\/td>\n25-200 ng\/mL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n25-200 ng\/mL<\/td>\n<\/tr>\n
7 g\u00fcn-1 ay<\/td>\n200-600 ng\/mL<\/td>\n<\/tr>\n
2-3 ay<\/td>\n50-300 ng\/mL<\/td>\n<\/tr>\n
4-6 ay<\/td>\n40-200 ng\/mL<\/td>\n<\/tr>\n
7-12 ay<\/td>\n15-140 ng\/mL<\/td>\n<\/tr>\n
1-5 ya\u015f<\/td>\n12-140 ng\/mL<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n15-140 ng\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n17-140 ng\/mL<\/td>\n<\/tr>\n
<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n15-220 ng\/mL<\/td>\n14-150 ng\/mL<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n15-220 ng\/mL<\/td>\n14-150 ng\/mL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n18-250 ng\/mL<\/td>\n18-200 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>D\u0259mir \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 ane\u00admi\u00adyas\u0131, xroniki x\u0259st\u0259lik anemiyas\u0131, tala\u00adse\u00admiya, hemoxromatoz v\u0259 d\u0259mir y\u00fck\u00adl\u0259m\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahid\u0259\u00adsin\u00add\u0259 is\u00adtifad\u0259 olunur. Qaraciy\u0259r x\u0259st\u0259\u00adlikl\u0259ri za\u00adman\u0131 d\u0259mir \u00e7at\u0131\u015fmazl\u0131\u011f\u0131na baxma\u00adyaraq ferritin normal s\u0259viy\u00ady\u0259d\u0259 ola bi\u00adl\u0259r. H\u0259m\u00e7inin k\u0259skin faza reaktantla\u00adr\u0131ndan biridir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FERRUM XLOR\u0130D<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>FeCl3<\/sub><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>S\u0259h\u0259r ilk sidik n\u00fcmun\u0259si al\u0131nmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Fenilalanin metabolit\u00adl\u0259\u00adrind\u0259n fenilpiruvat tur\u015fusu t\u0259yin olu\u00adnur. Fenilketonuriya v\u0259 dig\u0259r meta\u00adbolik x\u0259st\u0259likl\u0259rin diaqnozunda, d\u0259r\u00adman v\u0259 alkoqol istifad\u0259sinin qiym\u0259t\u00adl\u0259n\u00addi\u00adrilm\u0259sind\u0259 istifad\u0259 olunur. Bun\u00addan ba\u015fqa, p\u0259hriz m\u00fcalic\u0259sin\u0259 ca\u00adva\u00adb\u0131n m\u00fc\u015fahid\u0259si \u00fc\u00e7\u00fcn d\u0259 \u0259h\u0259miy\u00ady\u0259tlidir. Skri\u00adninq test kimi istifad\u0259 olunma\u00admal\u0131d\u0131r.\u00a0 Levadopa, salisi\u00adlatlar v\u0259 feni\u00adtiazidl\u0259r yalan\u00e7\u0131 pozitiv n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FOL TUR\u015eUSU<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Folat<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 10 saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 m\u0259sl\u0259h\u0259t g\u00f6r\u00fcl\u00fcr<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>3.1-17.5 ng\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Fol tur\u015fusu \u00e7at\u0131\u015fmaz\u00adl\u0131\u00ad\u011f\u0131n\u0131n diaqnoz v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fa\u00adhid\u0259sind\u0259, meqaloblast v\u0259 makrositar anemiyalar\u0131n qiym\u0259tl\u0259ndiril\u00adm\u0259sind\u0259 istifad\u0259 olunur. P\u0259hrizl\u0259 fol tur\u015fu\u00adsu\u00adnun q\u0259bulunun azalmas\u0131, hemodializ, malabsorbsiya, hamil\u0259lik, xroniki al\u00adkoqolizm v\u0259 fenitoin kimi b\u0259zi d\u0259r\u00admanlar serumda fol tur\u015fusunun miq\u00addar\u0131n\u0131 azald\u0131r, vegeterian p\u0259hriz is\u0259 bu g\u00f6st\u0259ricini art\u0131r\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FOL TUR\u015eUSU (ER\u0130TROS\u0130T DAX\u0130L\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Plaz\u00admas\u0131 ayr\u0131lm\u0131\u015f n\u00fcmun\u0259l\u0259r<\/p>\n

Referens:\u00a0<\/strong>120-860 ng\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Eritrosit daxili fol tur\u015fu\u00adsunun konsentrasiyas\u0131 serumdak\u0131na nisb\u0259t\u0259n\u00a0 daha \u00e7oxdur. Bu bax\u0131mdan orqanizmd\u0259ki fol tur\u015fusunun miqda\u00adr\u0131n\u0131n t\u0259yinind\u0259 eritrosit daxili fol tur\u00ad\u015fusunun s\u0259viyy\u0259sinin \u00f6l\u00e7\u00fclm\u0259si daha optimal g\u00f6st\u0259ricidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FOLAT (FOL TUR\u015eUSU)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Folat<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 10 saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 m\u0259sl\u0259h\u0259t g\u00f6r\u00fcl\u00fcr<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>3.1-17.5 ng\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Fol tur\u015fusu \u00e7at\u0131\u015fmaz\u00adl\u0131\u00ad\u011f\u0131n\u0131n diaqnoz v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fa\u00adhid\u0259sind\u0259, meqaloblast v\u0259 makrositar anemiyalar\u0131n qiym\u0259tl\u0259ndiril\u00adm\u0259sind\u0259 istifad\u0259 olunur. P\u0259hrizl\u0259 fol tur\u015fu\u00adsu\u00adnun q\u0259bulunun azalmas\u0131, hemodializ, malabsorbsiya, hamil\u0259lik, xroniki al\u00adkoqolizm v\u0259 fenitoin kimi b\u0259zi d\u0259r\u00admanlar serumda fol tur\u015fusunun miq\u00addar\u0131n\u0131 azald\u0131r, vegeterian p\u0259hriz is\u0259 bu g\u00f6st\u0259ricini art\u0131r\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FOSFOR<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>PO3<\/sub>; P; Qeyri \u00fczvi fosfor; Fosfat<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259 acqar\u0131na al\u0131nmal\u0131 v\u0259 serum m\u00fcmk\u00fcn q\u0259d\u0259r tez ayr\u0131lmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admo\u00adliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si qan\u0131<\/td>\n3.7-8.1<\/td>\n<\/tr>\n
Yeni do\u011fulmu\u015f<\/td>\n5.0-10.0<\/td>\n<\/tr>\n
7 g\u00fcn<\/td>\n5.0-10.0<\/td>\n<\/tr>\n
7 g\u00fcn- 1 ya\u015f<\/td>\n4.5-6.7<\/td>\n<\/tr>\n
2-12 ya\u015f<\/td>\n4.5-5.5<\/td>\n<\/tr>\n
13-60 ya\u015f<\/td>\n2.7-4.5<\/td>\n<\/tr>\n
60 ya\u015f<\/td>\n2.3-3.7\u00a0(Ki\u015fi)<\/td>\n<\/tr>\n
2.8-4.1 (Qad\u0131n)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Fosfor metobolizminin v\u0259 Ca-P m\u00fcvazin\u0259tinin qiym\u0259tl\u0259n\u00addiril\u00adm\u0259\u00adsind\u0259 istifad\u0259 olunur. Osteolitik s\u00fcm\u00fck metastazlar\u0131, sarkoidoz, s\u00fcd-q\u0259l\u0259vi sindromu, vitamin D intok\u00adsi\u00adkasiyas\u0131, b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, hipo\u00adpa\u00adratiroidizm, psevdohipo\u00adparatiroidizm, akromeqaliya, a\u011fciy\u0259r emboliyas\u0131,\u00a0<\/strong>lak\u00adtik asidoz \u00a0v\u0259 respirator asidoz zaman\u0131 serumda fosforun s\u0259viyy\u0259si art\u0131r, osteomalyasiya, steatoreya, renal tubulyar asidoz, Qram neqativ bakterial sep\u00adtisemiya, hipokalemiya vitamin D \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, malnutrisiya, ma\u00adlabsorbsiya, a\u011f\u0131r diarreya, qusma, birin\u00adcili hiperparatiroidizm, hiperkal\u00adsemiya, salisilat z\u0259h\u0259rl\u0259nm\u0259si, respi\u00adrator infeksiyalar, hiperinsulinemiya, respirator alkaloz, osteoblastik s\u00fcm\u00fck metastazlar\u0131 v\u0259 renal tubulyar defekt\u00adl\u0259rd\u0259 is\u0259 fosforun miqdar\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FOSFOR (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik, bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 sax\u00adlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir. 6N HCl v\u0259 bor tur\u015fusu \u00fcz\u0259rin\u0259 toplanan sidik\u00adl\u0259r d\u0259 q\u0259bul olunur<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 saatl\u0131q sidiyin miqdar\u0131 bildiril\u00adm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Sidikl\u0259 fosfor ifraz\u0131n\u0131n sutkal\u0131q ritmi vard\u0131r v\u0259 ax\u015fam saatlar\u0131 maksimum olur. P\u0259hriz, fosfor birl\u0259\u015fdir\u0259n antiasidl\u0259r, GH, insulin v\u0259 b\u00f6yr\u0259k funksiyalar\u0131 da sidikl\u0259 fosfor ifraz\u0131na t\u0259sir edir. Eyni zamanda menopauza v\u0259 uzanaraq istirah\u0259t etm\u0259k serumda fosforun s\u0259viyy\u0259sini art\u0131rd\u0131\u011f\u0131 halda, menst\u00adruasiya m\u00fcdd\u0259tind\u0259 serumda fosfor miqdar\u0131 azal\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:\u00a0<\/strong>24 saatl\u0131q sidik 0.4-1.3 g\/g\u00fcn<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0B\u00f6yr\u0259k funksiyalar\u0131n\u0131n v\u0259 kalsium fosfor m\u00fcvazin\u0259tinin qiym\u0259t\u00adl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olunur. Hi\u00adper\u00adparatiroidizm, vitamin D rezisten raxit, vitamin D intoksikasiyas\u0131, renal tubulyar z\u0259d\u0259l\u0259nm\u0259 v\u0259 irsi hipofos\u00adfa\u00adtemiyada sidikl\u0259 ifraz olunan fos\u00adfo\u00adrun miqdar\u0131 art\u0131r, hipoparati\u00adreoi\u00addizm, psevdohipoparatiroidizm v\u0259 parati\u00adroidekto\u00ad\u00admiyadan sonra is\u0259 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FRUKTOZAM\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0M\u00fcayin\u0259d\u0259n \u0259vv\u0259lki son 24 saat \u0259rzind\u0259 askorbin tur\u015fusu istifad\u0259 olunmamal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, ki\u00adnetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
<15 ya\u015f<\/td>\n165-229\u03bc mol\/L<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n205-285 \u03bcmol\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Son 2-3 h\u0259ft\u0259 m\u00fcdd\u0259\u00adtind\u0259ki orta ql\u00fckoza konsentrasiyas\u0131n\u0131 g\u00f6st\u0259rir. Qlikozill\u0259\u015fmi\u015f z\u00fclal miq\u00adda\u00adr\u0131n\u0131 g\u00f6st\u0259rdiyind\u0259n serumdak\u0131 \u00fcmumi z\u00fclal miqdar\u0131nda ba\u015f ver\u0259n d\u0259yi\u00ad\u015fik\u00adlikl\u0259r fruktozamin miqdar\u0131na da t\u0259sir ed\u0259 bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

GF-1 (SOMATOMED\u0130N C)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0IGF-14 \u0130nsulin-like gro\u00adwth faktor; Growth faktor 1; GF-1<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Growth hor\u00admonun \u0259ksin\u0259 g\u00fcn \u0259rzind\u0259 v\u0259 yem\u0259kl\u0259rd\u0259n sonra somatomedin C s\u0259viyy\u0259si sabit olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0IRMA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
<3 ya\u015f<\/td>\n50-143 ng\/mL<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n51-218 ng\/mL<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n106-250 ng\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n140-496 ng\/mL<\/td>\n<\/tr>\n
16-20 ya\u015f<\/td>\n150-562 ng\/mL<\/td>\n<\/tr>\n
21-25 ya\u015f<\/td>\n84-376 ng\/mL<\/td>\n<\/tr>\n
26-30 ya\u015f<\/td>\n90-271 ng\/mL<\/td>\n<\/tr>\n
31-35 ya\u015f<\/td>\n90-226 ng\/mL<\/td>\n<\/tr>\n
36-50 ya\u015f<\/td>\n90-210 ng\/mL<\/td>\n<\/tr>\n
>50 ya\u015f<\/td>\n70-197 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0GH sekresiyas\u0131n\u0131 v\u0259 t\u0259si\u00adrini t\u0259qib etm\u0259k \u00fc\u00e7\u00fcn istifad\u0259 olunur. IGFBP3 il\u0259 birlikd\u0259 istifad\u0259 olun\u00adduqda klinik h\u0259ssasl\u0131q v\u0259 spesifikliyi GH funksiya testl\u0259rind\u0259n daha y\u00fcks\u0259k olur. IGF-1 akromeqaliyada y\u00fcks\u0259k, GH \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, anoreksiya nervosa v\u0259 malnutrisiyas\u0131 olan \u015f\u0259xs\u00adl\u0259rd\u0259 is\u0259 a\u015fa\u011f\u0131 olur. Qidalanma v\u0259\u00adziyy\u0259tinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 prealbumin, RBP v\u0259 ya transfer\u00adrin\u00add\u0259n daha h\u0259ssas olmas\u0131 Soma\u00adto\u00admedin C-nin ba\u015fqa bir x\u00fcsusiy\u00ady\u0259tidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

GFR (KREAT\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, 24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum). 24 saatl\u0131q sidik soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir. Bor tur\u015fusu \u00fcz\u0259rin\u0259 toplanan sidikl\u0259r d\u0259 q\u0259bul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL serum, 10 mL sidik<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 sa\u00adatl\u0131q sidik miqdar\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, ki\u00adnetik<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n
Serum<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
<12 ya\u015f<\/td>\n0.30-0.90\u00a0mg\/dL<\/td>\n15 ya\u015f 0.30-0.90 mg\/dL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n0.20-0.75 mg\/dL<\/td>\n15 ya\u015f 0.30-0.95 mg\/dL<\/td>\n<\/tr>\n
24 saatl\u0131q sidik<\/td>\n40 mg\/g\u00fcn<\/td>\n80 mg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qida il\u0259 \u0259t q\u0259bulunun art\u00admas\u0131 v\u0259 \u0259z\u0259l\u0259 z\u0259d\u0259l\u0259nm\u0259l\u0259rind\u0259 se\u00adrum\u00adda kreatin s\u0259viyy\u0259si art\u0131r. Si\u00addik\u00add\u0259 kreatin miqdar\u0131 is\u0259 u\u015faqlarda, ha\u00admi\u00adl\u0259lik, uzun m\u00fcdd\u0259tli acl\u0131q, mio\u00adpa\u00adtiyalar, infeksiyalar, yan\u0131qlar, ley\u00adkoz, SLE v\u0259 b\u0259zi endokrin x\u0259st\u0259\u00adlik\u00adl\u0259rd\u0259 (hipertiroidizim, Addison x\u0259s\u00adt\u0259\u00adliyi, Cushing sindromu, akrome\u00adqaliya, diabetes mellitus) art\u0131r, hipo\u00adtiroidizimd\u0259 is\u0259 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

GGT (QAMMA QLUTAM\u0130L TRANSFERAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>\u03b3-Glutamil transferaza; GGT; Gama GT; Gama glutamil transpeptidaza<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, kinetik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si qan\u0131<\/td>\n11-194 IU\/L<\/td>\n<\/tr>\n
Yar\u0131m\u00e7\u0131qdo\u011fulan<\/td>\n11-194 IU\/L<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n10-300 IU\/L<\/td>\n<\/tr>\n
7 g\u00fcn-1 ay<\/td>\n7-180 IU\/L<\/td>\n<\/tr>\n
2-3 ay<\/td>\n7-100 IU\/L<\/td>\n<\/tr>\n
4 ay-15 ya\u015f<\/td>\n7-50 IU\/L<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n7-60 IU\/L (Ki\u015fi)<\/td>\n<\/tr>\n
7-40 IU\/L (Qad\u0131n)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qaraciy\u0259rin funksional test\u00adl\u0259rind\u0259n biridir, alkaqol v\u0259 d\u0259r\u00admanlar\u0131n qaraciy\u0259r\u0259 toksiki t\u0259sirinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur. Obst\u00adruktiv sar\u0131l\u0131q, qaraciy\u0259rdaxili xoles\u00adtaz, pankreatit v\u0259 qaraciy\u0259rd\u0259ki me\u00adtastatik karsinomalar\u0131n t\u0259yinind\u0259 d\u0259 \u0259h\u0259miyy\u0259tlidir. Serumda QQT-nin s\u0259\u00adviyy\u0259si, qaraciy\u0259r x\u0259st\u0259likl\u0259ri za\u00adman\u0131 ALP il\u0259 paralel d\u0259yi\u015fdiyi halda, s\u00fcm\u00fck x\u0259st\u0259likl\u0259rind\u0259 bu nisb\u0259t g\u00f6zl\u0259nilmir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HAM TEST\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Tur\u015fu hemolizi testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>X\u0259st\u0259d\u0259n v\u0259 eyni qan qruplu sa\u011flam \u015f\u0259xsd\u0259n EDTA-l\u0131 tam qan v\u0259 serum g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum) v\u0259 b\u0259n\u00f6v\u015f\u0259yi qa\u00adpaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (EDTA-l\u0131 tam qan)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>3 mL EDTA-l\u0131 tam qan v\u0259 3mL serum<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kvalitativ<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Paroksizmal nokturnal (gec\u0259) hemoqlobinuriyan\u0131n t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HAPTOGLOB\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>HPT<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Nefelometrik<\/p>\n

Referens:\u00a0<\/strong>30-200 mg\/dL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>\u0130n vivo hemolizin t\u0259\u00adyinind\u0259 istifad\u0259 olunan k\u0259skin faza z\u00fclal\u0131d\u0131r. K\u0259skin v\u0259 xroniki iltihabi prosesl\u0259r, neoplastik x\u0259st\u0259likl\u0259r, kor\u00adtikosteroid m\u00fcalic\u0259si v\u0259 biliar obst\u00adruksiyalarda serumda HPT-nin miq\u00addar\u0131 art\u0131r, in vivo hemoliz (hemo\u00adqlo\u00adbinopatiyalar, eritrosit membran de\u00adfektl\u0259ri, autoimmun hemolitik x\u0259s\u00adt\u0259likl\u0259r, mexaniki hemoliz, hiper\u00adsplenizm), qaraciy\u0259r x\u0259st\u0259likl\u0259ri, es\u00adte\u00adrogen m\u00fcalic\u0259si, hamil\u0259lik v\u0259 oral kontraseptiv istifad\u0259si\u00a0 zaman\u0131 is\u0259 bu g\u00f6st\u0259rici azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HbA1C (QLUKOHEMOGLOB\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>HbA1C<\/sub>; Hemoglobin A1C<\/sub><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>Turbidimetrik<\/p>\n

Referens:<\/strong>\u00a0%4.5-5.7<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Diabetes mellitusun uzun m\u00fcdd\u0259tli m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olu\u00adnur. Son 6-8 h\u0259ft\u0259 m\u00fcdd\u0259tind\u0259 qan\u00addak\u0131 ortalama ql\u00fckoza konsen\u00adtra\u00adsi\u00adyas\u0131n\u0131 g\u00f6st\u0259rir. Eritrositl\u0259rin \u00f6m\u00adr\u00fc\u00adn\u00fcn q\u0131sald\u0131\u011f\u0131 qeyri stabil hemo\u00adqlo\u00adbinl\u0259rin m\u00f6vcud olmas\u0131 (Hb SS, Hb CC, Hb SC v\u0259 s.) v\u0259 dig\u0259r hemolitik anemiyalar yaln\u0131\u015f a\u015fa\u011f\u0131 n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r. D\u0259mir \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 eritrositl\u0259rin \u00f6mr\u00fcn\u00fc uzadaraq yaln\u0131\u015f y\u00fcks\u0259k n\u0259tic\u0259nin \u0259ld\u0259 edilm\u0259sin\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HbM (METHEMOQLOB\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0MetHb; HbM<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admu\u00adn\u0259nin laxtal\u0131 v\u0259 ya hemolizli olmas\u0131<\/p>\n

Referens:<\/strong>\u00a0<1.5%<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Anadang\u0259lm\u0259 v\u0259 qaza\u00adn\u0131lm\u0131\u015f methemoqlobinemiya, karbon monooksid z\u0259h\u0259rl\u0259nm\u0259si, benzokain, nitroqliserin, lidokain, nitratlar, fena\u00adsetin, sulfanilamidl\u0259r v\u0259 radiasiya methemoqlobin s\u0259viyy\u0259sinin artma\u00ads\u0131na s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Hco3- (B\u0130KARBONAT)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>HCO3<\/sub><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Heparinli plazma, serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), Ya\u015f\u0131l qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (heparinli plazma)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nark\u0259n v\u0259 labaratoriya g\u00f6n\u00add\u0259\u00adril\u0259rk\u0259n anaerob \u015f\u0259rtl\u0259r\u0259 riay\u0259t olun\u00admal\u0131d\u0131r. G\u00f6zl\u0259y\u0259n n\u00fcmun\u0259l\u0259rd\u0259 bikarbonat s\u0259viyy\u0259si azal\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong>\u00a023-29 mEq\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Q\u0259l\u0259vi-tur\u015fu balans\u0131n\u0131n qiy\u00adm\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Kompensasiya olunmu\u015f respi\u00adrator asidoz, metabolik alkaloz, mor\u00adfin, barbituratlar, kortikosteroidl\u0259r v\u0259 b\u0259zi diuretik v\u0259 i\u015fl\u0259dicil\u0259rin istifa\u00add\u0259si zaman\u0131 plazmada HCO3<\/sub>\u00a0s\u0259viy\u00ady\u0259\u00adsi art\u0131r. Metabolik asidoz, kom\u00adpen\u00ad\u00ad\u00adsasiya olunmu\u015f respirator alka\u00adloz, etilenqlikol z\u0259h\u0259rl\u0259nm\u0259si, me\u00adtanol v\u0259 salisilat toksikozlar\u0131n\u0131n gec d\u00f6vrl\u0259rind\u0259, asetozolamid v\u0259 siklo\u00adsporin istifad\u0259si is\u0259 HCO3<\/sub>-\u00fcn s\u0259\u00adviyy\u0259sini azald\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Hcy (HOMOS\u0130STE\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hcy<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131\u00a0 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fcmun\u0259 al\u0131nd\u0131rdan sonra plazma hemoliz\u0259 u\u011framadan t\u0259cili ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259 acqar\u0131na g\u00f6t\u00fcr\u00fclm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>HPLC<\/p>\n

Referens:\u00a0<\/strong>\u03bcmol\/L<\/p>\n\n\n\n\n\n\n
Ya\u015f<\/td>\nNormal<\/td>\n\u015e\u00fcbh\u0259li<\/td>\nY\u00fcks\u0259k<\/td>\n<\/tr>\n
<15 ya\u015f<\/td>\n<8.0<\/td>\n8.0-10.0<\/td>\n>10.0<\/td>\n<\/tr>\n
15-65 ya\u015f<\/td>\n<12.0<\/td>\n12.0-15.0<\/td>\n>15.0<\/td>\n<\/tr>\n
>65 ya\u015f<\/td>\n<16.0<\/td>\n16.0-20.0<\/td>\n>20.0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Plazmadak\u0131 total homo\u00adsis\u00adtein s\u0259viyy\u0259si kardiovaskuliyar x\u0259s\u00adt\u0259likl\u0259r \u00fc\u00e7\u00fcn s\u0259rb\u0259st risk fak\u00adtorudur. Genetik mutasiyalar v\u0259 ya esensial vitamin kofaktorlar\u0131ndak\u0131 \u00e7at\u0131\u015fmazl\u0131q ferment funksiyalar\u0131na t\u0259sir ed\u0259r\u0259k homosisteinin s\u0259viyy\u0259\u00adsini art\u0131r\u0131r. Homosistein s\u0259viyy\u0259si y\u00fcks\u0259k olan \u015f\u0259xsl\u0259rd\u0259 ateroskleroz v\u0259 trombemboliya riski y\u00fcks\u0259k olur. H\u0259m\u00e7inin qanda v\u0259 sidikd\u0259 homo\u00adsistein s\u0259viyy\u0259sinin artm\u0131\u015f oldu\u011fu anadang\u0259lm\u0259 metobolizm poz\u011fun\u00adlu\u011fu olan homosis\u00adteinuriyan\u0131n diaq\u00adnos\u00adtikas\u0131nda da istifad\u0259 olunur. Vita\u00admin B12<\/sub>\u00a0\u00e7at\u0131\u015fmazl\u0131\u011f\u0131, ya\u015f v\u0259 siqaret istifad\u0259si homosistein s\u0259viyy\u0259sini art\u0131r\u0131r, fol tur\u015fusunun istifad\u0259si il\u0259 homosistein s\u0259viyy\u0259si azal\u0131r.<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HDL XOLESTEROL<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>HDL-C<\/strong><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik, ki\u00adnetik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
Erk\u0259n do\u011fulmu\u015f u\u015faqlarda<\/td>\n5-50 mg\/dL<\/td>\n<\/tr>\n
<1 ya\u015f<\/td>\n30-65 mg\/dL<\/td>\n<\/tr>\n
2-15 ya\u015f<\/td>\n35-75 mg\/dL<\/td>\n<\/tr>\n
<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
16-20 ya\u015f<\/td>\n40-70 mg\/dL<\/td>\n35-80 mg\/dL<\/td>\n<\/tr>\n
21-60 ya\u015f<\/td>\n40-70 mg\/dL<\/td>\n40-80 mg\/dL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n40-75 mg\/dL<\/td>\n40-80 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Koronar \u00fcr\u0259k x\u0259st\u0259liyi ris\u00adkinin qiym\u0259tl\u0259ndirilm\u0259si \u00fc\u00e7\u00fcn is\u00adti\u00adfad\u0259 olunur. 40mg\/dL-d\u0259n a\u015fa\u011f\u0131 n\u0259\u00adti\u00adc\u0259l\u0259r koronar \u00fcr\u0259k x\u0259st\u0259liyi \u00fc\u00e7\u00fcn risk faktoru hesab olunur. 60 mg\/dL-d\u0259n y\u00fcks\u0259k n\u0259tic\u0259l\u0259r is\u0259 HDL xoles\u00adto\u00adrol \u00fc\u00e7\u00fcn y\u00fcks\u0259k kimi qiym\u0259tl\u0259ndirilir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEMOQLOB\u0130N A1C (QLUKOHEMOGLOB\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>HbA1C<\/sub>; Hemoglobin A1C<\/sub><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>Turbidimetrik<\/p>\n

Referens:<\/strong>\u00a0%4.5-5.7<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Diabetes mellitusun uzun m\u00fcdd\u0259tli m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olu\u00adnur. Son 6-8 h\u0259ft\u0259 m\u00fcdd\u0259tind\u0259 qan\u00addak\u0131 ortalama ql\u00fckoza konsen\u00adtra\u00adsi\u00adyas\u0131n\u0131 g\u00f6st\u0259rir. Eritrositl\u0259rin \u00f6m\u00adr\u00fc\u00adn\u00fcn q\u0131sald\u0131\u011f\u0131 qeyri stabil hemo\u00adqlo\u00adbinl\u0259rin m\u00f6vcud olmas\u0131 (Hb SS, Hb CC, Hb SC v\u0259 s.) v\u0259 dig\u0259r hemolitik anemiyalar yaln\u0131\u015f a\u015fa\u011f\u0131 n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r. D\u0259mir \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 eritrositl\u0259rin \u00f6mr\u00fcn\u00fc uzadaraq yaln\u0131\u015f y\u00fcks\u0259k n\u0259tic\u0259nin \u0259ld\u0259 edilm\u0259sin\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HEMOS\u0130DER\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>\u00a0N\u00fc\u00admun\u0259 soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kimy\u0259vi + Mikroskopik<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Plazmadak\u0131 s\u0259rb\u0259st he\u00admo\u00adqlobinin miqdar\u0131n\u0131n y\u00fcks\u0259k olma\u00ads\u0131 v\u0259 bununla \u0259laq\u0259dar hemopeksin v\u0259 haptoqlobulin s\u0259viy\u00ady\u0259\u00adl\u0259rinin azal\u00admas\u0131 sidikd\u0259 hemosiderin tap\u0131lma\u00ads\u0131na s\u0259b\u0259b olur. Hemo\u00adsiderinuriya ad\u0259\u00adt\u0259n intravaskuliyar hemolizl\u0259 \u0259la\u00adq\u0259li olur. \u0130ntravas\u00adkuliyar hemoliz\u0259 s\u0259\u00adb\u0259b olan anemiyalarda v\u0259 hemo\u00adxromatozda hemosiderinuriya ba\u015f verir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Hg (C\u0130V\u018f)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hg<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan (\u0259vv\u0259ll\u0259r he\u00e7 istifad\u0259 olunmam\u0131\u015f v\u0259 ya nitrat tur\u015fusu il\u0259 yuyulmu\u015f v\u0259 distill\u0259, yaxud, ionsuzla\u015fd\u0131r\u0131lm\u0131\u015f su il\u0259 yaxalanm\u0131\u015f s\u0131naq \u015f\u00fc\u015f\u0259sind\u0259 g\u00f6n\u00add\u0259\u00adrilm\u0259lidir), sa\u00e7<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (EDTA-l\u0131 tam qan)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL EDTA-l\u0131 tam qan, 10 g sa\u00e7<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Tam qan<\/td>\n<10 \u03bcg\/L<\/td>\n<\/tr>\n
Sa\u00e7<\/td>\n<1\u03bcg\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0K\u0259skin v\u0259 ya xroniki civ\u0259 z\u0259h\u0259rl\u0259nm\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 isti\u00adfad\u0259 olunur. B\u0259zi d\u0259rmanlar, fun\u00adqu\u00adsidl\u0259r v\u0259 s\u0259naye madd\u0259l\u0259rind\u0259 civ\u0259y\u0259 rast g\u0259linir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

H\u0130DROKS\u0130PROL\u0130N, TOTAL<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>10 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>6N HCl, asetat tur\u015fusu v\u0259 ya bor tur\u015fusu \u00fcz\u0259rin\u0259 y\u0131\u011f\u0131lmal\u0131 v\u0259 i\u015f\u0131qdan qoru\u00adna\u00adraq g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>Sidiyin top\u00adlanmas\u0131ndan 3 g\u00fcn \u0259vv\u0259l \u0259t, toyuq m\u0259hsullar\u0131 v\u0259 jelatinli qidalar q\u0259bul olunmamal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
1-5 ya\u015f<\/td>\n20-65 mg\/g\u00fcn<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n35-99 mg\/g\u00fcn<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n63-180 mg\/g\u00fcn<\/td>\n<\/tr>\n
16-20 ya\u015f<\/td>\n20-55 mg\/g\u00fcn<\/td>\n<\/tr>\n
21-40 ya\u015f<\/td>\n15-42 mg\/g\u00fcn<\/td>\n<\/tr>\n
>40 ya\u015f<\/td>\n16-49 mg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Total kollagen turnover-ini g\u00f6st\u0259rir. S\u00fcm\u00fck rezorbsiyas\u0131 \u00fc\u00e7\u00fcn faydal\u0131 g\u00f6st\u0259ricidir. H\u0259m\u00e7inin birincili v\u0259 ikincili \u015fi\u015fl\u0259rl\u0259 \u0259laq\u0259li os\u00adteoparozlar\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 d\u0259 istifad\u0259 olunur. Akrome\u00adqa\u00adliya, hi\u00adpertiroidizim, Paget x\u0259st\u0259liyi, ric\u00adkets, osteomaliyasiya, b\u00f6y\u00fck s\u00fcm\u00fck\u00adl\u0259\u00adrin s\u0131n\u0131qlar\u0131, s\u00fcm\u00fck \u015fi\u015fl\u0259ri, os\u00adteo\u00adpa\u00adroz, sarkoidoz v\u0259 k\u0259skin osteo\u00admielitl\u0259rd\u0259 hidroksiprolinin miqdar\u0131 art\u0131r, hipotiroidizim, hipopi\u00adtuiterizm, hi\u00adpoparatiroidizm v\u0259 malnitura\u00adsi\u00adya\u00adda is\u0259 bu miqdar azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

H\u0130PPURAT TUR\u015eUSU<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0 Soyuq \u015f\u0259raitd\u0259 sax\u00adla\u00adn\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:\u00a0<\/strong>\u00a0<0.6 mg\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Toluen v\u0259 ksilen il\u0259 i\u015f\u00adl\u0259y\u0259n \u015f\u0259xsl\u0259rin bu madd\u0259l\u0259rin t\u0259si\u00adrin\u0259 m\u0259ruz qalma d\u0259r\u0259c\u0259sinin t\u0259yini \u00fc\u00e7\u00fcn istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HOMOGENT\u0130Z\u0130N TUR\u015eUSU<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259\u00adrilm\u0259\u00adlidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Kolorimetrik<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Alkaptonuriyan\u0131n diaq\u00adnos\u00adtikas\u0131nda istifad\u0259 olunur. Homo\u00adgentizin tur\u015fusu, tirozin metobo\u00adliz\u00admind\u0259 \u0259m\u0259l\u0259 g\u0259l\u0259n aral\u0131q m\u0259hsuldur. Homogentizin-oksidaza fermenti \u00e7a\u00adt\u0131\u015fmazl\u0131\u011f\u0131n\u0131n s\u0259b\u0259b oldu\u011fu alkapto\u00adnuriya x\u0259st\u0259liyind\u0259 b\u00fct\u00fcn toxu\u00adma\u00adlarda homogentizin tr\u015fusu toplan\u0131r. Askorbin tur\u015fusu, salisilat, gentizin tur\u015fusu v\u0259 L-dopa yalan\u00e7\u0131 pozitiv n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KAL\u0130UM<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0K+<\/sup><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Sutkal\u0131q va\u00adriasiyas\u0131 vard\u0131r. S\u0259h\u0259r saat 08.00-da maksimum, ax\u015fam 22.00-da is\u0259 mi\u00adnimum s\u0259viyy\u0259d\u0259 olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ISE<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si<\/td>\n5.0-10.2 mEq\/L<\/td>\n<\/tr>\n
Yenido\u011fulmu\u015f<\/td>\n3.0-6.0 mEq\/L<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n3.7-5.9 mEq\/L<\/td>\n<\/tr>\n
>7 g\u00fcn<\/td>\n3.5-5.5 mEq\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Elektrolit v\u0259 tur\u015fu-q\u0259\u00adl\u0259vi m\u00fcvazin\u0259tinin qiym\u0259tl\u0259n\u00addiril\u00adm\u0259si, b\u00f6y\u00adr\u0259k funksiyalar\u0131n\u0131n m\u00fc\u015fa\u00adhid\u0259\u00adsin\u00add\u0259 istifad\u0259 olunur. Trom\u00adbositoz, ley\u00adkemiya, hemoliz, toxu\u00adma z\u0259d\u0259l\u0259n\u00adm\u0259\u00adsi, epileptik status, b\u0259dxass\u0259li hi\u00adper\u00adpireksiya, asidoz, k\u0259skin b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, Addi\u00adson x\u0259st\u0259liyi, psev\u00ad\u00addohipoal\u00addos\u00adte\u00adro\u00adnizm, a\u011f\u0131r id\u00adman, \u015fok v\u0259 dehidrata\u00adsiyada serum\u00adda kaliumun s\u0259viyy\u0259si art\u0131r. Xroniki acl\u0131q, diarreya, qus\u00adma, ba\u011f\u0131rsaq fis\u00adtullar\u0131, b\u00f6yr\u0259k bo\u00adrucuqlar\u0131 asidozu, Fanconi sind\u00adromu, birincili v\u0259 ikin\u00adcili aldoste\u00adronizm, Cushing sind\u00adromu, Bartter sindromu, alkaloz v\u0259 osmotik diu\u00adrezd\u0259 is\u0259 serumda kalium konsen\u00adtrasiyas\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KADM\u0130UM<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Cd<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0\u00a0<\/strong>EDTA-l\u0131 tam qan, bird\u0259f\u0259lik sidik, 24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (EDTA-l\u0131 tam qan)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>1 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259ril\u00adm\u0259\u00adli\u00addir. 6N HCl, asetat tur\u015fusu v\u0259 ya bor tur\u015fusu \u00fcz\u0259rin\u0259 \u0259lav\u0259 edil\u0259n si\u00addikl\u0259r d\u0259 q\u0259bul edilir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Siqaret \u00e7\u0259\u00adk\u0259nl\u0259rd\u0259 qanda kadiyum s\u0259viyy\u0259si siqaret \u00e7\u0259km\u0259y\u0259nl\u0259r\u0259 nisb\u0259t\u0259n daha y\u00fcks\u0259kdir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>AAS-Zeeman<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n
Tam qan<\/td>\n0.3-1.2 \u03bcg\/L<\/td>\n<\/tr>\n
Bird\u0259f\u0259lik sidik<\/td>\n0.5-4.7 \u03bcg\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Kadmiuma m\u0259ruz qalan \u015f\u0259xsl\u0259r\u0259 bu madd\u0259nin n\u0259 d\u0259r\u0259c\u0259d\u0259 t\u0259sir etdiyini t\u0259yin etm\u0259k \u00fc\u00e7\u00fcn istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

K (KAL\u0130UM)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0K+<\/sup><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Sutkal\u0131q va\u00adriasiyas\u0131 vard\u0131r. S\u0259h\u0259r saat 08.00-da maksimum, ax\u015fam 22.00-da is\u0259 mi\u00adnimum s\u0259viyy\u0259d\u0259 olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ISE<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si<\/td>\n5.0-10.2 mEq\/L<\/td>\n<\/tr>\n
Yenido\u011fulmu\u015f<\/td>\n3.0-6.0 mEq\/L<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n3.7-5.9 mEq\/L<\/td>\n<\/tr>\n
>7 g\u00fcn<\/td>\n3.5-5.5 mEq\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Elektrolit v\u0259 tur\u015fu-q\u0259\u00adl\u0259vi m\u00fcvazin\u0259tinin qiym\u0259tl\u0259n\u00addiril\u00adm\u0259si, b\u00f6y\u00adr\u0259k funksiyalar\u0131n\u0131n m\u00fc\u015fa\u00adhid\u0259\u00adsin\u00add\u0259 istifad\u0259 olunur. Trom\u00adbositoz, ley\u00adkemiya, hemoliz, toxu\u00adma z\u0259d\u0259l\u0259n\u00adm\u0259\u00adsi, epileptik status, b\u0259dxass\u0259li hi\u00adper\u00adpireksiya, asidoz, k\u0259skin b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, Addi\u00adson x\u0259st\u0259liyi, psev\u00ad\u00addohipoal\u00addos\u00adte\u00adro\u00adnizm, a\u011f\u0131r id\u00adman, \u015fok v\u0259 dehidrata\u00adsiyada serum\u00adda kaliumun s\u0259viyy\u0259si art\u0131r. Xroniki acl\u0131q, diarreya, qus\u00adma, ba\u011f\u0131rsaq fis\u00adtullar\u0131, b\u00f6yr\u0259k bo\u00adrucuqlar\u0131 asidozu, Fanconi sind\u00adromu, birincili v\u0259 ikin\u00adcili aldoste\u00adronizm, Cushing sind\u00adromu, Bartter sindromu, alkaloz v\u0259 osmotik diu\u00adrezd\u0259 is\u0259 serumda kalium konsen\u00adtrasiyas\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

\u0130ONTOFEREZ (XLOR (T\u0259r))<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0T\u0259r testi; \u0130yontoferez<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>T\u0259r<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200\u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0\u00a0<\/strong>N\u00fcmun\u0259 laboratoriyada x\u00fcsusi qayda il\u0259 al\u0131n\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kondaktometrik<\/p>\n

Referens:<\/strong>\u00a0<60 mEq\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Mukovissidozun\u00a0(<\/strong>kistik fib\u00ad\u00adrozis) diaqnozunda istifad\u0259 olu\u00adnur. Mukovissidozlu x\u0259st\u0259l\u0259rd\u0259 t\u0259r il\u0259 duz itkisi \u00e7ox y\u00fcks\u0259lir. \u0130fraz nor\u00admal \u015f\u0259xsl\u0259r\u0259 nisb\u0259t\u0259n 2.5 d\u0259f\u0259 y\u00fck\u00ads\u0259kdir v\u0259 bu x\u0259st\u0259lik \u00fc\u00e7\u00fcn pato\u00adqno\u00admik hesab olunur. X\u0259st\u0259 infantlarda III-V h\u0259ft\u0259d\u0259n sonra po\u00adzitivl\u0259\u015fir. Ad\u00adrenal \u00e7at\u0131\u015fmazl\u0131q, ma\u00adlab\u00adsorbsiya, m\u0259d\u0259alt\u0131 v\u0259z \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131, hipo\u00adti\u00adroidi\u00adzim v\u0259 b\u0259zi b\u00f6yr\u0259k x\u0259st\u0259lik\u00adl\u0259\u00adrind\u0259 d\u0259 t\u0259rd\u0259ki Cl miqdar\u0131 y\u00fcks\u0259l\u0259 bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

\u0130ONLA\u015eMI\u015e KALS\u0130UM<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Ca\u00a01<\/sub>, Ca+2<\/sup><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Heparinli tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Ya\u015f\u0131l qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>1 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 anaerob m\u00fchitd\u0259 al\u0131nmal\u0131 v\u0259 q\u0131sa m\u00fcdd\u0259td\u0259, soyuq \u015f\u0259raitd\u0259 laboratoriyaya \u00e7atd\u0131r\u0131lmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>ISE<\/p>\n

Referens:<\/strong>\u00a01.12-1.32 mmol\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Kalsiumun fizioloji ba\u00adx\u0131m\u00addan aktiv olan formas\u0131d\u0131r. Total kal\u00adsiumun 50-55%-i bu formada olur. Anormal total kalsium n\u0259tic\u0259\u00adl\u0259rinin v\u0259 yenido\u011fulan\u0131n kalsium s\u0259\u00adviyy\u0259sinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 is\u00adti\u00adfad\u0259 olunur. Birincili hiperpa\u00adratiroidizm, D vita\u00admi\u00adninin h\u0259ddind\u0259n art\u0131q q\u0259bulu v\u0259 b\u0259zi malignizasiyalar zaman\u0131 ionla\u015fm\u0131\u015f kal\u00adsiumun miqdar\u0131 art\u0131r, birincili hipopa\u00adra\u00adtiroidizm, psevdohipoparatiroidizm, D vitamini \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, maqnezium \u00e7a\u00adt\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131, \u0259m\u0259liyyatdan sonrak\u0131 v\u0259\u00adziy\u00ady\u0259t\u00adl\u0259r, travma, sepsis, yan\u0131qlar, pank\u00adreatit v\u0259 \u00e7oxsayl\u0131 orqan \u00e7at\u0131\u015fmaz\u00adl\u0131\u011f\u0131nda is\u0259 bu g\u00f6st\u0259rici azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

\u0130NSUL\u0130N C-PEPT\u0130D (C-PEPT\u0130D)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>\u0130nsulin C-peptid; CPR; Birl\u0259\u015fdirici peptid; C-peptid reak\u00adtivliyi)<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 10 saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 laz\u0131md\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>0.15-1.30 pmol\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0C-peptid yaln\u0131z\u00a0 m\u0259d\u0259alt\u0131 v\u0259zin \u03b2 h\u00fcceyr\u0259l\u0259rind\u0259n ifraz olun\u00addu\u011fu \u00fc\u00e7\u00fcn, x\u00fcsusil\u0259 ekzogen insulin istifad\u0259 ed\u0259n diabet x\u0259st\u0259l\u0259rind\u0259, en\u00addogen insulin ifraz\u0131n\u0131n qiym\u0259tl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur. \u0130nsu\u00adlinoma, oral hipoqlikemik d\u0259\u00adr\u00adman\u00adlar, b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, II tip \u015f\u0259k\u0259rli diabet, ql\u00fckoza q\u0259bulu, azan sinirin sti\u00admuliyasiyas\u0131, tirotoksikoz, Cu\u00adshing sindromu, hipokalemiya, ha\u00admil\u0259lik v\u0259 akromeqaliya zaman\u0131 se\u00adrumda C-peptid s\u0259viyy\u0259si art\u0131r, I tip\u00a0 \u015f\u0259k\u0259rli diabet, insulin m\u00fcalic\u0259si, tiazid qrupundan olan diuretikl\u0259r, alkaqol q\u0259bulu v\u0259 pan\u00adkreatek\u00adto\u00admi\u00adyadan sonra is\u0259 C-peptid s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

IGF B\u0130RL\u018f\u015eD\u0130R\u0130C\u0130 PROTEIN-3<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0IGFBP-3; \u0130nsulin like growth factor binding protein-3<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>100 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>IRMA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<1 ya\u015f<\/td>\n1030-3090 ng\/mL<\/td>\n<\/td>\n<\/tr>\n
2-3 ya\u015f<\/td>\n1100-3990 ng\/mL<\/td>\n<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n1400-4250 ng\/mL<\/td>\n<\/td>\n<\/tr>\n
<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n2000-7740 ng\/mL<\/td>\n2000-7060 ng\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n1800-8410 ng\/mL<\/td>\n1820-7330 ng\/mL<\/td>\n<\/tr>\n
16-20 ya\u015f<\/td>\n2000-7480 ng\/mL<\/td>\n2590-7290 ng\/mL<\/td>\n<\/tr>\n
21-25 ya\u015f<\/td>\n2760-7350 ng\/mL<\/td>\n2930-7380 ng\/mL<\/td>\n<\/tr>\n
26-30 ya\u015f<\/td>\n2050-7600 ng\/mL<\/td>\n2330-6680 ng\/mL<\/td>\n<\/tr>\n
31-40 ya\u015f<\/td>\n1730-7260 ng\/mL<\/td>\n1730-7260 ng\/mL<\/td>\n<\/tr>\n
41-50 ya\u015f<\/td>\n2080-4310 ng\/mL<\/td>\n2080-4310 ng\/mL<\/td>\n<\/tr>\n
>50 ya\u015f<\/td>\n2020-3990 ng\/mL<\/td>\n2020-3990 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130nsulin like growth fak\u00adtor\u00adlar (\u0130GF-1 v\u0259 \u0130GF-2) qurulu\u015fca in\u00adsu\u00adlin\u0259 b\u0259nz\u0259m\u0259kl\u0259 yana\u015f\u0131 inki\u015fafa t\u0259\u00adsir ed\u0259n peptidl\u0259rd\u0259ndir. Qandak\u0131 \u0130GF-1 v\u0259 \u0130GF birl\u0259\u015fdirici z\u00fclallara bir\u00adl\u0259\u015f\u0259r\u0259k da\u015f\u0131n\u0131r. Bu proteinl\u0259rd\u0259n \u0259n \u00e7ox \u0130GFBP-3 rast g\u0259linir. H\u0259m\u00ad\u00e7i\u00adnin serumda \u0130GFBP-3 s\u0259viyy\u0259si g\u00fcn \u0259rzind\u0259 d\u0259 sabit qal\u0131r. Boyun inki\u00ad\u015faf\u00addan qalmas\u0131, akromeqaliya, qida\u00adlan\u00adma v\u0259ziyy\u0259tinin qiym\u0259tl\u0259ndi\u00adrilm\u0259\u00adsin\u00add\u0259 istifad\u0259 olunur. \u0130GF-1 il\u0259 bir\u00adlikd\u0259 t\u0259yini klinik \u0259h\u0259miyy\u0259tini daha da art\u0131r\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

I (YOD)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0I<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Ciddi d\u0259r\u0259c\u0259li \u00e7at\u0131\u015fmazl\u0131q<\/td>\n<2 mg\/dL<\/td>\n<\/tr>\n
Orta d\u0259r\u0259c\u0259li \u00e7at\u0131\u015fmazl\u0131q<\/td>\n2-5 mg\/dL<\/td>\n<\/tr>\n
Y\u00fcng\u00fcl d\u0259r\u0259c\u0259li \u00e7at\u0131\u015fmazl\u0131q<\/td>\n5-10 mg\/dL<\/td>\n<\/tr>\n
Normal yod q\u0259bulu<\/td>\n10-20 mg\/dL<\/td>\n<\/tr>\n
Normadan art\u0131q yod q\u0259bulu<\/td>\n20-30 mg\/dL<\/td>\n<\/tr>\n
H\u0259dsiz yod q\u0259bulu<\/td>\n>30 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0Yem\u0259kl\u0259r v\u0259 ya d\u0259r\u00adman\u00adlarla q\u0259bul olunan iyot miqdar\u0131n\u0131n d\u0259y\u0259rl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olunur.\u00a0\u00a0\u00a0<\/strong><\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

H\u018fLLOLAN TRANSFERR\u0130N RESEPTORU<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0sTfR<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Nefelometrik<\/p>\n

Referens:<\/strong>\u00a00.83-1.76 mg\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>D\u0259mir s\u0259viyy\u0259sinin qiy\u00adm\u0259t\u00adl\u0259ndirilm\u0259sind\u0259 d\u0259mir, d\u0259mir bir\u00adl\u0259\u015fdirm\u0259 qabiliyy\u0259ti v\u0259 ferritin testi il\u0259 birlikd\u0259 istifad\u0259 olunur. X\u00fcsusil\u0259 s\u00fcm\u00fck iliyi biopsiyas\u0131 m\u00fcmk\u00fcn ol\u00admayan x\u0259st\u0259l\u0259rd\u0259 d\u0259mir miqdar\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 sTfR s\u0259viy\u00ady\u0259\u00adsi \u0259h\u0259miyy\u0259tlidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HVA (HOMOVAN\u0130L\u0130N TUR\u015eUSU)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>HVA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik, bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Asetat tur\u015fusu \u00fcz\u0259\u00adri\u00adn\u0259 y\u0131\u011f\u0131lmal\u0131d\u0131r. 6N HCl \u00fcz\u0259rin\u0259 y\u0131\u011f\u0131\u00adlan sidikl\u0259r d\u0259 q\u0259bul olunur<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 sa\u00adatl\u0131q sidiyin miqdar\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>HPLC<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n
24 saatl\u0131q sidik<\/td>\n3-5 ya\u015f<\/td>\n1.4-4.3 mg\/g\u00fcn<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n2.1-4.7 mg\/g\u00fcn<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n2.4-8.7 mg\/g\u00fcn<\/td>\n<\/tr>\n
<15 ya\u015f<\/td>\n1.4-8.8 mg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0Dofaminin major ter\u00admi\u00adnal metabolitidir. Feoxromasitoma, neyroblastoma v\u0259 qanqlio\u00adblas\u00adto\u00adma\u00adn\u0131n diaqnoz v\u0259 m\u00fc\u015fahid\u0259sind\u0259 isti\u00adfad\u0259 olunur. 24 saatl\u0131q sidikd\u0259 m\u00fca\u00adyin\u0259si daha optimal n\u0259tic\u0259 verir<\/strong><\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

hs-CRP (C-REAKT\u0130V PROTE\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>CRP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0T\u00fcrbidimetrik<\/p>\n

Referens:\u00a0<\/strong><3 mg\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qeyri spesifik k\u0259skin faza reaktant\u0131d\u0131r. \u0130nfeksiya v\u0259 iltihabi prosesl\u0259rin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 is\u00adti\u00adfad\u0259 olunur. CRP virus v\u0259 spiroxet m\u0259n\u015f\u0259li infeksiyalar zaman\u0131 artma\u00add\u0131\u00ad\u011f\u0131ndan, x\u00fcsusil\u0259 bakterial infek\u00adsi\u00adyalar\u0131n t\u0259yinind\u0259 \u00e7ox \u0259h\u0259miyy\u0259tlidir. CRP-nin y\u00fcks\u0259lm\u0259si koronar \u00fcr\u0259k x\u0259st\u0259liyi riskinin erk\u0259n g\u00f6st\u0259ricisi oldu\u011fundan, bu riskin skrininqi m\u0259qs\u0259dil\u0259 d\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HPT (HAPTOGLOB\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>HPT<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Nefelometrik<\/p>\n

Referens:\u00a0<\/strong>30-200 mg\/dL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>\u0130n vivo hemolizin t\u0259\u00adyinind\u0259 istifad\u0259 olunan k\u0259skin faza z\u00fclal\u0131d\u0131r. K\u0259skin v\u0259 xroniki iltihabi prosesl\u0259r, neoplastik x\u0259st\u0259likl\u0259r, kor\u00adtikosteroid m\u00fcalic\u0259si v\u0259 biliar obst\u00adruksiyalarda serumda HPT-nin miq\u00addar\u0131 art\u0131r, in vivo hemoliz (hemo\u00adqlo\u00adbinopatiyalar, eritrosit membran de\u00adfektl\u0259ri, autoimmun hemolitik x\u0259s\u00adt\u0259likl\u0259r, mexaniki hemoliz, hiper\u00adsplenizm), qaraciy\u0259r x\u0259st\u0259likl\u0259ri, es\u00adte\u00adrogen m\u00fcalic\u0259si, hamil\u0259lik v\u0259 oral kontraseptiv istifad\u0259si\u00a0 zaman\u0131 is\u0259 bu g\u00f6st\u0259rici azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HOMOVAN\u0130L\u0130N TUR\u015eUSU<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>HVA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik, bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Asetat tur\u015fusu \u00fcz\u0259\u00adri\u00adn\u0259 y\u0131\u011f\u0131lmal\u0131d\u0131r. 6N HCl \u00fcz\u0259rin\u0259 y\u0131\u011f\u0131\u00adlan sidikl\u0259r d\u0259 q\u0259bul olunur<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 sa\u00adatl\u0131q sidiyin miqdar\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>HPLC<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n
24 saatl\u0131q sidik<\/td>\n3-5 ya\u015f<\/td>\n1.4-4.3 mg\/g\u00fcn<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n2.1-4.7 mg\/g\u00fcn<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n2.4-8.7 mg\/g\u00fcn<\/td>\n<\/tr>\n
<15 ya\u015f<\/td>\n1.4-8.8 mg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0Dofaminin major ter\u00admi\u00adnal metabolitidir. Feoxromasitoma, neyroblastoma v\u0259 qanqlio\u00adblas\u00adto\u00adma\u00adn\u0131n diaqnoz v\u0259 m\u00fc\u015fahid\u0259sind\u0259 isti\u00adfad\u0259 olunur. 24 saatl\u0131q sidikd\u0259 m\u00fca\u00adyin\u0259si daha optimal n\u0259tic\u0259 verir<\/strong><\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HOMOS\u0130ST\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259ril\u00adm\u0259lidir. Askorbin tur\u00ad\u015fusu interferensiyaya s\u0259b\u0259b oldu\u00ad\u011fun\u00addan, son 48 saat \u0259rzind\u0259 C vita\u00admini istifad\u0259 olunmamal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Kolorimetrik<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Homosistinuriyan\u0131n t\u0259yi\u00adnind\u0259 istifad\u0259 olunur. H\u0259m\u00e7inin ge\u00adne\u00adraliz\u0259 olunmu\u015f aminoasi\u00adduri\u00adya\u00adlar\u00adda da sidikd\u0259 homosistinin s\u0259viyy\u0259si y\u00fcks\u0259l\u0259 bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

HOMOS\u0130STE\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hcy<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131\u00a0 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fcmun\u0259 al\u0131nd\u0131rdan sonra plazma hemoliz\u0259 u\u011framadan t\u0259cili ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259 acqar\u0131na g\u00f6t\u00fcr\u00fclm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>HPLC<\/p>\n

Referens:\u00a0<\/strong>\u03bcmol\/L<\/p>\n\n\n\n\n\n\n
Ya\u015f<\/td>\nNormal<\/td>\n\u015e\u00fcbh\u0259li<\/td>\nY\u00fcks\u0259k<\/td>\n<\/tr>\n
<15 ya\u015f<\/td>\n<8.0<\/td>\n8.0-10.0<\/td>\n>10.0<\/td>\n<\/tr>\n
15-65 ya\u015f<\/td>\n<12.0<\/td>\n12.0-15.0<\/td>\n>15.0<\/td>\n<\/tr>\n
>65 ya\u015f<\/td>\n<16.0<\/td>\n16.0-20.0<\/td>\n>20.0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Plazmadak\u0131 total homo\u00adsis\u00adtein s\u0259viyy\u0259si kardiovaskuliyar x\u0259s\u00adt\u0259likl\u0259r \u00fc\u00e7\u00fcn s\u0259rb\u0259st risk fak\u00adtorudur. Genetik mutasiyalar v\u0259 ya esensial vitamin kofaktorlar\u0131ndak\u0131 \u00e7at\u0131\u015fmazl\u0131q ferment funksiyalar\u0131na t\u0259sir ed\u0259r\u0259k homosisteinin s\u0259viyy\u0259\u00adsini art\u0131r\u0131r. Homosistein s\u0259viyy\u0259si y\u00fcks\u0259k olan \u015f\u0259xsl\u0259rd\u0259 ateroskleroz v\u0259 trombemboliya riski y\u00fcks\u0259k olur. H\u0259m\u00e7inin qanda v\u0259 sidikd\u0259 homo\u00adsistein s\u0259viyy\u0259sinin artm\u0131\u015f oldu\u011fu anadang\u0259lm\u0259 metobolizm poz\u011fun\u00adlu\u011fu olan homosis\u00adteinuriyan\u0131n diaq\u00adnos\u00adtikas\u0131nda da istifad\u0259 olunur. Vita\u00admin B12<\/sub>\u00a0\u00e7at\u0131\u015fmazl\u0131\u011f\u0131, ya\u015f v\u0259 siqaret istifad\u0259si homosistein s\u0259viyy\u0259sini art\u0131r\u0131r, fol tur\u015fusunun istifad\u0259si il\u0259 homosistein s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KAL\u0130UM (BOM)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ISE<\/p>\n

Referens:<\/strong>\u00a02.2-3.3 mEq\/L<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KAL\u0130UM (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a024 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxla\u00adn\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a024 saatl\u0131q sidiyin miqdar\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ISE<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
<12 ya\u015f<\/td>\n15-55 mEq\/g\u00fcn<\/td>\n8-37 mEq\/g\u00fcn<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n20-60 mEq\/g\u00fcn<\/td>\n18-60 mEq\/g\u00fcn<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n25-125 mEq\/g\u00fcn<\/td>\n25-125 mEq\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Elektrolit v\u0259 tur\u015fu q\u0259l\u0259vi m\u00fcvazin\u0259tinin qiym\u0259tl\u0259ndiril\u00adm\u0259si, b\u00f6y\u00adr\u0259k funksiyalar\u0131n\u0131n m\u00fc\u015fahi\u00add\u0259\u00adsin\u00add\u0259 istifad\u0259 olunur. Cushing sind\u00adro\u00admu, birincili v\u0259 ikincili aldoste\u00adronizm, birincili b\u00f6yr\u0259k x\u0259st\u0259\u00adlikl\u0259ri v\u0259 kortizon m\u00fcalic\u0259si zaman\u0131 sidikl\u0259 ifraz olunan kalium miqdar\u0131 art\u0131r, Addisson x\u0259st\u0259liyind\u0259 is\u0259 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KALS\u0130UM<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Ca<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 10 saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 laz\u0131md\u0131r. N\u00fcmun\u0259 al\u0131nark\u0259n turna 10 d\u0259qiq\u0259d\u0259n \u00e7ox saxlan\u0131l\u00admamal\u0131d\u0131r. Qanda Ca s\u0259viyy\u0259si saat 02.00-04.00 aras\u0131nda minimal, 20.00 da is\u0259 maksimal s\u0259viyy\u0259d\u0259 olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, n\u00fcmun\u0259nin uy\u011fun olmayan s\u0131naq \u015f\u00fc\u015f\u0259sin\u0259 al\u0131nmas\u0131<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259sind\u0259n al\u0131nm\u0131\u015f qanda<\/td>\n8.2-11.5 mg\/dL<\/td>\n<\/tr>\n
Yenido\u011fulanlar<\/td>\n6.2-11.0 mg\/dL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n8.0-10.6 mg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-12 ya\u015f<\/td>\n8.8-10.8 mg\/dL<\/td>\n<\/tr>\n
13-60 ya\u015f<\/td>\n8.4-10.2 mg\/dL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n8.4-10.0 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0M\u00fcxt\u0259lif endokrin v\u0259 me\u00adtabolik poz\u011funluqlar\u0131n qiym\u0259tl\u0259n\u00addi\u00adrilm\u0259sind\u0259 istifad\u0259 olunur. \u0130lkin v\u0259 geriy\u0259 d\u00f6n\u0259n hiperparatiroidizm, s\u00fc\u00adm\u00fck metastazlar\u0131, m\u00fcxt\u0259lif\u00a0 b\u0259dxas\u00ads\u0259\u00adli t\u00f6r\u0259m\u0259l\u0259r, polisitemiya vera, feo\u00adxro\u00admasitoma, sarkoidoz, D vita\u00admini intoksikasiyas\u0131, s\u00fcd q\u0259l\u0259vi sind\u00adromu, tirotoksikoz, akromeqaliya v\u0259 dehidratasiyaya s\u0259b\u0259b olan hallarda serumda kalsium s\u0259viyy\u0259si art\u0131r. Hi\u00adpoparatiroidizm, psevdohipo\u00adparati\u00adroidzm, D vitamini \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, xro\u00adniki b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, Mg \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131, k\u0259skin pankreatit, hiper\u00adfosfatemiya, sistinoz, osto\u00admali\u00adya\u00adsi\u00adya, alkoqolizm, qaraciy\u0259r sirrozu v\u0259 hipoalbuminemiya zaman\u0131 serumda Ca s\u0259viyy\u0259si azal\u0131r. H\u0259m\u00e7inin total Ca s\u0259viyy\u0259si qandak\u0131 z\u00fclal konsen\u00adtrasiyas\u0131ndan as\u0131l\u0131d\u0131r. Z\u00fclal\u0131n miq\u00addar\u0131 1 g\/dL artarsa, Ca miqdar\u0131 t\u0259x\u00admin\u0259n 0.8 mg\/dL azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KALS\u0130UM (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik, bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq m\u00fchitd\u0259 sax\u00adlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir. 6N HCl, asetat v\u0259 ya bor tur\u015fusu \u00fcz\u0259rin\u0259 toplanan sidikl\u0259r d\u0259 q\u0259bul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>1 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 saatl\u0131q sidiiyin miqdar\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Sperktofotometrik<\/p>\n

Referens:<\/strong>\u00a024 saatl\u0131q sidik 0.1-0.3 g\/g\u00fcn<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Ca metobolizminin qiy\u00adm\u0259tl\u0259ndiilm\u0259sind\u0259 istifad\u0259 olunur. Hi\u00adperparatiroidizm, osteolitik s\u00fcm\u00fck metastazlar\u0131, mieoloma, osteopa\u00adroz, D vitamini intoksikasiyas\u0131, distal re\u00adnal tubulyar asidoz, idiopatik hiper\u00adkalsiuriya, tirotoksikoz, immo\u00adbili\u00adza\u00adsiya v\u0259 sarkoidozda sidikd\u0259 Ca s\u0259\u00adviyy\u0259si art\u0131r. Hipoparatiroidzm, psev\u00ad\u00addohipoparatiroidizm, rikets, k\u0259s\u00adkin nefrit, osteomalyasiya, serumda Ca s\u0259viyy\u0259sinin a\u015fa\u011f\u0131 oldu\u011fu hallar, osteoblastik metastazlar, hipo\u00adti\u00adroidizim v\u0259 celiac sprue x\u0259st\u0259liyind\u0259 is\u0259 Ca s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KOPROPORF\u0130R\u0130N (PORF\u0130R\u0130NL\u018fR)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a010 mL<\/p>\n

Testin t\u0259rkibi:<\/strong>\u00a0Uroporfirin I, III, koproporfirin I, III v\u0259 dig\u0259r porfirin izomerl\u0259ri<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Qa\u00adranl\u0131q v\u0259 soyuq \u015f\u0259raitd\u0259 toplanmal\u0131, i\u015f\u0131qdan qorunmaqla soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
Uropofinin I, III<\/td>\n25 mg\/g\u00fcn<\/td>\n<\/tr>\n
Koproporfirin I<\/td>\n25 mg\/g\u00fcn<\/td>\n<\/tr>\n
Koproporfirin III<\/td>\n75 mg\/g\u00fcn<\/td>\n<\/tr>\n
Total porfirinl\u0259r<\/td>\n150 mg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Porfiriyalar\u0131n t\u0259yinind\u0259 v\u0259 tipinin m\u00fc\u0259yy\u0259nl\u0259\u015fdirilm\u0259sind\u0259 is\u00adtifad\u0259 olunur. X\u00fcsusil\u0259 d\u0259ri\u00a0 foto\u00adh\u0259ssasl\u0131\u011f\u0131 m\u00fc\u015fahid\u0259 olunan porfiri\u00adyalarda sidik porfirinl\u0259ri \u0259h\u0259\u00admiy\u00ady\u0259t\u00adlidir. HPLC \u00fcsulu il\u0259 sidikd\u0259ki b\u00fct\u00fcn porfirin n\u00f6vl\u0259ri v\u0259 izomerl\u0259ri k\u0259\u00admiyy\u0259tc\u0259 t\u0259yin oluna bil\u0259r. H\u0259m\u00e7inin civ\u0259 z\u0259h\u0259rl\u0259nm\u0259si, qaraciy\u0259r x\u0259s\u00adt\u0259\u00adliyi, k\u0259skin miokard infarkt\u0131, he\u00admo\u00adlitik v\u0259 pernisitoz anemiyalar, alko\u00adqol m\u0259n\u015f\u0259li sirroz, idman, Hodgkin x\u0259st\u0259liyi, leykoz, triotoksikoz v\u0259 vi\u00adtamin \u00e7at\u0131\u015f\u00admazl\u0131qlar\u0131 kimi s\u0259b\u0259b\u00adl\u0259r\u00add\u0259n \u0259m\u0259l\u0259 g\u0259l\u0259n qazan\u0131lm\u0131\u015f por\u00adfi\u00adri\u00adyalardada sidikd\u0259 koproporfirinin s\u0259viyy\u0259si art\u0131r. K\u0259skin porfiriyalar\u0131n qiym\u0259t\u00adl\u0259ndirilm\u0259sind\u0259 is\u0259 sidikd\u0259 ALA v\u0259 porfobilinogen s\u0259viyy\u0259si is\u00adtifad\u0259 olunmal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KREAT\u0130N FOSFOK\u0130NAZA (KREAT\u0130N K\u0130NAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0CK; Total kreatin kinaza; CPK; Kreatin fosfokinaza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, ki\u00adnetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admoliz<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n
<7 g\u00fcn<\/td>\n22-500 IU\/L<\/td>\n<\/tr>\n
7 g\u00fcn-1ay<\/td>\n22-240 IU\/L<\/td>\n<\/tr>\n
<1 ay<\/td>\n22-220 IU\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Skelet v\u0259 \u00fcr\u0259k \u0259z\u0259l\u0259sind\u0259 degenrasiyaya s\u0259b\u0259b olan hallar\u0131n qiym\u0259tl\u0259ndirilm\u0259sid\u0259 istifad\u0259 olunur. KM\u0130, proqressiv \u0259z\u0259l\u0259 distrofiyalar\u0131, polimiozit, yan\u0131qlar, travma, a\u011f\u0131r id\u00adman, status epileptikus, \u0259m\u0259liyyat\u00addan sonrak\u0131 d\u00f6vr, yay\u0131lm\u0131\u015f beyin infarkt\u0131, hamil\u0259liyin son d\u00f6vrl\u0259ri v\u0259 do\u011fu\u015f, b\u0259dxass\u0259li hipertermiya, \u0130M infeksiyalar, q\u0131colmalar v\u0259 \u00fcr\u0259yin de\u00adfibriliyasiyas\u0131ndan sonra CK s\u0259\u00adviyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KREAT\u0130N K\u0130NAZA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0CK; Total kreatin kinaza; CPK; Kreatin fosfokinaza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, ki\u00adnetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admoliz<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n
<7 g\u00fcn<\/td>\n22-500 IU\/L<\/td>\n<\/tr>\n
7 g\u00fcn-1ay<\/td>\n22-240 IU\/L<\/td>\n<\/tr>\n
<1 ay<\/td>\n22-220 IU\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Skelet v\u0259 \u00fcr\u0259k \u0259z\u0259l\u0259sind\u0259 degenrasiyaya s\u0259b\u0259b olan hallar\u0131n qiym\u0259tl\u0259ndirilm\u0259sid\u0259 istifad\u0259 olunur. KM\u0130, proqressiv \u0259z\u0259l\u0259 distrofiyalar\u0131, polimiozit, yan\u0131qlar, travma, a\u011f\u0131r id\u00adman, status epileptikus, \u0259m\u0259liyyat\u00addan sonrak\u0131 d\u00f6vr, yay\u0131lm\u0131\u015f beyin infarkt\u0131, hamil\u0259liyin son d\u00f6vrl\u0259ri v\u0259 do\u011fu\u015f, b\u0259dxass\u0259li hipertermiya, \u0130M infeksiyalar, q\u0131colmalar v\u0259 \u00fcr\u0259yin de\u00adfibriliyasiyas\u0131ndan sonra CK s\u0259\u00adviyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KREAT\u0130N K\u0130NAZA, MB<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0\u0130mmunoinhibasiya (spek\u00adtro\u00adfotometrik, kinetik) v\u0259 ya mass \u00f6l\u00e7m\u0259 (MEIA)<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n
\u0130mmunoinhibasiya<\/td>\n<25 U\/L<\/td>\n<\/tr>\n
MEIA<\/td>\n<5 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>KM\u0130-nin diaqnosti\u00adka\u00ads\u0131n\u00adda istifad\u0259 olunur. CK\/CK-MB nisb\u0259ti m\u0259sl\u0259h\u0259t g\u00f6r\u00fcl\u00fcr. KM\u0130-d\u0259n sonra 4-8 saat \u0259rzind\u0259 y\u00fcks\u0259lm\u0259y\u0259 ba\u015flay\u0131r v\u0259 24 saata pik s\u0259viyy\u0259y\u0259 \u00e7a\u00adt\u0131r. H\u0259m\u00ad\u00e7inin \u00fcr\u0259k travmalar\u0131, mio\u00adkardit, kongestiv \u00fcr\u0259k \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131, koronar angioqrafiya, \u00fcr\u0259k c\u0259r\u00adra\u00adhiy\u0259si, \u0259z\u0259l\u0259 distrofiyas\u0131, poli\u00admio\u00adzit, SLE, ya\u00adn\u0131qlar, Reye sindromu, hipotermiya v\u0259 hipertermiyada CK-MB s\u0259viyy\u0259si y\u00fcks\u0259lir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KREAT\u0130N\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, ki\u00adnetik<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si qan\u0131<\/td>\n0.6-1.2 mg\/dL<\/td>\n<\/tr>\n
Yenido\u011fulmu\u015f<\/td>\n0.3-1.0 mg\/dL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n0.3-1.0 mg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-3 ay<\/td>\n0.2-0.4 mg\/dL<\/td>\n<\/tr>\n
4 ay-5 ya\u015f<\/td>\n0.3-0.7 mg\/dL<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n0.5-1.0 mg\/dL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n0.5-1.2 mg\/dL<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\nKi\u015fi: 0.5-1.4 mg\/dL<\/td>\n<\/tr>\n
Qad\u0131n: 0.5-1.3 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0B\u00f6yr\u0259k funksiyalar\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olnur. B\u00f6yr\u0259k x\u0259st\u0259likl\u0259ri, \u015fok, b\u0259d xass\u0259li t\u00f6r\u0259m\u0259l\u0259r, SLE, diabetik nefropatiya, k\u0259skin \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 akro\u00adme\u00adqaliyada serumda kreatininin s\u0259viy\u00ady\u0259si art\u0131r, \u0259z\u0259l\u0259 distrofiyas\u0131 v\u0259 dia\u00adbetik ketoasidozda is\u0259 azal\u0131r. B\u00f6\u00ady\u00fck\u00adl\u0259rd\u0259 kreatinin il\u0259 birlikd\u0259 MDRD formuluna \u0259sas\u0259n hesablanan qlo\u00admerulyar filtrasiya s\u00fcr\u0259ti (GFR) d\u0259y\u0259ri d\u0259 verilir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KREAT\u0130N\u0130N (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik, bird\u0259flik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 sax\u00adlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir. 6N HCl v\u0259 ya bor tur\u015fusu \u00fcz\u0259rin\u0259 top\u00adlanan sidikl\u0259r d\u0259 q\u0259bul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 sa\u00adatl\u0131q sidik miqdar\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, ki\u00adnetik<\/p>\n

Referens:<\/strong>\u00a024 saatl\u0131q sidik<\/p>\n\n\n\n\n\n\n\n\n\n
<3 ay<\/td>\n0.02-0.10 g\/g\u00fcn<\/td>\n<\/tr>\n
4-12 ay<\/td>\n0.10-0.50 g\/g\u00fcn<\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n0.10-0.60 g\/g\u00fcn<\/td>\n<\/tr>\n
<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
4-12 ya\u015f<\/td>\n0.30-0.80 g\/g\u00fcn<\/td>\n0.10-0.60 g\/g\u00fcn<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n0.40-1.10 g\/g\u00fcn<\/td>\n0.30-1.10 g\/g\u00fcn<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n0.80-1.80 g\/g\u00fcn<\/td>\n0.60-1.60 g\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0B\u00f6yr\u0259k funksiyalar\u0131n\u0131n qiym\u0259tl\u0259nirilm\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KREAT\u0130N\u0130N KL\u0130RENS\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum v\u0259 24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum). 24 saatl\u0131q sidik soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6n\u00add\u0259rilm\u0259lidir. 6N HCl v\u0259 ya bor tur\u00ad\u015fusu \u00fcz\u0259rin\u0259 toplanan sidikl\u0259r d\u0259 q\u0259\u00adbul olunur<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200\u03bcL serum v\u0259 1 mL sidik<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a024 sa\u00adatl\u0131q sidik miqdar\u0131 bildirilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0X\u0259st\u0259 mua\u00adyin\u0259 m\u00fcdd\u0259tind\u0259 \u00e7ay v\u0259 q\u0259hv\u0259 i\u00e7\u00adm\u0259\u00adm\u0259li, h\u0259r hans\u0131 bir d\u0259rman preparat\u0131 istifad\u0259 etm\u0259m\u0259li, idmanla m\u0259\u015f\u011ful olmamal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, kinetik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
1-3 ya\u015f<\/td>\n45-65 mL\/dk<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n60-80 mL\/dk<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n70-100 mL\/dk<\/td>\n<\/tr>\n
<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
13-50 ya\u015f<\/td>\n90-137 mL\/dk<\/td>\n80-125 mL\/dk<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n85-132 mL\/dk<\/td>\n75-120 mL\/dk<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n80-132 mL\/dk<\/td>\n70-120 mL\/dk<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0B\u00f6yr\u0259k funksiyalar\u0131n\u0131n qiy\u00adm\u0259tl\u0259nirilm\u0259si v\u0259 b\u00f6yr\u0259k x\u0259st\u0259\u00adlik\u00adl\u0259rinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olu\u00adnur. Qlomerulyar filtirasiya s\u00fcr\u0259tini azal\u00addan h\u0259r hans\u0131 b\u00f6yr\u0259k x\u0259st\u0259liyi, \u015fok, hipovolemiya, nefrotoksik d\u0259r\u00admanlar, k\u0259skin \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 de\u00adhidratasiya kreatinin klirensind\u0259 azal\u00admaya s\u0259b\u0259b olur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KREAT\u0130N\u0130N KL\u0130RENS\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum v\u0259 24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum). 24 saatl\u0131q sidik soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6n\u00add\u0259rilm\u0259lidir. 6N HCl v\u0259 ya bor tur\u00ad\u015fusu \u00fcz\u0259rin\u0259 toplanan sidikl\u0259r d\u0259 q\u0259\u00adbul olunur<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200\u03bcL serum v\u0259 1 mL sidik<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a024 sa\u00adatl\u0131q sidik miqdar\u0131 bildirilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0X\u0259st\u0259 mua\u00adyin\u0259 m\u00fcdd\u0259tind\u0259 \u00e7ay v\u0259 q\u0259hv\u0259 i\u00e7\u00adm\u0259\u00adm\u0259li, h\u0259r hans\u0131 bir d\u0259rman preparat\u0131 istifad\u0259 etm\u0259m\u0259li, idmanla m\u0259\u015f\u011ful olmamal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, kinetik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
1-3 ya\u015f<\/td>\n45-65 mL\/dk<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n60-80 mL\/dk<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n70-100 mL\/dk<\/td>\n<\/tr>\n
<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
13-50 ya\u015f<\/td>\n90-137 mL\/dk<\/td>\n80-125 mL\/dk<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n85-132 mL\/dk<\/td>\n75-120 mL\/dk<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n80-132 mL\/dk<\/td>\n70-120 mL\/dk<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0B\u00f6yr\u0259k funksiyalar\u0131n\u0131n qiy\u00adm\u0259tl\u0259nirilm\u0259si v\u0259 b\u00f6yr\u0259k x\u0259st\u0259\u00adlik\u00adl\u0259rinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olu\u00adnur. Qlomerulyar filtirasiya s\u00fcr\u0259tini azal\u00addan h\u0259r hans\u0131 b\u00f6yr\u0259k x\u0259st\u0259liyi, \u015fok, hipovolemiya, nefrotoksik d\u0259r\u00admanlar, k\u0259skin \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 de\u00adhidratasiya kreatinin klirensind\u0259 azal\u00admaya s\u0259b\u0259b olur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

M\u0130KROALBUM\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a024 saatl\u0131q sidik, bir gec\u0259lik sidik, bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitda sax\u00adlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0Sidik toplanma vaxt\u0131 v\u0259 miqdar\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0\u0130mmunturbidimetrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
24 saatl\u0131q sidik<\/td>\n30 mg\/g\u00fcn<\/td>\n<\/tr>\n
Bir gec\u0259lik sidik<\/td>\n20 mg\/g\u00fcn<\/td>\n<\/tr>\n
Bird\u0259fik sidik<\/td>\n30 mg\/g kreatinin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Diabetik nefropariya, retinopatiya v\u0259 I tip \u015f\u0259k\u0259rli diabetin erk\u0259n diaqnozunda, m\u00fcalic\u0259nin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Mg (MAQNEZ\u0130UM)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Mg<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (\u0259vv\u0259ll\u0259r he\u00e7 istifad\u0259 olunmam\u0131\u015f v\u0259 ya nitrat tur\u015fusu il\u0259 yuyulmu\u015f v\u0259 distill\u0259 v\u0259 ya ionsuzla\u015fd\u0131r\u0131lm\u0131\u015f su il\u0259 yaxalanm\u0131\u015f s\u0131naq \u015f\u00fc\u015f\u0259l\u0259rind\u0259 g\u00f6nd\u0259rilm\u0259lidir)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn x\u0259st\u0259 acqar\u0131na olmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz<\/p>\n

Referens:<\/strong>\u00a01.2-2.5 mg\/dL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Maqnezium metobalizmi v\u0259 elektrolit m\u00fcvazin\u0259tinin qiym\u0259t\u00adl\u0259n\u00addirilm\u0259si il\u0259 preeklampsiya m\u00fca\u00adli\u00adc\u0259si alan x\u0259st\u0259l\u0259rin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur. Maqneziumun se\u00adrumdak\u0131 konsentrasiyas\u0131 ad\u0259t\u0259n BOM v\u0259 eritrositl\u0259rd\u0259ki il\u0259 paralel h\u0259r\u0259k\u0259t edir. Dehidratasiya, b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, adrenokortikal \u00e7at\u0131\u015f\u00admazl\u0131q, Addison x\u0259st\u0259liyi, travma, hipotiroidizim v\u0259 multiple mielo\u00admada serumda Mg s\u0259viyy\u0259si art\u0131r, p\u0259hriz il\u0259 Mg q\u0259bulunun azalmas\u0131, k\u0259skin pankreatit, hipoparatiroidizm, xroniki alkoqolizm, delirium tre\u00admens, xroniki qlomeru\u00adlonefrit, hiper\u00adal\u00addosteronizm, diabetik ketoasidoz v\u0259 hamil\u0259likd\u0259 is\u0259 Mg s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

MET\u0130LH\u0130PPURAT TUR\u015eUSU<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Orto-, meta- v\u0259 ya para-metilhippur tur\u015fusu<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong>\u00a0<50 mg\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Ksilen il\u0259 i\u015fl\u0259y\u0259n \u015f\u0259xsl\u0259rin bu madd\u0259nin t\u0259sirin\u0259 m\u0259ruz qalma d\u0259r\u0259c\u0259sinin t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

METHEMOQLOB\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0MetHb; HbM<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0N\u00fc\u00admu\u00adn\u0259nin laxtal\u0131 v\u0259 ya hemolizli olmas\u0131<\/p>\n

Referens:<\/strong>\u00a0<1.5%<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Anadang\u0259lm\u0259 v\u0259 qaza\u00adn\u0131lm\u0131\u015f methemoqlobinemiya, karbon monooksid z\u0259h\u0259rl\u0259nm\u0259si, benzokain, nitroqliserin, lidokain, nitratlar, fena\u00adsetin, sulfanilamidl\u0259r v\u0259 radiasiya methemoqlobin s\u0259viyy\u0259sinin artma\u00ads\u0131na s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Mb (MYOQLOB\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Mb<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0T\u00fcrbidimetrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Ki\u015fi<\/td>\n16-74 ng\/mL<\/td>\n<\/tr>\n
Qad\u0131n<\/td>\n7-64 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Serumda mioqlobinin s\u0259\u00adviy\u00ady\u0259si birba\u015fa \u0259z\u0259l\u0259 k\u00fctl\u0259si il\u0259 \u0259la\u00adq\u0259\u00addar\u00add\u0131r. Skelet v\u0259 \u00fcr\u0259k \u0259z\u0259l\u0259sind\u0259 z\u0259d\u0259\u00adl\u0259n\u00adm\u0259, nekroz v\u0259 ya lizis\u0259 s\u0259b\u0259b olan b\u00fc\u00adt\u00fcn hallar (m\u0259s. iskemiya, rab\u00addomioliz, miopatiya, \u0259z\u0259l\u0259 distro\u00adfiyas\u0131, miozit), uremiya, travma, if\u00adlic, iltihabi mio\u00adpa\u00adtiya, \u0259z\u0259l\u0259daxili in\u00adyeksiya, idman v\u0259 yan\u0131qlarda se\u00adrum\u00adda mioqlobin s\u0259viy\u00ady\u0259\u00adsi art\u0131r, qanda mioqlobin\u0259 qar\u015f\u0131 an\u00adti\u00adcisim olduqda v\u0259 revmatoid artritd\u0259 is\u0259 azal\u0131r. KM\u0130-dan sonra 1-4-c\u00fc saatlarda mioqlobin s\u0259viyy\u0259si y\u00fcks\u0259lir v\u0259 24-c\u00fc saatda normala enir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

MAQNEZ\u0130UM (Eritrositdaxili)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS<\/p>\n

Referens:<\/strong>\u00a04.0-6.4 mg\/dL<\/p>\n

\u0130stifad\u00ad\u0259si:\u00a0<\/strong>Eritrositdaxili Mg kon\u00adsen\u00adtrasiyas\u0131 ad\u0259t\u0259n serum Mg konsentrasiyas\u0131 il\u0259 paralel d\u0259yi\u015fir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

MAQNEZ\u0130UM<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Mg<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (\u0259vv\u0259ll\u0259r he\u00e7 istifad\u0259 olunmam\u0131\u015f v\u0259 ya nitrat tur\u015fusu il\u0259 yuyulmu\u015f v\u0259 distill\u0259 v\u0259 ya ionsuzla\u015fd\u0131r\u0131lm\u0131\u015f su il\u0259 yaxalanm\u0131\u015f s\u0131naq \u015f\u00fc\u015f\u0259l\u0259rind\u0259 g\u00f6nd\u0259rilm\u0259lidir)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn x\u0259st\u0259 acqar\u0131na olmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz<\/p>\n

Referens:<\/strong>\u00a01.2-2.5 mg\/dL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Maqnezium metobalizmi v\u0259 elektrolit m\u00fcvazin\u0259tinin qiym\u0259t\u00adl\u0259n\u00addirilm\u0259si il\u0259 preeklampsiya m\u00fca\u00adli\u00adc\u0259si alan x\u0259st\u0259l\u0259rin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur. Maqneziumun se\u00adrumdak\u0131 konsentrasiyas\u0131 ad\u0259t\u0259n BOM v\u0259 eritrositl\u0259rd\u0259ki il\u0259 paralel h\u0259r\u0259k\u0259t edir. Dehidratasiya, b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, adrenokortikal \u00e7at\u0131\u015f\u00admazl\u0131q, Addison x\u0259st\u0259liyi, travma, hipotiroidizim v\u0259 multiple mielo\u00admada serumda Mg s\u0259viyy\u0259si art\u0131r, p\u0259hriz il\u0259 Mg q\u0259bulunun azalmas\u0131, k\u0259skin pankreatit, hipoparatiroidizm, xroniki alkoqolizm, delirium tre\u00admens, xroniki qlomeru\u00adlonefrit, hiper\u00adal\u00addosteronizm, diabetik ketoasidoz v\u0259 hamil\u0259likd\u0259 is\u0259 Mg s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

MANDEL\u0130K TUR\u015eUSU<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259\u00adril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong>\u00a0<5 mg\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Etilbenzin v\u0259 styren il\u0259 i\u015fl\u0259y\u0259n \u015f\u0259xsl\u0259rin bu madd\u0259l\u0259rin t\u0259sirin\u0259 m\u0259ruz qalma d\u0259r\u0259c\u0259sinin t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

MAGNEZ\u0130UM (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir. 6N HCl, asetat tur\u015fusu v\u0259 ya bor tur\u015fusu \u00fcz\u0259rin\u0259 toplanan\u00a0 sidikl\u0259r d\u0259 q\u0259bul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 saatl\u0131q sidiyin miqdar\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS<\/p>\n

Referens:<\/strong>\u00a050-150 mg\/g\u00fcn<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Mg metobolizmi v\u0259 elektrolit m\u00fcvazin\u0259tinin qiym\u0259tl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 edilir. Qida il\u0259 q\u0259bul edil\u0259n Mg miqdar\u0131 sidikl\u0259 ifraz olunan miqdara t\u0259sir edir. H\u0259m\u00e7inin alkoqol istifad\u0259si, diuretikl\u0259r, Bartter sindromu, kortikosteroidl\u0259r v\u0259 cisplatin sidikl\u0259 ifraz olunan Mg miqdar\u0131n\u0131 art\u0131r\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Lp (L\u0130POPROTE\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Lp (a)<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 10 saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 laz\u0131md\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0\u0130mmunoturbidimetrik<\/p>\n

Referens:<\/strong>\u00a0<30 mg\/dL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Lp(a) s\u0259viyy\u0259sinin y\u00fcks\u0259k olmas\u0131 miokard infarkt\u0131, iflic v\u0259 koronar arteriyalar\u0131n x\u0259st\u0259liyi \u00fc\u00e7\u00fcn riski art\u0131ran faktordur. H\u0259m\u00e7inin kontrolsuz diabet v\u0259 a\u011f\u0131r hipotiroidizimd\u0259 d\u0259 Lp(a) s\u0259viyy\u0259si arta bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

L\u0130ZOS\u0130M<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Muramidaza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>RID<\/p>\n

Referens:<\/strong>\u00a09.6-16.8 mg\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qranulosit v\u0259 monosit \u00e7ev\u00adrilm\u0259sinin (turn over) g\u00f6st\u0259\u00adri\u00adcisidir. Qranulositar v\u0259 ya monositar leykozlar, mielopro\u00adliferativ x\u0259st\u0259\u00adlik\u00adl\u0259r v\u0259 b\u0259dxass\u0259li histiositozun t\u0259yi\u00adnind\u0259 istifad\u0259 olunur. K\u0259skin mo\u00adnositar v\u0259 ya mielomonositar ley\u00adkozlar, xroniki mieloid\u00a0 leyke\u00admi\u00adyalar, polisitemiya vera, b\u0259zi b\u00f6yr\u0259k x\u0259st\u0259likl\u0259ri v\u0259 xroniki infeksiyalarda (m\u0259s.v\u0259r\u0259m)\u00a0 serumda lizosimin s\u0259viyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

L\u0130T\u0130UM<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Li<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>500 \u03bcL<\/p>\n

N\u00fcnum\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>X\u0259s\u00adt\u0259nin q\u0259bul etdiyi son d\u0259rman preparat\u0131n\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildi\u00adrilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259 son dozadan \u0259n az\u0131 12 saat sonra al\u0131nmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n0.5-1.0 mEq\/L<\/td>\n<\/tr>\n
Toksiki konsentrasiya<\/td>\n>2.0 mEq\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

L\u0130POPROTE\u0130N ELEKTROFOREZ\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Lipid elektroforezi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, EDTA-l\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), b\u0259n\u00f6v\u015f\u0259yi qa\u00adpaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (EDTA-l\u0131 plazma)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>400 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 12-14 saatl\u0131q acl\u0131q vacibdir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0 M\u00fcayi\u00adn\u0259d\u0259n \u0259vv\u0259lki son 2 h\u0259ft\u0259 \u0259rzind\u0259 normal p\u0259hriz saxlan\u0131lmal\u0131d\u0131r. Son 24 saat m\u00fcdd\u0259tind\u0259 spirtli i\u00e7kil\u0259rd\u0259n istifad\u0259 olunmamal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Elektroforez<\/p>\n

Referens:<\/strong>\u00a0N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Serum \u00fcmumi xolesterol v\u0259 ya lipoprotein miqdar\u0131nda anor\u00admall\u0131q olan x\u0259st\u0259l\u0259rin qiym\u0259t\u00adl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

L\u0130POPROTE\u0130N (a)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Lp (a)<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 10 saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 laz\u0131md\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0\u0130mmunoturbidimetrik<\/p>\n

Referens:<\/strong>\u00a0<30 mg\/dL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Lp(a) s\u0259viyy\u0259sinin y\u00fcks\u0259k olmas\u0131 miokard infarkt\u0131, iflic v\u0259 koronar arteriyalar\u0131n x\u0259st\u0259liyi \u00fc\u00e7\u00fcn riski art\u0131ran faktordur. H\u0259m\u00e7inin kontrolsuz diabet v\u0259 a\u011f\u0131r hipotiroidizimd\u0259 d\u0259 Lp(a) s\u0259viyy\u0259si arta bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

L\u0130P\u0130D ELEKTROFOREZ\u0130 (L\u0130POPROTE\u0130N ELEKTROFOREZ\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Lipid elektroforezi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, EDTA-l\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), b\u0259n\u00f6v\u015f\u0259yi qa\u00adpaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (EDTA-l\u0131 plazma)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>400 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>N\u00fc\u00admun\u0259 al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 12-14 saatl\u0131q acl\u0131q vacibdir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0 M\u00fcayi\u00adn\u0259d\u0259n \u0259vv\u0259lki son 2 h\u0259ft\u0259 \u0259rzind\u0259 normal p\u0259hriz saxlan\u0131lmal\u0131d\u0131r. Son 24 saat m\u00fcdd\u0259tind\u0259 spirtli i\u00e7kil\u0259rd\u0259n istifad\u0259 olunmamal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Elektroforez<\/p>\n

Referens:<\/strong>\u00a0N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Serum \u00fcmumi xolesterol v\u0259 ya lipoprotein miqdar\u0131nda anor\u00admall\u0131q olan x\u0259st\u0259l\u0259rin qiym\u0259t\u00adl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

L\u0130PAZA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>Triasilqliserol asilhidrolaza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kolorimetrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
<12 ya\u015f<\/td>\n<60 U\/L<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n13-60 U\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>M\u0259d\u0259alt\u0131 v\u0259zin funksional testl\u0259rind\u0259ndir. Pankreatitl\u0259r, \u00f6d kis\u0259si koliti, bo\u011fulmu\u015f v\u0259 ya infarkta u\u011fram\u0131\u015f ba\u011f\u0131rsaq, m\u0259d\u0259alt\u0131 v\u0259zin kistalar\u0131 v\u0259 ya psevdokistl\u0259ri v\u0259 peri\u00adtonitl\u0259r zaman\u0131 serumda lipazan\u0131n s\u0259viyy\u0259si art\u0131r. K\u0259skin pankreatitd\u0259 serumda lipazan\u0131n aktivliyi, ami\u00adlazadan daha uzun m\u00fcdd\u0259t y\u00fcks\u0259k qal\u0131r. H\u0259m\u00e7inin k\u0259skin pankreatit \u00fc\u00e7\u00fcn lipazan\u0131n h\u0259ssasl\u0131\u011f\u0131 v\u0259 spe\u00adsifikliyi amilazadan daha y\u00fcks\u0259kdir. Pankreatitl\u0259rd\u0259 assit mayesind\u0259ki lipaza da y\u00fcks\u0259l\u0259 bil\u0259r. A\u011fciy\u0259r \u015fi\u015f\u00adl\u0259ri il\u0259 \u0259laq\u0259dar olaraq \u0259m\u0259l\u0259 g\u0259l\u0259n plevral transsudatlarda da nadir hallarda lipaza s\u0259viyy\u0259si art\u0131r. ERCP, oddi sfinktorunda spazma s\u0259b\u0259b olan narkotik analgetikl\u0259r v\u0259 heparin d\u0259 serumda lipaza s\u0259viy\u00ady\u0259sinin y\u00fcks\u0259lm\u0259sin\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LES\u0130T\u0130N \/ SP\u0130NQOMYEL\u0130N N\u0130SB\u018fT\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0L\/S nisb\u0259ti; Amnion mayesi fosfolipidl\u0259ri<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Amnion mayesi<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Nazik t\u0259b\u0259q\u0259li xroma\u00adtoqrafiya<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Sar\u0131l\u0131ql\u0131 (ikterik) v\u0259 ya hemorragik n\u00fcmun\u0259l\u0259r, n\u00fcmun\u0259nin anan\u0131n sidiyi v\u0259 ya mekonium il\u0259 kontamin\u0259 olmas\u0131<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
<1.5<\/td>\nYeti\u015fm\u0259mi\u015f (immature)<\/td>\n<\/tr>\n
1.5-1.9<\/td>\nKe\u00e7id (transizyonal)<\/td>\n<\/tr>\n
>2.0<\/td>\nYeti\u015fmi\u015f (mature)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u00f6l\u00fcn a\u011fciy\u0259rinin inki\u015fa\u00adf\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 isti\u00adfad\u0259 olunur. L\/S nisb\u0259ti hamil\u0259liyin 34-c\u00fc h\u0259ft\u0259sind\u0259n sonra artma\u011fa ba\u015flad\u0131\u00ad\u011f\u0131ndan, x\u0259st\u0259nin hamil\u0259lik ya\u015f\u0131 n\u0259z\u0259r\u0259 al\u0131naraq n\u0259tic\u0259 qiy\u00adm\u0259tl\u0259n\u00addirilm\u0259lidir. L\/S m\u00fcayin\u0259sind\u0259ki ye\u00adti\u015f\u00admi\u015f (mature) n\u0259tic\u0259l\u0259rin prediktiv d\u0259y\u0259ri 95-100 %, yeti\u015fm\u0259mi\u015f (immature) n\u0259tic\u0259l\u0259rin d\u0259y\u0259ri is\u0259 33-50 % aras\u0131nda olur. Kontrol edilm\u0259\u00ady\u0259n diabetli hamil\u0259likl\u0259d\u0259 L\/S nisb\u0259\u00adtinin d\u0259yi\u015f\u0259 bilm\u0259 ehtimal\u0131 n\u0259z\u0259r\u0259 al\u0131nmal\u0131d\u0131r. Plazmada lesitin v\u0259 spin\u00adqomielin oldu\u011fundan, aminion ma\u00adyesin\u0259 qan qar\u0131\u015fmas\u0131 L\/S m\u00fcayi\u00adn\u0259sinin n\u0259tic\u0259sin\u0259 t\u0259sir ed\u0259 bil\u0259r. H\u0259m\u00e7inin\u00a0 mekoniumda lesitin v\u0259 spinqomiyelin olmasa da, amniyon mayesind\u0259 mekoniumun olmas\u0131 n\u0259tic\u0259nin h\u0259ssasl\u0131\u011f\u0131n\u0131 azalda bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LDL XOLESTEROL (Birba\u015fa \u00d6l\u00e7m\u0259)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0LDL-C<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259 al\u0131n\u00admas\u0131 \u00fc\u00e7\u00fcn 10 saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 laz\u0131md\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, fer\u00admen\u00adtativ<\/p>\n

Referens:<\/strong>\u00a060-130 mg\/dL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0LDL xollesterol d\u0259y\u0259ri (mg\/dL)<\/p>\n\n\n\n\n\n\n\n
Optimal<\/td>\n<100<\/td>\n<\/tr>\n
Normal<\/td>\n100-129<\/td>\n<\/tr>\n
S\u0259rh\u0259d\u0259 yax\u0131n y\u00fcks\u0259k<\/td>\n130-159<\/td>\n<\/tr>\n
Y\u00fcks\u0259k<\/td>\n160-189<\/td>\n<\/tr>\n
\u00c7ox y\u00fcks\u0259k<\/td>\n>189<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LAKTOZA TOLERANS TEST\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Boz qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200\u03bcL<\/p>\n

Testin t\u0259tbiqi:<\/strong>\u00a050 g v\u0259 ya 2 g\/kg laktoza 400 mL suda h\u0259ll edil\u0259r\u0259k x\u0259st\u0259y\u0259 verilir. Sonra 0, 30, 45, 60 v\u0259 90-c\u0131 d\u0259qiq\u0259l\u0259rd\u0259 qan al\u0131n\u0131b ql\u00fckozan\u0131n s\u0259viyy\u0259si \u00f6l\u00e7\u00fcl\u00fcr<\/p>\n

undefined<\/p>\n

Testin \u015f\u0259rhi:\u00a0<\/strong>M\u00fcayin\u0259 m\u00fcdd\u0259tind\u0259 ql\u00fckozan\u0131n s\u0259viyy\u0259sind\u0259 30 mg\/dL-d\u0259n \u00e7ox artma olmamal\u0131d\u0131r. 20 mg\/dL-d\u0259n az artma is\u0259 anormal q\u0259bul edilir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0M\u00fcayin\u0259nin apar\u0131lmas\u0131 \u00fc\u00e7\u00fcn 8 saatl\u0131q acl\u0131q la\u00adz\u0131md\u0131r. H\u0259m\u00e7iniin m\u00fcayin\u0259 m\u00fcd\u00add\u0259tind\u0259 siaqret \u00e7\u0259kilm\u0259ki v\u0259 saqq\u0131z \u00e7eyn\u0259m\u0259k olmaz<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, fer\u00admen\u00adtativ, kinetik<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Nazik ba\u011f\u0131rsa\u011f\u0131n selikli qi\u015fas\u0131nda laktaza \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 \u0259la\u00adq\u0259dar olaraq inki\u015faf ed\u0259n karbohidrat sorulma poz\u011funluqlar\u0131n\u0131n qiym\u0259tl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LAKTAT DEH\u0130DROGENAZA \u0130ZOENZ\u0130ML\u018fR\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0LDH izoenziml\u0259ri; LDH izoenzim elektroforezi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Elektroforez<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
LD1<\/td>\n17-31%<\/td>\n<\/tr>\n
LD2<\/td>\n35-48%<\/td>\n<\/tr>\n
LD3<\/td>\n15-29%<\/td>\n<\/tr>\n
LD4<\/td>\n4-9.5%<\/td>\n<\/tr>\n
LD5<\/td>\n3-10 %<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>LDH y\u00fcks\u0259kliyinin s\u0259b\u0259\u00adbini t\u0259yin etm\u0259k m\u0259qs\u0259dil\u0259 istifad\u0259 olunur. KM\u0130, qaraciy\u0259r x\u0259st\u0259likl\u0259ri, neoplaziyalar v\u0259 skelet \u0259z\u0259l\u0259si x\u0259s\u00adt\u0259likl\u0259rinin differensasiyas\u0131nda \u0259h\u0259\u00admiy\u00ady\u0259tlidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LAKTAT DEH\u0130DROGENAZA (Maye)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>BOM, maye<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, ki\u00adnetik<\/p>\n

Referens:<\/strong>\u00a010-40 IU\/L (BOM)<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130ntraserebral lokaliza\u00adsi\u00adyal\u0131 \u015fi\u015fl\u0259r, leykemiya v\u0259 ya limfo\u00adsarkoma, menengit, subaraxnoidal qan\u00adaxma v\u0259 serebrovaskulyar pro\u00adses\u00adl\u0259rd\u0259 BOM-da LDH s\u0259viyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LAKTAT DEH\u0130DROGENAZA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0LDH; LD; S\u00fcd tur\u015fusu dehidrogenazas\u0131<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, ki\u00adnetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
<3 ay<\/td>\n100-450 IU\/L<\/td>\n<\/tr>\n
4-12 ay<\/td>\n100-400 IU\/L<\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n100-300 IU\/L<\/td>\n<\/tr>\n
4-12 ya\u015f<\/td>\n100-250 IU\/L<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n90-240 IU\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u00dcr\u0259k v\u0259 qaraciy\u0259r x\u0259st\u0259\u00adlikl\u0259rininn diaqnostikas\u0131nda istifad\u0259 olunur. KM\u0130, meqaloblastik v\u0259 per\u00adnisitoz anemiya, qaraciy\u0259r x\u0259st\u0259\u00adlik\u00adl\u0259ri, \u015fok, hipoksiya, sirroz, obstruktiv sar\u0131l\u0131q, b\u00f6yr\u0259k x\u0259st\u0259likl\u0259ri, \u0259z\u0259l\u0259 x\u0259st\u0259likl\u0259ri, neoplastik x\u0259st\u0259likl\u0259r, k\u0259skin \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, leykemiya, hemolitik anemiya, oraq heceyr\u0259li anemiya, limfoma, b\u00f6yr\u0259k infarkt\u0131 v\u0259 k\u0259skin pankreatitd\u0259 LDH s\u0259viyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

L \/ S NISB\u018fTI (LES\u0130T\u0130N \/ SP\u0130NQOMYEL\u0130N N\u0130SB\u018fT\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0L\/S nisb\u0259ti; Amnion mayesi fosfolipidl\u0259ri<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Amnion mayesi<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Nazik t\u0259b\u0259q\u0259li xroma\u00adtoqrafiya<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Sar\u0131l\u0131ql\u0131 (ikterik) v\u0259 ya hemorragik n\u00fcmun\u0259l\u0259r, n\u00fcmun\u0259nin anan\u0131n sidiyi v\u0259 ya mekonium il\u0259 kontamin\u0259 olmas\u0131<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
<1.5<\/td>\nYeti\u015fm\u0259mi\u015f (immature)<\/td>\n<\/tr>\n
1.5-1.9<\/td>\nKe\u00e7id (transizyonal)<\/td>\n<\/tr>\n
>2.0<\/td>\nYeti\u015fmi\u015f (mature)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u00f6l\u00fcn a\u011fciy\u0259rinin inki\u015fa\u00adf\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 isti\u00adfad\u0259 olunur. L\/S nisb\u0259ti hamil\u0259liyin 34-c\u00fc h\u0259ft\u0259sind\u0259n sonra artma\u011fa ba\u015flad\u0131\u00ad\u011f\u0131ndan, x\u0259st\u0259nin hamil\u0259lik ya\u015f\u0131 n\u0259z\u0259r\u0259 al\u0131naraq n\u0259tic\u0259 qiy\u00adm\u0259tl\u0259n\u00addirilm\u0259lidir. L\/S m\u00fcayin\u0259sind\u0259ki ye\u00adti\u015f\u00admi\u015f (mature) n\u0259tic\u0259l\u0259rin prediktiv d\u0259y\u0259ri 95-100 %, yeti\u015fm\u0259mi\u015f (immature) n\u0259tic\u0259l\u0259rin d\u0259y\u0259ri is\u0259 33-50 % aras\u0131nda olur. Kontrol edilm\u0259\u00ady\u0259n diabetli hamil\u0259likl\u0259d\u0259 L\/S nisb\u0259\u00adtinin d\u0259yi\u015f\u0259 bilm\u0259 ehtimal\u0131 n\u0259z\u0259r\u0259 al\u0131nmal\u0131d\u0131r. Plazmada lesitin v\u0259 spin\u00adqomielin oldu\u011fundan, aminion ma\u00adyesin\u0259 qan qar\u0131\u015fmas\u0131 L\/S m\u00fcayi\u00adn\u0259sinin n\u0259tic\u0259sin\u0259 t\u0259sir ed\u0259 bil\u0259r. H\u0259m\u00e7inin\u00a0 mekoniumda lesitin v\u0259 spinqomiyelin olmasa da, amniyon mayesind\u0259 mekoniumun olmas\u0131 n\u0259tic\u0259nin h\u0259ssasl\u0131\u011f\u0131n\u0131 azalda bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KS\u0130LOZA ABSORB\u0130SYA TEST\u0130 (D-KS\u0130LOZA ABSORBS\u0130YA TEST\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Ksiloza absorbsiya testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum v\u0259 sidik<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Sidik qaranl\u0131q yerd\u0259 toplanmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 saxlanmal\u0131d\u0131r<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>X\u0259st\u0259 10 saatl\u0131q s\u0259h\u0259r a\u015fl\u0131\u011f\u0131 il\u0259 labarotoriyaya g\u0259lm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:\u00a0<\/strong>N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Malabsorbsiyan\u0131n t\u0259yini v\u0259 nazik ba\u011f\u0131rsa\u011f\u0131n proksimal hiss\u0259\u00adsind\u0259ki karbohidrat absorbsiyas\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Ba\u011f\u0131rsaq malabsorbsiyas\u0131, nazik ba\u011f\u0131rsaqda bakterial \u00e7oxalma, qus\u00adma, assit, gecikmi\u015f m\u0259d\u0259 bo\u015falmas\u0131 v\u0259 Whipple x\u0259st\u0259liyind\u0259 qan v\u0259 sidikd\u0259 ksilozan\u0131n miqdar\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

M\u0130S<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Cu<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS-Zeeman<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
<3 ay<\/td>\n20-70 \u03bcg\/dL<\/td>\n<\/tr>\n
4 ay-5 ya\u015f<\/td>\n85-190 \u03bcg\/dL<\/td>\n<\/tr>\n
6-15 ya\u015f<\/td>\n80-160 \u03bcg\/dL<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n80-155 \u03bcg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Mis metabolizminin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. \u0130nfeksiya, iltihab, hamil\u0259lik, ley\u00adkoz, biliar sirroz, Hockin x\u0259st\u0259liyi, pelleqra, a\u011fciy\u0259r v\u0259r\u0259mi, anemiya, talasemiya minor v\u0259 major, k\u0259skin miokard infarkt\u0131, beyin infarkt\u0131, revmatoid artrid, hipotireoidizim, hipertireoidizim, birl\u0259\u015fdirici toxuma x\u0259st\u0259likl\u0259ri, SLE v\u0259 b\u0259zi b\u0259dxass\u0259li t\u00f6r\u0259m\u0259l\u0259rd\u0259 serumda Cu-un s\u0259viy\u00ady\u0259si art\u0131r, Wilson x\u0259st\u0259liyi, qastro\u00adintestinal\u00a0 sistem x\u0259st\u0259likl\u0259ri, muko\u00advissidoz, nefrotik sindrom, yan\u0131qlar, z\u00fclal malnutrisiyas\u0131 v\u0259 xronik i\u015femik \u00fcr\u0259k x\u0259st\u0259likl\u0259rind\u0259 is\u0259 Cu s\u0259viyy\u0259si azal\u0131r. H\u0259m\u00e7inin esterogen, oral kontraseptiv v\u0259 antiepileptikl\u0259rin isti\u00adfad\u0259si v\u0259 hamil\u0259lik zaman\u0131, qaraciy\u0259rd\u0259 seruloplazmin sintezinin artmas\u0131 il\u0259 \u0259laq\u0259dar olaraq serumda Cu s\u0259viyy\u0259si d\u0259 art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

M\u0130S (Eritrosit i\u00e7i)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam kan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>2 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS-Zeeman<\/p>\n

Referens:\u00a0<\/strong>90-150 \u03bcg\/dL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>A\u011fciy\u0259r v\u0259r\u0259mind\u0259 erit\u00adrosit daxili Cu s\u0259viyy\u0259sinin artmas\u0131 xarakterikdir. H\u0259m\u00e7inin qur\u011fu\u015fun\u00a0 z\u0259h\u0259rl\u0259nm\u0259l\u0259rind\u0259 eritrosit daxili Cu s\u0259viyy\u0259si art\u0131r, z\u00fclal malnutri\u00adsiya\u00ads\u0131nda is\u0259 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

M\u0130S (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik, bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxlanmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir. 6N HCl,asetat tur\u015fusu v\u0259 ya bor tur\u015fusu \u00fcz\u0259rin\u0259 y\u0131\u011f\u0131lan sidik n\u00fcmun\u0259l\u0259ri d\u0259 q\u0259bul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 saatl\u0131q sidiyin miqdar\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS-Zeeman<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Bird\u0259f\u0259lik sidik<\/td>\n2-80\u03bcg\/L<\/td>\n<\/tr>\n
24 saatl\u0131q sidik<\/td>\n3-35\u03bcg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Wilson x\u0259st\u0259liyind\u0259 m\u00fca\u00adlic\u0259nin m\u00fc\u015fahid\u0259si \u00fc\u00e7\u00fcn istifad\u0259 olunur. Sidikd\u0259 misin s\u0259viyy\u0259sinin \u00f6l\u00e7\u00fclm\u0259si \u00fc\u00e7\u00fcn 24 saatl\u0131q sidik n\u00fc\u00admu\u00adn\u0259sinin g\u00f6t\u00fcr\u00fclm\u0259si m\u0259sl\u0259h\u0259tdir. Wilson x\u0259st\u0259liyi il\u0259 yana\u015f\u0131, xroniki aktiv hepatit, biliar sirroz, revmatoid artrit v\u0259 proteinuriyalarda da sidikl\u0259 xaric olunan misin miqdar\u0131 y\u00fcks\u0259k olur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

M\u0130S OKS\u0130DAZA (SERULOPLAZM\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Mis oksidaza; Cp<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Nefolometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
<6 ay<\/td>\n\u00a05-18 mg\/dL<\/td>\n<\/tr>\n
7-12 ay<\/td>\n33-43 mg\/dL<\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n26-55 mg\/dL<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n27-56 mg\/dL<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n20-54 mg\/dL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n20-63 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Mis birl\u0259\u015fdirici z\u00fclald\u0131r. Wilson x\u0259st\u0259liyinin diaqnos\u00adtikas\u0131nda v\u0259 k\u0259skin faza reaktant\u0131 kimi istifad\u0259 olunur. Hamil\u0259lik, esterogen v\u0259 oral kontraseptiv istifad\u0259si, iltihab, toxu\u00adma nekrozu, osteosarkomalar, biliar sirroz v\u0259 travmalarda serumda seru\u00adloplazminin s\u0259viyy\u0259si art\u0131r, Wilson x\u0259s\u00adt\u0259liyi, Menkes kinky hair sind\u00adro\u00admu v\u0259 qastroenteropatiyalarda azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PAP (PROSTAT\u0130K TUR\u015e FOSFATAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0PAP; Prostat spesifik tur\u015f fosfataza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0Rek\u00adtal m\u00fcayin\u0259 v\u0259 kateter istifad\u0259sin\u00add\u0259n sonra n\u00fcmun\u0259 al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 72 saat g\u00f6zl\u0259m\u0259k laz\u0131md\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz, lipemiya, sar\u0131l\u0131q v\u0259 radioizotop istifad\u0259si<\/p>\n

Referens:<\/strong>\u00a0<3 ng\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Prostatdan ifraz olunan qlikoproteindir. Prostat v\u0259zinin b\u0259d\u00adxass\u0259li \u015fi\u015fl\u0259ri, biopsiya, kate\u00adteri\u00adzasiya, \u0259laq\u0259d\u0259n sonra, \u0259m\u0259liyyatdan sonrak\u0131 d\u00f6vr, xo\u015fxass\u0259li prostat hiperplaziyas\u0131, prostatit, prostat infarkt\u0131 v\u0259 s. hallarda prostatik tur\u015f fosfataza s\u0259viyy\u0259si art\u0131r. Prostat x\u0259r\u00e7\u0259ngl\u0259ri \u00fc\u00e7\u00fcn skrininq m\u0259qs\u0259dil\u0259 istifad\u0259 etm\u0259k olmaz. Klinik istifad\u0259si metastatik prostat v\u0259zi x\u0259r\u00e7\u0259ngl\u0259rinin t\u0259sdiql\u0259nm\u0259si v\u0259 d\u0259r\u0259c\u0259l\u0259nd\u0259rilm\u0259si il\u0259 m\u0259hduddur. H\u0259m\u00e7inin radikal prostatektomiyal\u0131 x\u0259st\u0259l\u0259rd\u0259 t\u0259krarlanman\u0131n (rekur\u00adrens) m\u00fc\u015fahid\u0259si v\u0259 m\u00fcalic\u0259y\u0259 cavab\u0131n m\u00fc\u015fahid\u0259sind\u0259 d\u0259 k\u00f6m\u0259k\u00e7i testdir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PANKREAT\u0130K AM\u0130LAZA<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum, sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum). Sidik n\u00fcmun\u0259si soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, Fer\u00admen\u00adtativ<\/p>\n

Referens:<\/strong>\u00a011-54 U\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0M\u0259d\u0259alt\u0131 v\u0259z x\u0259st\u0259lik\u00adl\u0259\u00adrinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olunur. Amilaza aktivliyinin \u0259n y\u00fcks\u0259k oldu\u011fu toxumalar pankreas v\u0259 qulaqalt\u0131 v\u0259zdir. H\u0259m\u00e7inin yumurtal\u0131qlar, nazik v\u0259 yo\u011fun ba\u00ad\u011f\u0131rsaqlar v\u0259 skelet \u0259z\u0259l\u0259l\u0259rind\u0259 d\u0259 az miqdarda amilaza vard\u0131r. Pankreatik amilazan\u0131n t\u0259dqiqi il\u0259 yaln\u0131z pan\u00adkreas m\u0259n\u015f\u0259li amilaza t\u0259yin olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PA (PREALBUM\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Transthyretin; PA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Nefelometrik<\/p>\n

Referens:<\/strong>\u00a017-42 mg\/dL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qidalanman\u0131n qiym\u0259t\u00adl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur. X\u00fc\u00adsu\u00adsil\u0259 yenido\u011fulmu\u015f infantlar v\u0259 pa\u00adrenteral qidalanma m\u00fcalic\u0259si alan x\u0259st\u0259l\u0259rin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur. H\u0259m\u00ad\u00e7i\u00adnin neqativ k\u0259skin faza reak\u00adtant\u00adla\u00adr\u0131ndan biridir. Oral kontraseptiv, korti\u00adkosteroid, ana\u00adbo\u00adlik steroid istifad\u0259si v\u0259 Hodgkin x\u0259st\u0259liyind\u0259 prealbumin s\u0259viyy\u0259si art\u0131r, malnutrisiya, iltihab, b\u0259d xass\u0259li t\u00f6r\u0259m\u0259l\u0259r, xroniki x\u0259st\u0259likl\u0259r, sirroz v\u0259 z\u00fclal itkisi olan hallarda is\u0259 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

P (FOSFOR)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>PO3<\/sub>; P; Qeyri \u00fczvi fosfor; Fosfat<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259 acqar\u0131na al\u0131nmal\u0131 v\u0259 serum m\u00fcmk\u00fcn q\u0259d\u0259r tez ayr\u0131lmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admo\u00adliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si qan\u0131<\/td>\n3.7-8.1<\/td>\n<\/tr>\n
Yeni do\u011fulmu\u015f<\/td>\n5.0-10.0<\/td>\n<\/tr>\n
7 g\u00fcn<\/td>\n5.0-10.0<\/td>\n<\/tr>\n
7 g\u00fcn- 1 ya\u015f<\/td>\n4.5-6.7<\/td>\n<\/tr>\n
2-12 ya\u015f<\/td>\n4.5-5.5<\/td>\n<\/tr>\n
13-60 ya\u015f<\/td>\n2.7-4.5<\/td>\n<\/tr>\n
60 ya\u015f<\/td>\n2.3-3.7\u00a0(Ki\u015fi)<\/td>\n<\/tr>\n
2.8-4.1 (Qad\u0131n)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Fosfor metobolizminin v\u0259 Ca-P m\u00fcvazin\u0259tinin qiym\u0259tl\u0259n\u00addiril\u00adm\u0259\u00adsind\u0259 istifad\u0259 olunur. Osteolitik s\u00fcm\u00fck metastazlar\u0131, sarkoidoz, s\u00fcd-q\u0259l\u0259vi sindromu, vitamin D intok\u00adsi\u00adkasiyas\u0131, b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, hipo\u00adpa\u00adratiroidizm, psevdohipo\u00adparatiroidizm, akromeqaliya, a\u011fciy\u0259r emboliyas\u0131,\u00a0<\/strong>lak\u00adtik asidoz \u00a0v\u0259 respirator asidoz zaman\u0131 serumda fosforun s\u0259viyy\u0259si art\u0131r, osteomalyasiya, steatoreya, renal tubulyar asidoz, Qram neqativ bakterial sep\u00adtisemiya, hipokalemiya vitamin D \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, malnutrisiya, ma\u00adlabsorbsiya, a\u011f\u0131r diarreya, qusma, birin\u00adcili hiperparatiroidizm, hiperkal\u00adsemiya, salisilat z\u0259h\u0259rl\u0259nm\u0259si, respi\u00adrator infeksiyalar, hiperinsulinemiya, respirator alkaloz, osteoblastik s\u00fcm\u00fck metastazlar\u0131 v\u0259 renal tubulyar defekt\u00adl\u0259rd\u0259 is\u0259 fosforun miqdar\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

OSMOLYARLIQ (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a024 saatl\u0131q sidik, bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Osmometrik<\/p>\n

Referens:<\/strong>\u00a0300-1090 mOsm\/kg<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0B\u00f6yr\u0259k funksiyalar\u0131n\u0131n, elektrolit v\u0259 su m\u00fcvazin\u0259tinin m\u00fc\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur. Diabetes insipitus v\u0259 birincili polidipsiyada sidiyin osmolyarl\u0131\u011f\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

OSMOLYARLIQ (Nisbi \u00e7\u0259ki)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Osmometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
<60 ya\u015f<\/td>\n275-295 mOsm\/kg<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n280-300 mOsm\/kg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Osmolyarl\u0131q 1 kq m\u0259hlul\u00addak\u0131 h\u0259ll olmu\u015f hiss\u0259cikl\u0259rin miq\u00addar\u0131n\u0131 g\u00f6st\u0259rir. Eloktrolit m\u00fcvazin\u0259ti v\u0259 hidratasiyan\u0131n\u00a0 qiym\u0259tl\u0259ndiril\u00adm\u0259\u00adsind\u0259 istifad\u0259 olunur. Dehidratasiya, hiperosmoliyar qeyri-ketotik diabetik koma, diabetik ketoasidoz, hiper\u00adnatremik etanol z\u0259h\u0259rl\u0259nm\u0259si, \u015f\u0259k\u0259r\u00adsiz diabet, hiperkalsemiya v\u0259 sereb\u00adral lezyonlarda serumun osmol\u00adyar\u00adl\u0131\u011f\u0131 art\u0131r, adrenokortikal \u00e7a\u0131\u015fmazl\u0131q, panhipopituiterizim v\u0259 h\u0259dd\u0259n art\u0131q maye q\u0259bulu il\u0259 osmolyarl\u0131q azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

OKSALAT<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a06N HCl \u00fcz\u0259rin\u0259 toplanmal\u0131d\u0131r. Asetat v\u0259 ya bor tur\u015fusu \u00fcz\u0259rin\u0259 toplanan sidik n\u00fcmun\u0259l\u0259ri v\u0259 toplanma m\u00fcdd\u0259tind\u0259 soyuq m\u00fchitd\u0259 saxlan\u0131lan n\u00fcmun\u0259l\u0259r d\u0259 q\u0259bul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a024 saatl\u0131q sidik miqdar\u0131 bildirilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Son 24 saat \u0259rzind\u0259 C vitaminind\u0259n istifad\u0259 edilm\u0259m\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, fer\u00admentativ<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
<15 ya\u015f<\/td>\n0.01-0.46 mmol\/g\u00fcn<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n0.08-0.49 mmol\/g\u00fcn (Ki\u015fi)<\/td>\n<\/tr>\n
0.04-0.32 mmol\/g\u00fcn (Qad\u0131n)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Urolitiaz\u0131n qiym\u0259tl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur. Birincili hiperoksaluriya, \u015f\u0259k\u0259rli diabet, sir\u00adroz, piridoksin \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, sar\u00adkoidoz, m\u0259d\u0259alt\u0131 v\u0259z \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, seliakiya (celiac sprue), ileal re\u00adzek\u00adsiya, yeyunoileal \u015funtlar, \u00f6d yollar\u0131 x\u0259st\u0259likl\u0259ri v\u0259 nazik ba\u011f\u0131rsaq x\u0259st\u0259\u00adlikl\u0259rind\u0259 sidikd\u0259 oksalat miqdar\u0131 art\u0131r, b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131nda is\u0259 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

N\u018fC\u0130SD\u018f TR\u0130PS\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>T\u0259z\u0259 g\u00f6t\u00fcr\u00fclm\u00fc\u015f n\u0259cis<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0T\u0259miz a\u011fz\u0131 qapaql\u0131 qab<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Mukovissidozun (Kistik fibrozis) diaqnozunda istifad\u0259 olu\u00adnun skrininq tetl\u0259rd\u0259n biridir. N\u0259\u00adcisd\u0259ki tripsin miqdar\u0131 malab\u00adsorb\u00adsiyada art\u0131r, m\u0259d\u0259alt\u0131 v\u0259z funksi\u00adyas\u0131n\u0131n itirilm\u0259si v\u0259 mukovissidoz zaman\u0131 azal\u0131r. 4 ya\u015f\u0131ndan b\u00f6y\u00fck u\u015faqlarda miqdar\u0131 a\u015fa\u011f\u0131 olur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

N\u018fC\u0130SD\u018f STERKOB\u0130L\u0130NOGEN<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>N\u0259cis<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0T\u0259miz a\u011fz\u0131 qapaql\u0131 qab<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kimy\u0259vi<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u00d6d\u00fcn 12 barmaq ba\u011f\u0131r\u00adsa\u011fa g\u0259lm\u0259sin\u0259 mane olan obs\u00adt\u00adruksiyalar\u0131n qiym\u0259rl\u0259ndirilm\u0259sind\u0259, x\u00fcsusil\u0259 d\u0259 biliar atreziya ehti\u00admal\u0131n\u0131n t\u0259dqiqind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

N\u018fC\u0130SD\u018f REDUKS\u0130YA ED\u0130C\u0130 MADD\u018f (REDUKS\u0130YA ED\u0130C\u0130 MADD\u018f (N\u0259cis))<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>T\u0259z\u0259 n\u0259cis<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0T\u0259miz, a\u011fz\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01g<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kimy\u0259vi<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

N\u018fC\u0130SD\u018f pH T\u018fY\u0130N\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>T\u0259z\u0259 g\u00f6t\u00fcr\u00fclm\u00fc\u015f n\u0259cis n\u00fcmun\u0259si<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0T\u0259miz a\u011fz\u0131 qapaql\u0131 qab<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0N\u0259cisin pH-\u0131 neytral v\u0259 ya z\u0259if q\u0259l\u0259vi olmal\u0131d\u0131r. Karbohidrat v\u0259 ya z\u00fclal par\u00e7alanmas\u0131n\u0131n t\u0259yi\u00adnind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

NUKLEAR MATR\u0130KS PROTE\u0130N 22<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0NMP-22<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Bird\u0259f\u0259lik sidik (Bax n\u00fcmun\u0259 alma)<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Sidik n\u00fcmun\u0259si laboratoriya t\u0259r\u0259find\u0259n veril\u0259n x\u00fc\u00adsusi stabilizatorun \u00fcz\u0259rin\u0259 al\u0131n\u00admal\u0131d\u0131r<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a010 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0 Saat 24.00-08.00 aras\u0131nda, s\u0259h\u0259r ilk sidik n\u00fcmun\u0259si al\u0131naraq 10 mL-i labo\u00adratoriya t\u0259r\u0259find\u0259n veril\u0259n stabi\u00adlizatorla g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0EIA<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n
Y>16 ya\u015f<\/td>\n<10 U\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Sidik yollar\u0131 transizional h\u00fcceyr\u0259 karsinomalar\u0131nda sidikd\u0259 NMP-22 nin s\u0259viyy\u0259si y\u00fcks\u0259lir. Bu x\u0259st\u0259l\u0259rd\u0259 NMP22 s\u0259viyy\u0259si il\u0259 x\u0259st\u0259liyin d\u0259r\u0259c\u0259si d\u00fcz m\u00fct\u0259nasibdir. H\u0259m\u00e7inin \u0259m\u0259liyyatdan sonrak\u0131 t\u0259krarlanman\u0131n m\u00fc\u015fahid\u0259sind\u0259 d\u0259 istifad\u0259 olunur. \u0130dman h\u0259r\u0259k\u0259tl\u0259ri v\u0259 sistemik kimy\u0259vi terapiya yalan\u00e7\u0131 y\u00fcks\u0259k n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r. Sistoskopiya v\u0259 sidik yollar\u0131na kateterl\u0259 m\u00fcdaxil\u0259d\u0259n sonra toxuma z\u0259d\u0259l\u0259nm\u0259si oldu\u011fu \u00fc\u00e7\u00fcn 5 g\u00fcn m\u00fcdd\u0259tind\u0259 NMP-22 s\u0259viyy\u0259si y\u00fcks\u0259k ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

NTx (N-TELOPEPT\u0130D)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0NTx<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0S\u0259h\u0259r ikinci sidik, 24 saatl\u0131q sidik, bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 toplan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir. Bor tur\u015fusu \u00fcz\u0259rin\u0259 toplanan sidikl\u0259r d\u0259 q\u0259bul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0S\u0259h\u0259r ikinci sidik al\u0131nacaqsa, sidiyin ha\u00adm\u0131s\u0131n\u0131 bir qaba toplay\u0131b 5 mL-ini soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0EIA<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
20-50 ya\u015f<\/td>\nKi\u015fi<\/td>\n3-63 nmol BCE \/ nmol kreatinin<\/td>\n<\/tr>\n
<\/td>\nQad\u0131n<\/td>\n5-65 nmol BCE \/ nmol kreatinin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0S\u00fcm\u00fck z\u0259d\u0259l\u0259nm\u0259sini g\u00f6st\u0259r\u0259n markerl\u0259rd\u0259ndir. Osteopa\u00adrozun diaqnoz v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur. M\u00fcalic\u0259nin m\u00fc\u015fahid\u0259si \u00fc\u00e7\u00fcn ilk n\u00f6vb\u0259d\u0259 m\u00fca\u00adlic\u0259d\u0259n \u0259vv\u0259l bazal NTx miqdar\u0131n\u0131n t\u0259yini \u0259h\u0259miyy\u0259tlidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

NSE (NEYRON SPES\u0130F\u0130K ENOLAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0NSE<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250\u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0 N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra hemoliz\u0259 u\u011framadan serum d\u0259rhal ayr\u0131lmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0IRMA<\/p>\n

Referens:<\/strong>\u00a0<12.5 \u03bcg\/dL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0APUD h\u00fcceyr\u0259li neyro\u00adendokrin \u015fi\u015fl\u0259r\u0259 (m\u0259s. neyro\u00adblas\u00adtoma, retinoblastoma, tiroid medullar karsinomas\u0131, karsinoid \u015fi\u015fl\u0259r, feoxro\u00admositoma v\u0259 ki\u00e7ik h\u00fcceyr\u0259li a\u011fciy\u0259r karsinomas\u0131) spesifik markerdir. Bu \u015fi\u015fl\u0259rin diaqnoz v\u0259 m\u00fc\u015fahid\u0259sind\u0259 NSE istifad\u0259 olunur. X\u00fcsusil\u0259 neyro\u00adblastoma v\u0259 a\u011fciy\u0259r ca \u00fc\u00e7\u00fcn h\u0259s\u00adsasl\u0131\u011f\u0131 y\u00fcks\u0259kdir. H\u0259m\u00e7inin septik \u015fok, pnevmoniya v\u0259 sinir travmalar\u0131 da NSE s\u0259viyy\u0259sind\u0259 y\u00fcks\u0259lm\u0259y\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

NMP-22 (NUKLEAR MATR\u0130KS PROTE\u0130N 22)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0NMP-22<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Bird\u0259f\u0259lik sidik (Bax n\u00fcmun\u0259 alma)<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Sidik n\u00fcmun\u0259si laboratoriya t\u0259r\u0259find\u0259n veril\u0259n x\u00fc\u00adsusi stabilizatorun \u00fcz\u0259rin\u0259 al\u0131n\u00admal\u0131d\u0131r<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a010 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0 Saat 24.00-08.00 aras\u0131nda, s\u0259h\u0259r ilk sidik n\u00fcmun\u0259si al\u0131naraq 10 mL-i labo\u00adratoriya t\u0259r\u0259find\u0259n veril\u0259n stabi\u00adlizatorla g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0EIA<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n
Y>16 ya\u015f<\/td>\n<10 U\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Sidik yollar\u0131 transizional h\u00fcceyr\u0259 karsinomalar\u0131nda sidikd\u0259 NMP-22 nin s\u0259viyy\u0259si y\u00fcks\u0259lir. Bu x\u0259st\u0259l\u0259rd\u0259 NMP22 s\u0259viyy\u0259si il\u0259 x\u0259st\u0259liyin d\u0259r\u0259c\u0259si d\u00fcz m\u00fct\u0259nasibdir. H\u0259m\u00e7inin \u0259m\u0259liyyatdan sonrak\u0131 t\u0259krarlanman\u0131n m\u00fc\u015fahid\u0259sind\u0259 d\u0259 istifad\u0259 olunur. \u0130dman h\u0259r\u0259k\u0259tl\u0259ri v\u0259 sistemik kimy\u0259vi terapiya yalan\u00e7\u0131 y\u00fcks\u0259k n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r. Sistoskopiya v\u0259 sidik yollar\u0131na kateterl\u0259 m\u00fcdaxil\u0259d\u0259n sonra toxuma z\u0259d\u0259l\u0259nm\u0259si oldu\u011fu \u00fc\u00e7\u00fcn 5 g\u00fcn m\u00fcdd\u0259tind\u0259 NMP-22 s\u0259viyy\u0259si y\u00fcks\u0259k ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

N\u0130KEL<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Ni<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a010 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a024 saatl\u0131q sidik miqdar\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS<\/p>\n

Referens:<\/strong>\u00a00.1-8.0 \u03bcg\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>\u00a0Xroniki nikel\u0259 m\u0259ruz qalman\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 isti\u00adfa\u00add\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

NH3 (AMMONYAK)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>NH3<\/sub>; NH4<\/sub>; Ammonium<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0EDTA-l\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>S\u0131naq \u015f\u00fc\u015f\u0259sinin \u00fcz\u0259rind\u0259ki x\u0259tt\u0259 q\u0259d\u0259r qan al\u0131nmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259, gecik\u00adm\u0259\u00add\u0259n laboratoriyaya \u00e7atd\u0131r\u0131l\u00admal\u0131d\u0131r. Gecikdirilmi\u015f n\u00fcmun\u0259l\u0259rd\u0259 ammon\u00adyak s\u0259viyy\u0259sinin arta bilm\u0259 ehtimal\u0131 n\u0259z\u0259r\u0259 al\u0131nmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik, fer\u00admentativ<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>S\u0131\u00adnaq \u015f\u00fc\u015f\u0259sind\u0259ki i\u015far\u0259li yer\u0259 q\u0259d\u0259r qan al\u0131nmamas\u0131, n\u00fcmun\u0259nin soyuq \u015f\u0259raitd\u0259 laboratoriyaya \u00e7atd\u0131r\u0131l\u00adma\u00admas\u0131, hemolizli v\u0259 ya uzun m\u00fcdd\u0259t g\u00f6zl\u0259mi\u015f olmas\u0131, lipemiya<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259sind\u0259n al\u0131nm\u0131\u015f qanda<\/td>\n0.90-1.50<\/td>\n<\/tr>\n
Erk\u0259n do\u011fulmu\u015f u\u015faqlarda<\/td>\n0.90-3.00<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n0.90-3.00<\/td>\n<\/tr>\n
7 g\u00fcn-1 ay<\/td>\n0.30-2.00<\/td>\n<\/tr>\n
2-3 ay<\/td>\n0.30-1.50<\/td>\n<\/tr>\n
4-12ay<\/td>\n0.30-1.40<\/td>\n<\/tr>\n
>1 ya\u015f<\/td>\n0.24-1.02\u00a0(Ki\u015fi)<\/td>\n<\/tr>\n
>1 ya\u015f<\/td>\n0.19-0.87 (Qad\u0131n)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qaraciy\u0259r ensefalopa\u00adti\u00adya\u00ads\u0131n\u0131n diaqnozu v\u0259 hiperalimen\u00adtasiya m\u00fcalic\u0259si alan x\u0259st\u0259l\u0259rin m\u00fc\u015fa\u00adhi\u00add\u0259\u00adsind\u0259 istifad\u0259 olunur. Qaraciy\u0259r \u00e7a\u00adt\u0131\u015f\u00ad\u00admazl\u0131\u011f\u0131, Reye sindromu, sirroz, m\u0259d\u0259-ba\u011f\u0131rsaq qanaxmalar\u0131, portal-sistemik \u015funtlar v\u0259 b\u0259zi b\u00f6yr\u0259k x\u0259s\u00adt\u0259likl\u0259rind\u0259 d\u0259 ammonyak s\u0259viyy\u0259si arta bil\u0259r. Sidik c\u00f6vh\u0259ri m\u00fcbadi\u00adl\u0259\u00adsi\u00adnin pozulmas\u0131 il\u0259 m\u00fc\u015faiy\u0259t olunan x\u0259st\u0259likl\u0259rd\u0259n I tip hiperammo\u00adniemi\u00adya, argininemiya v\u0259 ornitinemiyada acl\u0131q amonyak s\u0259viyy\u0259si artd\u0131\u011f\u0131 hal\u00adda, II tip hiperammoniemiya, sitruli\u00adnuriya, argininosuksinl-asiduriya v\u0259 lizin intolerans\u0131 zaman\u0131 is\u0259 p\u0259hrizl\u0259 z\u00fclal q\u0259bulunun ard\u0131ndan ammonyak s\u0259viyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

NEYTROF\u0130L Q\u018fL\u018fV\u0130 FOSFATAZA (LEYKOS\u0130T Q\u018fL\u018fV\u0130 FOSFATAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0LAP; LAP skoru; LAPA; Neytrofil q\u0259l\u0259vi fosfataza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Heparinli v\u0259 ya adi qandan t\u0259z\u0259 haz\u0131rlanm\u0131\u015f 8-10 \u0259d\u0259d preparat (yaxma). (barmaq ucundan hazirlanan yaxmalar da istifad\u0259 oluna bil\u0259r)<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0X\u00fcsusi boyama + mikro\u00adskopik m\u00fcayin\u0259<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Uy\u00ad\u011fun olmayan s\u0131naq \u015f\u00fc\u015f\u0259si v\u0259 ya uzun m\u00fcdd\u0259t saxlan\u0131lm\u0131\u015f qandan haz\u0131r\u00adlanan yaxmalar<\/p>\n

Referens:<\/strong>\u00a030-140 %<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Xroniki mieloid leykoz il\u0259 leykomoid reaksiyas\u0131 v\u0259 polisi\u00adtemia vera il\u0259 ikincili polisite\u00admi\u00adya\u00adn\u0131n differensasiyas\u0131nda istifad\u0259 olu\u00adnur. Polisitemia vera, leykomoid reaksiyalar, Daun sindromu, mielo\u00adproliferativ x\u0259st\u0259likl\u0259r, stress, hami\u00adl\u0259\u00adlik, k\u0259skin limfositar leykoz, Hodgkin limfomas\u0131, aplastik ane\u00admiya v\u0259 bakterial infeksiyalarda LAP y\u00fcks\u0259lir, xroniki mieloid ley\u00adkoz, sideroblastik anemiya, \u0130TP (\u0130m\u00admun Trombositopenik Purpura), PHN (Paroksizmal Nokturnal Hemo\u00adqlobinuriya), kollagen toxuma x\u0259st\u0259\u00adlikl\u0259ri, k\u0259skin mielositar leykoz, sir\u00adroz, k\u0259skin \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, \u015f\u0259k\u0259rli diabet, podaqra, pernisitoz anemiya v\u0259 sarkoidozda is\u0259 LAP azal\u0131r. H\u0259m\u00ad\u00e7inin xroniki mieloid leykozun re\u00admis\u00adsiya d\u00f6vr\u00fcnd\u0259 LAP normalla\u015fa bi\u00adl\u0259r. Blast krizi v\u0259 ya aqressiv fazada is\u0259 LAP arta bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

NATR\u0130UM (T\u0259r)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>T\u0259r<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0100 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>ISE<\/p>\n

Referens:<\/strong>\u00a010-40 mEq\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Mukovissidozun diaq\u00adnozunda istifad\u0259 olunur. Mukovis\u00adsidoz, Addison x\u0259st\u0259liyi, irsi hipo\u00adparatiroidizm v\u0259 hipoparatiroidzmd\u0259 t\u0259rl\u0259 ifraz olunan Na miqdar\u0131 art\u0131r, adrenokortikal hiperfunksiyada is\u0259 azal\u0131r. H\u0259m\u00e7inin qida il\u0259 q\u0259bul edil\u0259n duzun m\u0259hdudla\u015fd\u0131r\u0131lmas\u0131 ya\u00adlan\u00e7\u0131 a\u015fa\u011f\u0131 n\u0259tic\u0259l\u0259r\u0259, mekonium ileus, ektodermal displaziya, muko\u00adpo\u00adlisaxaridoz, G6PD \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, al\u00adkaqol m\u0259n\u015f\u0259li pankreatit v\u0259 mal\u00adnutrisiya is\u0259 yalan\u00e7\u0131 y\u00fcks\u0259k n\u0259ti\u00adc\u0259l\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

NATR\u0130UM (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 sax\u00adlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>1 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a024 saatl\u0131q sidiyin miqdar\u0131 bildiril\u00adm\u0259lidir. Sidikl\u0259 Na ifraz\u0131n\u0131n sutkal\u0131q variasiyas\u0131 var. Sidikd\u0259 Na s\u0259viyy\u0259si g\u00fcnd\u00fcz \u0259n y\u00fcks\u0259k s\u0259viyy\u0259d\u0259 olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ISE<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
<12 ya\u015f<\/td>\n40-115 mEq\/g\u00fcn<\/td>\n20-70 mEq\/g\u00fcn<\/td>\n<\/tr>\n
12-15 ya\u015f<\/td>\n60-180 mEq\/g\u00fcn<\/td>\n50-170 mEq\/g\u00fcn<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n40-220 mEq\/g\u00fcn<\/td>\n40-220 mEq\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Sidikl\u0259 Na ifraz\u0131 qida q\u0259bulu v\u0259 hidratasiya d\u0259r\u0259c\u0259sind\u0259n as\u0131l\u0131d\u0131r. Qida il\u0259 Na q\u0259bulunun azal\u00admas\u0131, postmenstrual diurez, b\u00f6y\u00adr\u0259k\u00ad\u00fcst\u00fc v\u0259zin \u00e7at\u0131\u015fmal\u0131\u011f\u0131, tubuloin\u00adter\u00adsitisial x\u0259st\u0259likl\u0259r, renal tubulyar asidozu, diuretikl\u0259rl\u0259 m\u00fcalic\u0259, Bart\u00adter sindromu v\u0259 alkaloz zaman\u0131 sidikl\u0259 ifraz olunan Na miqdar\u0131 art\u0131r, qida il\u0259 Na q\u0259bulunun azalmas\u0131 pre\u00admenstrual d\u00f6vr, adrenokortikal hi\u00adper\u00adfunksiya, qlomerulyar filtrasiya s\u00fcr\u0259tinin azald\u0131\u011f\u0131 hallar, diarreya v\u0259 h\u0259ddind\u0259n art\u0131q t\u0259rl\u0259m\u0259 zaman\u0131 is\u0259 sidikl\u0259 ifraz olunan Na miqdar\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

NATR\u0130UM (BOM)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ISE<\/p>\n

Referens:<\/strong>\u00a0142-150 mEq\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0BOM elektrolit m\u00fcva\u00adzi\u00adn\u0259tinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 isti\u00adfa\u00add\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

NATR\u0130UM<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Na<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ISE<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
Yenido\u011fulan<\/td>\n116-140 mEq\/L<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n134-146 mEq\/L<\/td>\n<\/tr>\n
>7 g\u00fcn<\/td>\n130-150 mEq\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Elektrolit v\u0259 su m\u00fcva\u00adzi\u00adn\u0259tinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifa\u00add\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

NAG (N-ASET\u0130L-QLUKOZAM\u0130N\u0130DAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0NAG; Total heksoza\u00admi\u00adnidaza; \u03b2-N-asetil- heksozaminidaza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik<\/p>\n

Referens:<\/strong>\u00a01.5-6.1 U\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0B\u00f6yr\u0259k x\u0259st\u0259likl\u0259rinin diaqnostikas\u0131nda istifad\u0259 olunur. B\u00f6y\u00adr\u0259k z\u0259d\u0259l\u0259nm\u0259si olan hallarda si\u00addikd\u0259 NAG s\u0259viyy\u0259si art\u0131r. Nefro\u00adtoksik d\u0259r\u00admanlarla \u0259laq\u0259dar olaraq \u0259m\u0259l\u0259 g\u0259l\u0259n b\u00f6yr\u0259k z\u0259d\u0259l\u0259n\u00adm\u0259\u00adl\u0259\u00adrin\u00add\u0259 sidikd\u0259 NAG s\u0259viyy\u0259si, serum\u00addak\u0131 kreatinin s\u0259viyy\u0259sind\u0259n daha tez y\u00fcks\u0259lir. B\u00f6yr\u0259k transplan\u00adta\u00adsi\u00adyalar\u0131n\u00addan sonra orqan r\u0259ddinin er\u00adk\u0259n diaqnozunda da NAG \u00e7ox d\u0259y\u0259rlidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Na-N\u0130TROPRUSS\u0130AT TEST\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik (s\u0259h\u0259r ilk sidik m\u0259sl\u0259h\u0259t g\u00f6r\u00fcl\u00fcr)<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 sax\u00adlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kolorimetrik<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Sistinuriyan\u0131n t\u0259yinind\u0259 is\u00adtifad\u0259 olunur. Skrininq test oldu\u00ad\u011fundan pozitiv n\u0259tic\u0259l\u0259r d\u0259qiql\u0259\u015fdi\u00adrilm\u0259lidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Na (NATR\u0130UM)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Na<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ISE<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
Yenido\u011fulan<\/td>\n116-140 mEq\/L<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n134-146 mEq\/L<\/td>\n<\/tr>\n
>7 g\u00fcn<\/td>\n130-150 mEq\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Elektrolit v\u0259 su m\u00fcva\u00adzi\u00adn\u0259tinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifa\u00add\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

N-TELOPEPT\u0130D<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0NTx<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0S\u0259h\u0259r ikinci sidik, 24 saatl\u0131q sidik, bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 toplan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir. Bor tur\u015fusu \u00fcz\u0259rin\u0259 toplanan sidikl\u0259r d\u0259 q\u0259bul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0S\u0259h\u0259r ikinci sidik al\u0131nacaqsa, sidiyin ha\u00adm\u0131s\u0131n\u0131 bir qaba toplay\u0131b 5 mL-ini soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0EIA<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
20-50 ya\u015f<\/td>\nKi\u015fi<\/td>\n3-63 nmol BCE \/ nmol kreatinin<\/td>\n<\/tr>\n
<\/td>\nQad\u0131n<\/td>\n5-65 nmol BCE \/ nmol kreatinin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0S\u00fcm\u00fck z\u0259d\u0259l\u0259nm\u0259sini g\u00f6st\u0259r\u0259n markerl\u0259rd\u0259ndir. Osteopa\u00adrozun diaqnoz v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur. M\u00fcalic\u0259nin m\u00fc\u015fahid\u0259si \u00fc\u00e7\u00fcn ilk n\u00f6vb\u0259d\u0259 m\u00fca\u00adlic\u0259d\u0259n \u0259vv\u0259l bazal NTx miqdar\u0131n\u0131n t\u0259yini \u0259h\u0259miyy\u0259tlidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

N-ASET\u0130L-QLUKOZAM\u0130N\u0130DAZA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0NAG; Total heksoza\u00admi\u00adnidaza; \u03b2-N-asetil- heksozaminidaza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik<\/p>\n

Referens:<\/strong>\u00a01.5-6.1 U\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0B\u00f6yr\u0259k x\u0259st\u0259likl\u0259rinin diaqnostikas\u0131nda istifad\u0259 olunur. B\u00f6y\u00adr\u0259k z\u0259d\u0259l\u0259nm\u0259si olan hallarda si\u00addikd\u0259 NAG s\u0259viyy\u0259si art\u0131r. Nefro\u00adtoksik d\u0259r\u00admanlarla \u0259laq\u0259dar olaraq \u0259m\u0259l\u0259 g\u0259l\u0259n b\u00f6yr\u0259k z\u0259d\u0259l\u0259n\u00adm\u0259\u00adl\u0259\u00adrin\u00add\u0259 sidikd\u0259 NAG s\u0259viyy\u0259si, serum\u00addak\u0131 kreatinin s\u0259viyy\u0259sind\u0259n daha tez y\u00fcks\u0259lir. B\u00f6yr\u0259k transplan\u00adta\u00adsi\u00adyalar\u0131n\u00addan sonra orqan r\u0259ddinin er\u00adk\u0259n diaqnozunda da NAG \u00e7ox d\u0259y\u0259rlidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

MYOQLOB\u0130N (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Turbidimetrik<\/p>\n

Referens:<\/strong>\u00a0<200 ng\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Sidikd\u0259ki mioqlobin kon\u00adsentrasiyas\u0131 b\u00f6yr\u0259k funksiyalar\u0131ndan as\u0131l\u0131d\u0131r. Skelet v\u0259 ya \u00fcr\u0259k \u0259z\u0259l\u0259sinin z\u0259d\u0259l\u0259nm\u0259si, ikincili toksik mio\u00adqlo\u00adbinuriya (Haff x\u0259st\u0259liyi), elektrik \u015fo\u00adku v\u0259 termal yan\u0131qlarda sidikd\u0259 mio\u00adqlobin s\u0259viyy\u0259si art\u0131r. Y\u00fcks\u0259k mio\u00adqlo\u00adbin miqdar\u0131 nefrotoksikdir v\u0259 k\u0259s\u00adkin tubulyar nekroza s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

MYOQLOB\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Mb<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0T\u00fcrbidimetrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Ki\u015fi<\/td>\n16-74 ng\/mL<\/td>\n<\/tr>\n
Qad\u0131n<\/td>\n7-64 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Serumda mioqlobinin s\u0259\u00adviy\u00ady\u0259si birba\u015fa \u0259z\u0259l\u0259 k\u00fctl\u0259si il\u0259 \u0259la\u00adq\u0259\u00addar\u00add\u0131r. Skelet v\u0259 \u00fcr\u0259k \u0259z\u0259l\u0259sind\u0259 z\u0259d\u0259\u00adl\u0259n\u00adm\u0259, nekroz v\u0259 ya lizis\u0259 s\u0259b\u0259b olan b\u00fc\u00adt\u00fcn hallar (m\u0259s. iskemiya, rab\u00addomioliz, miopatiya, \u0259z\u0259l\u0259 distro\u00adfiyas\u0131, miozit), uremiya, travma, if\u00adlic, iltihabi mio\u00adpa\u00adtiya, \u0259z\u0259l\u0259daxili in\u00adyeksiya, idman v\u0259 yan\u0131qlarda se\u00adrum\u00adda mioqlobin s\u0259viy\u00ady\u0259\u00adsi art\u0131r, qanda mioqlobin\u0259 qar\u015f\u0131 an\u00adti\u00adcisim olduqda v\u0259 revmatoid artritd\u0259 is\u0259 azal\u0131r. KM\u0130-dan sonra 1-4-c\u00fc saatlarda mioqlobin s\u0259viyy\u0259si y\u00fcks\u0259lir v\u0259 24-c\u00fc saatda normala enir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

MURAM\u0130DAZA (L\u0130ZOS\u0130M)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Muramidaza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>RID<\/p>\n

Referens:<\/strong>\u00a09.6-16.8 mg\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qranulosit v\u0259 monosit \u00e7ev\u00adrilm\u0259sinin (turn over) g\u00f6st\u0259\u00adri\u00adcisidir. Qranulositar v\u0259 ya monositar leykozlar, mielopro\u00adliferativ x\u0259st\u0259\u00adlik\u00adl\u0259r v\u0259 b\u0259dxass\u0259li histiositozun t\u0259yi\u00adnind\u0259 istifad\u0259 olunur. K\u0259skin mo\u00adnositar v\u0259 ya mielomonositar ley\u00adkozlar, xroniki mieloid\u00a0 leyke\u00admi\u00adyalar, polisitemiya vera, b\u0259zi b\u00f6yr\u0259k x\u0259st\u0259likl\u0259ri v\u0259 xroniki infeksiyalarda (m\u0259s.v\u0259r\u0259m)\u00a0 serumda lizosimin s\u0259viyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Pb (C\u0130V\u018f)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Hg<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan (\u0259vv\u0259ll\u0259r he\u00e7 istifad\u0259 olunmam\u0131\u015f v\u0259 ya nitrat tur\u015fusu il\u0259 yuyulmu\u015f v\u0259 distill\u0259, yaxud, ionsuzla\u015fd\u0131r\u0131lm\u0131\u015f su il\u0259 yaxalanm\u0131\u015f s\u0131naq \u015f\u00fc\u015f\u0259sind\u0259 g\u00f6n\u00add\u0259\u00adrilm\u0259lidir), sa\u00e7<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (EDTA-l\u0131 tam qan)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL EDTA-l\u0131 tam qan, 10 g sa\u00e7<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Tam qan<\/td>\n<10 \u03bcg\/L<\/td>\n<\/tr>\n
Sa\u00e7<\/td>\n<1\u03bcg\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0K\u0259skin v\u0259 ya xroniki civ\u0259 z\u0259h\u0259rl\u0259nm\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 isti\u00adfad\u0259 olunur. B\u0259zi d\u0259rmanlar, fun\u00adqu\u00adsidl\u0259r v\u0259 s\u0259naye madd\u0259l\u0259rind\u0259 civ\u0259y\u0259 rast g\u0259linir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PchE (PSEVDOXOL\u0130NESTERAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>PchE; kolinesteraz II; SchE; Axilkolin axilhidrolaza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
Ki\u015fi<\/td>\n5400-13200 U\/L<\/td>\n<\/tr>\n
Qad\u0131n<\/td>\n15 ya\u015f<\/td>\n5400-13200 U\/L<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n4300-11500 U\/L<\/td>\n<\/tr>\n
50 ya\u015f<\/td>\n5400-13200 U\/L<\/td>\n<\/tr>\n
Hamil\u0259<\/td>\n3700-9300 U\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qaraciy\u0259rin funksional testl\u0259rind\u0259n biridir. Uzanm\u0131\u015f anes\u00adteziya sinir qaz\u0131 v\u0259 \u00fczvi fosforlu insektisid z\u0259h\u0259rl\u0259nm\u0259l\u0259rinin qiym\u0259t\u00adl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur. Ge\u00adnetik psevdo-xolinesteraza variant\u00adlar\u0131 (anesteziyan\u0131n uzanmas\u0131na s\u0259b\u0259b olur), hepatitl\u0259r, sirroz, malnutrisiya, anemiyalar, k\u0259skin infeksiyalar, k\u0259s\u00adkin miokard infarkt\u0131, a\u011fciy\u0259r emboliyas\u0131, \u0259m\u0259liyyatdan sonrak\u0131 d\u00f6vr, xroniki b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, hamil\u0259liyin son d\u00f6vrl\u0259ri v\u0259 serumda albumin konsentrasiyas\u0131n\u0131 azaldan hallarda serumda psevdo-xolines\u00adterazan\u0131n miqdar\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

P\u0130RUVAT K\u0130NAZA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0PK<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz<\/p>\n

Referens:<\/strong>\u00a060-220 MU\/milyard eritrosit<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Piruvat kinaza \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131 anadang\u0259lm\u0259 qeyri-sferositar hemolitik anemiyaya s\u0259b\u0259b olur. H\u0259m\u00e7inin k\u0259skin miokard infarkt\u0131, \u0259z\u0259l\u0259 x\u0259st\u0259likl\u0259ri, Duchenne \u0259z\u0259l\u0259 distrofiyas\u0131 v\u0259 idman da piruvat ki\u00adnaza s\u0259viyy\u0259sind\u0259 atrmaya s\u0259b\u0259b olur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

P\u0130RUVAT TUR\u015eUSU (P\u0130RUVAT)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Piruvat tur\u015fusu<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Tam qan, BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a08%-li perxlorat tur\u00ad\u015fulu d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (laborato\u00adri\u00adyadan verilir)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fc\u00admun\u0259nin stabill\u0259\u015fdirilm\u0259si m\u0259qs\u0259\u00addil\u0259 tam qan v\u0259 ya BOM-dan 2 mL g\u00f6\u00adt\u00fcr\u00fcl\u00fcr, \u00fcz\u0259rin\u0259 4 mL 8%-li perxlorat tur\u015fusu \u0259lav\u0259 olunaraq 30 san. qa\u00adr\u0131\u015fd\u0131r\u0131l\u0131r. Daha sonra n\u00fc\u00admun\u0259 5 d\u0259qiq\u0259 soyuducuda saxlan\u0131lmal\u0131 v\u0259 sentrifuqadan ke\u00e7iril\u0259r\u0259k \u0259ld\u0259 edil\u0259n supernatant g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0X\u0259st\u0259 ac v\u0259 istirah\u0259t etmi\u015f olmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrometrik, fer\u00admen\u00adtativ<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Tam qan<\/td>\n0.3-1.0 mg\/dL<\/td>\n<\/tr>\n
BOM<\/td>\n0.5-1.7 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Metabolik asidozun qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Plazmada piruvat s\u0259viyy\u0259si qidalanma, cinsiyy\u0259t, ya\u015f, sutkal\u0131q ritm, fiziki aktivlik, menstrual tsikl,\u00a0 hamil\u0259lik v\u0259 \u0259traf m\u00fchit faktor\u00adla\u00adr\u0131ndan as\u0131l\u0131 olaraq d\u0259yi\u015fir. Qaraciy\u0259r x\u0259st\u0259likl\u0259ri, \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, ure\u00admiya, a\u011f\u0131r metal z\u0259h\u0259rl\u0259nm\u0259si, I tip \u015f\u0259k\u0259rli diabet, \u00fcr\u0259k dayanmas\u0131, hemorragiya, k\u0259skin miokard infarkt\u0131, \u015fok, diabetik ketoasidoz, b\u0259dxass\u0259li hipertermiya v\u0259 Reye sindromunda piruvat s\u0259viyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PK (P\u0130RUVAT K\u0130NAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0PK<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz<\/p>\n

Referens:<\/strong>\u00a060-220 MU\/milyard eritrosit<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Piruvat kinaza \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131 anadang\u0259lm\u0259 qeyri-sferositar hemolitik anemiyaya s\u0259b\u0259b olur. H\u0259m\u00e7inin k\u0259skin miokard infarkt\u0131, \u0259z\u0259l\u0259 x\u0259st\u0259likl\u0259ri, Duchenne \u0259z\u0259l\u0259 distrofiyas\u0131 v\u0259 idman da piruvat ki\u00adnaza s\u0259viyy\u0259sind\u0259 atrmaya s\u0259b\u0259b olur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PLAP (TEMPERATURA DAVAMLI Q\u018fL\u018fV\u0130 FOSFATAZA (65 oC))<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Plasentar Q\u0259l\u0259vi Fosfa\u00adtaza; PLAP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik, kine\u00adtik<\/p>\n

Referens:<\/strong>\u00a0<1%<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Q\u0259l\u0259vi fosfatazan\u0131n tem\u00adpe\u00adratura davaml\u0131, plasentar izoen\u00adzi\u00admidir. Hamil\u0259liyin 12-ci h\u0259ft\u0259sind\u0259n etibar\u0259n tap\u0131l\u0131r. H\u0259m\u00e7inin semino\u00adma\u00adlar\u0131n 50%-i v\u0259 s\u00fcd v\u0259zi v\u0259 yu\u00admur\u00adtal\u0131q x\u0259r\u00e7\u0259ngli x\u0259st\u0259l\u0259rin 20 %-ind\u0259 d\u0259 plasentar q\u0259l\u0259vi fosfataza tap\u0131la il\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PLASENTAL Q\u018fL\u018fV\u0130 FOSFATAZA (TEMPERATURA DAVAMLI Q\u018fL\u018fV\u0130 FOSFATAZA (65 oC))<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Plasentar Q\u0259l\u0259vi Fosfa\u00adtaza; PLAP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik, kine\u00adtik<\/p>\n

Referens:<\/strong>\u00a0<1%<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Q\u0259l\u0259vi fosfatazan\u0131n tem\u00adpe\u00adratura davaml\u0131, plasentar izoen\u00adzi\u00admidir. Hamil\u0259liyin 12-ci h\u0259ft\u0259sind\u0259n etibar\u0259n tap\u0131l\u0131r. H\u0259m\u00e7inin semino\u00adma\u00adlar\u0131n 50%-i v\u0259 s\u00fcd v\u0259zi v\u0259 yu\u00admur\u00adtal\u0131q x\u0259r\u00e7\u0259ngli x\u0259st\u0259l\u0259rin 20 %-ind\u0259 d\u0259 plasentar q\u0259l\u0259vi fosfataza tap\u0131la il\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PORF\u0130R\u0130NL\u018fR<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a010 mL<\/p>\n

Testin t\u0259rkibi:<\/strong>\u00a0Uroporfirin I, III, koproporfirin I, III v\u0259 dig\u0259r porfirin izomerl\u0259ri<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Qa\u00adranl\u0131q v\u0259 soyuq \u015f\u0259raitd\u0259 toplanmal\u0131, i\u015f\u0131qdan qorunmaqla soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
Uropofinin I, III<\/td>\n25 mg\/g\u00fcn<\/td>\n<\/tr>\n
Koproporfirin I<\/td>\n25 mg\/g\u00fcn<\/td>\n<\/tr>\n
Koproporfirin III<\/td>\n75 mg\/g\u00fcn<\/td>\n<\/tr>\n
Total porfirinl\u0259r<\/td>\n150 mg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Porfiriyalar\u0131n t\u0259yinind\u0259 v\u0259 tipinin m\u00fc\u0259yy\u0259nl\u0259\u015fdirilm\u0259sind\u0259 is\u00adtifad\u0259 olunur. X\u00fcsusil\u0259 d\u0259ri\u00a0 foto\u00adh\u0259ssasl\u0131\u011f\u0131 m\u00fc\u015fahid\u0259 olunan porfiri\u00adyalarda sidik porfirinl\u0259ri \u0259h\u0259\u00admiy\u00ady\u0259t\u00adlidir. HPLC \u00fcsulu il\u0259 sidikd\u0259ki b\u00fct\u00fcn porfirin n\u00f6vl\u0259ri v\u0259 izomerl\u0259ri k\u0259\u00admiyy\u0259tc\u0259 t\u0259yin oluna bil\u0259r. H\u0259m\u00e7inin civ\u0259 z\u0259h\u0259rl\u0259nm\u0259si, qaraciy\u0259r x\u0259s\u00adt\u0259\u00adliyi, k\u0259skin miokard infarkt\u0131, he\u00admo\u00adlitik v\u0259 pernisitoz anemiyalar, alko\u00adqol m\u0259n\u015f\u0259li sirroz, idman, Hodgkin x\u0259st\u0259liyi, leykoz, triotoksikoz v\u0259 vi\u00adtamin \u00e7at\u0131\u015f\u00admazl\u0131qlar\u0131 kimi s\u0259b\u0259b\u00adl\u0259r\u00add\u0259n \u0259m\u0259l\u0259 g\u0259l\u0259n qazan\u0131lm\u0131\u015f por\u00adfi\u00adri\u00adyalardada sidikd\u0259 koproporfirinin s\u0259viyy\u0259si art\u0131r. K\u0259skin porfiriyalar\u0131n qiym\u0259t\u00adl\u0259ndirilm\u0259sind\u0259 is\u0259 sidikd\u0259 ALA v\u0259 porfobilinogen s\u0259viyy\u0259si is\u00adtifad\u0259 olunmal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PORFOB\u0130L\u0130NOGEN<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a024 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Asetat tur\u015fusu v\u0259 ya 6N HCl \u00fcz\u0259rin\u0259 qaranl\u0131q \u015f\u0259raitd\u0259 toplan\u0131lmal\u0131 v\u0259 i\u015f\u0131qdan qorunaraq g\u00f6nd\u0259rilm\u0259lidir. N\u00fcmun\u0259 24 saat \u0259rzind\u0259 laboratoriyaya \u00e7atd\u0131r\u0131lmal\u0131d\u0131r<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a010 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>\u00a024 saatl\u0131q sidik miqdar\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Xromatoqrafik, spek\u00adtrometrik<\/p>\n

Referens:<\/strong>\u00a0<2 mg\/g\u00fcn<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0K\u0259skin fasil\u0259li porfiriya v\u0259 dig\u0259r k\u0259skin tutmalarla m\u00fc\u015fahid\u0259 olunan porfiriyalar\u0131n diferensa\u00adsiyas\u0131nda istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PR\u0130D\u0130NOL\u0130N KOLLAGEN CROSSL\u0130NKS<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Pyrilinks; Pyrilinks-D<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a024 saatl\u0131q sidik, bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a06N HCl \u00fcz\u0259rin\u0259 toplan\u0131lmal\u0131d\u0131r. Asetat tur\u015fusu v\u0259 bor tur\u015fusu \u00fcz\u0259rin\u0259 toplanan sidik n\u00fcmun\u0259l\u0259ri d\u0259 q\u0259bul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

Test i\u015feri\u011fi<\/strong>:<\/strong>\u00a0Pridinolin, Deok\u00adsipri\u00addinolin<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Pridinolin<\/td>\n<\/tr>\n
Ki\u015fi<\/td>\n>20 ya\u015f<\/td>\n18-40 nM\/mM kreatinin<\/td>\n<\/tr>\n
Qad\u0131n<\/td>\n20-50 ya\u015f<\/td>\n20-62 nM\/mM kreatinin<\/td>\n<\/tr>\n
Deoksipridinolin<\/td>\n<\/tr>\n
Ki\u015fi<\/td>\n>20 ya\u015f<\/td>\n5-14 nM\/mM kreatinin<\/td>\n<\/tr>\n
Qad\u0131n<\/td>\n20-50 ya\u015f<\/td>\n5-22 nM\/mM kreatinin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0S\u00fcm\u00fck metobolizminin q\u0131y\u00adm\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. S\u00fcm\u00fck rezorbsiyas\u0131 \u00fc\u00e7\u00fcn spe\u00adsifik g\u00f6st\u0259ricidir. X\u00fcsusil\u0259 x\u0259st\u0259liyin aktivliyinin t\u0259yini v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 \u0259h\u0259miyy\u0259tlidir. Pri\u00addi\u00adnolin q\u0131\u011f\u0131rdaq v\u0259 s\u00fcm\u00fckl\u0259rd\u0259, de\u00adok\u00adsipiridinolin is\u0259 s\u00fcm\u00fck v\u0259 di\u015f to\u00adxu\u00admas\u0131nda olur. Osteoporoz, birincili hiperparatiroidzm, hipertiroidzm, Pa\u00adget x\u0259st\u0259liyi v\u0259 s\u00fcm\u00fck metastazlar\u0131 sidikd\u0259 pridinolin kollagen \u00e7arpaz ba\u011flar\u0131nda (crosslink) art\u0131ma s\u0259b\u0259b olur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

REDUKS\u0130YA ED\u0130C\u0130 MADD\u018f (N\u0259cis)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>T\u0259z\u0259 n\u0259cis<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0T\u0259miz, a\u011fz\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01g<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kimy\u0259vi<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

REDUKS\u0130YA ED\u0130C\u0130 MADD\u018f (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kimy\u0259vi<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Sidikd\u0259 reduksiya edici madd\u0259nin olmas\u0131n\u0131n qiym\u0259tl\u0259n\u00addi\u00adril\u00adm\u0259\u00adsind\u0259 istifad\u0259 olunur. Ql\u00fckozuriya, hamil\u0259liyin son d\u00f6vrl\u0259ri, laktasiya, qalaktozemiya, esensial pentozuriya, \u0259z\u0259l\u0259 distrofiyas\u0131 v\u0259 infantlarda sidikd\u0259 reduksiya edici madd\u0259 a\u015fkar oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

QUR\u011eU\u015eUN<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Pb<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0EDTA-l\u0131 v\u0259 ya he\u00adparinli tam qan, 24 saatl\u0131q sidik, bird\u0259f\u0259lik sidik, BOM, sa\u00e7<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi (EDTA-l\u0131) v\u0259 ya ya\u015f\u0131l (heparinli) qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si, gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si (BOM) (He\u00e7 istifad\u0259 olunmam\u0131\u015f v\u0259 ya nitrat tur\u015fusu il\u0259 yuyulmu\u015f v\u0259 distill\u0259 v\u0259 ya ionsuzla\u015fd\u0131r\u0131lm\u0131\u015f\u00a0 su il\u0259 yaxalanm\u0131\u015f s\u0131naq \u015f\u00fc\u015f\u0259l\u0259rind\u0259 g\u00f6nd\u0259\u00adrilm\u0259lidir)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>1 mL (serum, si\u00addik, BOM), 0.5 g sa\u00e7 (\u0259ns\u0259d\u0259n al\u0131nan \u00fcmun\u0259 m\u0259sl\u0259h\u0259t g\u00f6r\u00fcl\u00fcr)<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 sa\u00adatl\u0131q sidik soyuq \u015f\u0259raitd\u0259 sax\u00adla\u00adn\u0131l\u00admal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir. 6N HCl, ase\u00adtat tur\u015fusu v\u0259 ya bor tur\u015fusu \u00fcz\u0259\u00adrin\u0259 toplanm\u0131\u015f sidik n\u00fcmun\u0259l\u0259ri d\u0259 q\u0259bul olunur<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS-Zeeman<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
<\/td>\n<15 ya\u015f<\/td>\n>15 ya\u015f<\/td>\n<\/tr>\n
Tam qan<\/td>\n<1020 \u03bcg\/dL<\/td>\n<20 \u03bcg\/dL<\/td>\n<\/tr>\n
Sidik<\/td>\n<8020 \u03bcg\/L<\/td>\n<\/td>\n<\/tr>\n
Sa\u00e7<\/td>\n<520 \u03bcg\/g sa\u00e7<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qur\u011fu\u015fun z\u0259h\u0259rl\u0259n\u00adm\u0259\u00adsi\u00adnin t\u0259yinind\u0259 istifad\u0259 olunur. Qur\u00ad\u011fu\u015fun z\u0259h\u0259rl\u0131nm\u0259sind\u0259, anoreksiya, qar\u0131n a\u011fr\u0131s\u0131, qusma, \u0259s\u0259bilik, apatiya, ensefalopatiya, anemiya v\u0259 periferik nevropatiyalarda rast g\u0259linir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

QL\u00dcKOZAM\u0130NOQL\u0130KANLAR<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq m\u00fchitd\u0259 sax\u00adlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>30 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 saat\u00adl\u0131q sidiyin miqdar\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
<3 ay<\/td>\n<40.0 mg\/mmol kreatinin<\/td>\n<\/tr>\n
4-6 ay<\/td>\n<25.0 mg\/mmol kreatinin<\/td>\n<\/tr>\n
7 ay-1 ya\u015f<\/td>\n<17.5 mg\/mmol kreatinin<\/td>\n<\/tr>\n
2-3 ya\u015f<\/td>\n<12.4 mg\/mmol kreatinin<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n<9.6 mg\/mmol kreatinin<\/td>\n<\/tr>\n
6-11 ya\u015f<\/td>\n<8.0 mg\/mmol kreatinin<\/td>\n<\/tr>\n
12-15 ya\u015f<\/td>\n<4.1 mg\/mmol kreatinin<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n<3.4 mg\/mmol kreatinin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Mukopolisaxaridozlar\u0131n skri\u00adninqi m\u0259qs\u0259dil\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

QL\u00dcKOZA-6-FOSFAT DEH\u0130DROGENAZA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>G6PD<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, ki\u00adnetik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
<1 ya\u015f<\/td>\n6.5-14.4 U\/g Hb<\/td>\n<\/tr>\n
>1 ya\u015f<\/td>\n4.6-13.5 U\/g Hb<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0G6PD \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 \u0259la\u00adq\u0259dar inki\u015faf ed\u0259n hemolitik ane\u00admi\u00adyalar\u0131n t\u0259yinind\u0259 istifad\u0259 olur. G\u0259nc eritrositl\u0259rd\u0259 G6PD ak\u00adtivliyi y\u00fcks\u0259k oldu\u011fundan he\u00admo\u00adlitik epi\u00adzod\u00addan sonra \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 t\u0259yini \u0259k\u00ads\u0259r hallarda m\u00fcmk\u00fcn olmur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

QL\u00dcKOZA (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik, Bir\u00add\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 sax\u00adlan\u0131lmall\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir. Bor tur\u00ad\u015fusu \u00fcz\u0259rin\u0259 toplanan sidik n\u00fcmun\u0259l\u0259ri d\u0259 g\u00f6nd\u0259ril\u0259 bil\u0259r<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>1 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 saatl\u0131q sidiyin miqdar\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, fer\u00admentativ, kinetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Si\u00addiyin 5 g\u00fcnd\u0259n art\u0131q soyuducuda sax\u00adlan\u0131lmas\u0131<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Bird\u0259f\u0259lik sidik<\/td>\n1.0-15.0 mg\/dL<\/td>\n<\/tr>\n
24 saatl\u0131q sidik<\/td>\n0.5 g\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0B\u00f6yr\u0259k funksiyalar\u0131n\u0131n qiy\u00adm\u0259tl\u0259ndirilm\u0259sind\u0259 v\u0259 \u015f\u0259k\u0259rli dia\u00adbet x\u0259st\u0259liyinin m\u00fc\u015fahid\u0259sind\u0259 isti\u00adfad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

QL\u00dcKOZA (Maye)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>BOM, perikardial, peritoneal, plevral v\u0259 sinovial ma\u00adyel\u0259r<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Gelsiz d\u00fcz steril s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>200\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, fer\u00admentativ, kinetik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
BOM<\/td>\n<12 ya\u015f<\/td>\n60-80 mg\/dL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n50-75 mg\/dL<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n40-70 mg\/dL<\/td>\n<\/tr>\n
Preval Maye<\/td>\n<7 g\u00fcn<\/td>\n40-60 mg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn- 1 ay<\/td>\n50-80 mg\/dL<\/td>\n<\/tr>\n
2 ay-15 ya\u015f<\/td>\n60-100 mg\/dL<\/td>\n<\/tr>\n
16-60 ya\u015f<\/td>\n70-110 mg\/dL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n80-115 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Normada BOM-da ql\u00fcko\u00adza\u00adn\u0131n s\u0259viyy\u0259si, h\u0259min vaxt qanda t\u0259\u00adyin olunan ql\u00fckoza miqdar\u0131n\u0131n 60-80%-n\u0259 b\u0259r\u0259b\u0259r olur. Bakterial me\u00adnengitl\u0259r, m\u0259rk\u0259zi sinir sisteminin b\u0259dxass\u0259li \u015fi\u015fl\u0259ri, revmatoid me\u00adnen\u00adgit v\u0259 hipoqlikemiya BOM ql\u00fckoza miqdar\u0131n\u0131n azalmas\u0131na s\u0259b\u0259b olur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

QL\u00dcKOZA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Acl\u0131q qan \u015f\u0259k\u0259ri; AQ\u015e<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, florid\/ok\u00adsa\u00adlatl\u0131 plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Boz qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (florid\/oksalatl\u0131 plazma), Q\u0131r\u00adm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200\u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0Q\u0131r\u00adm\u0131\u00adz\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259sin\u0259 qan al\u0131\u00adn\u0131bsa gecikm\u0259d\u0259n sentrifuqadan ke\u00ad\u00e7i\u00adril\u0259r\u0259k serumu tez ayr\u0131lmal\u0131d\u0131r<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 8 saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 laz\u0131md\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, fer\u00admen\u00adtativ, kinetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Se\u00adrum ayr\u0131lmadan q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259sind\u0259 saxlan\u0131lm\u0131\u015f qan<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si qan\u0131<\/td>\n45-96 mg\/dL<\/td>\n<\/tr>\n
Yar\u0131m\u00e7\u0131q do\u011fulan<\/td>\n20-60 mg\/dL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n40-60 mg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-1 ay<\/td>\n50-80 mg\/dL<\/td>\n<\/tr>\n
2 ay-15 ya\u015f<\/td>\n60-100 mg\/dL<\/td>\n<\/tr>\n
16-60 ya\u015f<\/td>\n70-100 mg\/dL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n80-115 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Karbohidrat metobo\u00adliz\u00admi\u00adnin qiym\u0259tl\u0259ndirilm\u0259siond\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

QLUKOHEMOGLOB\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>HbA1C<\/sub>; Hemoglobin A1C<\/sub><\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>Turbidimetrik<\/p>\n

Referens:<\/strong>\u00a0%4.5-5.7<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Diabetes mellitusun uzun m\u00fcdd\u0259tli m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olu\u00adnur. Son 6-8 h\u0259ft\u0259 m\u00fcdd\u0259tind\u0259 qan\u00addak\u0131 ortalama ql\u00fckoza konsen\u00adtra\u00adsi\u00adyas\u0131n\u0131 g\u00f6st\u0259rir. Eritrositl\u0259rin \u00f6m\u00adr\u00fc\u00adn\u00fcn q\u0131sald\u0131\u011f\u0131 qeyri stabil hemo\u00adqlo\u00adbinl\u0259rin m\u00f6vcud olmas\u0131 (Hb SS, Hb CC, Hb SC v\u0259 s.) v\u0259 dig\u0259r hemolitik anemiyalar yaln\u0131\u015f a\u015fa\u011f\u0131 n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r. D\u0259mir \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 eritrositl\u0259rin \u00f6mr\u00fcn\u00fc uzadaraq yaln\u0131\u015f y\u00fcks\u0259k n\u0259tic\u0259nin \u0259ld\u0259 edilm\u0259sin\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

QLOMERULYAR F\u0130LTRAS\u0130YA SUR\u018fT\u0130 (KREAT\u0130N\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, ki\u00adnetik<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si qan\u0131<\/td>\n0.6-1.2 mg\/dL<\/td>\n<\/tr>\n
Yenido\u011fulmu\u015f<\/td>\n0.3-1.0 mg\/dL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n0.3-1.0 mg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-3 ay<\/td>\n0.2-0.4 mg\/dL<\/td>\n<\/tr>\n
4 ay-5 ya\u015f<\/td>\n0.3-0.7 mg\/dL<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n0.5-1.0 mg\/dL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n0.5-1.2 mg\/dL<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\nKi\u015fi: 0.5-1.4 mg\/dL<\/td>\n<\/tr>\n
Qad\u0131n: 0.5-1.3 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0B\u00f6yr\u0259k funksiyalar\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olnur. B\u00f6yr\u0259k x\u0259st\u0259likl\u0259ri, \u015fok, b\u0259d xass\u0259li t\u00f6r\u0259m\u0259l\u0259r, SLE, diabetik nefropatiya, k\u0259skin \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 akro\u00adme\u00adqaliyada serumda kreatininin s\u0259viy\u00ady\u0259si art\u0131r, \u0259z\u0259l\u0259 distrofiyas\u0131 v\u0259 dia\u00adbetik ketoasidozda is\u0259 azal\u0131r. B\u00f6\u00ady\u00fck\u00adl\u0259rd\u0259 kreatinin il\u0259 birlikd\u0259 MDRD formuluna \u0259sas\u0259n hesablanan qlo\u00admerulyar filtrasiya s\u00fcr\u0259ti (GFR) d\u0259y\u0259ri d\u0259 verilir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

QEYR\u0130 \u00dcZV\u0130 FOSFOR (FOSFOR)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>PO3<\/sub>; P; Qeyri \u00fczvi fosfor; Fosfat<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259 acqar\u0131na al\u0131nmal\u0131 v\u0259 serum m\u00fcmk\u00fcn q\u0259d\u0259r tez ayr\u0131lmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admo\u00adliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si qan\u0131<\/td>\n3.7-8.1<\/td>\n<\/tr>\n
Yeni do\u011fulmu\u015f<\/td>\n5.0-10.0<\/td>\n<\/tr>\n
7 g\u00fcn<\/td>\n5.0-10.0<\/td>\n<\/tr>\n
7 g\u00fcn- 1 ya\u015f<\/td>\n4.5-6.7<\/td>\n<\/tr>\n
2-12 ya\u015f<\/td>\n4.5-5.5<\/td>\n<\/tr>\n
13-60 ya\u015f<\/td>\n2.7-4.5<\/td>\n<\/tr>\n
60 ya\u015f<\/td>\n2.3-3.7\u00a0(Ki\u015fi)<\/td>\n<\/tr>\n
2.8-4.1 (Qad\u0131n)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Fosfor metobolizminin v\u0259 Ca-P m\u00fcvazin\u0259tinin qiym\u0259tl\u0259n\u00addiril\u00adm\u0259\u00adsind\u0259 istifad\u0259 olunur. Osteolitik s\u00fcm\u00fck metastazlar\u0131, sarkoidoz, s\u00fcd-q\u0259l\u0259vi sindromu, vitamin D intok\u00adsi\u00adkasiyas\u0131, b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, hipo\u00adpa\u00adratiroidizm, psevdohipo\u00adparatiroidizm, akromeqaliya, a\u011fciy\u0259r emboliyas\u0131,\u00a0<\/strong>lak\u00adtik asidoz \u00a0v\u0259 respirator asidoz zaman\u0131 serumda fosforun s\u0259viyy\u0259si art\u0131r, osteomalyasiya, steatoreya, renal tubulyar asidoz, Qram neqativ bakterial sep\u00adtisemiya, hipokalemiya vitamin D \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, malnutrisiya, ma\u00adlabsorbsiya, a\u011f\u0131r diarreya, qusma, birin\u00adcili hiperparatiroidizm, hiperkal\u00adsemiya, salisilat z\u0259h\u0259rl\u0259nm\u0259si, respi\u00adrator infeksiyalar, hiperinsulinemiya, respirator alkaloz, osteoblastik s\u00fcm\u00fck metastazlar\u0131 v\u0259 renal tubulyar defekt\u00adl\u0259rd\u0259 is\u0259 fosforun miqdar\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

QEYR\u0130 PROSTAT\u0130K TUR\u015e FOSFATAZA<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Ki\u015fi<\/td>\n<3.9 U\/mL<\/td>\n<\/tr>\n
Qad\u0131n<\/td>\n<2.9 U\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Prostatdan k\u0259nar toxu\u00adma\u00adlara aid (qaraciy\u0259r, dalaq, eritrositl\u0259r, trombositl\u0259r v\u0259 s\u00fcm\u00fck iliyi) tur\u015f fosfataza s\u0259viyy\u0259sinin qiym\u0259tl\u0259ndi\u00adrilm\u0259sind\u0259 istifad\u0259 olunur. Yetkin ya\u015fl\u0131 normal ki\u015fil\u0259rd\u0259 \u00fcmumi tur\u015f fosfataza miqdar\u0131n\u0131n t\u0259xmin\u0259n yar\u0131s\u0131 prostatdan k\u0259nar toxumalardan qaynaqlan\u0131r. Qad\u0131nlarda is\u0259 \u00fcmumi tur\u015f fosfatazan\u0131n b\u00f6y\u00fck hiss\u0259sini qaraciy\u0259r, eritrosit v\u0259 trombosit m\u0259n\u015f\u0259li tur\u015f fosfataza t\u0259\u015fkil edir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

QASTR\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>N\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 10 saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 laz\u0131md\u0131r. H\u0259m\u00e7inin sutkal\u0131q ritmi var\u00add\u0131r v\u0259 03.00-07.00 saatlar\u0131 ara\u00ads\u0131n\u00adda \u0259n a\u015fa\u011f\u0131 s\u0259viyy\u0259d\u0259 olur. Qast\u00adro\u00adskopiyadan sonra n\u00fcmun\u0259 al\u0131nma\u00admal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>h\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>25-125 pg\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Zollinger-Ellison sind\u00adromu, axlorhidriya v\u0259 ya pernisitoz ane\u00admiya, \u00e7oxsayl\u0131 endokirin neo\u00adpla\u00adziyalar v\u0259 dig\u0259r hiperqastri\u00adne\u00admi\u00adya\u00adlar\u0131n t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

QAN pH<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Heparinli tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Ya\u015f\u0131l qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>1 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0Ar\u00adte\u00adrial qan al\u0131nmal\u0131, anaerob v\u0259 soyuq \u015f\u0259raitd\u0259 t\u0259cili laboratoriyaya \u00e7atd\u0131r\u0131l\u00admal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>ISE<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Ge\u00adcik\u00adtirilmi\u015f n\u00fcmun\u0259<\/p>\n

Referens:<\/strong>\u00a07.35-7.45<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Tur\u015fu-q\u0259l\u0259vi m\u00fcvazi\u00adn\u0259\u00adti\u00adnin qiym\u0259tl\u0259ndirilm\u0259si<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

QAMMA QLUTAM\u0130L TRANSFERAZA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>\u03b3-Glutamil transferaza; GGT; Gama GT; Gama glutamil transpeptidaza<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, kinetik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si qan\u0131<\/td>\n11-194 IU\/L<\/td>\n<\/tr>\n
Yar\u0131m\u00e7\u0131qdo\u011fulan<\/td>\n11-194 IU\/L<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n10-300 IU\/L<\/td>\n<\/tr>\n
7 g\u00fcn-1 ay<\/td>\n7-180 IU\/L<\/td>\n<\/tr>\n
2-3 ay<\/td>\n7-100 IU\/L<\/td>\n<\/tr>\n
4 ay-15 ya\u015f<\/td>\n7-50 IU\/L<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n7-60 IU\/L (Ki\u015fi)<\/td>\n<\/tr>\n
7-40 IU\/L (Qad\u0131n)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qaraciy\u0259rin funksional test\u00adl\u0259rind\u0259n biridir, alkaqol v\u0259 d\u0259r\u00admanlar\u0131n qaraciy\u0259r\u0259 toksiki t\u0259sirinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur. Obst\u00adruktiv sar\u0131l\u0131q, qaraciy\u0259rdaxili xoles\u00adtaz, pankreatit v\u0259 qaraciy\u0259rd\u0259ki me\u00adtastatik karsinomalar\u0131n t\u0259yinind\u0259 d\u0259 \u0259h\u0259miyy\u0259tlidir. Serumda QQT-nin s\u0259\u00adviyy\u0259si, qaraciy\u0259r x\u0259st\u0259likl\u0259ri za\u00adman\u0131 ALP il\u0259 paralel d\u0259yi\u015fdiyi halda, s\u00fcm\u00fck x\u0259st\u0259likl\u0259rind\u0259 bu nisb\u0259t g\u00f6zl\u0259nilmir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PSEVDOXOL\u0130NESTERAZA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>PchE; kolinesteraz II; SchE; Axilkolin axilhidrolaza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
Ki\u015fi<\/td>\n5400-13200 U\/L<\/td>\n<\/tr>\n
Qad\u0131n<\/td>\n15 ya\u015f<\/td>\n5400-13200 U\/L<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n4300-11500 U\/L<\/td>\n<\/tr>\n
50 ya\u015f<\/td>\n5400-13200 U\/L<\/td>\n<\/tr>\n
Hamil\u0259<\/td>\n3700-9300 U\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qaraciy\u0259rin funksional testl\u0259rind\u0259n biridir. Uzanm\u0131\u015f anes\u00adteziya sinir qaz\u0131 v\u0259 \u00fczvi fosforlu insektisid z\u0259h\u0259rl\u0259nm\u0259l\u0259rinin qiym\u0259t\u00adl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur. Ge\u00adnetik psevdo-xolinesteraza variant\u00adlar\u0131 (anesteziyan\u0131n uzanmas\u0131na s\u0259b\u0259b olur), hepatitl\u0259r, sirroz, malnutrisiya, anemiyalar, k\u0259skin infeksiyalar, k\u0259s\u00adkin miokard infarkt\u0131, a\u011fciy\u0259r emboliyas\u0131, \u0259m\u0259liyyatdan sonrak\u0131 d\u00f6vr, xroniki b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, hamil\u0259liyin son d\u00f6vrl\u0259ri v\u0259 serumda albumin konsentrasiyas\u0131n\u0131 azaldan hallarda serumda psevdo-xolines\u00adterazan\u0131n miqdar\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PROTE\u0130N ELEKTROFOREZ\u0130 (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Elektroforez<\/p>\n

Referens:<\/strong>\u00a0N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Normada sidikl\u0259 \u00e7ox az miqdarda z\u00fclal ifraz olunur, b\u0259zi x\u0259st\u0259likl\u0259rd\u0259 is\u0259 z\u00fclal ifraz\u0131 art\u0131r. Sidikl\u0259 ifraz olunan proteinl\u0259rin tipi diaqnostika bax\u0131m\u0131ndan \u0259h\u0259miy\u00ady\u0259tlidir. Lipoid nefrozda selektiv proteinuriya (albumin), qlomeru\u00adlo\u00adnef\u00adritl\u0259rd\u0259 is\u0259 qeyri-selektiv pro\u00adteinu\u00adriya m\u00fc\u015fahid\u0259 olunur. H\u0259m\u00e7inin Bence-Jones z\u00fclallar\u0131 da beta v\u0259 qamma b\u00f6lg\u0259l\u0259rin\u0259 yer d\u0259yi\u015fir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PROTE\u0130N ELEKTROFOREZ\u0130<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Elektroforez<\/p>\n

Referens:<\/strong>\u00a0Albumin
\nAlfa-1: 58.8-69.6 %
\nAlfa-2: 3.7-13.1%
\nBeta: 8.9-13.6%
\nQamma: 8.4-18.3%<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Serum protein elektro\u00adforezi iltihab, z\u00fclal itkisi, qamma\u00adpatiyalar v\u0259 dig\u0259r disproteinemiyalar \u00fc\u00e7\u00fcn geni\u015f istifad\u0259 olunan skrininq testidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

REVMATO\u0130D FAKTOR<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0RF<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Turbidimetrik<\/p>\n

Referens:<\/strong>\u00a0<20 IU\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0IgG-y\u0259 qar\u015f\u0131 \u0259m\u0259l\u0259 g\u0259l\u0259n anticisiml\u0259ridir. Revmatoid artrit, birl\u0259\u015fdirici toxuma x\u0259st\u0259liyi, \u015eeqren sindromu, sklerodermiya, derma\u00adtomiozit, SLE kimi autoimmun x\u0259st\u0259likl\u0259r, infeksion mononukleoz kimi b\u0259zi virus x\u0259st\u0259likl\u0259ri v\u0259 b\u0259zi k\u0259skin iltihabi x\u0259st\u0259likl\u0259rd\u0259 serumda RF s\u0259viyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

RF (REVMATO\u0130D FAKTOR)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0RF<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Turbidimetrik<\/p>\n

Referens:<\/strong>\u00a0<20 IU\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0IgG-y\u0259 qar\u015f\u0131 \u0259m\u0259l\u0259 g\u0259l\u0259n anticisiml\u0259ridir. Revmatoid artrit, birl\u0259\u015fdirici toxuma x\u0259st\u0259liyi, \u015eeqren sindromu, sklerodermiya, derma\u00adtomiozit, SLE kimi autoimmun x\u0259st\u0259likl\u0259r, infeksion mononukleoz kimi b\u0259zi virus x\u0259st\u0259likl\u0259ri v\u0259 b\u0259zi k\u0259skin iltihabi x\u0259st\u0259likl\u0259rd\u0259 serumda RF s\u0259viyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

SAXAROZA HEMOL\u0130Z TEST\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0\u015e\u0259k\u0259r su testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>X\u0259st\u0259d\u0259n v\u0259 eyni qan qrupundan olan sa\u011flam insandan al\u0131nm\u0131\u015f EDTA-l\u0131 tam qan v\u0259 serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u0259\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a03 mL EDTA-l\u0131 tam qan v\u0259 3 mL serum<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kalitativ (keyfiyy\u0259t)<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
Lizis<\/td>\n<5%<\/td>\nNeqativ<\/td>\n<\/tr>\n
<\/td>\n6-10%<\/td>\n\u015e\u00fcbh\u0259li<\/td>\n<\/tr>\n
<\/td>\n>10%<\/td>\nPovitiv<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Paroksizmal nokturnal (gec\u0259) hemoqlobinuriyan\u0131n t\u0259yinind\u0259 istifad\u0259 olunan skrininq testdir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Se (SELEN)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Se<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum, 24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), 24 saatl\u0131q sidik soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6n\u00add\u0259\u00adrilm\u0259lidir. 6N HCl, asetat tur\u015fusu v\u0259 ya bor tur\u015fusu \u00fcz\u0259rin\u0259 toplanm\u0131\u015f sidik n\u00fcmun\u0259l\u0259ri d\u0259 q\u0259bul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL (serum) (daha \u0259vv\u0259l he\u00e7 istifad\u0259 edilm\u0259mi\u015f v\u0259 ya nitrat tur\u015fusu il\u0259 yuyulmu\u015f\u00a0 v\u0259 distill\u0259 v\u0259 ya ionsuzla\u015fd\u0131r\u0131lm\u0131\u015f su il\u0259 yaxalanm\u0131\u015f\u00a0 s\u0131naq \u015f\u00fc\u015f\u0259l\u0259rind\u0259 g\u00f6nd\u0259\u00adrilm\u0259lidir, 10 mL (24 saatl\u0131q sidik).<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 saatl\u0131q sidik miqdar\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS-FIAS<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Serum<\/td>\n46-143 \u03bcg\/L<\/td>\n<\/tr>\n
24 saatl\u0131q sidik<\/td>\n<35 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Retikuloendotelial neo\u00adplaziyalar v\u0259 s\u0259nayed\u0259 \u00e7al\u0131\u015fanlar\u0131n selen toksikozlar\u0131nda qanda selen s\u0259viyy\u0259si y\u00fcks\u0259lir, m\u0259d\u0259-ba\u011f\u0131rsaq sistemi x\u0259r\u00e7\u0259ngl\u0259ri, malnutirasiya, total parenteral qidalanma, hami\u00adl\u0259lik, sirroz v\u0259 hepatitl\u0259rd\u0259 Se s\u0259\u00adviyy\u0259si azal\u0131r. Se z\u0259h\u0259rl\u0259nm\u0259l\u0259rind\u0259 n\u0259f\u0259s v\u0259 sidikd\u0259 sar\u0131msaq qoxusu, a\u011f\u0131zda metallik dad, ba\u015f a\u011fr\u0131s\u0131, \u00fcr\u0259k bulanma, qusma, a\u011fciy\u0259r \u00f6demi v\u0259 qan d\u00f6vran\u0131n\u0131n kollaps\u0131 ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

SELEN<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Se<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum, 24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum), 24 saatl\u0131q sidik soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6n\u00add\u0259\u00adrilm\u0259lidir. 6N HCl, asetat tur\u015fusu v\u0259 ya bor tur\u015fusu \u00fcz\u0259rin\u0259 toplanm\u0131\u015f sidik n\u00fcmun\u0259l\u0259ri d\u0259 q\u0259bul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL (serum) (daha \u0259vv\u0259l he\u00e7 istifad\u0259 edilm\u0259mi\u015f v\u0259 ya nitrat tur\u015fusu il\u0259 yuyulmu\u015f\u00a0 v\u0259 distill\u0259 v\u0259 ya ionsuzla\u015fd\u0131r\u0131lm\u0131\u015f su il\u0259 yaxalanm\u0131\u015f\u00a0 s\u0131naq \u015f\u00fc\u015f\u0259l\u0259rind\u0259 g\u00f6nd\u0259\u00adrilm\u0259lidir, 10 mL (24 saatl\u0131q sidik).<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 saatl\u0131q sidik miqdar\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS-FIAS<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Serum<\/td>\n46-143 \u03bcg\/L<\/td>\n<\/tr>\n
24 saatl\u0131q sidik<\/td>\n<35 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Retikuloendotelial neo\u00adplaziyalar v\u0259 s\u0259nayed\u0259 \u00e7al\u0131\u015fanlar\u0131n selen toksikozlar\u0131nda qanda selen s\u0259viyy\u0259si y\u00fcks\u0259lir, m\u0259d\u0259-ba\u011f\u0131rsaq sistemi x\u0259r\u00e7\u0259ngl\u0259ri, malnutirasiya, total parenteral qidalanma, hami\u00adl\u0259lik, sirroz v\u0259 hepatitl\u0259rd\u0259 Se s\u0259\u00adviyy\u0259si azal\u0131r. Se z\u0259h\u0259rl\u0259nm\u0259l\u0259rind\u0259 n\u0259f\u0259s v\u0259 sidikd\u0259 sar\u0131msaq qoxusu, a\u011f\u0131zda metallik dad, ba\u015f a\u011fr\u0131s\u0131, \u00fcr\u0259k bulanma, qusma, a\u011fciy\u0259r \u00f6demi v\u0259 qan d\u00f6vran\u0131n\u0131n kollaps\u0131 ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

SEROTON\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>5-OH triptamin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259< qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Serotonin t\u0259rkilbi qoz, banan, bad\u0131mcan, po\u00admidor, f\u0131nd\u0131q, f\u0131st\u0131q, avokado v\u0259 s. b\u0259zi meyv\u0259 v\u0259 t\u0259r\u0259v\u0259zl\u0259r son 72 saat \u0259rzind\u0259 yeyilm\u0259m\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n
Serum<\/td>\n>15 ya\u015f<\/td>\n50-230 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Karsinoid \u015fi\u015fl\u0259rin di\u00adaq\u00adnoz v\u0259 m\u00fcalic\u0259sinin\u00a0 m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur. Karsinoid sindrom, miqren, \u015fizofreniya, esensial hiper\u00adten\u00adziya, Huntington x\u0259st\u0259liyi v\u0259 Duchenne \u0259z\u0259l\u0259 distrofiyas\u0131nda se\u00adrumda serotonin miqdar\u0131art\u0131r. Dum\u00adping sindromu, k\u0259skin ba\u011f\u0131rsaq obstruksiyas\u0131, kistik fibrozis v\u0259 k\u0259s\u00adkin miokard infarkt\u0131nda da se\u00adrotonin s\u0259viyy\u0259sind\u0259 y\u00fcng\u00fcl y\u00fcks\u0259lm\u0259 ola bil\u0259r. Litium, MAO inhibitorlar\u0131, me\u00adtildopa, morfin v\u0259 rezerpin isti\u00adfad\u0259si serotonin s\u0259viyy\u0259sin\u0259 tesir ed\u0259 bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

SERULOPLAZM\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Mis oksidaza; Cp<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Nefolometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
<6 ay<\/td>\n\u00a05-18 mg\/dL<\/td>\n<\/tr>\n
7-12 ay<\/td>\n33-43 mg\/dL<\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n26-55 mg\/dL<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n27-56 mg\/dL<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n20-54 mg\/dL<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n20-63 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Mis birl\u0259\u015fdirici z\u00fclald\u0131r. Wilson x\u0259st\u0259liyinin diaqnos\u00adtikas\u0131nda v\u0259 k\u0259skin faza reaktant\u0131 kimi istifad\u0259 olunur. Hamil\u0259lik, esterogen v\u0259 oral kontraseptiv istifad\u0259si, iltihab, toxu\u00adma nekrozu, osteosarkomalar, biliar sirroz v\u0259 travmalarda serumda seru\u00adloplazminin s\u0259viyy\u0259si art\u0131r, Wilson x\u0259s\u00adt\u0259liyi, Menkes kinky hair sind\u00adro\u00admu v\u0259 qastroenteropatiyalarda azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

SERUM GLUTAMAT OKSALOASETAT TRANSM\u0130NAZA (ASPARTAT AM\u0130NOTRANSFERAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>AST; SGOT; Serum glu\u00adtamik oksaloasetik transminaz<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Sperktrofotometrik, ki\u00adnetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
<7 g\u00fcn<\/td>\n25-75 IU\/L<\/td>\n<\/tr>\n
7 ya\u015f-1ya\u015f<\/td>\n15-60 IU\/L<\/td>\n<\/tr>\n
2-12 ya\u015f<\/td>\n15-50 IU\/L<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n10-45 IU\/L<\/td>\n<\/tr>\n
16-60 ya\u015f<\/td>\n10-42 IU\/L<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n12-50 IU\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Orqanizmin b\u00fct\u00fcn toxu\u00adma\u00adlar\u0131nda olsa da, qaraciy\u0259r, \u00fcr\u0259k v\u0259 sklet \u0259z\u0259l\u0259sind\u0259 daha \u00e7ox toplan\u0131r. H\u0259r hans\u0131 bir s\u0259b\u0259bd\u0259n qaraciy\u0259r h\u00fc\u00adcey\u00adr\u0259sinin z\u0259d\u0259l\u0259nm\u0259si v\u0259 ya da\u011f\u0131l\u00admas\u0131, xolestatik v\u0259 obstruktiv sar\u0131l\u0131q, xroniki hepatil\u0259r, infeksion monu\u00adnukleoz, \u00fcr\u0259k v\u0259 ya sklet \u0259z\u0259l\u0259sinin nek\u00adroz v\u0259 ya travmas\u0131,\u00a0 h\u0259m\u00e7inin iltihabi x\u0259st\u0259likl\u0259ri, k\u0259skin miokard infakt\u0131, a\u011f\u0131r idman, \u00fcr\u0259k \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u00ad\u011f\u0131, a\u011f\u0131r d\u0259r\u0259c\u0259li yan\u0131qlar, hipoti\u00adro\u00adidizm, ba\u011f\u0131rsaq obstruksiyalar\u0131, b\u0259d\u00adxass\u0259li hipertermiya v\u0259 talasemiya ma\u00adjor zaman\u0131 serumda\u00a0 AST s\u0259viy\u00ady\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

SERUM GLUTAMAT P\u0130RUVAT TRANSAM\u0130NAZA (ALAN\u0130N AM\u0130NOTRANSFERAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ALT, Serum glutamik piruvat transaminaza, SGPT<\/p>\n

N\u00fcmun\u0259 qab\u0131:\u00a0<\/strong>\u00a0q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250 \u03bcl<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0spektrofotometrik, kinetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0he\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
g\u00f6b\u0259k ciy\u0259sind\u0259n al\u0131nm\u0131\u015f qanda<\/td>\n10-90 u\/l<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n10-90 u\/l<\/td>\n<\/tr>\n
7 g\u00fcn-1 ya\u015f<\/td>\n10-80 u\/l<\/td>\n<\/tr>\n
1-60 ya\u015f<\/td>\n10-60 u\/l<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n10-70 u\/l<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qaraciy\u0259rin funksional test\u00adl\u0259rind\u0259n biridir. Qaraciy\u0259r x\u0259s\u00adt\u0259\u00adlikl\u0259ri, \u00f6d yollar\u0131 obstruksiyas\u0131, \u0259z\u0259l\u0259 z\u0259d\u0259l\u0259nm\u0259l\u0259ri, \u0259z\u0259l\u0259 distrofiyalar\u0131, k\u0259skin pankreatit, k\u0259skin \u00fcr\u0259k \u00e7a\u00adt\u0131\u015fmazl\u0131\u011f\u0131, b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 hepatatoksik preparatlar\u00a0 ALT-nin miq\u00ad\u00addar\u0131nda artmaya s\u0259b\u0259b olur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

S\u0130DEROF\u0130L\u0130N (TRANSFERR\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Siderofilin; Tf<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, 24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum), 24 saatl\u0131q sidik soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a024 saatl\u0131q sidiyin miqdar\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Nefelometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Serum<\/td>\n<6 ay<\/td>\n130-275 mg\/dL<\/td>\n<\/tr>\n
>6 ay<\/td>\n200-360 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Plazmada d\u0259mir trans\u00adportunu t\u0259min ed\u0259n major z\u00fclald\u0131r. D\u0259\u00admir \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 anemiyas\u0131, hami\u00adl\u0259lik, esterogen istifad\u0259si v\u0259 h\u0259r n\u00f6v k\u0259skin iltihabi hallarda serum trans\u00adferrin s\u0259viyy\u0259si art\u0131r, irsi atrans\u00adfer\u00adrinemiya, xroniki iltihabi x\u0259st\u0259likl\u0259r, b\u0259dxass\u0259li t\u00f6r\u0259m\u0259l\u0259r, hepatosellular x\u0259st\u0259likl\u0259r, malnutirasiya v\u0259 nefrotik sindromda is\u0259 transferrinin s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

S\u0130AN\u0130D<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Cn<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong>\u00a0<0.2 mg\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Sianidin bu madd\u0259 il\u0259 i\u015fl\u0259y\u0259n \u015f\u0259xsl\u0259r\u0259 t\u0259sirinin t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Sink (Eritrosit daxili)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS<\/p>\n

Referens:<\/strong>\u00a01000-2000 \u03bcg\/dL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qandak\u0131 \u00fcmumi sinkin 75-88 %-i eritrositl\u0259rin daxilind\u0259 yer\u00adl\u0259\u015fir. X\u00fcsusil\u0259 oraq h\u00fcceyr\u0259li anemiyada eritrosit daxili sinkin s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

SGPT (ALAN\u0130N AM\u0130NOTRANSFERAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ALT, Serum glutamik piruvat transaminaza, SGPT<\/p>\n

N\u00fcmun\u0259 qab\u0131:\u00a0<\/strong>\u00a0q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250 \u03bcl<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0spektrofotometrik, kinetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0he\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
g\u00f6b\u0259k ciy\u0259sind\u0259n al\u0131nm\u0131\u015f qanda<\/td>\n10-90 u\/l<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n10-90 u\/l<\/td>\n<\/tr>\n
7 g\u00fcn-1 ya\u015f<\/td>\n10-80 u\/l<\/td>\n<\/tr>\n
1-60 ya\u015f<\/td>\n10-60 u\/l<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n10-70 u\/l<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qaraciy\u0259rin funksional test\u00adl\u0259rind\u0259n biridir. Qaraciy\u0259r x\u0259s\u00adt\u0259\u00adlikl\u0259ri, \u00f6d yollar\u0131 obstruksiyas\u0131, \u0259z\u0259l\u0259 z\u0259d\u0259l\u0259nm\u0259l\u0259ri, \u0259z\u0259l\u0259 distrofiyalar\u0131, k\u0259skin pankreatit, k\u0259skin \u00fcr\u0259k \u00e7a\u00adt\u0131\u015fmazl\u0131\u011f\u0131, b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 hepatatoksik preparatlar\u00a0 ALT-nin miq\u00ad\u00addar\u0131nda artmaya s\u0259b\u0259b olur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

SGOT (ASPARTAT AM\u0130NOTRANSFERAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>AST; SGOT; Serum glu\u00adtamik oksaloasetik transminaz<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Sperktrofotometrik, ki\u00adnetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
<7 g\u00fcn<\/td>\n25-75 IU\/L<\/td>\n<\/tr>\n
7 ya\u015f-1ya\u015f<\/td>\n15-60 IU\/L<\/td>\n<\/tr>\n
2-12 ya\u015f<\/td>\n15-50 IU\/L<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n10-45 IU\/L<\/td>\n<\/tr>\n
16-60 ya\u015f<\/td>\n10-42 IU\/L<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n12-50 IU\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Orqanizmin b\u00fct\u00fcn toxu\u00adma\u00adlar\u0131nda olsa da, qaraciy\u0259r, \u00fcr\u0259k v\u0259 sklet \u0259z\u0259l\u0259sind\u0259 daha \u00e7ox toplan\u0131r. H\u0259r hans\u0131 bir s\u0259b\u0259bd\u0259n qaraciy\u0259r h\u00fc\u00adcey\u00adr\u0259sinin z\u0259d\u0259l\u0259nm\u0259si v\u0259 ya da\u011f\u0131l\u00admas\u0131, xolestatik v\u0259 obstruktiv sar\u0131l\u0131q, xroniki hepatil\u0259r, infeksion monu\u00adnukleoz, \u00fcr\u0259k v\u0259 ya sklet \u0259z\u0259l\u0259sinin nek\u00adroz v\u0259 ya travmas\u0131,\u00a0 h\u0259m\u00e7inin iltihabi x\u0259st\u0259likl\u0259ri, k\u0259skin miokard infakt\u0131, a\u011f\u0131r idman, \u00fcr\u0259k \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u00ad\u011f\u0131, a\u011f\u0131r d\u0259r\u0259c\u0259li yan\u0131qlar, hipoti\u00adro\u00adidizm, ba\u011f\u0131rsaq obstruksiyalar\u0131, b\u0259d\u00adxass\u0259li hipertermiya v\u0259 talasemiya ma\u00adjor zaman\u0131 serumda\u00a0 AST s\u0259viy\u00ady\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

S\u0130D\u0130K TUR\u015eUSU<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Urat; UA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, fer\u00admentativ<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
1 h\u0259ft\u0259-5 ya\u015f<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n3.0-7.2 mg\/dL<\/td>\n2.6-6.0 mg\/dL<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n3.5-7.2mg\/dL<\/td>\n2.6-6.3 mg\/dL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n3.5-7.5mg\/dL<\/td>\n2.6-6.5 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Podaqra v\u0259 dig\u0259r purin m\u00fcbadil\u0259si poz\u011funluqlar\u0131n\u0131n diaqnoz v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 isti\u00adfad\u0259 olunur. Podaqra, b\u00f6yr\u0259k \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131, leykoz, multiple myeloma, po\u00adlisitemia, limfoma, hamil\u0259lik tok\u00adsemiyas\u0131, psoriaz, polikistik b\u00f6yr\u0259k x\u0259st\u0259liyi, purinl\u0259 z\u0259ngin qidalanma (qaraciy\u0259r, b\u00f6yr\u0259k v\u0259 s.)a\u011f\u0131r idman\u00addan sonra qanda sidik tur\u015fusumiqdar\u0131 y\u00fcks\u0259ldiyi halda, Wilson x\u0259st\u0259liyi, Fanconi sindromu, ksanturiya v\u0259 purinl\u0259 m\u0259hdud qidalanma zaman\u0131\u00a0 is\u0259 bu g\u00f6st\u0259ricinin qanda s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

S\u0130D\u0130K TUR\u015eUSU (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a024 saatl\u0131q sidiyin miqdar\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, fer\u00admentativ (enzimatik)<\/p>\n

Referens:<\/strong>\u00a00.25-0.75 mg\/g\u00fcn<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>B\u00f6yr\u0259k da\u015f\u0131 olan x\u0259st\u0259\u00adl\u0259rin qiym\u0259tl\u0259ndirilm\u0259si v\u0259 m\u00fc\u015fahi\u00add\u0259sind\u0259 istifad\u0259 olunur. Sidikl\u0259 ifraz olunan sidik tur\u015fusunun miqdar\u0131n\u0131n artmas\u0131 ad\u0259t\u0259n artm\u0131\u015f plazma UA s\u0259viyy\u0259si il\u0259 b\u0259rab\u0259rdir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

sTfR (H\u018fLLOLAN TRANSFERR\u0130N RESEPTORU)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0sTfR<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Nefelometrik<\/p>\n

Referens:<\/strong>\u00a00.83-1.76 mg\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>D\u0259mir s\u0259viyy\u0259sinin qiy\u00adm\u0259t\u00adl\u0259ndirilm\u0259sind\u0259 d\u0259mir, d\u0259mir bir\u00adl\u0259\u015fdirm\u0259 qabiliyy\u0259ti v\u0259 ferritin testi il\u0259 birlikd\u0259 istifad\u0259 olunur. X\u00fcsusil\u0259 s\u00fcm\u00fck iliyi biopsiyas\u0131 m\u00fcmk\u00fcn ol\u00admayan x\u0259st\u0259l\u0259rd\u0259 d\u0259mir miqdar\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 sTfR s\u0259viy\u00ady\u0259\u00adsi \u0259h\u0259miyy\u0259tlidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

STERKOB\u0130L\u0130NOGEN (N\u018fC\u0130SD\u018f STERKOB\u0130L\u0130NOGEN)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>N\u0259cis<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0T\u0259miz a\u011fz\u0131 qapaql\u0131 qab<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kimy\u0259vi<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u00d6d\u00fcn 12 barmaq ba\u011f\u0131r\u00adsa\u011fa g\u0259lm\u0259sin\u0259 mane olan obs\u00adt\u00adruksiyalar\u0131n qiym\u0259rl\u0259ndirilm\u0259sind\u0259, x\u00fcsusil\u0259 d\u0259 biliar atreziya ehti\u00admal\u0131n\u0131n t\u0259dqiqind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

SPERMA YUMA (SPERMA HAZIRLAMA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Sperma yuma; Sil select; swim up<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>T\u0259z\u0259 eakuylat\u00a0 (n\u00fc\u00admun\u0259 laboratoriyaya verilm\u0259lidir)<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0T\u0259miz, a\u011fz\u0131 qapaql\u0131 qab<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0Ham\u0131s\u0131<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Sil-select v\u0259 ya swim up<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0U\u015faql\u0131qdaxili mayalan\u00add\u0131r\u00adma \u00fc\u00e7\u00fcn keyfiyy\u0259tli spermata\u00adzoidl\u0259rin ayr\u0131lma prosesidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

SPERMA HAZIRLAMA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Sperma yuma; Sil select; swim up<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>T\u0259z\u0259 eakuylat\u00a0 (n\u00fc\u00admun\u0259 laboratoriyaya verilm\u0259lidir)<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0T\u0259miz, a\u011fz\u0131 qapaql\u0131 qab<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0Ham\u0131s\u0131<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Sil-select v\u0259 ya swim up<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0U\u015faql\u0131qdaxili mayalan\u00add\u0131r\u00adma \u00fc\u00e7\u00fcn keyfiyy\u0259tli spermata\u00adzoidl\u0259rin ayr\u0131lma prosesidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

SOMATOMED\u0130N C<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0IGF-14 \u0130nsulin-like gro\u00adwth faktor; Growth faktor 1; GF-1<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Growth hor\u00admonun \u0259ksin\u0259 g\u00fcn \u0259rzind\u0259 v\u0259 yem\u0259kl\u0259rd\u0259n sonra somatomedin C s\u0259viyy\u0259si sabit olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0IRMA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
<3 ya\u015f<\/td>\n50-143 ng\/mL<\/td>\n<\/tr>\n
4-5 ya\u015f<\/td>\n51-218 ng\/mL<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n106-250 ng\/mL<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n140-496 ng\/mL<\/td>\n<\/tr>\n
16-20 ya\u015f<\/td>\n150-562 ng\/mL<\/td>\n<\/tr>\n
21-25 ya\u015f<\/td>\n84-376 ng\/mL<\/td>\n<\/tr>\n
26-30 ya\u015f<\/td>\n90-271 ng\/mL<\/td>\n<\/tr>\n
31-35 ya\u015f<\/td>\n90-226 ng\/mL<\/td>\n<\/tr>\n
36-50 ya\u015f<\/td>\n90-210 ng\/mL<\/td>\n<\/tr>\n
>50 ya\u015f<\/td>\n70-197 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0GH sekresiyas\u0131n\u0131 v\u0259 t\u0259si\u00adrini t\u0259qib etm\u0259k \u00fc\u00e7\u00fcn istifad\u0259 olunur. IGFBP3 il\u0259 birlikd\u0259 istifad\u0259 olun\u00adduqda klinik h\u0259ssasl\u0131q v\u0259 spesifikliyi GH funksiya testl\u0259rind\u0259n daha y\u00fcks\u0259k olur. IGF-1 akromeqaliyada y\u00fcks\u0259k, GH \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, anoreksiya nervosa v\u0259 malnutrisiyas\u0131 olan \u015f\u0259xs\u00adl\u0259rd\u0259 is\u0259 a\u015fa\u011f\u0131 olur. Qidalanma v\u0259\u00adziyy\u0259tinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 prealbumin, RBP v\u0259 ya transfer\u00adrin\u00add\u0259n daha h\u0259ssas olmas\u0131 Soma\u00adto\u00admedin C-nin ba\u015fqa bir x\u00fcsusiy\u00ady\u0259tidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

S\u0130TRAT TUR\u015eUSU<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Sitrat<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 sax\u00adlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a024 saatl\u0131q sidik miqdar\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, fermentativ (enzimatik)<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
>15 ya\u015f<\/td>\nKi\u015fi<\/td>\n116-931 mg\/g\u00fcn<\/td>\n<\/tr>\n
Qad\u0131n<\/td>\n252-1164 mg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Kalsium t\u0259rkibli b\u00f6yr\u0259k da\u015f\u0131 olan x\u0259st\u0259l\u0259rin v\u0259 b\u00f6yr\u0259k bo\u00adru\u00adcuqlar\u0131 asidozunun (renal tubulyar asidoz) diaqnoz v\u0259 m\u00fc\u015fahi\u00add\u0259sind\u0259 istifad\u0259 olunur. Sidikd\u0259ki sitrat kris\u00adtal \u0259m\u0259l\u0259 g\u0259lm\u0259sini inhibisiya ed\u0259r\u0259k x\u00fcsusil\u0259 kalsium t\u0259rkibli b\u00f6yr\u0259k da\u015flar\u0131n\u0131n \u0259m\u0259l\u0259 g\u0259lm\u0259sinin qar\u015f\u0131s\u0131n\u0131 al\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

S\u0130TRAT (S\u0130TRAT TUR\u015eUSU)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Sitrat<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 sax\u00adlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a024 saatl\u0131q sidik miqdar\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, fermentativ (enzimatik)<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
>15 ya\u015f<\/td>\nKi\u015fi<\/td>\n116-931 mg\/g\u00fcn<\/td>\n<\/tr>\n
Qad\u0131n<\/td>\n252-1164 mg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Kalsium t\u0259rkibli b\u00f6yr\u0259k da\u015f\u0131 olan x\u0259st\u0259l\u0259rin v\u0259 b\u00f6yr\u0259k bo\u00adru\u00adcuqlar\u0131 asidozunun (renal tubulyar asidoz) diaqnoz v\u0259 m\u00fc\u015fahi\u00add\u0259sind\u0259 istifad\u0259 olunur. Sidikd\u0259ki sitrat kris\u00adtal \u0259m\u0259l\u0259 g\u0259lm\u0259sini inhibisiya ed\u0259r\u0259k x\u00fcsusil\u0259 kalsium t\u0259rkibli b\u00f6yr\u0259k da\u015flar\u0131n\u0131n \u0259m\u0259l\u0259 g\u0259lm\u0259sinin qar\u015f\u0131s\u0131n\u0131 al\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

S\u0130STAT\u0130N C<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015fl\u0259m\u0259 zaman\u0131:\u00a0<\/strong>H\u0259r g\u00fcn<\/p>\n

N\u0259tic\u0259 verm\u0259 zaman\u0131:\u00a0<\/strong>2 saat<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Nefolometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Ki\u015fi<\/td>\n0.57-0.96 mg\/L<\/td>\n<\/tr>\n
Qad\u0131n<\/td>\n0.50-0.96 mg\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0B\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131qlar\u0131n\u0131n t\u0259yini v\u0259 t\u0259qibind\u0259 istifad\u0259 olunur. Sabit endogen sekresiya s\u00fcr\u0259ti olub, qlomerulalardan s\u0259rb\u0259st s\u00fcz\u00fcl\u00fcr v\u0259 b\u00f6yr\u0259k borucuqlar\u0131ndan reabsorbsiya edilmir. Bu x\u00fcsusiyy\u0259tl\u0259rind\u0259n do\u00adlay\u0131 qlomerulyar filtirasiya sur\u0259tinin (GFR) qiym\u0259tl\u0259ndirilm\u0259sind\u0259 sistatin C s\u0259viyy\u0259si \u0259lveri\u015fli g\u00f6st\u0259ricidir. GFR azald\u0131qda serumda sistatin C s\u0259viyy\u0259si art\u0131r. \u018fz\u0259l\u0259 k\u00fctl\u0259si, p\u0259hriz v\u0259 k\u0259skin iltihabi prosesl\u0259rin t\u0259sirin\u0259 m\u0259ruz qalmad\u0131\u011f\u0131 \u00fc\u00e7\u00fcn, b\u00f6yr\u0259k funksiyalar\u0131n\u0131n qiym\u0259tl\u0259n\u00addiril\u00adm\u0259\u00adsin\u00add\u0259 kreatinin v\u0259 dig\u0259r markerl\u0259rl\u0259 m\u00fcqayis\u0259d\u0259 daha \u00fcst\u00fcnd\u00fcr<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

S\u0130NK (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik, bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir. 6N HCl, asetat tur\u015fusu v\u0259 ya bor tur\u015fusu \u00fcz\u0259rin\u0259 y\u0131\u011f\u0131lan sidik n\u00fcmun\u0259l\u0259ri d\u0259 q\u0259bul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Bird\u0259f\u0259lik sidik<\/td>\n180-850 \u03bcg\/L<\/td>\n<\/tr>\n
24 saatl\u0131q sidik<\/td>\n290-800 \u03bcg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Serumda sink s\u0259viy\u00ady\u0259\u00adsinin normadan k\u0259nara\u00e7\u0131xma hal\u00adla\u00adr\u0131n\u0131n ara\u015fd\u0131r\u0131lmas\u0131 \u00fc\u00e7\u00fcn istifad\u0259 olu\u00adnur. Hiperparatiroidizm, alkoqolizm, oraq h\u00fcceyr\u0259li anemiya, virus hepa\u00adtitl\u0259ri, qaraciy\u0259r sirrozu,\u00a0 total paren\u00adteral qidalanma v\u0259 c\u0259rrahi \u0259m\u0259liy\u00adyatdan sonra sidikl\u0259 ifraz olunan sinkin miqdar\u0131 art\u0131r, hipoqonodal c\u0131rtdanboyluq (dwarfizm) zaman\u0131 sidikl\u0259 ifraz olunan sinkin miqdar\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

S\u0130NK (Sa\u00e7)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Sa\u00e7 (\u0259ns\u0259d\u0259n al\u0131nmas\u0131 m\u0259sl\u0259h\u0259t g\u00f6r\u00fcl\u00fcr)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 g<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Boyad\u0131lm\u0131\u015f v\u0259 ya d\u0259yi\u015fdirilmi\u015f t\u00fckl\u0259rd\u0259 sinkin s\u0259viyy\u0259si y\u00fcks\u0259k ola bil\u0259r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS<\/p>\n

Referens:<\/strong>\u00a0100-280\u00a0 \u03bcq\/q sa\u00e7<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Sink \u00e7at\u0131\u015fmazl\u0131\u011f\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Diabetes mellitus, celiac sprue v\u0259 z\u00fclal malnutirasiyas\u0131nda sa\u00e7dak\u0131 sink s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

S\u0130NK<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Zn<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Serum 45 d\u0259qiq\u0259 \u0259rzind\u0259 ayr\u0131lmal\u0131d\u0131r<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259 al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 10 saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 laz\u0131md\u0131r. Qanda Zn s\u0259viyy\u0259sinin g\u00fcnl\u00fck ritmi var. S\u0259h\u0259r saat 09.00 v\u0259 ax\u015fam saat 18.00 pik s\u0259viyy\u0259y\u0259 \u00e7at\u0131r. Yem\u0259kd\u0259n sonra is\u0259 Zn s\u0259viyy\u0259si azal\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Hemoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
<1 ay<\/td>\n50-125 \u03bcg\/dL<\/td>\n<\/tr>\n
1 ay-15 ya\u015f<\/td>\n60-135 \u03bcg\/dL<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n70-150 \u03bcg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Zn yaran\u0131n sa\u011falmas\u0131, immun funksiyalar, v\u0259 d\u00f6l\u00fcn inki\u015faf\u0131 \u00fc\u00e7\u00fcn laz\u0131m olan elemetdir. Osteosar\u00adkoma, koronar \u00fcr\u0259k x\u0259st\u0259likl\u0259ri, ate\u00adroskleroz v\u0259 anemiyalarda se\u00adrumda Zn s\u0259viyy\u0259si a\u015fa\u011f\u0131, acroder\u00admatitis enteropatika, a\u011fciy\u0259r v\u0259r\u0259mi, m\u0259d\u0259-ba\u011f\u0131rsaq sistemi x\u0259st\u0259\u00adlikl\u0259ri, talasemiya major k\u0259skin miokard infa\u00adkt\u0131, hepatosellular x\u0259st\u0259likl\u0259r, k\u0259skin infeksiyalar, leykoz, linfoma v\u0259 hamil\u0259likd\u0259 is\u0259 serumda Zn s\u0259\u00adviyy\u0259si y\u00fcks\u0259k olur. Zn azl\u0131\u011f\u0131nda dadbilm\u0259 v\u0259 yaran\u0131n sa\u011falmas\u0131 po\u00adzulur, d\u0259ri z\u0259d\u0259l\u0259ri, allopsiya, ane\u00admiya, hepatosple\u00adnomeqaliya, abdo\u00admi\u00adnal a\u011fr\u0131, diarreya v\u0259 hipoalbu\u00adminemiya ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

S\u0130L SELECT (SPERMA HAZIRLAMA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Sperma yuma; Sil select; swim up<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>T\u0259z\u0259 eakuylat\u00a0 (n\u00fc\u00admun\u0259 laboratoriyaya verilm\u0259lidir)<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0T\u0259miz, a\u011fz\u0131 qapaql\u0131 qab<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0Ham\u0131s\u0131<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Sil-select v\u0259 ya swim up<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0U\u015faql\u0131qdaxili mayalan\u00add\u0131r\u00adma \u00fc\u00e7\u00fcn keyfiyy\u0259tli spermata\u00adzoidl\u0259rin ayr\u0131lma prosesidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

STREPTOL\u0130Z\u0130N O ANT\u0130C\u0130S\u0130M\u0130 (ANT\u0130STREPTOL\u0130Z\u0130N O)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ASO; Streptolizin O an\u00adticisimi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0T\u00fcrbidimetrik<\/p>\n

Referens:\u00a0<\/strong><200 IU\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Streptococcus pyogenes<\/em>-\u0259 m\u0259xsus streptolizin O-ya qar\u015f\u0131 \u0259m\u0259l\u0259 g\u0259l\u0259n anticisiml\u0259rdir. A qrup beta-hemolitik streptokok infeksiyalar\u0131n\u0131n diaqnostika v\u0259 m\u00fc\u015fahid\u0259sind\u0259 istifa\u00add\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

SULFAT<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxla\u00adn\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a024 saatl\u0131q sidik miqdar\u0131 bilirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>Spektrofotometrik<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Sidikd\u0259ki sulfat miqdar\u0131 qida il\u0259 z\u00fclal q\u0259bulunun (x\u00fcsusil\u0259 \u0259t, bal\u0131q, toyuq) g\u00f6st\u0259ricisidir. Bu ba\u00adx\u0131mdan heyvani z\u00fclallar\u0131n qida il\u0259 q\u0259bulunun qiym\u0259tl\u0259ndirilm\u0259sind\u0259 is\u00adti\u00adfad\u0259 olunur. H\u0259m\u00e7inin b\u00f6yr\u0259k da\u015f\u0131 olan x\u0259st\u0259l\u0259rd\u0259 d\u0259 sidikl\u0259 ifraz olunan sulfat miqdar\u0131 art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

S\u00dcD TUR\u015eUSU<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Laktat; L-laktat<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Oksalatl\u0131 v\u0259 ya heparinli plazma<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Boz qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si( oksalatl\u0131), ya\u015f\u0131l qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (heparinli)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200\u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fc\u00admun\u0259 al\u0131nd\u0131qdan sonra plazma he\u00admoliz\u0259 u\u011framadan d\u0259rhal ayr\u0131lmal\u0131 v\u0259 soyuq \u015f\u0259ratid\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0X\u0259st\u0259 \u0259n az\u0131 30 d\u0259qiq\u0259 istirah\u0259t etmi\u015f ol\u00admal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Fermentativ, kolori\u00admetrik<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Fermentativ, kolori\u00admetrik<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Metabolik asidoz, dehid\u00adra\u00adtasiya v\u0259 diabetik asidozun qiy\u00adm\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olnur. \u0130dman h\u0259r\u0259k\u0259tl\u0259ri, hipervin\u00adtiliyasiya v\u0259 qan alark\u0259n turnan\u0131n uzun m\u00fcdd\u0259t qalmas\u0131 s\u00fcd tur\u015fusunun s\u0259viyy\u0259sini art\u0131r\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

S\u00dcD TUR\u015eUSU (BOM)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Boz qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Fermentativ, kolo\u00adri\u00admetrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
Yenido\u011fulmu\u015f<\/td>\n10-60 mg\/dL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n10-40 mg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-1 ay<\/td>\n10-25 mg\/dL<\/td>\n<\/tr>\n
>1 ay<\/td>\n10-22 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0M\u0259rk\u0259zi sinir sistemi x\u0259s\u00adt\u0259likl\u0259rinin qiym\u0259tl\u0259ndirilm\u0259si m\u0259q\u00ads\u0259\u00addil\u0259 bakterial v\u0259 virus m\u0259n\u015f\u0259li me\u00adnengitl\u0259rin differen\u00adsiasiyas\u0131nda isti\u00adfad\u0259 olunur. Virus menengitl\u0259rind\u0259 BOM-da s\u00fcd tur\u015fusunun s\u0259viyy\u0259si 35 mg\/dL-d\u0259n\u00a0 az, bakterial menen\u00adgitl\u0259rd\u0259 is\u0259 35 mg\/dL-d\u0259n\u00a0 y\u00fcks\u0259k olur. Serebral qan d\u00f6vran\u0131 v\u0259 ya ok\u00adsi\u00adgenl\u0259 t\u0259chizat\u0131n azalmas\u0131, intrak\u00adra\u00adnial t\u0259zyiqin artmas\u0131, travma, iflic, intrakranial hemorragiya, da\u011f\u0131n\u0131q skleroz, birincili v\u0259 ya metastatik MSS \u015fi\u015fl\u0259ri, hipokapniya zaman\u0131 v\u0259 bakterial (o c\u00fcml\u0259d\u0259n v\u0259r\u0259m) me\u00adnen\u00adgitl\u0259rd\u0259 BOM-da s\u00fcd tur\u015fusunun s\u0259viyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TAF (TOTAL TUR\u015eU FOSFATAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TAF; TAP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum (1 mL seruma 20 mL 10%-li asetat tur\u015fusu \u0259lav\u0259 edil\u0259r\u0259k n\u00fcmun\u0259 asidifikasiya edildikd\u0259n sonra g\u00f6nd\u0259rilm\u0259lidir)<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
<1 ya\u015f<\/td>\n1.50-13.00 U\/L<\/td>\n1.00-11.00 U\/L<\/td>\n<\/tr>\n
2-5 ya\u015f<\/td>\n0.75-10.00 U\/L<\/td>\n0.75-8.50 U\/L<\/td>\n<\/tr>\n
>5 ya\u015f<\/td>\n0.50-6.50 U\/L<\/td>\n0.50-5.50 U\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Prostat x\u0259st\u0259likl\u0259rinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Prostatdan ba\u015fqa b\u0259zi toxu\u00adma\u00adlarda da (qaraciy\u0259r, dalaq, eritro\u00adsit\u00adl\u0259r, trombositl\u0259r v\u0259 s\u00fcm\u00fck iliyi) tur\u015f fosfatazaya rast g\u0259linir. Bu orqan\u00adlardak\u0131 b\u0259zi x\u0259st\u0259likl\u0259rin d\u0259 total tur\u015f fosfataza s\u0259viyy\u0259sind\u0259 y\u00fcks\u0259lm\u0259y\u0259 s\u0259b\u0259b ola bil\u0259c\u0259yini unutmaq olmaz<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TAP (TOTAL TUR\u015eU FOSFATAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TAF; TAP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum (1 mL seruma 20 mL 10%-li asetat tur\u015fusu \u0259lav\u0259 edil\u0259r\u0259k n\u00fcmun\u0259 asidifikasiya edildikd\u0259n sonra g\u00f6nd\u0259rilm\u0259lidir)<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
<1 ya\u015f<\/td>\n1.50-13.00 U\/L<\/td>\n1.00-11.00 U\/L<\/td>\n<\/tr>\n
2-5 ya\u015f<\/td>\n0.75-10.00 U\/L<\/td>\n0.75-8.50 U\/L<\/td>\n<\/tr>\n
>5 ya\u015f<\/td>\n0.50-6.50 U\/L<\/td>\n0.50-5.50 U\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Prostat x\u0259st\u0259likl\u0259rinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Prostatdan ba\u015fqa b\u0259zi toxu\u00adma\u00adlarda da (qaraciy\u0259r, dalaq, eritro\u00adsit\u00adl\u0259r, trombositl\u0259r v\u0259 s\u00fcm\u00fck iliyi) tur\u015f fosfatazaya rast g\u0259linir. Bu orqan\u00adlardak\u0131 b\u0259zi x\u0259st\u0259likl\u0259rin d\u0259 total tur\u015f fosfataza s\u0259viyy\u0259sind\u0259 y\u00fcks\u0259lm\u0259y\u0259 s\u0259b\u0259b ola bil\u0259c\u0259yini unutmaq olmaz<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TCA (TR\u0130XLOROASETAT TUR\u015eUSU)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TCA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong>\u00a0<50 \u03bcmol\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Trixloretilen il\u0259 i\u015fl\u0259y\u0259n \u015f\u0259xsl\u0259rin bu madd\u0259nin t\u0259sirin\u0259 m\u0259ruz qalma d\u0259r\u0259c\u0259sinin t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TCE (TR\u0130XLOROETANOL)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TCE<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong>\u00a0<30 mg\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Trixloretilen il\u0259 i\u015fl\u0259y\u0259n \u015f\u0259xsl\u0259rin bu madd\u0259nin t\u0259sirin\u0259 m\u0259ruz qalma d\u0259r\u0259c\u0259sinin t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TEMPERATURA DAVAMLI Q\u018fL\u018fV\u0130 FOSFATAZA (56 oC)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik, kine\u00adtik<\/p>\n

Referens:\u00a0<\/strong>25-35%<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Q\u0259l\u0259vi fosfataza y\u00fcks\u0259k\u00adlikl\u0259rinin s\u0259b\u0259binin axtar\u0131lmas\u0131nda istifad\u0259 olunur. Klinikada \u0259n \u0259h\u0259\u00admiyy\u0259tli istifad\u0259 sah\u0259si s\u00fcm\u00fck v\u0259 qa\u00adraciy\u0259r m\u0259n\u015f\u0259li ALP-nin bir-birind\u0259n ayr\u0131lmas\u0131d\u0131r.\u00a0 Bunun \u00fc\u00e7\u00fcn tempe\u00adra\u00adturla inaktivasiya istifad\u0259 oluna bil\u0259r. 56o<\/sup>C-d\u0259 16 d\u0259qiq\u0259d\u0259 s\u00fcm\u00fck m\u0259n\u015f\u0259li ALP-nin 90-100 %-i inaktivasiya olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TOTAL PROTE\u0130N (BOM)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0BOM-un hemorragik olmas\u0131<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
Yenido\u011fulmu\u015f<\/td>\n15-130 mg\/dL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n20-120 mg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-1 ay<\/td>\n20-80 mg\/dL<\/td>\n<\/tr>\n
>1 ay<\/td>\n15-45 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0MSS x\u0259st\u0259likl\u0259rinin qiy\u00adm\u0259t\u00adl\u0259mndirilm\u0259sind\u0259 istifad\u0259 olunur. Menengit v\u0259 ensefalomielit kimi qan-beyin baryerinin pozuldu\u011fu hal\u00adlarda BOM-da total protein s\u0259viyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TOTAL PROTE\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TP, \u00fcmumi z\u00fclal<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0Turnan\u0131n uzun m\u00fcdd\u0259t qalmas\u0131 il\u0259 \u0259laq\u0259dar meydana \u00e7\u0131xan venoz staz n\u0259tic\u0259sind\u0259 v\u0259 ayaq \u00fcst\u0259 dayanark\u0259n serumda total protein s\u0259viyy\u0259si y\u00fcks\u0259lir. Hamil\u0259liyin son trimesteri v\u0259 uzunm\u00fcdd\u0259tli yataq istirah\u0259ti is\u0259 total protein s\u0259viyy\u0259sinin azalmas\u0131na s\u0259b\u0259b olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si<\/td>\n4.8-8.0 g\/dL<\/td>\n<\/tr>\n
Yenido\u011fulan<\/td>\n3.6-6.0 g\/dL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n4.6-7.0 g\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-3 ay<\/td>\n4.4-7.6 g\/dL<\/td>\n<\/tr>\n
4-6 ay<\/td>\n4.4-7.0 g\/dL<\/td>\n<\/tr>\n
7-12 ay<\/td>\n5.1-7.3 g\/dL<\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n5.1-7.5 g\/dL<\/td>\n<\/tr>\n
4-15 ya\u015f<\/td>\n6.0-8.0 g\/dL<\/td>\n<\/tr>\n
16-60 ya\u015f<\/td>\n6.2-8.3 g\/dL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n6.0-8.1 g\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qidalanman\u0131n qiym\u0259tl\u0259n\u00addiril\u00adm\u0259sind\u0259, b\u00f6yr\u0259k v\u0259 qaraciy\u0259r x\u0259s\u00adt\u0259likl\u0259rinin m\u00fc\u015fahid\u0259sind\u0259 isti\u00adfad\u0259 olunur. Hiperimmunqlo\u00adbuline\u00admiya, poliklonal v\u0259 ya monoklonal qammopatiyalar v\u0259 h\u0259dsiz dehid\u00adra\u00adta\u00adsiya zaman\u0131 serumda protein s\u0259viy\u00ady\u0259si art\u0131r, protein itkisi olan qastro\u00adenteropatiyalar, yan\u0131qlar, nefrotik sindrom, xroniki qaraciy\u0259r x\u0259st\u0259\u00adlikl\u0259ri, malabsorbsiya, malnutirasiya v\u0259 aqammaqlo\u00adbulinemiyalarda is\u0259 protein s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TOTAL KREAT\u0130N K\u0130NAZA (KREAT\u0130N K\u0130NAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0CK; Total kreatin kinaza; CPK; Kreatin fosfokinaza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, ki\u00adnetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admoliz<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n
<7 g\u00fcn<\/td>\n22-500 IU\/L<\/td>\n<\/tr>\n
7 g\u00fcn-1ay<\/td>\n22-240 IU\/L<\/td>\n<\/tr>\n
<1 ay<\/td>\n22-220 IU\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Skelet v\u0259 \u00fcr\u0259k \u0259z\u0259l\u0259sind\u0259 degenrasiyaya s\u0259b\u0259b olan hallar\u0131n qiym\u0259tl\u0259ndirilm\u0259sid\u0259 istifad\u0259 olunur. KM\u0130, proqressiv \u0259z\u0259l\u0259 distrofiyalar\u0131, polimiozit, yan\u0131qlar, travma, a\u011f\u0131r id\u00adman, status epileptikus, \u0259m\u0259liyyat\u00addan sonrak\u0131 d\u00f6vr, yay\u0131lm\u0131\u015f beyin infarkt\u0131, hamil\u0259liyin son d\u00f6vrl\u0259ri v\u0259 do\u011fu\u015f, b\u0259dxass\u0259li hipertermiya, \u0130M infeksiyalar, q\u0131colmalar v\u0259 \u00fcr\u0259yin de\u00adfibriliyasiyas\u0131ndan sonra CK s\u0259\u00adviyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TOTAL HEGSOZAM\u0130N\u0130DAZA (N-ASET\u0130L-QLUKOZAM\u0130N\u0130DAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0NAG; Total heksoza\u00admi\u00adnidaza; \u03b2-N-asetil- heksozaminidaza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik<\/p>\n

Referens:<\/strong>\u00a01.5-6.1 U\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0B\u00f6yr\u0259k x\u0259st\u0259likl\u0259rinin diaqnostikas\u0131nda istifad\u0259 olunur. B\u00f6y\u00adr\u0259k z\u0259d\u0259l\u0259nm\u0259si olan hallarda si\u00addikd\u0259 NAG s\u0259viyy\u0259si art\u0131r. Nefro\u00adtoksik d\u0259r\u00admanlarla \u0259laq\u0259dar olaraq \u0259m\u0259l\u0259 g\u0259l\u0259n b\u00f6yr\u0259k z\u0259d\u0259l\u0259n\u00adm\u0259\u00adl\u0259\u00adrin\u00add\u0259 sidikd\u0259 NAG s\u0259viyy\u0259si, serum\u00addak\u0131 kreatinin s\u0259viyy\u0259sind\u0259n daha tez y\u00fcks\u0259lir. B\u00f6yr\u0259k transplan\u00adta\u00adsi\u00adyalar\u0131n\u00addan sonra orqan r\u0259ddinin er\u00adk\u0259n diaqnozunda da NAG \u00e7ox d\u0259y\u0259rlidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TnT (TROPON\u0130N T)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0FnT; TropT<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong>\u00a0<0.04 ng\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0K\u0259skin miokard in\u00adfark\u00adt\u0131n\u0131n t\u0259yinind\u0259 istifad\u0259 olunur. H\u0259s\u00adsasl\u0131\u011f\u0131 troponin I-\u0259 nisb\u0259t\u0259n daha y\u00fcks\u0259kdir. K\u0259skin miokard infark\u00adt\u0131ndan 2-6 saat sonra y\u00fcks\u0259lir v\u0259 24 saata pik s\u0259viyy\u0259y\u0259\u00a0 \u00e7at\u0131r. Y\u00fcks\u0259lm\u0259 6 g\u00fcn davam ed\u0259 bil\u0259r. Sonra t\u0259x\u00admin\u0259n 20 g\u00fcn \u0259rzind\u0259 y\u00fcks\u0259k qal\u0131r. K\u0259skin miokard infarkt\u0131, qeyri stabil angina, PTCA v\u0259 miokardit troponin T s\u0259viyy\u0259sind\u0259 y\u00fcks\u0259lmy\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Tnl (TROPON\u0130N I)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0FnI; TropI<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259dd\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong>\u00a0<0.4 ng\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0K\u0259skin miokard infarkt\u0131n\u0131n t\u0259yinind\u0259 istifad\u0259 olunur. K\u0259skin miokard infarkt\u0131ndan 2-6 saat sonra kardiak troponin I y\u00fcks\u0259lir v\u0259 15-20 saat sonra pik s\u0259viyy\u0259y\u0259 \u00e7at\u0131r. Dig\u0259r kardiak markerl\u0259rin (CK-MB, mioqlobin v\u0259 s.) \u0259ksin\u0259, g\u00fcnl\u0259rl\u0259 (t\u0259qrib\u0259n 7 g\u00fcn) y\u00fcks\u0259k qa\u0131r. K\u0259skin \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, \u00fcr\u0259k travmas\u0131, qeyri stabil angina v\u0259 \u00fcr\u0259k \u0259m\u0259liyyat\u0131ndan sonra da troponin I y\u00fcks\u0259l\u0259 bil\u0259r. K\u0259skin miokard infarkt\u0131n\u0131n diaqnozu \u00fc\u00e7\u00fcn bir d\u0259f\u0259 t\u0259yin etm\u0259k yet\u0259rsizdir, m\u00fcayin\u0259 ard\u0131c\u0131l bir ne\u00e7\u0259 d\u0259f\u0259 t\u0259krarlanmal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

T\u0130MOTAKS\u0130N (BETA-2 M\u0130KROGLOBUL\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim: \u03b2<\/strong>2<\/sub>M; Timotaksin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong>\u00a00.6-3.8 mg\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130ltihab, autoimmun x\u0259s\u00adtl\u0259\u00ad\u00adlikl\u0259r, limfa v\u0259zil\u0259rinin b\u0259dxass\u0259li \u015fi\u015fl\u0259ri (M\u0259s. multiple myleoma) v\u0259 vi\u00adrus infeksiyalar\u0131nda serumda\u00a0\u03b2<\/strong>2<\/sub>M s\u0259viyy\u0259si arta bil\u0259r. X\u00fcsusil\u0259, mul\u00adtiple myelomada proqnostik \u0259h\u0259\u00admiy\u00ady\u0259t\u0259 malikdir. 4 mg\/L-d\u0259n y\u00fcks\u0259k n\u0259tic\u0259l\u0259r m\u0259nfi proqnozu bildirir. H\u0259m\u00e7inin tubulyar funksiya poz\u00ad\u011funlu\u011fu olan x\u0259st\u0259l\u0259rd\u0259 serumda\u00a0\u03b2<\/strong>2<\/sub>M miqdar\u0131 azal\u0131r, sidikd\u0259\u00a0\u03b2<\/strong>2<\/sub>M miq\u00addar\u0131 y\u00fcks\u0259k olur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TIBC (D\u018fM\u0130R B\u0130RL\u018f\u015eD\u0130RM\u018f QAB\u0130L\u0130YY\u018fT\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TIBC; Total iron binding capacity<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin\u00a0 10 saatl\u0131q acl\u0131qdan sonra al\u0131nmas\u0131 m\u0259sl\u0259h\u0259t g\u00f6r\u00fcl\u00fcr<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kolorimetrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
<1 ya\u015f<\/td>\n100-400 \u03bcg\/dL<\/td>\n<\/tr>\n
>1 ya\u015f<\/td>\n250-450 \u03bcg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Serumda d\u0259mir miqda\u00adr\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olunur. Hipoxrom anemiyalar, k\u0259s\u00adkin hepatitl\u0259r v\u0259 hamil\u0259liyin son h\u0259ft\u0259l\u0259rind\u0259 TIBC art\u0131r, d\u0259mir \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131 il\u0259 \u0259laq\u0259dar olmayan ane\u00admiyalar, xroniki infeksiyalar, b\u0259d\u00adxass\u0259li t\u00f6r\u0259m\u0259l\u0259r, sirroz, hemo\u00adxromatoz, b\u00f6yr\u0259k x\u0259st\u0259likl\u0259ri v\u0259 tala\u00adsemiyalarda is\u0259 bu g\u00f6st\u0259rici azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TG (TR\u0130QL\u0130SER\u0130D)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 12 \u00a0saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 laz\u0131md\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, fer\u00admen\u00adtativ<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
<5 ya\u015f<\/td>\n30-100 mg\/dL<\/td>\n35-110 mg\/dL<\/td>\n<\/tr>\n
6-15 ya\u015f<\/td>\n30-125 mg\/dL<\/td>\n35-130 mg\/dL<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n50-150 mg\/dL<\/td>\n50-150 mg\/dL<\/td>\n<\/tr>\n
>50 ya\u015f<\/td>\n55-150 mg\/dL<\/td>\n55-150 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Hiperlipidemiyan\u0131n qiy\u00adm\u0259t\u00adl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur. B\u00f6y\u00fckl\u0259rd\u0259 150 mg\/dL-d\u0259n a\u015fa\u011f\u0131 nor\u00admal, 150-199 mg\/dL s\u0259rh\u0259dd\u0259 y\u00fcks\u0259k, 200-499 mg\/dL y\u00fcks\u0259k v\u0259 499 mg\/dL-d\u0259n yuxar\u0131 is\u0259 \u00e7ox y\u00fcks\u0259k qiym\u0259tl\u0259ndirilir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TF (TRANSFERR\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Siderofilin; Tf<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, 24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum), 24 saatl\u0131q sidik soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a024 saatl\u0131q sidiyin miqdar\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Nefelometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Serum<\/td>\n<6 ay<\/td>\n130-275 mg\/dL<\/td>\n<\/tr>\n
>6 ay<\/td>\n200-360 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Plazmada d\u0259mir trans\u00adportunu t\u0259min ed\u0259n major z\u00fclald\u0131r. D\u0259\u00admir \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 anemiyas\u0131, hami\u00adl\u0259lik, esterogen istifad\u0259si v\u0259 h\u0259r n\u00f6v k\u0259skin iltihabi hallarda serum trans\u00adferrin s\u0259viyy\u0259si art\u0131r, irsi atrans\u00adfer\u00adrinemiya, xroniki iltihabi x\u0259st\u0259likl\u0259r, b\u0259dxass\u0259li t\u00f6r\u0259m\u0259l\u0259r, hepatosellular x\u0259st\u0259likl\u0259r, malnutirasiya v\u0259 nefrotik sindromda is\u0259 transferrinin s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TEMPERATURA DAVAMLI Q\u018fL\u018fV\u0130 FOSFATAZA (65 oC)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Plasentar Q\u0259l\u0259vi Fosfa\u00adtaza; PLAP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik, kine\u00adtik<\/p>\n

Referens:<\/strong>\u00a0<1%<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Q\u0259l\u0259vi fosfatazan\u0131n tem\u00adpe\u00adratura davaml\u0131, plasentar izoen\u00adzi\u00admidir. Hamil\u0259liyin 12-ci h\u0259ft\u0259sind\u0259n etibar\u0259n tap\u0131l\u0131r. H\u0259m\u00e7inin semino\u00adma\u00adlar\u0131n 50%-i v\u0259 s\u00fcd v\u0259zi v\u0259 yu\u00admur\u00adtal\u0131q x\u0259r\u00e7\u0259ngli x\u0259st\u0259l\u0259rin 20 %-ind\u0259 d\u0259 plasentar q\u0259l\u0259vi fosfataza tap\u0131la il\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TOTAL PROTE\u0130N (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0H\u0259r g\u00fcn<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>1 mL<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131<\/strong>:<\/strong>\u00a024 saatl\u0131q sidiyin miqdar\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong>\u00a0<0.14 g\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0B\u00f6yr\u0259k funksiyalar\u0131n\u0131n m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur. Qlo\u00admerulyar v\u0259 tubulyar z\u0259d\u0259l\u0259nm\u0259l\u0259r v\u0259 h\u0259dsiz sintezl\u0259 \u0259laq\u0259li (m\u0259s. qam\u00admopatiyalar) proteinuriya ba\u015f ver\u0259 bil\u0259r. Nefrotik sindrom, diabetik nef\u00adropatiya, multiple myeloma, mo\u00adnoklonal qammopatiyalar, b\u00f6yr\u0259k bo\u00adrucuqlar\u0131n\u0131n funksional poz\u011fun\u00adluqlar\u0131 v\u0259 sidik yollar\u0131 infeksiyalar\u0131, h\u0259m\u00e7inin b\u0259dxass\u0259li t\u00f6r\u0259m\u0259l\u0259r si\u00addik\u00adl\u0259 ifraz olunan total protein miqda\u00adr\u0131n\u0131n artmas\u0131na s\u0259b\u0259b olur. Bundan ba\u015fqa, idman h\u0259r\u0259k\u0259tl\u0259ri, h\u0259rar\u0259t v\u0259 hamil\u0259lik m\u00fcv\u0259qq\u0259ti, menstrual qanaxma, prostat mayel\u0259ri, eakulyat v\u0259 q\u0259l\u0259vi xass\u0259li sidik yalan\u00e7\u0131 y\u00fcks\u0259k n\u0259tic\u0259l\u0259r\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TOTAL TUR\u015eU FOSFATAZA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TAF; TAP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum (1 mL seruma 20 mL 10%-li asetat tur\u015fusu \u0259lav\u0259 edil\u0259r\u0259k n\u00fcmun\u0259 asidifikasiya edildikd\u0259n sonra g\u00f6nd\u0259rilm\u0259lidir)<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
<1 ya\u015f<\/td>\n1.50-13.00 U\/L<\/td>\n1.00-11.00 U\/L<\/td>\n<\/tr>\n
2-5 ya\u015f<\/td>\n0.75-10.00 U\/L<\/td>\n0.75-8.50 U\/L<\/td>\n<\/tr>\n
>5 ya\u015f<\/td>\n0.50-6.50 U\/L<\/td>\n0.50-5.50 U\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Prostat x\u0259st\u0259likl\u0259rinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Prostatdan ba\u015fqa b\u0259zi toxu\u00adma\u00adlarda da (qaraciy\u0259r, dalaq, eritro\u00adsit\u00adl\u0259r, trombositl\u0259r v\u0259 s\u00fcm\u00fck iliyi) tur\u015f fosfatazaya rast g\u0259linir. Bu orqan\u00adlardak\u0131 b\u0259zi x\u0259st\u0259likl\u0259rin d\u0259 total tur\u015f fosfataza s\u0259viyy\u0259sind\u0259 y\u00fcks\u0259lm\u0259y\u0259 s\u0259b\u0259b ola bil\u0259c\u0259yini unutmaq olmaz<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TOTAL XOLESTEROL (XOLESTEROL (Total))<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Total xolesterol<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250\u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Pay\u0131z v\u0259 q\u0131\u015f aylar\u0131nda serumda \u00fcmumi xolesto\u00adrolun s\u0259viyy\u0259si daha y\u00fcks\u0259k olur. H\u0259m\u00e7inin qan alma v\u0259ziyy\u0259ti, \u0259n son q\u0259bul edil\u0259n qida, emosioanal stress v\u0259 menstural sikl d\u0259 \u00fcmumi xoles\u00adterol miqdar\u0131na t\u0259sir edir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik, fer\u00admen\u00adtativ.<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si qan\u0131 kan\u0131<\/td>\n45-100 mg\/dL<\/td>\n<\/tr>\n
<3 ay<\/td>\n50-135 mg\/dL<\/td>\n<\/tr>\n
4-6 ay<\/td>\n60-145 mg\/dL<\/td>\n<\/tr>\n
7-12 ay<\/td>\n60-160 mg\/dL<\/td>\n<\/tr>\n
1-5 ya\u015f<\/td>\n70-175 mg\/dL<\/td>\n<\/tr>\n
6-15 ya\u015f<\/td>\n110-200 mg\/dL<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n125-200 mg\/dL<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n135-200 mg\/dL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n140-200 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hipolipidemiya v\u0259 hiper\u00adlipidemiyan\u0131n diaqnozunda isti\u00adfad\u0259 olu\u00adnur. Xolesterol s\u0259viyy\u0259sinin b\u00f6\u00ady\u00fck\u00adl\u0259rd\u0259 200 mg\/dL, u\u015faqlarda is\u0259 170 mg\/dL-d\u0259n az olmal\u0131d\u0131r. B\u00f6\u00ady\u00fck\u00adl\u0259rd\u0259 200-239 mg\/dL \u201cs\u0259rh\u0259d\u0259 yax\u0131n y\u00fcks\u0259k\u201d, >239 mg\/dL is\u0259 \u201cy\u00fcks\u0259k\u201d kimi qiym\u0259tl\u0259ndirilm\u0259lidir. Boy v\u0259 \u00e7\u0259ki \u00f6l\u00e7\u00fcl\u0259rinin d\u0259 verilm\u0259si laz\u0131m g\u0259ldikd\u0259, b\u0259d\u0259n k\u00fctl\u0259 indeksi (body mass index) hesablan\u0131laraq verilir.<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TP (TOTAL PROTE\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TP, \u00fcmumi z\u00fclal<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0Turnan\u0131n uzun m\u00fcdd\u0259t qalmas\u0131 il\u0259 \u0259laq\u0259dar meydana \u00e7\u0131xan venoz staz n\u0259tic\u0259sind\u0259 v\u0259 ayaq \u00fcst\u0259 dayanark\u0259n serumda total protein s\u0259viyy\u0259si y\u00fcks\u0259lir. Hamil\u0259liyin son trimesteri v\u0259 uzunm\u00fcdd\u0259tli yataq istirah\u0259ti is\u0259 total protein s\u0259viyy\u0259sinin azalmas\u0131na s\u0259b\u0259b olur<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si<\/td>\n4.8-8.0 g\/dL<\/td>\n<\/tr>\n
Yenido\u011fulan<\/td>\n3.6-6.0 g\/dL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n4.6-7.0 g\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-3 ay<\/td>\n4.4-7.6 g\/dL<\/td>\n<\/tr>\n
4-6 ay<\/td>\n4.4-7.0 g\/dL<\/td>\n<\/tr>\n
7-12 ay<\/td>\n5.1-7.3 g\/dL<\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n5.1-7.5 g\/dL<\/td>\n<\/tr>\n
4-15 ya\u015f<\/td>\n6.0-8.0 g\/dL<\/td>\n<\/tr>\n
16-60 ya\u015f<\/td>\n6.2-8.3 g\/dL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n6.0-8.1 g\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qidalanman\u0131n qiym\u0259tl\u0259n\u00addiril\u00adm\u0259sind\u0259, b\u00f6yr\u0259k v\u0259 qaraciy\u0259r x\u0259s\u00adt\u0259likl\u0259rinin m\u00fc\u015fahid\u0259sind\u0259 isti\u00adfad\u0259 olunur. Hiperimmunqlo\u00adbuline\u00admiya, poliklonal v\u0259 ya monoklonal qammopatiyalar v\u0259 h\u0259dsiz dehid\u00adra\u00adta\u00adsiya zaman\u0131 serumda protein s\u0259viy\u00ady\u0259si art\u0131r, protein itkisi olan qastro\u00adenteropatiyalar, yan\u0131qlar, nefrotik sindrom, xroniki qaraciy\u0259r x\u0259st\u0259\u00adlikl\u0259ri, malabsorbsiya, malnutirasiya v\u0259 aqammaqlo\u00adbulinemiyalarda is\u0259 protein s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TRANSFERR\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Siderofilin; Tf<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum, 24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (serum), 24 saatl\u0131q sidik soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a024 saatl\u0131q sidiyin miqdar\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Nefelometrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Serum<\/td>\n<6 ay<\/td>\n130-275 mg\/dL<\/td>\n<\/tr>\n
>6 ay<\/td>\n200-360 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Plazmada d\u0259mir trans\u00adportunu t\u0259min ed\u0259n major z\u00fclald\u0131r. D\u0259\u00admir \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 anemiyas\u0131, hami\u00adl\u0259lik, esterogen istifad\u0259si v\u0259 h\u0259r n\u00f6v k\u0259skin iltihabi hallarda serum trans\u00adferrin s\u0259viyy\u0259si art\u0131r, irsi atrans\u00adfer\u00adrinemiya, xroniki iltihabi x\u0259st\u0259likl\u0259r, b\u0259dxass\u0259li t\u00f6r\u0259m\u0259l\u0259r, hepatosellular x\u0259st\u0259likl\u0259r, malnutirasiya v\u0259 nefrotik sindromda is\u0259 transferrinin s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TRANSHYRETIN (PREALBUM\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Transthyretin; PA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Nefelometrik<\/p>\n

Referens:<\/strong>\u00a017-42 mg\/dL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qidalanman\u0131n qiym\u0259t\u00adl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur. X\u00fc\u00adsu\u00adsil\u0259 yenido\u011fulmu\u015f infantlar v\u0259 pa\u00adrenteral qidalanma m\u00fcalic\u0259si alan x\u0259st\u0259l\u0259rin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur. H\u0259m\u00ad\u00e7i\u00adnin neqativ k\u0259skin faza reak\u00adtant\u00adla\u00adr\u0131ndan biridir. Oral kontraseptiv, korti\u00adkosteroid, ana\u00adbo\u00adlik steroid istifad\u0259si v\u0259 Hodgkin x\u0259st\u0259liyind\u0259 prealbumin s\u0259viyy\u0259si art\u0131r, malnutrisiya, iltihab, b\u0259d xass\u0259li t\u00f6r\u0259m\u0259l\u0259r, xroniki x\u0259st\u0259likl\u0259r, sirroz v\u0259 z\u00fclal itkisi olan hallarda is\u0259 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TR\u0130AS\u0130LQL\u0130SEROL AS\u0130LH\u0130DROLAZA (L\u0130PAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>Triasilqliserol asilhidrolaza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kolorimetrik<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
<12 ya\u015f<\/td>\n<60 U\/L<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n13-60 U\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>M\u0259d\u0259alt\u0131 v\u0259zin funksional testl\u0259rind\u0259ndir. Pankreatitl\u0259r, \u00f6d kis\u0259si koliti, bo\u011fulmu\u015f v\u0259 ya infarkta u\u011fram\u0131\u015f ba\u011f\u0131rsaq, m\u0259d\u0259alt\u0131 v\u0259zin kistalar\u0131 v\u0259 ya psevdokistl\u0259ri v\u0259 peri\u00adtonitl\u0259r zaman\u0131 serumda lipazan\u0131n s\u0259viyy\u0259si art\u0131r. K\u0259skin pankreatitd\u0259 serumda lipazan\u0131n aktivliyi, ami\u00adlazadan daha uzun m\u00fcdd\u0259t y\u00fcks\u0259k qal\u0131r. H\u0259m\u00e7inin k\u0259skin pankreatit \u00fc\u00e7\u00fcn lipazan\u0131n h\u0259ssasl\u0131\u011f\u0131 v\u0259 spe\u00adsifikliyi amilazadan daha y\u00fcks\u0259kdir. Pankreatitl\u0259rd\u0259 assit mayesind\u0259ki lipaza da y\u00fcks\u0259l\u0259 bil\u0259r. A\u011fciy\u0259r \u015fi\u015f\u00adl\u0259ri il\u0259 \u0259laq\u0259dar olaraq \u0259m\u0259l\u0259 g\u0259l\u0259n plevral transsudatlarda da nadir hallarda lipaza s\u0259viyy\u0259si art\u0131r. ERCP, oddi sfinktorunda spazma s\u0259b\u0259b olan narkotik analgetikl\u0259r v\u0259 heparin d\u0259 serumda lipaza s\u0259viy\u00ady\u0259sinin y\u00fcks\u0259lm\u0259sin\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TR\u0130PS\u0130N (N\u018fC\u0130SD\u018f TR\u0130PS\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>T\u0259z\u0259 g\u00f6t\u00fcr\u00fclm\u00fc\u015f n\u0259cis<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0T\u0259miz a\u011fz\u0131 qapaql\u0131 qab<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Mukovissidozun (Kistik fibrozis) diaqnozunda istifad\u0259 olu\u00adnun skrininq tetl\u0259rd\u0259n biridir. N\u0259\u00adcisd\u0259ki tripsin miqdar\u0131 malab\u00adsorb\u00adsiyada art\u0131r, m\u0259d\u0259alt\u0131 v\u0259z funksi\u00adyas\u0131n\u0131n itirilm\u0259si v\u0259 mukovissidoz zaman\u0131 azal\u0131r. 4 ya\u015f\u0131ndan b\u00f6y\u00fck u\u015faqlarda miqdar\u0131 a\u015fa\u011f\u0131 olur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TR\u0130PTOM\u0130N (SEROTON\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>5-OH triptamin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259< qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Serotonin t\u0259rkilbi qoz, banan, bad\u0131mcan, po\u00admidor, f\u0131nd\u0131q, f\u0131st\u0131q, avokado v\u0259 s. b\u0259zi meyv\u0259 v\u0259 t\u0259r\u0259v\u0259zl\u0259r son 72 saat \u0259rzind\u0259 yeyilm\u0259m\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n
Serum<\/td>\n>15 ya\u015f<\/td>\n50-230 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Karsinoid \u015fi\u015fl\u0259rin di\u00adaq\u00adnoz v\u0259 m\u00fcalic\u0259sinin\u00a0 m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur. Karsinoid sindrom, miqren, \u015fizofreniya, esensial hiper\u00adten\u00adziya, Huntington x\u0259st\u0259liyi v\u0259 Duchenne \u0259z\u0259l\u0259 distrofiyas\u0131nda se\u00adrumda serotonin miqdar\u0131art\u0131r. Dum\u00adping sindromu, k\u0259skin ba\u011f\u0131rsaq obstruksiyas\u0131, kistik fibrozis v\u0259 k\u0259s\u00adkin miokard infarkt\u0131nda da se\u00adrotonin s\u0259viyy\u0259sind\u0259 y\u00fcng\u00fcl y\u00fcks\u0259lm\u0259 ola bil\u0259r. Litium, MAO inhibitorlar\u0131, me\u00adtildopa, morfin v\u0259 rezerpin isti\u00adfad\u0259si serotonin s\u0259viyy\u0259sin\u0259 tesir ed\u0259 bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TR\u0130QL\u0130SER\u0130D<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TG<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259nin al\u0131nmas\u0131 \u00fc\u00e7\u00fcn 12 \u00a0saatl\u0131q s\u0259h\u0259r acl\u0131\u011f\u0131 laz\u0131md\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, fer\u00admen\u00adtativ<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
Ya\u015f<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
<5 ya\u015f<\/td>\n30-100 mg\/dL<\/td>\n35-110 mg\/dL<\/td>\n<\/tr>\n
6-15 ya\u015f<\/td>\n30-125 mg\/dL<\/td>\n35-130 mg\/dL<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n50-150 mg\/dL<\/td>\n50-150 mg\/dL<\/td>\n<\/tr>\n
>50 ya\u015f<\/td>\n55-150 mg\/dL<\/td>\n55-150 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Hiperlipidemiyan\u0131n qiy\u00adm\u0259t\u00adl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur. B\u00f6y\u00fckl\u0259rd\u0259 150 mg\/dL-d\u0259n a\u015fa\u011f\u0131 nor\u00admal, 150-199 mg\/dL s\u0259rh\u0259dd\u0259 y\u00fcks\u0259k, 200-499 mg\/dL y\u00fcks\u0259k v\u0259 499 mg\/dL-d\u0259n yuxar\u0131 is\u0259 \u00e7ox y\u00fcks\u0259k qiym\u0259tl\u0259ndirilir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TR\u0130XLOROASETAT TUR\u015eUSU<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TCA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong>\u00a0<50 \u03bcmol\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Trixloretilen il\u0259 i\u015fl\u0259y\u0259n \u015f\u0259xsl\u0259rin bu madd\u0259nin t\u0259sirin\u0259 m\u0259ruz qalma d\u0259r\u0259c\u0259sinin t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

UREA N\u0130TROGEN\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0BUN<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, fer\u00admentativ, kinetik<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si<\/td>\n21-40 mg\/dL<\/td>\n<\/tr>\n
Premat\u00fcre<\/td>\n3-25 mg\/dL<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n4-12 mg\/dL<\/td>\n<\/tr>\n
7 g\u00fcn-6 ay<\/td>\n5-15 mg\/dL<\/td>\n<\/tr>\n
7 ay-3 ya\u015f<\/td>\n5-18 mg\/dL<\/td>\n<\/tr>\n
4-15 ya\u015f<\/td>\n5-25 mg\/dL<\/td>\n<\/tr>\n
16-60 ya\u015f<\/td>\n7-25 mg\/dL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n7-28 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>B\u00f6yr\u0259yin funksional test\u00adl\u0259rind\u0259n biridir. Z\u00fclal m\u00fcbadil\u0259sinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Ya\u015f v\u0259 qida il\u0259 q\u0259bul olunan z\u00fclal miqda\u0131 art\u0131qca BUN s\u0259viyy\u0259si d\u0259 art\u0131r. B\u00f6yr\u0259k perfuziyas\u0131n\u0131n azal\u00add\u0131\u011f\u0131 hallar, k\u0259skin v\u0259 xroniki b\u00f6yr\u0259k x\u0259st\u0259likl\u0259ri, postrenal obstruksiya v\u0259 y\u00fcks\u0259k z\u00fclall\u0131 qidalanma serumda BUN s\u0259viyy\u0259sini art\u0131r\u0131r. Az z\u00fclall\u0131 qidalanma, hamil\u0259liyin son m\u0259r\u00adh\u0259l\u0259si, infantilizm, akromeqaliya, a\u011f\u0131r qaraciy\u0259r x\u0259st\u0259likl\u0259ri v\u0259 celiac sprue zaman\u0131 is\u0259 serumda BUN s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

URAT (S\u0130D\u0130K TUR\u015eUSU)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Urat; UA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, fer\u00admentativ<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
1 h\u0259ft\u0259-5 ya\u015f<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
<\/td>\nKi\u015fi<\/td>\nQad\u0131n<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n3.0-7.2 mg\/dL<\/td>\n2.6-6.0 mg\/dL<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n3.5-7.2mg\/dL<\/td>\n2.6-6.3 mg\/dL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n3.5-7.5mg\/dL<\/td>\n2.6-6.5 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Podaqra v\u0259 dig\u0259r purin m\u00fcbadil\u0259si poz\u011funluqlar\u0131n\u0131n diaqnoz v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 isti\u00adfad\u0259 olunur. Podaqra, b\u00f6yr\u0259k \u00e7at\u0131\u015f\u00admazl\u0131\u011f\u0131, leykoz, multiple myeloma, po\u00adlisitemia, limfoma, hamil\u0259lik tok\u00adsemiyas\u0131, psoriaz, polikistik b\u00f6yr\u0259k x\u0259st\u0259liyi, purinl\u0259 z\u0259ngin qidalanma (qaraciy\u0259r, b\u00f6yr\u0259k v\u0259 s.)a\u011f\u0131r idman\u00addan sonra qanda sidik tur\u015fusumiqdar\u0131 y\u00fcks\u0259ldiyi halda, Wilson x\u0259st\u0259liyi, Fanconi sindromu, ksanturiya v\u0259 purinl\u0259 m\u0259hdud qidalanma zaman\u0131\u00a0 is\u0259 bu g\u00f6st\u0259ricinin qanda s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

T\u018fR TEST\u0130 (XLOR (T\u0259r))<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0T\u0259r testi; \u0130yontoferez<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>T\u0259r<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200\u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0\u00a0<\/strong>N\u00fcmun\u0259 laboratoriyada x\u00fcsusi qayda il\u0259 al\u0131n\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kondaktometrik<\/p>\n

Referens:<\/strong>\u00a0<60 mEq\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Mukovissidozun\u00a0(<\/strong>kistik fib\u00ad\u00adrozis) diaqnozunda istifad\u0259 olu\u00adnur. Mukovissidozlu x\u0259st\u0259l\u0259rd\u0259 t\u0259r il\u0259 duz itkisi \u00e7ox y\u00fcks\u0259lir. \u0130fraz nor\u00admal \u015f\u0259xsl\u0259r\u0259 nisb\u0259t\u0259n 2.5 d\u0259f\u0259 y\u00fck\u00ads\u0259kdir v\u0259 bu x\u0259st\u0259lik \u00fc\u00e7\u00fcn pato\u00adqno\u00admik hesab olunur. X\u0259st\u0259 infantlarda III-V h\u0259ft\u0259d\u0259n sonra po\u00adzitivl\u0259\u015fir. Ad\u00adrenal \u00e7at\u0131\u015fmazl\u0131q, ma\u00adlab\u00adsorbsiya, m\u0259d\u0259alt\u0131 v\u0259z \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131, hipo\u00adti\u00adroidi\u00adzim v\u0259 b\u0259zi b\u00f6yr\u0259k x\u0259st\u0259lik\u00adl\u0259\u00adrind\u0259 d\u0259 t\u0259rd\u0259ki Cl miqdar\u0131 y\u00fcks\u0259l\u0259 bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TUR\u015eU HEMOL\u0130Z TEST\u0130 (HAM TEST\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Tur\u015fu hemolizi testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>X\u0259st\u0259d\u0259n v\u0259 eyni qan qruplu sa\u011flam \u015f\u0259xsd\u0259n EDTA-l\u0131 tam qan v\u0259 serum g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum) v\u0259 b\u0259n\u00f6v\u015f\u0259yi qa\u00adpaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (EDTA-l\u0131 tam qan)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>3 mL EDTA-l\u0131 tam qan v\u0259 3mL serum<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kvalitativ<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Paroksizmal nokturnal (gec\u0259) hemoqlobinuriyan\u0131n t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TRP (BORUCUQ FOSFAT REABSORBS\u0130YASI)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Tubulyar fosfat reabsorb\u00adsiyas\u0131, TRP<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0S\u0259h\u0259r 2-4 saatl\u0131q\u00a0 sidik v\u0259 eyni zamanda al\u0131nan serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum). Y\u0131\u011f\u0131lan sidik so\u00adyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6n\u00add\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL serum v\u0259 10 mL sidik<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0X\u0259st\u0259 m\u00fca\u00adyin\u0259d\u0259n\u00a0 \u0259vv\u0259lki 5 g\u00fcn \u0259rzind\u0259 nor\u00admal kalsium v\u0259 fosfor t\u0259rkibli p\u0259hriz q\u0259bul etm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong>\u00a078-91 %<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Paratiroid v\u0259zi funksi\u00adya\u00adlar\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 isti\u00adfa\u00add\u0259 olunur. Hipoparatiroidizm v\u0259 psev\u00addohipoparatiroidizmd\u0259 TRP ar\u00adt\u0131r, hiperparatiroidizmd\u0259 is\u0259 azal\u0131r. Hiperparatiroidizmi olan x\u0259st\u0259l\u0259rin 25 %-d\u0259 yalan\u00e7\u0131 neqativ n\u0259tic\u0259 \u0259ld\u0259 oluna bil\u0259r.
\nTRP %=100x(1<\/strong>– sidik fosforu\u00a0x<\/strong>\u00a0serum kreatinini\u00a0\/<\/strong>\u00a0sidik kreatinini\u00a0x\u00a0<\/strong>serum fosforu)<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TROPON\u0130N T<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0FnT; TropT<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ECLIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong>\u00a0<0.04 ng\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0K\u0259skin miokard in\u00adfark\u00adt\u0131n\u0131n t\u0259yinind\u0259 istifad\u0259 olunur. H\u0259s\u00adsasl\u0131\u011f\u0131 troponin I-\u0259 nisb\u0259t\u0259n daha y\u00fcks\u0259kdir. K\u0259skin miokard infark\u00adt\u0131ndan 2-6 saat sonra y\u00fcks\u0259lir v\u0259 24 saata pik s\u0259viyy\u0259y\u0259\u00a0 \u00e7at\u0131r. Y\u00fcks\u0259lm\u0259 6 g\u00fcn davam ed\u0259 bil\u0259r. Sonra t\u0259x\u00admin\u0259n 20 g\u00fcn \u0259rzind\u0259 y\u00fcks\u0259k qal\u0131r. K\u0259skin miokard infarkt\u0131, qeyri stabil angina, PTCA v\u0259 miokardit troponin T s\u0259viyy\u0259sind\u0259 y\u00fcks\u0259lmy\u0259 s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TROPON\u0130N I<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0FnI; TropI<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0400 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0MEIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259dd\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong>\u00a0<0.4 ng\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0K\u0259skin miokard infarkt\u0131n\u0131n t\u0259yinind\u0259 istifad\u0259 olunur. K\u0259skin miokard infarkt\u0131ndan 2-6 saat sonra kardiak troponin I y\u00fcks\u0259lir v\u0259 15-20 saat sonra pik s\u0259viyy\u0259y\u0259 \u00e7at\u0131r. Dig\u0259r kardiak markerl\u0259rin (CK-MB, mioqlobin v\u0259 s.) \u0259ksin\u0259, g\u00fcnl\u0259rl\u0259 (t\u0259qrib\u0259n 7 g\u00fcn) y\u00fcks\u0259k qa\u0131r. K\u0259skin \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, \u00fcr\u0259k travmas\u0131, qeyri stabil angina v\u0259 \u00fcr\u0259k \u0259m\u0259liyyat\u0131ndan sonra da troponin I y\u00fcks\u0259l\u0259 bil\u0259r. K\u0259skin miokard infarkt\u0131n\u0131n diaqnozu \u00fc\u00e7\u00fcn bir d\u0259f\u0259 t\u0259yin etm\u0259k yet\u0259rsizdir, m\u00fcayin\u0259 ard\u0131c\u0131l bir ne\u00e7\u0259 d\u0259f\u0259 t\u0259krarlanmal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TR\u0130XLOROETANOL<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TCE<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:<\/strong>\u00a0<30 mg\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Trixloretilen il\u0259 i\u015fl\u0259y\u0259n \u015f\u0259xsl\u0259rin bu madd\u0259nin t\u0259sirin\u0259 m\u0259ruz qalma d\u0259r\u0259c\u0259sinin t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

\u015e\u018fK\u018fR XROMATOQRAF\u0130YASI<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik, n\u0259cis<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL (bird\u0259f\u0259lik sidik), 10 g (n\u0259cis)<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Ka\u011f\u0131z xromatoqrafiyas\u0131<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Sidik v\u0259 n\u0259cisd\u0259 ql\u00fc\u00adkozan\u0131n varl\u0131\u011f\u0131n\u0131n qiym\u0259tl\u0259ndi\u00adrilm\u0259sind\u0259 istifad\u0259 olunur. Ql\u00fckoza, qalaktoza, laktoza, saxaroza, ksiloza v\u0259 fruktozan\u0131n varl\u0131\u011f\u0131 semikantitativ olaraq ara\u015fd\u0131r\u0131l\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

\u015e\u018fK\u018fR SU TEST\u0130 (SAXAROZA HEMOL\u0130Z TEST\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0\u015e\u0259k\u0259r su testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>X\u0259st\u0259d\u0259n v\u0259 eyni qan qrupundan olan sa\u011flam insandan al\u0131nm\u0131\u015f EDTA-l\u0131 tam qan v\u0259 serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u0259\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a03 mL EDTA-l\u0131 tam qan v\u0259 3 mL serum<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kalitativ (keyfiyy\u0259t)<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
Lizis<\/td>\n<5%<\/td>\nNeqativ<\/td>\n<\/tr>\n
<\/td>\n6-10%<\/td>\n\u015e\u00fcbh\u0259li<\/td>\n<\/tr>\n
<\/td>\n>10%<\/td>\nPovitiv<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Paroksizmal nokturnal (gec\u0259) hemoqlobinuriyan\u0131n t\u0259yinind\u0259 istifad\u0259 olunan skrininq testdir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

Zn (S\u0130NK)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS<\/p>\n

Referens:<\/strong>\u00a01000-2000 \u03bcg\/dL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qandak\u0131 \u00fcmumi sinkin 75-88 %-i eritrositl\u0259rin daxilind\u0259 yer\u00adl\u0259\u015fir. X\u00fcsusil\u0259 oraq h\u00fcceyr\u0259li anemiyada eritrosit daxili sinkin s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

YOD<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0I<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Ciddi d\u0259r\u0259c\u0259li \u00e7at\u0131\u015fmazl\u0131q<\/td>\n<2 mg\/dL<\/td>\n<\/tr>\n
Orta d\u0259r\u0259c\u0259li \u00e7at\u0131\u015fmazl\u0131q<\/td>\n2-5 mg\/dL<\/td>\n<\/tr>\n
Y\u00fcng\u00fcl d\u0259r\u0259c\u0259li \u00e7at\u0131\u015fmazl\u0131q<\/td>\n5-10 mg\/dL<\/td>\n<\/tr>\n
Normal yod q\u0259bulu<\/td>\n10-20 mg\/dL<\/td>\n<\/tr>\n
Normadan art\u0131q yod q\u0259bulu<\/td>\n20-30 mg\/dL<\/td>\n<\/tr>\n
H\u0259dsiz yod q\u0259bulu<\/td>\n>30 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0Yem\u0259kl\u0259r v\u0259 ya d\u0259r\u00adman\u00adlarla q\u0259bul olunan iyot miqdar\u0131n\u0131n d\u0259y\u0259rl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olunur.\u00a0\u00a0\u00a0<\/strong><\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

XYLOSE ABSORBS\u0130YA TEST\u0130 (D-KS\u0130LOZA ABSORBS\u0130YA TEST\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Ksiloza absorbsiya testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum v\u0259 sidik<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Sidik qaranl\u0131q yerd\u0259 toplanmal\u0131 v\u0259 soyuq \u015f\u0259raitd\u0259 saxlanmal\u0131d\u0131r<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:\u00a0<\/strong>X\u0259st\u0259 10 saatl\u0131q s\u0259h\u0259r a\u015fl\u0131\u011f\u0131 il\u0259 labarotoriyaya g\u0259lm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

Referens:\u00a0<\/strong>N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Malabsorbsiyan\u0131n t\u0259yini v\u0259 nazik ba\u011f\u0131rsa\u011f\u0131n proksimal hiss\u0259\u00adsind\u0259ki karbohidrat absorbsiyas\u0131n\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Ba\u011f\u0131rsaq malabsorbsiyas\u0131, nazik ba\u011f\u0131rsaqda bakterial \u00e7oxalma, qus\u00adma, assit, gecikmi\u015f m\u0259d\u0259 bo\u015falmas\u0131 v\u0259 Whipple x\u0259st\u0259liyind\u0259 qan v\u0259 sidikd\u0259 ksilozan\u0131n miqdar\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

XROM<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Cr<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik, bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 sax\u00adlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir. Asetat tur\u015fusu v\u0259 ya bor tur\u015fusu \u00fcz\u0259rin\u0259 y\u0131\u011f\u0131lan sidikl\u0259r d\u0259 q\u0259bul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>AAS-Zeeman<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n
24 saatl\u0131q sidik<\/td>\n<0.52 \u03bcg\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Xroma m\u0259ruz qalan \u015f\u0259xs\u00adl\u0259r\u0259 bu madd\u0259nin t\u0259sir d\u0259r\u0259c\u0259sini g\u00f6st\u0259rir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

XOL\u0130NESTERAZA II (PSEVDOXOL\u0130NESTERAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>PchE; kolinesteraz II; SchE; Axilkolin axilhidrolaza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
Ki\u015fi<\/td>\n5400-13200 U\/L<\/td>\n<\/tr>\n
Qad\u0131n<\/td>\n15 ya\u015f<\/td>\n5400-13200 U\/L<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n4300-11500 U\/L<\/td>\n<\/tr>\n
50 ya\u015f<\/td>\n5400-13200 U\/L<\/td>\n<\/tr>\n
Hamil\u0259<\/td>\n3700-9300 U\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qaraciy\u0259rin funksional testl\u0259rind\u0259n biridir. Uzanm\u0131\u015f anes\u00adteziya sinir qaz\u0131 v\u0259 \u00fczvi fosforlu insektisid z\u0259h\u0259rl\u0259nm\u0259l\u0259rinin qiym\u0259t\u00adl\u0259n\u00addirilm\u0259sind\u0259 istifad\u0259 olunur. Ge\u00adnetik psevdo-xolinesteraza variant\u00adlar\u0131 (anesteziyan\u0131n uzanmas\u0131na s\u0259b\u0259b olur), hepatitl\u0259r, sirroz, malnutrisiya, anemiyalar, k\u0259skin infeksiyalar, k\u0259s\u00adkin miokard infarkt\u0131, a\u011fciy\u0259r emboliyas\u0131, \u0259m\u0259liyyatdan sonrak\u0131 d\u00f6vr, xroniki b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, hamil\u0259liyin son d\u00f6vrl\u0259ri v\u0259 serumda albumin konsentrasiyas\u0131n\u0131 azaldan hallarda serumda psevdo-xolines\u00adterazan\u0131n miqdar\u0131 azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

XOLESTEROL (Total)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Total xolesterol<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>250\u03bcL<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0Pay\u0131z v\u0259 q\u0131\u015f aylar\u0131nda serumda \u00fcmumi xolesto\u00adrolun s\u0259viyy\u0259si daha y\u00fcks\u0259k olur. H\u0259m\u00e7inin qan alma v\u0259ziyy\u0259ti, \u0259n son q\u0259bul edil\u0259n qida, emosioanal stress v\u0259 menstural sikl d\u0259 \u00fcmumi xoles\u00adterol miqdar\u0131na t\u0259sir edir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik, fer\u00admen\u00adtativ.<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259si qan\u0131 kan\u0131<\/td>\n45-100 mg\/dL<\/td>\n<\/tr>\n
<3 ay<\/td>\n50-135 mg\/dL<\/td>\n<\/tr>\n
4-6 ay<\/td>\n60-145 mg\/dL<\/td>\n<\/tr>\n
7-12 ay<\/td>\n60-160 mg\/dL<\/td>\n<\/tr>\n
1-5 ya\u015f<\/td>\n70-175 mg\/dL<\/td>\n<\/tr>\n
6-15 ya\u015f<\/td>\n110-200 mg\/dL<\/td>\n<\/tr>\n
16-50 ya\u015f<\/td>\n125-200 mg\/dL<\/td>\n<\/tr>\n
51-60 ya\u015f<\/td>\n135-200 mg\/dL<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n140-200 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Hipolipidemiya v\u0259 hiper\u00adlipidemiyan\u0131n diaqnozunda isti\u00adfad\u0259 olu\u00adnur. Xolesterol s\u0259viyy\u0259sinin b\u00f6\u00ady\u00fck\u00adl\u0259rd\u0259 200 mg\/dL, u\u015faqlarda is\u0259 170 mg\/dL-d\u0259n az olmal\u0131d\u0131r. B\u00f6\u00ady\u00fck\u00adl\u0259rd\u0259 200-239 mg\/dL \u201cs\u0259rh\u0259d\u0259 yax\u0131n y\u00fcks\u0259k\u201d, >239 mg\/dL is\u0259 \u201cy\u00fcks\u0259k\u201d kimi qiym\u0259tl\u0259ndirilm\u0259lidir. Boy v\u0259 \u00e7\u0259ki \u00f6l\u00e7\u00fcl\u0259rinin d\u0259 verilm\u0259si laz\u0131m g\u0259ldikd\u0259, b\u0259d\u0259n k\u00fctl\u0259 indeksi (body mass index) hesablan\u0131laraq verilir.<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

XLOR (T\u0259r)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0T\u0259r testi; \u0130yontoferez<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>T\u0259r<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200\u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0\u00a0<\/strong>N\u00fcmun\u0259 laboratoriyada x\u00fcsusi qayda il\u0259 al\u0131n\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kondaktometrik<\/p>\n

Referens:<\/strong>\u00a0<60 mEq\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Mukovissidozun\u00a0(<\/strong>kistik fib\u00ad\u00adrozis) diaqnozunda istifad\u0259 olu\u00adnur. Mukovissidozlu x\u0259st\u0259l\u0259rd\u0259 t\u0259r il\u0259 duz itkisi \u00e7ox y\u00fcks\u0259lir. \u0130fraz nor\u00admal \u015f\u0259xsl\u0259r\u0259 nisb\u0259t\u0259n 2.5 d\u0259f\u0259 y\u00fck\u00ads\u0259kdir v\u0259 bu x\u0259st\u0259lik \u00fc\u00e7\u00fcn pato\u00adqno\u00admik hesab olunur. X\u0259st\u0259 infantlarda III-V h\u0259ft\u0259d\u0259n sonra po\u00adzitivl\u0259\u015fir. Ad\u00adrenal \u00e7at\u0131\u015fmazl\u0131q, ma\u00adlab\u00adsorbsiya, m\u0259d\u0259alt\u0131 v\u0259z \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131, hipo\u00adti\u00adroidi\u00adzim v\u0259 b\u0259zi b\u00f6yr\u0259k x\u0259st\u0259lik\u00adl\u0259\u00adrind\u0259 d\u0259 t\u0259rd\u0259ki Cl miqdar\u0131 y\u00fcks\u0259l\u0259 bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

XLOR (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0H\u0259r g\u00fcn<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 sax\u00adla\u00adn\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir. Bor tur\u00ad\u015fu\u00adsu \u00fcz\u0259rin\u0259 toplanm\u0131\u015f sidikl\u0259r d\u0259 q\u0259bul olunur<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>24 saatl\u0131q sidiyin miqdar\u0131 bildirm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ISE<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
<7 g\u00fcn<\/td>\n2-10 mEq\/g\u00fcn<\/td>\n<\/tr>\n
7 g\u00fcn-5 ya\u015f<\/td>\n15-40 mEq\/g\u00fcn<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\nKi\u015fi: 35-110 mEq\/g\u00fcn<\/td>\nQad\u0131n: 15-75 mEq\/g\u00fcn<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\nKi\u015fi: 60-175 mEq\/g\u00fcn<\/td>\nQad\u0131n: 35-175 mEq\/g\u00fcn<\/td>\n<\/tr>\n
16-60 ya\u015f<\/td>\n110-250 mEq\/g\u00fcn<\/td>\n<\/td>\n<\/tr>\n
>60 ya\u015f<\/td>\n65-200 mEq\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Normada sidikd\u0259ki xlo\u00adrun miqdar\u0131 qida il\u0259 q\u0259bul edil\u0259n xlo\u00adrun miqdar\u0131ndan as\u0131l\u0131d\u0131r. Duz q\u0259bu\u00adlunun artmas\u0131, hans\u0131sa s\u0259b\u0259bd\u0259n olan massiv diurez, kalium itkisi, adre\u00adnokortikal \u00e7at\u0131\u015fmazl\u0131q v\u0259 Bartter sindromunda sidikl\u0259 ifraz olunan Cl s\u0259viyy\u0259si art\u0131r, duz q\u0259bulunu azal\u00admas\u0131, ekstrarenal Cl itkisi (qusma, ba\u011f\u0131rsaq fistulu, a\u011f\u0131r diarreya) v\u0259 adrenokortikal hiperfunksiya kimi hallarda is\u0259 sidikl\u0259 xaric olunan Cl s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

XLOR (BOM)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>BOM<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Gelsiz d\u00fcz s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0ISE<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
<1 ya\u015f<\/td>\n110-130 mEq\/L<\/td>\n<\/tr>\n
>1 ya\u015f<\/td>\n110-130 mEq\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Serumda Cl s\u0259viyy\u0259si ar\u00adtan hallarda BOM-dak\u0131 Cl s\u0259viyy\u0259si d\u0259 art\u0131r. V\u0259r\u0259m menengiti, dig\u0259r bak\u00adterial menengitl\u0259r v\u0259 serumda Cl s\u0259\u00adviyy\u0259sini azaldan hallarda is\u0259 BOM-da xlor s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

XLOR<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Cl<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>ISE<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n\n
G\u00f6b\u0259k ciy\u0259sind\u0259n al\u0131nm\u0131\u015f qanda<\/td>\n96-104 mEq\/L<\/td>\n<\/tr>\n
Yenido\u011fulmu\u015f<\/td>\n95-110 mEq\/L<\/td>\n<\/tr>\n
<7 g\u00fcn<\/td>\n96-110 mEq\/L<\/td>\n<\/tr>\n
>7 g\u00fcn<\/td>\n95-110 mEq\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>Elektrolit m\u00fcvazin\u0259ti, tur\u00ad\u015fu-q\u0259l\u0259vi v\u0259 su metabolizminin qiy\u00adm\u0259t\u00adl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olunur. De\u00adhidratasiya, b\u00f6yr\u0259k borucuq\u00adlar\u0131\u00adn\u0131n asidozu, k\u0259skin b\u00f6yr\u0259k \u00e7at\u0131\u015f\u00admaz\u00adl\u0131\u011f\u0131, \u015f\u0259k\u0259rsiz diabet (diapedes in\u00adsi\u00adpi\u00addus), salisilat intoksikasiyas\u0131 v\u0259 res\u00adpi\u00adrator alkaloz zaman\u0131 se\u00adrum\u00adda Cl s\u0259\u00adviyy\u0259si art\u0131r, h\u0259dd\u0259n \u00e7ox qusma, al\u00addosteronizim, respirator asidoz v\u0259 su intoksikasiyas\u0131 hallar\u0131nda is\u0259 bu g\u00f6st\u0259rici azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

UROPORF\u0130R\u0130N (PORF\u0130R\u0130NL\u018fR)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a010 mL<\/p>\n

Testin t\u0259rkibi:<\/strong>\u00a0Uroporfirin I, III, koproporfirin I, III v\u0259 dig\u0259r porfirin izomerl\u0259ri<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Qa\u00adranl\u0131q v\u0259 soyuq \u015f\u0259raitd\u0259 toplanmal\u0131, i\u015f\u0131qdan qorunmaqla soyuq \u015f\u0259raitd\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
Uropofinin I, III<\/td>\n25 mg\/g\u00fcn<\/td>\n<\/tr>\n
Koproporfirin I<\/td>\n25 mg\/g\u00fcn<\/td>\n<\/tr>\n
Koproporfirin III<\/td>\n75 mg\/g\u00fcn<\/td>\n<\/tr>\n
Total porfirinl\u0259r<\/td>\n150 mg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Porfiriyalar\u0131n t\u0259yinind\u0259 v\u0259 tipinin m\u00fc\u0259yy\u0259nl\u0259\u015fdirilm\u0259sind\u0259 is\u00adtifad\u0259 olunur. X\u00fcsusil\u0259 d\u0259ri\u00a0 foto\u00adh\u0259ssasl\u0131\u011f\u0131 m\u00fc\u015fahid\u0259 olunan porfiri\u00adyalarda sidik porfirinl\u0259ri \u0259h\u0259\u00admiy\u00ady\u0259t\u00adlidir. HPLC \u00fcsulu il\u0259 sidikd\u0259ki b\u00fct\u00fcn porfirin n\u00f6vl\u0259ri v\u0259 izomerl\u0259ri k\u0259\u00admiyy\u0259tc\u0259 t\u0259yin oluna bil\u0259r. H\u0259m\u00e7inin civ\u0259 z\u0259h\u0259rl\u0259nm\u0259si, qaraciy\u0259r x\u0259s\u00adt\u0259\u00adliyi, k\u0259skin miokard infarkt\u0131, he\u00admo\u00adlitik v\u0259 pernisitoz anemiyalar, alko\u00adqol m\u0259n\u015f\u0259li sirroz, idman, Hodgkin x\u0259st\u0259liyi, leykoz, triotoksikoz v\u0259 vi\u00adtamin \u00e7at\u0131\u015f\u00admazl\u0131qlar\u0131 kimi s\u0259b\u0259b\u00adl\u0259r\u00add\u0259n \u0259m\u0259l\u0259 g\u0259l\u0259n qazan\u0131lm\u0131\u015f por\u00adfi\u00adri\u00adyalardada sidikd\u0259 koproporfirinin s\u0259viyy\u0259si art\u0131r. K\u0259skin porfiriyalar\u0131n qiym\u0259t\u00adl\u0259ndirilm\u0259sind\u0259 is\u0259 sidikd\u0259 ALA v\u0259 porfobilinogen s\u0259viyy\u0259si is\u00adtifad\u0259 olunmal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

UROPEPS\u0130NOGEN<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Qoruyucuya ehtiyac yoxdur<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a024 saatl\u0131q sidiyin miqdar\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

UREA N\u0130TROGEN\u0130 (Sidik)<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a024 saatl\u0131q sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a010 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a024 saatl\u0131q sidiyin miqdar\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, fer\u00admentativ, kinetik<\/p>\n

Referens:<\/strong>\u00a012-20 g\/g\u00fcn<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0B\u00f6yr\u0259yin funksional test\u00adl\u0259rind\u0259n biridir. Y\u00fcks\u0259k z\u00fclall\u0131 qida\u00adlanma, hipertiroidizim v\u0259 \u0259m\u0259liy\u00adyat\u00addan sorak\u0131 d\u00f6vrd\u0259 sidikd\u0259 BUN s\u0259\u00adviyy\u0259si art\u0131r. Az z\u00fclall\u0131 qidalanmada, hamil\u0259likd\u0259, infantlar v\u0259 u\u015faqlarda, akromeqaliya, qaraciy\u0259r x\u0259st\u0259likl\u0259ri, toksemiya v\u0259 b\u00f6yr\u0259k x\u0259st\u0259likl\u0259rind\u0259 sidikd\u0259 BUN s\u0259viyy\u0259si azal\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LD (LAKTAT DEH\u0130DROGENAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0LDH; LD; S\u00fcd tur\u015fusu dehidrogenazas\u0131<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, ki\u00adnetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
<3 ay<\/td>\n100-450 IU\/L<\/td>\n<\/tr>\n
4-12 ay<\/td>\n100-400 IU\/L<\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n100-300 IU\/L<\/td>\n<\/tr>\n
4-12 ya\u015f<\/td>\n100-250 IU\/L<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n90-240 IU\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u00dcr\u0259k v\u0259 qaraciy\u0259r x\u0259st\u0259\u00adlikl\u0259rininn diaqnostikas\u0131nda istifad\u0259 olunur. KM\u0130, meqaloblastik v\u0259 per\u00adnisitoz anemiya, qaraciy\u0259r x\u0259st\u0259\u00adlik\u00adl\u0259ri, \u015fok, hipoksiya, sirroz, obstruktiv sar\u0131l\u0131q, b\u00f6yr\u0259k x\u0259st\u0259likl\u0259ri, \u0259z\u0259l\u0259 x\u0259st\u0259likl\u0259ri, neoplastik x\u0259st\u0259likl\u0259r, k\u0259skin \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, leykemiya, hemolitik anemiya, oraq heceyr\u0259li anemiya, limfoma, b\u00f6yr\u0259k infarkt\u0131 v\u0259 k\u0259skin pankreatitd\u0259 LDH s\u0259viyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LDH (LAKTAT DEH\u0130DROGENAZA)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0LDH; LD; S\u00fcd tur\u015fusu dehidrogenazas\u0131<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Spektrofotometrik, ki\u00adnetik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
<3 ay<\/td>\n100-450 IU\/L<\/td>\n<\/tr>\n
4-12 ay<\/td>\n100-400 IU\/L<\/td>\n<\/tr>\n
1-3 ya\u015f<\/td>\n100-300 IU\/L<\/td>\n<\/tr>\n
4-12 ya\u015f<\/td>\n100-250 IU\/L<\/td>\n<\/tr>\n
>12 ya\u015f<\/td>\n90-240 IU\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u00dcr\u0259k v\u0259 qaraciy\u0259r x\u0259st\u0259\u00adlikl\u0259rininn diaqnostikas\u0131nda istifad\u0259 olunur. KM\u0130, meqaloblastik v\u0259 per\u00adnisitoz anemiya, qaraciy\u0259r x\u0259st\u0259\u00adlik\u00adl\u0259ri, \u015fok, hipoksiya, sirroz, obstruktiv sar\u0131l\u0131q, b\u00f6yr\u0259k x\u0259st\u0259likl\u0259ri, \u0259z\u0259l\u0259 x\u0259st\u0259likl\u0259ri, neoplastik x\u0259st\u0259likl\u0259r, k\u0259skin \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, leykemiya, hemolitik anemiya, oraq heceyr\u0259li anemiya, limfoma, b\u00f6yr\u0259k infarkt\u0131 v\u0259 k\u0259skin pankreatitd\u0259 LDH s\u0259viyy\u0259si art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LDH \u0130ZOENZ\u0130M ELEKTROFOREZ\u0130 (LAKTAT DEH\u0130DROGENAZA \u0130ZOENZ\u0130ML\u018fR\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0LDH izoenziml\u0259ri; LDH izoenzim elektroforezi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500\u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Elektroforez<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
LD1<\/td>\n17-31%<\/td>\n<\/tr>\n
LD2<\/td>\n35-48%<\/td>\n<\/tr>\n
LD3<\/td>\n15-29%<\/td>\n<\/tr>\n
LD4<\/td>\n4-9.5%<\/td>\n<\/tr>\n
LD5<\/td>\n3-10 %<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>LDH y\u00fcks\u0259kliyinin s\u0259b\u0259\u00adbini t\u0259yin etm\u0259k m\u0259qs\u0259dil\u0259 istifad\u0259 olunur. KM\u0130, qaraciy\u0259r x\u0259st\u0259likl\u0259ri, neoplaziyalar v\u0259 skelet \u0259z\u0259l\u0259si x\u0259s\u00adt\u0259likl\u0259rinin differensasiyas\u0131nda \u0259h\u0259\u00admiy\u00ady\u0259tlidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

N-ASET\u0130L-QLUKOZAM\u0130N\u0130DAZA<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0NAG; Total heksoza\u00admi\u00adnidaza; \u03b2-N-asetil- heksozaminidaza<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Spektrofotometrik<\/p>\n

Referens:<\/strong>\u00a01.5-6.1 U\/L<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0B\u00f6yr\u0259k x\u0259st\u0259likl\u0259rinin diaqnostikas\u0131nda istifad\u0259 olunur. B\u00f6y\u00adr\u0259k z\u0259d\u0259l\u0259nm\u0259si olan hallarda si\u00addikd\u0259 NAG s\u0259viyy\u0259si art\u0131r. Nefro\u00adtoksik d\u0259r\u00admanlarla \u0259laq\u0259dar olaraq \u0259m\u0259l\u0259 g\u0259l\u0259n b\u00f6yr\u0259k z\u0259d\u0259l\u0259n\u00adm\u0259\u00adl\u0259\u00adrin\u00add\u0259 sidikd\u0259 NAG s\u0259viyy\u0259si, serum\u00addak\u0131 kreatinin s\u0259viyy\u0259sind\u0259n daha tez y\u00fcks\u0259lir. B\u00f6yr\u0259k transplan\u00adta\u00adsi\u00adyalar\u0131n\u00addan sonra orqan r\u0259ddinin er\u00adk\u0259n diaqnozunda da NAG \u00e7ox d\u0259y\u0259rlidir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TUR\u015eU HEMOL\u0130Z TEST\u0130 (HAM TEST\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Tur\u015fu hemolizi testi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>X\u0259st\u0259d\u0259n v\u0259 eyni qan qruplu sa\u011flam \u015f\u0259xsd\u0259n EDTA-l\u0131 tam qan v\u0259 serum g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si (serum) v\u0259 b\u0259n\u00f6v\u015f\u0259yi qa\u00adpaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si (EDTA-l\u0131 tam qan)<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>3 mL EDTA-l\u0131 tam qan v\u0259 3mL serum<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Kvalitativ<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Paroksizmal nokturnal (gec\u0259) hemoqlobinuriyan\u0131n t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

VAN\u0130LMANDEL\u0130N TUR\u015eUSU<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0VMA; 3-Metoksi-4-Hid\u00adrok\u00adsimandelik tur\u015fu<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>24 saatl\u0131q sidik, bird\u0259f\u0259lik sidik<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Asetat tur\u015fusu \u00fcz\u0259tin\u0259 toplanaraq g\u00f6nd\u0259rilm\u0259lidir. 6N HCl v\u0259 ya bor tur\u015fusu \u00fcz\u0259rin\u0259 toplanan sidikl\u0259rd\u0259 q\u0259bul edilir<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a05 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n\n
6-12 ay<\/td>\n0.50-2.00 mg\/g\u00fcn<\/td>\n<\/tr>\n
1-5 ya\u015f<\/td>\n0.50-2.50 mg\/g\u00fcn<\/td>\n<\/tr>\n
6-12 ya\u015f<\/td>\n0.75-3.00 mg\/g\u00fcn<\/td>\n<\/tr>\n
13-15 ya\u015f<\/td>\n1.00-6.00 mg\/g\u00fcn<\/td>\n<\/tr>\n
>15 ya\u015f<\/td>\n3.00-9.00 mg\/g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Feoxromasitoman\u0131n diaq\u00adnozu v\u0259 m\u00fcalic\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur. H\u0259m\u00e7inin neyro\u00adblas\u00adtoma, qanqlioneyroma v\u0259 karsinoid \u015fi\u015fl\u0259rin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 isti\u00adfad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section><\/div>[\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-15873","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/pages\/15873","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/comments?post=15873"}],"version-history":[{"count":2,"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/pages\/15873\/revisions"}],"predecessor-version":[{"id":15912,"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/pages\/15873\/revisions\/15912"}],"wp:attachment":[{"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/media?parent=15873"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}